[
    {
        "instruction":"已知信息：\n'(2) If the application items are not within the scope of authority of drug regulatory department in accordance with the law, the relevant department shall make a decision of non-acceptance, issue a notification of non-acceptance, and inform the applicant to resubmit the application to the applicable administrative authority；'可被翻译为：（二）申请事项依法不属于药品监督管理部门职权范围的，应当作出不予受理的决定，出具不予受理通知书，并告知申请人向有关行政机关申请；\n'Article 17 Where the provincial drug regulatory department decides to grant approval, it shall, within 10 days after the decision of approval is made, serve the approval document for crude drugs importation or for supplementary application for crude drugs importation to the applicant; where the drug regulatory department decides to grant disapproval, it shall, within 10 days after the decision of disapproval is made, serve a Notice of Review Opinions to the applicant with the reasons explained, and inform the applicant of the right to apply for administrative reconsideration or bring an administrative suit according to law.'可被翻译为：第十七条 省级药品监督管理部门决定予以批准的，应当在作出批准决定后10日内，向申请人送达进口药材批件或者进口药材补充申请批件；决定不予批准的，应当在作出不予批准决定后10日内，向申请人送达审查意见通知书，并说明理由，告知申请人享有依法申请行政复议或者提起行政诉讼的权利。\n\n根据上述已知信息，请将'Article 155 The written non-acceptance or unapproval decision made by drug regulatory departments by law shall provide the reasons thereof, and inform the applicant of the right to apply for administrative reconsideration or to bring an administrative suit by law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百五十五条 药品监督管理部门依法作出不予受理或者不予批准的书面决定，应当说明理由，并告知申请人享有依法提请行政复议或者提起行政诉讼的权利。"
    },
    {
        "instruction":"已知信息：\n'Where applying for registration of a domestic medical device subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.'可被翻译为：按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品不得委托其他企业生产。\n'Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.'可被翻译为：第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。\n\n根据上述已知信息，请将'Where applying for registration of a in-vitro diagnostic reagent subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品不得委托其他企业生产。"
    },
    {
        "instruction":"已知信息：\n'After receiving the report, the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device distributor or using unit is located shall, in a timely manner, inform the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located.'可被翻译为：医疗器械经营企业、使用单位所在地省、自治区、直辖市食品药品监督管理部门收到报告后，应当及时通报医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门。\n'Article 18 If a medical device manufacturer establishes the manufacturing premises across the province, autonomous region or municipality directly under the central government, it shall apply to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the manufacturing premises is located for Medical Device Manufacturing License.'可被翻译为：第十八条  医疗器械生产企业跨省、自治区、直辖市设立生产场地的，应当向新设生产场地所在地省、自治区、直辖市药品监督管理部门申请医疗器械生产许可。\n\n根据上述已知信息，请将'Article 7 Upon finding that the medical device it sells and uses may be a detective product, the medical device distributor or using unit shall immediately suspend the sale or use of the medical device, notify the medical device manufacturer or supplier in a timely manner, and report the findings to the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where it is located; if the using unit is a medical institution, it shall also report the findings to the health administration department of the province, autonomous region, or municipality directly under the Central Government where it is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七条 医疗器械经营企业、使用单位发现其经营、使用的医疗器械可能为缺陷产品的，应当立即暂停销售或者使用该医疗器械，及时通知医疗器械生产企业或者供货商，并向所在地省、自治区、直辖市食品药品监督管理部门报告；使用单位为医疗机构的，还应当同时向所在地省、自治区、直辖市卫生行政部门报告。"
    },
    {
        "instruction":"已知信息：\n'A method of treating human diseases by using preparations made from extracts of the internal organs or tissues of certain animals.'可被翻译为：应用某些动物的内脏或组织器官提取物制成的制剂来防治人体疾病的方法。\n'A retrospective study method in which the cause is explored by the results. It is based on the present diagnosis of a particular disease'可被翻译为：一种由结果探索病因的回顾性研究方法。其基本原理是以现在确诊的患有某特定疾病\n\n根据上述已知信息，请将'A method of treating a disease, such as by directly combating or removing the cause of the disease itself. Is the theory and treatment method used in Western medicine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对造成疾病本身的原因直接对抗、移除等治疗疾病的方法。是西医所使用的理论和治疗方法。"
    },
    {
        "instruction":"已知信息：\n'I. If M9 requirements are met according to the assessment by the applicant, the applicant can directly propose exemption of human bio equivalence test in the drug registration application. NMPA will not issue a separate catalogue of varieties exempted from human bioequivalence test or subject to simplified human bio equivalence test.'可被翻译为：一、如果经申报人评估符合M9要求，申报人可直接在药品注册申请中提出免除人体生物等效性试验。国家药监局不会单独发布免人生物等效性试验或简化人生物等效性试验的品种目录。\n'III. In case of inconsistency between the previously issued Guideline for Exemption from Human Bio equivalence Tests and the M9 Guideline, the M9 Guideline shall prevail.'可被翻译为：三、如果先前发布的《人类生物等效性试验豁免指南》与M9指南不一致，应以M9指南为准。\n\n根据上述已知信息，请将'II. Applying for exemption from human bio equivalence tests shall be indicated in the application form. If the exemption cannot be made after evaluation, and the substantial defects cannot be corrected, the applicant will not be required to provide supplementary materials, and the registration application shall be disapproved.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二、申请豁免进行人体生物等效性试验，须在申请表中注明。经评审不能豁免，实质缺陷不能纠正的，不要求申请人提供补充材料，不予批准注册申请。"
    },
    {
        "instruction":"已知信息：\n'Article 17 The following terms are defined as follows:'可被翻译为：第十七条 本规则下列用语的含义：\n'Article 4 The terms in the Provisions are defined as follows:'可被翻译为：第四条  本办法下列用语的含义：\n\n根据上述已知信息，请将'Article 178 The terms in this GSP are defined as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十八条 本规范下列术语的含义是："
    },
    {
        "instruction":"已知信息：\n'Article 53 After CDE notifies the applicant of registration inspection within the prescribed time limit, in principle, CFDI shall terminate the relevant registration inspection task, explain the reasons and basis, and inform the CED in case of the following circumstances.'可被翻译为：第五十三条 药品审评中心在规定时限内通知申请人进行注册核查后，原则上出现以下情形的，核查中心终止相关注册核查任务，说明原因及依据后告知药品审评中心。\n'Article 23 CFDI shall organize the implementation of the registration inspection work within the registration inspection time limit, determine the inspection time, and notify the applicant and the inspected institution to accept the registration inspection. If a dynamic manufacturing on-site inspection is required, Manufacturing Site Inspection time shall be determined based on the applicant's dynamic production arrangement.'可被翻译为：第二十三条 核查中心在注册核查时限内，组织实施注册核查工作，确定核查时间，通知申请人和被核查单位接受注册核查。需要进行动态生产现场核查的，结合申请人动态生产安排确定生产现场核查时间。\n\n根据上述已知信息，请将'Article 51 The necessary feedback or explanation submitted by the applicant after the on-site inspection, the delay of the on-site inspection by the applicant due to force majeure, and the convening of the expert consultation meeting shall not be included in the time limit. Where relevant circumstances affect the time limit for registration inspection, CFDI shall notify CDE.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十一条 申请人现场核查后进行的必要反馈或者提交解释说明、申请人因不可抗力原因延迟现场核查、召开专家咨询会等时间，不计入时限。相关情况影响注册核查时限的，核查中心应当通知药品审评中心。"
    },
    {
        "instruction":"已知信息：\n'The coordinates of the mass-charge ratio of the molecular ions ([M+H][M-H], [M+Na]+, etc.) and all the fragment ions obtained by the full scan and the relative intensity of their corresponding ion currents. According to the mass spectrometry to determine the structure of the analytical compound, the molecular formula.'可被翻译为：全扫描得到的分子离子([M+H][M-H]、[M+Na]+等)及所有碎片离子的质荷比与其对应的离子流的相对强度的坐标图。根据质谱图来决定解析化合物的结构、分子式。\n'The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.'可被翻译为：以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。\n\n根据上述已知信息，请将'The horizontal coordinate is the mass charge ratio (m\/z), the vertical coordinate is the relative strength of the ion, with the base peak of 100%, after computer processing of mass spectrum rod-like spectrum.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"横坐标是质荷比（m\/z）、纵坐标是离子的相对强度，以基峰为100%、经过计算机处理的质谱棒状谱图。"
    },
    {
        "instruction":"已知信息：\n'· Suitable storage and transport.'可被翻译为：适当的储存和运输。\n'(I) Freezer adapted to their business scale and varieties; for vaccines, two or more independent freezers shall be equipped;'可被翻译为：（一）与其经营规模和品种相适应的冷库，储存疫苗的应当配备两个以上独立冷库；\n\n根据上述已知信息，请将'(1) equipped with appropriate scale and sufficient capacity reserved.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）具备适度规模和足够的产能储备；"
    },
    {
        "instruction":"已知信息：\n'Medical device sold by its registrant and filing applicant at their residence or manufacturing site may not apply for medical device distribution licensing or filing, but shall comply with the specified distribution conditions; for Class II and Class III medical devices stored and sold at other sites, application for medical device distribution licensing or filing shall be made as required.'可被翻译为：医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存、销售第二、三类医疗器械的，应当按照规定办理医疗器械经营许可或者备案。\n'Article 42 If a medical device distributor finds that the medical devices involved in its distribution activities do not conform to mandatory standards, or to registered or filed technical specifications for the products, or have other defects, it shall suspend the distribution immediately, notify the registrant, filing entity and other relevant units of the medical devices, and record the conditions of distribution suspension and notification. If the registrant and filing entity of the medical devices deem that the products need to be recalled, recalls shall be performed immediately.'可被翻译为：第四十二条  医疗器械经营企业发现其经营的医疗器械不符合强制性标准、经注册或者备案的产品技术要求，或者存在其他缺陷的，应当立即停止经营，通知医疗器械注册人、备案人等有关单位，并记录停止经营和通知情况。医疗器械注册人、备案人认为需要召回的，应当立即召回。\n\n根据上述已知信息，请将'Article 27 If the registrant or filing entity of medical devices sells its registered and filed medical devices at its domicile or manufacturing address, it does not need to apply for Medical Device Distribution License or filing, but shall meet the prescribed distribution conditions; if it stores and sells the medical devices in other places, it shall apply for Medical Device Distribution License or filing as stipulated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条  医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存并销售医疗器械的，应当按照规定办理医疗器械经营许可或者备案。"
    },
    {
        "instruction":"已知信息：\n'absorbance ratio'可被翻译为：吸光度比值\n'The upper-bound excess lifetime cancer risk estimated to result from continuous exposure to an agent at a concentration of 1 µg\/L in water, or 1 µg\/m3 in air. The interpretation of inhalation unit risk would be as follows: if unit risk = 2 x 10-6 per µg\/L, 2 excess cancer cases (upper bound estimate) are expected to develop per 1,000,000 people if exposed daily for a lifetime to 1 µg of the chemical in 1 liter of drinking water. (US EPA)'可被翻译为：连续暴露于 1µg\/L（水中）或 1µg\/m3（空气）某试剂，估计高于终身患癌风险的上限。吸入单位风险可做如下解释：如果单位风险=2×10-6 \/µg\/L，假设终身每天都饮用1升含有1µg 某化学物质的饮用水，预计每 100 万人发现 2 例以上癌症病例（上限估计）。（美国环境保护署）\n\n根据上述已知信息，请将'Absorbance when the solution concentration is l%(g\/ml) and the liquid layer thickness is 1cm.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当溶液浓度为l%(g\/ml),液层厚度为1cm时的吸光度。"
    },
    {
        "instruction":"已知信息：\n'In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of cosmetics, the NMPA has developed the Rules for Registration and Notification Dossiers of Cosmetics, which is hereby issued and shall take effect as of May 1, 2021.'可被翻译为：为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品注册与备案工作，国家药监局制定了《化妆品注册备案资料管理规定》，现予公布，自2021年5月1日起施行。\n'The Provisions for Registration and Filing of Cosmetics adopted at the 14th Executive Meeting of the State Administration for Market Regulation on December 31, 2020 is hereby promulgated and shall go into effect as of May 1, 2021.'可被翻译为：《化妆品注册备案管理办法》已于2020年12月31日经国家市场监督管理总局2020年第14次局务会议审议通过，现予公布，自2021年5月1日起施行。\n\n根据上述已知信息，请将'To implement the newly revised Regulationson the Supervision and Administration of Cosmetics (hereinafter referred to as the Regulations), reinforce the administration of cosmetics registration and notification, protect consumers' health rights, and standardize and promote the healthy development of the cosmetics industry, the NMPA drafted the Provisions for Registration and Notification of Cosmetics (hereinafter referred to as the Provisions).The Provisions has been adopted upon deliberation at the 14th Executive Meeting of the State Administration of Market Regulation on December 31, 2020, and shall go into effect as of May 1, 2021.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为贯彻落实新颁布的《化妆品监督管理条例》（以下简称《条例》），加强化妆品注册和备案管理，保障消费者健康权益，规范和促进化妆品行业健康发展，国家药监局起草了《化妆品注册备案管理办法》（以下简称《办法》）。2020年12月31日，国家市场监督管理总局2020年第14次局务会议审议通过《办法》，自2021年5月1日起实施。"
    },
    {
        "instruction":"已知信息：\n'repeat donor'可被翻译为：重复捐赠\n'repeatedly reactive'可被翻译为：多次反应\n\n根据上述已知信息，请将'A donation is considered to be repeatedly reactive if it is found reactive in a screening test, is retested in duplicate using the same assay, and at least one of the repeat tests is also reactive.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在筛选试验中发现具有反应性，使用相同的方法进行两次重新测试，并且至少有一次重复测试也是具有反应性的，则认为捐赠具有重复反应性。"
    },
    {
        "instruction":"已知信息：\n'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government where the registration department is located shall be adopted for domestic class II medical devices.'可被翻译为：境内第二类医疗器械为注册审批部门所在地省、自治区、直辖市简称；\n'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government combines the abbreviation of city divided into districts where filing department is located (if there is no corresponding city divided into districts, only use the abbreviation of province, autonomous region or municipality directly under the central government) shall be adopted for domestic class I in-vitro diagnostic reagent.'可被翻译为：境内第一类体外诊断试剂为备案部门所在地省、自治区、直辖市简称加所在地设区的市级行政区域的简称（无相应设区的市级行政区域时，仅为省、自治区、直辖市的简称）；\n\n根据上述已知信息，请将'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government where the registration authority is located shall be adopted for domestic class II in-vitro diagnostic reagents.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"境内第二类体外诊断试剂为注册审批部门所在地省、自治区、直辖市简称；"
    },
    {
        "instruction":"已知信息：\n'Article 35 After receiving the application for medical device clinical trial, the ethics committee shall hold a meeting to review and discuss it, issue written opinions affixed with the seal, and attach the list of attendants, specialties and their own signatures. The comments of the ethics committee may be:'可被翻译为：第三十五条 伦理委员会接到医疗器械临床试验的申请后应当召开会议，审阅讨论，签发书面意见、盖章，并附出席会议的人员名单、专业以及本人签名。伦理委员会的意见可以是：\n'The ethics committee refers to the independent institution which is set up by the clinical trial institution to examine the scientific and ethical nature of medical device clinical trial projects.'可被翻译为：伦理委员会，是指临床试验机构设置的对医疗器械临床试验项目的科学性和伦理性进行审查的独立的机构。\n\n根据上述已知信息，请将'Article 30 The ethics committee of the medical device clinical trial institution shall consist of at least five members, including medical professionals and non-medical professionals, covering different sexes. In the non-medical professionals, at least one is a legal professional and one is independent of the clinical trial institution. The members of the ethics committee shall have the qualification or experience to assess and evaluate the scientific, medical and ethical aspects of the clinical trial. All members shall be familiar with the ethical guidelines and related regulations of medical device clinical trials and follow the articles of the ethics committee.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十条 医疗器械临床试验机构伦理委员会应当至少由5名委员组成，包括医学专业人员、非医学专业人员，其中应当有不同性别的委员。非医学专业委员中至少有1名为法律工作者，1名为该临床试验机构以外的人员。伦理委员会委员应当具有评估和评价该项临床试验的科学、医学和伦理学等方面的资格或者经验。所有委员应当熟悉医疗器械临床试验的伦理准则和相关规定，并遵守伦理委员会的章程。"
    },
    {
        "instruction":"已知信息：\n'Adding an appropriate amount of electrolyte to the suspension to adjust the self-potential can make the repulsive force between the particles slightly lower than the attractive force, forming a loose flocculent aggregate, which is restored to a uniform suspension by shaking.'可被翻译为：混悬剂中加入适量的电解质调节自电位，可使微粒间的排斥力稍低于吸引力，形成疏松的絮状聚集体，经振摇恢复成均匀的混悬剂的现象。\n'If the electrolyte is added to the suspension to increase the potential of the particle surface, the electrostatic repulsion hinders the collision between the particles and the aggregation, the flocculation state disappears, the added electrolyte is called the deflocculant.'可被翻译为：如果在混悬剂中因加入电解质使微粒表面的&电位升高，静电排斥力阻碍了微粒之间的碰撞聚集，絮凝状态消失，所加入的电解质称为反絮凝剂。\n\n根据上述已知信息，请将'If the appropriate amount of electrolyte is added to the suspension, the J potential can be reduced to an appropriate degree, even if the repulsive force between the particles is slightly lower than the attractive force, at this time the particles gather into a loose flocculent aggregate, which can be restored to a uniform suspension by shaking, the added electrolyte is called a flocculant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"混悬剂中如果加入适量的电解质，可使J电位降低到适当的程度，即使微粒间的排斥力稍低于吸引力，此时微粒聚集成疏松的絮状聚集体，经振摇可恢复成均匀的混悬剂，所加电解质称为絮凝剂。"
    },
    {
        "instruction":"已知信息：\n'Class 2: Modified new drugs that have not been marketed in China or overseas. They refer to drugs that have their structure, dosage form, formulation and process, route of administration and indications optimized on the basis of known active ingredients and have significant clinical advantages.'可被翻译为：2类：境内外均未上市的改良型新药。指在已知活性成份的基础上，对其结构、剂型、处方工艺、给药途径、适应症等进行优化，且具有明显临床优势的药品。\n'(1) Class 1 chemical drugs are innovative drugs that contain new compounds with clear structures and pharmacological effects and have clinical values. Class 2.1 drugs in modified new drugs are not included. New compound preparations containing new compounds with clear structures and pharmacological effects shall be applied in accordance with Class 1 chemical drugs.'可被翻译为：（一）化学药品1类为创新药，应含有新的结构明确的、具有药理作用的化合物，且具有临床价值，不包括改良型新药中2.1类的药品。含有新的结构明确的、具有药理作用的化合物的新复方制剂，应按照化学药品1类申报。\n\n根据上述已知信息，请将'Class 1: Innovative drugs that have not been marketed in China or overseas. They refer to drugs that contain new compounds with clear structures and pharmacological effects, and have clinical values.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1类：境内外均未上市的创新药。指含含有新的结构明确的、具有药理作用的化合物，且具有临床价值的药品。"
    },
    {
        "instruction":"已知信息：\n'Article 271: Operation procedures should be established to define the process of recording, evaluating, investigating, and handling of complaints. The measures for a complaint due to a possible product defect should also be defined. Consideration of the necessity of a recall from the market should be included.'可被翻译为：第二百七十一条 应当建立操作规程，规定投诉登记、评价、调查和处理的程序，并规定因可能的产品缺陷发生投诉时所采取的措施，包括考虑是否有必要从市场召回药品。\n'All handling of materials and products should be carried out according to operation procedures and master manufacturing documents, and recorded accordingly.'可被翻译为：物料和产品的处理应当按照操作规程或工艺规程执行，并有记录。\n\n根据上述已知信息，请将'Article 248: The manufacturer should establish operation procedures for deviation handling, define the reporting, recording, investigation, treatment and corrective actions adopted and all should be recorded accordingly.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百四十八条 企业应当建立偏差处理的操作规程，规定偏差的报告、记录、调查、处理以及所采取的纠正措施，并有相应的记录。"
    },
    {
        "instruction":"已知信息：\n'Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China'可被翻译为：境外已上市境内未上市药品临床技术要求\n'Notice of CDE of China NMPA on Issuing the Technical Requirements for CMC Study and Evaluation of Chemical Drugs Marketed Overseas But Not Marketed in China (Interim)'可被翻译为：国家药监局药品监督管理总局关于印发《境外上市未在境内上市化学药品CMC研究评价技术要求(暂行)》的通知\n\n根据上述已知信息，请将'Center for Drug Evaluation, NMPA issued the Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局药审中心关于发布《境外已上市境内未上市药品临床技术要求》"
    },
    {
        "instruction":"已知信息：\n'A method of statistical analysis that determines a quantitative relationship of interdependence between two or more variables.'可被翻译为：确定两种或两种以上变数间相互依赖的定量关系的一种统计分析方法。\n'The extent to which a variable (e.g. a rating scale) measures what it is supposed to measure.'可被翻译为：是指一个指标（如量表）测量它所预期测量的内容的程\n度。\n\n根据上述已知信息，请将'A method used to determine the reliability of an analytical outcome (e.g., cost-effectiveness analysis, decision analysis). The extent to which an important variable (e.g., cost, outcome, probability of an event, etc.) is affected by examining the possible range of variation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用来测定某种分析结果（如成本-效果分析、决策分析）可靠性的方法。通过检验重要变量（如成本、结果、事件的概率等）可能的变化范围来判断对分析结果产生影响的程度。"
    },
    {
        "instruction":"已知信息：\n'A technique for measuring the relationship between mass and temperature of a substance at a programmed temperature.'可被翻译为：在程序控制温度下，测量物质的质量与温度关系的一类技术。\n'The technique of measuring the relationship between the sound emitted by a substance and its temperature under programmed temperature control.'可被翻译为：在程序控制温度下，测量物质发出的声音与温度关系的技术。\n\n根据上述已知信息，请将'The amount of heat absorbed or emitted per unit mass of a substance by lowering its temperature by 1k or increasing it by 1 ° C.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单位质量的某种物质，温度降低1k或升高1℃所吸收或放出的热量。"
    },
    {
        "instruction":"已知信息：\n'(2) Name, address, contacts of registrant or filing entity; for import medical devices, name, address and contacts of the agent shall be also specified.'可被翻译为：（二）注册人或者备案人的名称、住所、联系方式，进口医疗器械还应当载明代理人的名称、住所及联系方式；\n'Article 26 The legal representative and principal responsible person of the registrant or filing entity of medical devices shall assume full responsibility for quality and safety of the medical devices manufactured.'可被翻译为：第二十六条  医疗器械注册人、备案人的法定代表人、主要负责人对其生产的医疗器械质量安全全面负责。\n\n根据上述已知信息，请将'Article 61 The registrant or filing entity of imported medical devices shall designate the domestic enterprise legal person as the agent, who shall assist the registrant or filing entity to fulfill the obligations prescribed in the Regulations on Supervision and Administration of Medical Devices and these Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十一条  进口医疗器械注册人、备案人应当指定我国境内企业法人作为代理人，代理人应当协助注册人、备案人履行医疗器械监督管理条例和本办法规定的义务。"
    },
    {
        "instruction":"已知信息：\n'12.20. Information on packaging to be transferred from the SU to the RU should include specifications for a suitable container and closure system, as well as any relevant additional information on design, packing, processing or labelling requirements and tamper-evident and anti- counterfeiting measures.'可被翻译为：准备从SU转给RU的包装信息应该包括有适当的容器和密闭器系统质量标准，以及其它设计、包装、处理或贴标要求和防拆封和防伪及措施信息。\n'8.2. The SU should provide the RU with information on relevant health, safety and environmental issues, including:'可被翻译为：SU应向RU提供与卫生、安全和环境问题有关的信息，包括：\n\n根据上述已知信息，请将'12.16. The SU should provide the product information including its qualitative and quantitative composition, physical description, method of manufacture, in-process controls, control method and specifications, packaging components and configurations, and any safety and handling considerations to the RU.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SU应向RU提供产品信息，包括其定性和定量配方、物理描述、生产方法、中控、检测方法和质量标准、包装部件和参数，以及所有安全和处置注意事项。"
    },
    {
        "instruction":"已知信息：\n'Article 13 Where an unannounced inspection is organized by a higher level food and drug regulatory department, the local food and drug regulatory department may be notified at an appropriate time. The local food and drug regulatory department shall assign personnel to assist the inspection, and they shall follow the arrangements of the inspection team.'可被翻译为：第十三条 上级食品药品监督管理部门组织实施飞行检查的，可以适时通知被检查单位所在地食品药品监督管理部门。被检查单位所在地食品药品监督管理部门应当派员协助检查，协助检查的人员应当服从检查组的安排。\n'Article 21 The duration of on-site inspection shall be determined by the inspection team in accordance with the needs of the inspection and principles of making the issues clear and ascertain. The inspection team shall not terminate the inspection without the consent of the food and drug regulatory department organizing the unannounced inspection.'可被翻译为：第二十一条 现场检查时间由检查组根据检查需要确定，以能够查清查实问题为原则。\n\n根据上述已知信息，请将'Article 14 The food and drug regulatory department organizing the conduction of the unannounced inspection shall strengthen the leadership over the inspection team, timely adjust coping strategies according to the feedback of on-site inspection, initiate the coordination mechanisms when necessary, and assign relevant personnel to inspection sites for coordination and leadership.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 组织实施飞行检查的食品药品监督管理部门应当加强对检查组的指挥，根据现场检查反馈的情况及时调整应对策略，必要时启动协调机制，并可以派相关人员赴现场协调和指挥。"
    },
    {
        "instruction":"已知信息：\n'Article 191: At all times during processing, containers of all materials, intermediate or bulk products, major items of equipment, and where appropriate rooms used should be labeled or otherwise identified with an indication of the product or material being processed, its strength and batch number. Where applicable, this indication should also mention the stage of the manufacturing process.'可被翻译为：第一百九十一条 生产期间使用的所有物料、中间产品或待包装产品的容器及主要设备、必要的操作室应当贴签标识或以其他方式标明生产中的产品或物料名称、规格和批号，如有必要，还应当标明生产工序。\n'Article 89: Main fixed pipes should be clearly labeled to indicate the contents and the direction of flow.'可被翻译为：第八十九条 主要固定管道应当标明内容物名称和流向。\n\n根据上述已知信息，请将'Article 87: Production equipment should be clearly labeled to indicate the equipment reference number and the contents (e.g. product name, strength, batch number, etc.). The equipment without contents should be labeled to indicate its cleaning status.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十七条 生产设备应当有明显的状态标识，标明设备编号和内容物（如名称、规格、批号）；没有内容物的应当标明清洁状态。"
    },
    {
        "instruction":"已知信息：\n'The standard extracting, rinsing and soaking fluid for medical devices is pyrogen-free water. The analytical approach for testing medical devices is covered in USP. If the extraction fluid shows endotoxin interfering results, modification of testing may be necessary depending on the product configuration. Alternate diluents must be verified to not interfere with the endotoxin assay prior to use.'可被翻译为：医疗器械的标准萃取、淋洗和浸泡流体为无热源水。检测医疗器械的分析方法在USP 中写明。如果萃取流体显示出内毒素干扰结果，可能需要根据产品参数设置对检测进行 修改。替代稀释剂在使用前必须确认其不会干扰内毒素分析。\n'Question 2: Can INTERMEDIATE (IN-PROCESS) sample aliquots be \"pooled\" into a composite and screened for bacterial endotoxin?'可被翻译为：问2：中间体样品等分样是否可以“合并”至组合样中用于细菌内毒素筛选？\n\n根据上述已知信息，请将'Finished medical devices may also be pooled into a composite sample and assayed for bacterial endotoxins. Testing for medical devices should be conducted using rinsing\/eluting and sampling techniques as described in ISO 10993-1 and ISO 10993-12, as also used for inhibition\/enhancement.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"成品组合器械可能亦会合并成组合样品进行细菌内毒素检测。器械的检测应该使用 ISO 10993-1 和 ISO 10993-12所述淋洗\/洗脱和取样技术，这也用于抑制\/增强。"
    },
    {
        "instruction":"已知信息：\n'An emerging discipline that uses chemical tools to study biological systems.'可被翻译为：利用化学工具来研究生物体系的-种新兴学科。\n'combinatorial chemistry'可被翻译为：组合化学\n\n根据上述已知信息，请将'A new discipline in the fields of combinatorial genomics, proteomics, combinatorial chemistry and cell screening.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"组合基因组学、蛋白质组学、组合化学及细胞筛选等领域的新学科。"
    },
    {
        "instruction":"已知信息：\n'II. From May 1, 2022, electronic registration certificate will be issued to special cosmetics approved of change or renewal of registration.'可被翻译为：二、自2022年5月1日起，特殊化妆品获准注册证变更、延续的，开始发放电子注册证。\n'(1) In the name of the registrants and filing persons, handling the registration and filing of cosmetics and new cosmetic ingredients;'可被翻译为：（一）以注册人、备案人的名义，办理化妆品、化妆品新原料注册、备案；\n\n根据上述已知信息，请将'I. From January 1, 2022, electronic registration certificate will be issued to special cosmetics and new cosmetic ingredients with application submitted and approved for registration according to the Provisions for the Registration and Filing of Cosmetics.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一、自2022年1月1日起，按照《化妆品注册备案管理办法》提出申请并获准注册的特殊化妆品和化妆品新原料，开始发放电子注册证。"
    },
    {
        "instruction":"已知信息：\n'(I) Before unsealing the sample, the outer package, shipping mark number or contract number, and name and quantity of the product shall be checked against the materials submitted for testing. After unsealing, the name of drug, the name of factory and the batch number of the drugs in the sub-package shall be checked, and whether the package is intact and clean without water stain, mildew or other material pollution shall be determined. If the drugs within part of the packages deteriorate, samples shall be taken for testing separately.'可被翻译为：（一）抽样启封前，应当与报验资料核对外包装，唛头号或合同编号，以及品名、数量等。启封后应当核对小包装品名、厂名和批号等，并注意检查包装的完整性和清洁程度以及有无水迹、霉烂或其它物质污染等。如有部分包件变质，应当另行抽样检验。\n'(V) The package, label and package insert of drugs shall comply with relevant provisions;'可被翻译为：（五）药品包装、标签、说明书符合有关规定；\n\n根据上述已知信息，请将'Article 78 Acceptance inspection personnel shall inspect and check the appearance, package, label, package insert and relevant supporting documents of the sampled drugs one by one; after the acceptance inspection, the intact samples taken shall be put back into the original packaging box, sealed and marked.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十八条 验收人员应当对抽样药品的外观、包装、标签、说明书以及相关的证明文件等逐一进行检查、核对；验收结束后，应当将抽取的完好样品放回原包装箱，加封并标示。"
    },
    {
        "instruction":"已知信息：\n'(13) Free treatment items and other related compensation that the subjects may obtain during the trial.'可被翻译为：（十三）受试者在试验期间可能获得的免费诊疗项目和其他相关补助。\n'3. The Ethics Committee pays close attention to whether injuries of subjects receive timely medical treatment, and monitors whether the sponsor and the investigator timely delivers the compensation to the subjects.'可被翻译为：3.伦理委员会关注受试者的损害是否得到及时的医学处理，监督申办者、研究者及时兑现给与受试者的补偿或赔偿。\n\n根据上述已知信息，请将'(11) The subjects may receive treatment and economic compensation for any trial-related injuries.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）如发生与试验相关的伤害，受试者可以获得治疗和经济补偿；"
    },
    {
        "instruction":"已知信息：\n'sampling inspector'可被翻译为：抽样检查\n'Person responsible for performing the sampling operations.'可被翻译为：负责执行抽样操作的人。\n\n根据上述已知信息，请将'Person responsible for performing the sampling operations. The sampling inspector need not be a qualified analyst. However, everyone called upon to take samples should be trained in the practical aspects of sampling and should have sufficient knowledge of pharmaceutical substances to execute the work effectively and safely. A conscientious approach, with meticulous attention to detail and cleanliness, is essential. The sampling inspector must remain alert to any signs of contamination, deterioration or tampering. Any suspicious signs should be recorded in detail in the sampling record.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"负责执行抽样操作的人员。抽样检验员不必是合格的分析员。然而，每个被要求取样的人都应该接受取样实践方面的培训，并且应该有足够的药物知识来有效和安全地执行工作。认真负责的方法，对细节和清洁的细致关注是必不可少的。抽样检查员必须对任何污染、变质或篡改的迹象保持警惕。任何可疑迹象都应详细记录在抽样记录中。"
    },
    {
        "instruction":"已知信息：\n'(1) Model or specifications;'可被翻译为：（一）型号、规格；\n'When monosaccharides form a ring structure, the original hydroxyl group is transformed into two different configurations (a or similar isomers).'可被翻译为：单糖形成环状结构时，原来的戮基转变成羟基时形成的两种不同构型（a或似的同分异构体。\n\n根据上述已知信息，请将'The original type, form, style, or structure, or the typical example, reference, or standard of a class of things.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"泛指原始类型、形式，体例或结构，或代表某类别事物的典型个例、基准物或标准物。"
    },
    {
        "instruction":"已知信息：\n'(I)  Make major mistakes, causing serious consequences;'可被翻译为：（一）发生重大差错、造成严重后果的；\n'(7) having any other dereliction of duty in vaccine administration, resulting in serious negative effects or heavy losses.'可被翻译为：（七）其他未履行疫苗监督管理职责的行为，造成严重不良影响或者重大损失。\n\n根据上述已知信息，请将'(1) performing responsibility insufficiently, resulting in serious negative effects or heavy losses;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）履行职责不力，造成严重不良影响或者重大损失；"
    },
    {
        "instruction":"已知信息：\n'Upon receipt of the Report of Testing for Import Drugs, the local drug regulatory department at ports of entry shall promptly take administrative enforcement measures to seize and detain all such drugs, and make an administrative handling decision within 7 days. In the case of applying for verification test, an administrative handling decision must be made within 15 days since the day of issuing the testing report. Relevant information shall be reported to the State Food and Drug Administration in a timely manner and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'可被翻译为：所在地口岸药品监督管理局收到《进口药品检验报告书》后，应当及时采取对全部药品予以查封、扣押的行政强制措施,并在7日内作出行政处理决定。对申请复验的，必须自检验报告书发出之日起15日内作出行政处理决定。有关情况应当及时报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。\n'If the drug meets relevant standards based on verification test, the drug regulatory department at ports of entry shall lift the administrative enforcement measures such as seizure and detention, and report the handling situation to the State Food and Drug Administration and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'可被翻译为：经复验符合标准规定的，口岸药品监督管理局应当解除查封、扣押的行政强制措施，并将处理情况报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。\n\n根据上述已知信息，请将'Article 32 Where no application for verification testis submitted within the prescribed time or the drug still fails to meet relevant standards based on the verification test, drug regulatory department at ports of entry shall make an administrative handling decision in accordance with the Drug Administration Law and relevant regulations. Relevant information shall be reported to the State Food and Drug Administration in a timely manner and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 未在规定时间内提出复验或者经复验仍不符合标准规定的，口岸药品监督管理局应当按照《药品管理法》以及有关规定作出行政处理决定。有关情况应当及时报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。"
    },
    {
        "instruction":"已知信息：\n'An investigation to determine the most probable root cause(s).'可被翻译为：进行调查，确定最可能的根本原因。\n'A method of treating a disease, such as by directly combating or removing the cause of the disease itself. Is the theory and treatment method used in Western medicine.'可被翻译为：对造成疾病本身的原因直接对抗、移除等治疗疾病的方法。是西医所使用的理论和治疗方法。\n\n根据上述已知信息，请将'A retrospective study method in which the cause is explored by the results. It is based on the present diagnosis of a particular disease'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种由结果探索病因的回顾性研究方法。其基本原理是以现在确诊的患有某特定疾病"
    },
    {
        "instruction":"已知信息：\n'1) Name of the material or product, dosage form, strength, batch number or shipping batch number, where appropriate, the name of the manufacturer and\/or supplier;'可被翻译为：1.产品或物料的名称、剂型、规格、批号或供货批号，必要时注明供应商和生产商（如不同）的名称或来源；\n'1. The designated name and the internal code reference of the material;'可被翻译为：（一）指定的物料名称和企业内部的物料代码；\n\n根据上述已知信息，请将'1. The name of the material on the delivery note and the containers;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）交货单和包装容器上所注物料的名称；"
    },
    {
        "instruction":"已知信息：\n'Drug regulatory department shall supervise and inspect the approved clinical trials.'可被翻译为：药品监督管理部门应当对批准的临床试验进行监督检查。\n'The supervision refers to the activities performed by special personnel who are selected by the sponsor of carrying out the evaluation and investigation of the clinical trial institutions and the investigators, and verifying, recording and reporting data during the clinical trial, so as to ensure that the clinical trial carried out is in conformity with the clinical trial protocol, standard operating procedures, this GCP and applicable management requirements.'可被翻译为：监查，是指申办者为保证开展的临床试验能够遵循临床试验方案、标准操作规程、本规范和有关适用的管理要求，选派专门人员对临床试验机构、研究者进行评价调查，对临床试验过程中的数据进行验证并记录和报告的活动。\n\n根据上述已知信息，请将'The inspection refers to the supervision and administration activities carried out by the regulatory department for inspecting relevant clinical trial documents, facilities, records and other aspects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"检查，是指监管部门对临床试验的有关文件、设施、记录和其他方面进行的监督管理活动。"
    },
    {
        "instruction":"已知信息：\n'(5) an applicant fails to provide supplementary data within the prescribed timeline;'可被翻译为：（五）未能在规定的时限内补充资料的；\n'Article 87 After the drug registration application is accepted, where it is necessary for the applicant to provide new technical dossier on the basis of the original submission dossier, the CDE shall, in principle, make a one-time requirement for supplementary dossier. The CDE shall list all the issues and inform the applicant in a written notice to submit supplementary dossier within 80 days. The applicant shall submit all the supplementary dossier together as required in one submission, and the time needed for the supplement of dossier will not be counted into the drug review timeline. The CDE shall restart review upon receiving all the supplementary dossier from the applicant, and the review timeline shall be extended by 1\/3 of the original review timeline; where the priority review and approval procedure is applicable, the review timeline shall be extended by 1\/4 of the original review timeline.'可被翻译为：第八十七条 药品注册申请受理后，需要申请人在原申报资料基础上补充新的技术资料的，药品审评中心原则上提出一次补充资料要求，列明全部问题后，以书面方式通知申请人在八十日内补充提交资料。申请人应当一次性按要求提交全部补充资料，补充资料时间不计入药品审评时限。药品审评中心收到申请人全部补充资料后启动审评，审评时限延长三分之一；适用优先审评审批程序的，审评时限延长四分之一。\n\n根据上述已知信息，请将'(4) The applicant fails to submit supplementary dossier within the specified timeline;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请人未能在规定时限内补充资料的；"
    },
    {
        "instruction":"已知信息：\n'I. Applicants are required to carry out the study in accordance with the ICH Guidelines as early as possible based on current technical requirements. For relevant studies that start 6 months after the issuance date of this Announcement(based on the time point of the trial record), the above ICH Guidelines shall apply.'可被翻译为：1. 申请人需在现行技术要求基础上，尽早按照ICH指导原则的要求开展研究。本公告发布之日起6个月后开始的相关研究（以试验记录时间点为准），适用上述ICH指导原则。\n'Guidelines S5 (R3) and S11 shall be applicable to the non-clinical studies starting upon issuance of this Announcement. The designation of the starting date of nonclinical study shall be in accordance with the relevant provisions specified in the Good Laboratory Practice.'可被翻译为：自本公告发布之日起开始的非临床研究适用S5（R3）和S11指导原则。非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。\n\n根据上述已知信息，请将'I. The sponsors shall conduct research in accordance with the ICH guidelines as soon as possible on the basis of the existing technical requirements. The 13 ICH safety guidelines shall be adopted for non-clinical studies starting from May 1, 2020, and the starting dates of non-clinical studies shall be determined in accordance with the relevant provisions of the Good Laboratory Practice.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一、申请人需在现行技术要求基础上尽早按照ICH指导原则开展研究；自2020年5月1日起开始的非临床研究适用13个ICH非临床指导原则，非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。"
    },
    {
        "instruction":"已知信息：\n'h2 receptor antagonist'可被翻译为：H2受体拮抗剂\n'Drugs that inhibit the secretion of gastric juices (or stomach acid). The main ones are H2 blockers such as famotidine, etc.; Proton pump inhibitors such as omeprazole, etc.; And anticholinergics, such as ranunculine and pirenzil.'可被翻译为：抑制胃液（或胃酸）分泌的药物。主要有H2阻滞剂，如法莫替丁等；质子泵抑制剂，如奥美拉唑等;抗胆碱药，如山莨若碱、哌仑西平等。\n\n根据上述已知信息，请将'Competitively binds to the h2 receptor, antagonizing histamine compounds that promote gastric acid secretion, increase heart rate, and inhibit smooth muscle contractiles.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"竞争性地与h2受体结合，拮抗组胺促进胃酸分泌，增加心率及抑制平滑肌收缩功能的化合物。"
    },
    {
        "instruction":"已知信息：\n'Article 7 People's governments at or above the county level shall incorporate the vaccine safety, immunization work into the national economic and social development plans of the corresponding level, enhance the capacity building of vaccine administration, and establish and improve the work mechanism for vaccine administration.'可被翻译为：第七条 县级以上人民政府应当将疫苗安全工作和预防接种工作纳入本级国民经济和社会发展规划，加强疫苗监督管理能力建设，建立健全疫苗监督管理工作机制。\n'\"Immunization program vaccines\" are vaccines to be inoculated in citizens as per the government provisions, including vaccines confirmed in the national immunization program, vaccines added by people's governments of provinces, autonomous regions and municipalities directly under the Central Government while implementing the national immunization program, vaccines for emergency immunization or cluster immunization organized by the people's governments or their competent health departments at or above the county level.'可被翻译为：免疫规划疫苗，是指居民应当按照政府的规定接种的疫苗，包括国家免疫规划确定的疫苗，省、自治区、直辖市人民政府在执行国家免疫规划时增加的疫苗，以及县级以上人民政府或者其卫生健康主管部门组织的应急接种或者群体性预防接种所使用的疫苗。\n\n根据上述已知信息，请将'Article 63 To ensure the implementation of national immunization program, the people's government at or above the county level shall incorporate into the budget of the people's governments at the same level the funds needed for vaccine safety, procurement of immunization program vaccines, immunization and information-based construction.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条 县级以上人民政府应当将疫苗安全工作、购买免疫规划疫苗和预防接种工作以及信息化建设等所需经费纳入本级政府预算，保证免疫规划制度的实施。"
    },
    {
        "instruction":"已知信息：\n'The diameter of a spherical particle with the same settling velocity and density as the particle being measured when determined by sedimentation method.'可被翻译为：沉降法测定时，与被测粒子沉降速度和密度相同的球形微粒的直径。\n'The diameter of a spherical particle that has the same surface area, volume, or circumscribed circle as the particle under test.'可被翻译为：与被测粒子具有相同的表面积、体积或外接圆的球形粒子的直径。\n\n根据上述已知信息，请将'The diameter of a spherical particle with the same settling velocity as the particle calculated by the settling formula.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据沉降公式计算出的与粒子具有相同沉降速度的球形粒子的直径。"
    },
    {
        "instruction":"已知信息：\n'Article 65 In case of any major safety event related to drug quality, the drug MAH shall immediately take such control actions as sealing the drug product and related active drug ingredients, excipients and primary packaging materials and container in direct contact with the drug product and relevant manufacturing line and immediately report such events to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the MAH is located and other relevant agencies. The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall report the events to the provincial people's government as well as NMPA within 24 hours.'可被翻译为：第六十五条 发生与药品质量有关的重大安全事件，药品上市许可持有人应当立即对有关药品及其原料、辅料以及直接接触药品的包装材料和容器、相关生产线等采取封存等控制措施，并立即报告所在地省、自治区、直辖市药品监督管理部门和有关部门，省、自治区、直辖市药品监督管理部门应当在二十四小时内报告省级人民政府，同时报告国家药品监督管理局。\n'Where an MAH stops manufacture of drugs in shortage, it shall report to the drug regulatory department under the State Council or the drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the Central Government.'可被翻译为：药品上市许可持有人停止生产短缺药品的，应当按照规定向国务院药品监督管理部门或者省、自治区、直辖市人民政府药品监督管理部门报告。\n\n根据上述已知信息，请将'Article 46 With respect to the drugs included in the list of drugs in shortage, the shutdown of which shall be reported to applicable authorities. If any drug MAH intends to shut down the manufacturing of such drugs, it shall report the shutdown to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the drug MAH is located 6 months ahead of the shutdown. In the event of unexpected shutdown, the drug MAH shall report it to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where it is located within 3 days. Where necessary, a report shall be made to the NMPA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十六条 列入国家实施停产报告的短缺药品清单的药品，药品上市许可持有人停止生产的，应当在计划停产实施六个月前向所在地省、自治区、直辖市药品监督管理部门报告；发生非预期停产的，在三日内报告所在地省、自治区、直辖市药品监督管理部门。必要时，向国家药品监督管理局报告。"
    },
    {
        "instruction":"已知信息：\n'A uniform semi-solid preparation for external use made by mixing a drug with an oily or water-soluble substrate.'可被翻译为：药物与油脂性或水溶性基质混合制成的均匀的半固体外用制剂。\n'A single or multilayer film-like preparation in which the drug is dissolved or dispersed or encased in a film-forming material.'可被翻译为：药物溶解或分散或包裹于成膜材料中而制成的单层或多层膜状制剂。\n\n根据上述已知信息，请将'A uniform semisolid preparation for external use in which the drug is dissolved or dispersed in a emulsion type matrix.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物溶解或分散于乳状液型基质中形成的均匀的半固体外用制剂。"
    },
    {
        "instruction":"已知信息：\n'The speed of air supplied by unidirectional airflow systems should be clearly justified in the qualification protocol including the location for air speed measurement. Air speed should be designed, measured and maintained to ensure that appropriate unidirectional air movement provides protection of the product and open\ncomponents at the working position (e.g. where high-risk operations occur and where product and\/or components are exposed). Unidirectional airflow systems should provide a homogeneous air speed in a range of 0.36 - 0.54 m\/s (guidance value) at the working position, unless otherwise scientifically justified in the CCS. Airflow\nvisualization studies should correlate with the air speed measurement.'可被翻译为：单向流系统送风速度的合理性应在确认方案中明确论证，包括风速的测定位置。风速的设计、测定和维持应确保在工作区域（例如，在进行高风险操作的区域以及产品和\/或组分暴露的区域）有合适的单向气流为产品和开放组件提供保护。除非在 CCS 中另有科学论证，否则单向流系统应在工作区域提供 0.36-0.54m\/s（指导值）的均匀风速。气流可视化研究应与风速测定相关联。\n'RABS:\nThe design of RABS should ensure grade A conditions with unidirectional airflow and first air protection in thecritical zone. A positive airflow from the critical zone to the supporting background environment should be maintained.'可被翻译为：RABS 的设计应通过具有单向流和关键区域初始气流保护确保 A 级条件。应保持从关键区到支持性背景环境的正向气流。\n\n根据上述已知信息，请将'Air velocity test (Note: For grade B, C and D the air velocity test should be performed according to a risk assessment documented as part of the CCS. However, it is required for filling zones supplied with unidirectional airflow (e.g. when filling terminally sterilised products or background to grade A and RABS). For grades with non-unidirectional airflow, a measurement of recovery testing should replace velocity testing).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"风速测试（注：对于 B 级、C 级和 D 级，风速测试应按照风险评估的结果进行，并将该风险评估包含到CCS 中。但是，使用单向流的灌装区（例如，灌装最终灭菌产品时或 A 级和 RABS 的背景区）需要进行测试。对于非单向流的级别，应以自净测试代替风速测试）。"
    },
    {
        "instruction":"已知信息：\n'The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.'可被翻译为：以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。\n'Also known as relativemolecularmass (relativemolecularmass). The ratio of the average mass of a molecule or specific unit of a substance to 1\/12 of the mass of a 12C atom. Equal to the sum of the atomic weights of all the atoms in the molecule.'可被翻译为：又称\"相对分子质量（relativemolecularmass）\"。物质分子或特定单元的平均质量与12C原子质量的1\/12之比。等于分子中全部原子的原子量之和。\n\n根据上述已知信息，请将'An isotopic peak consisting of the most abundant nuclides in mass spectrometry. For example, the average atomic weight of the hydrogen atom is 1.00794, and the mass of the most abundant isotope,H, is 1.00783.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"质谱分析中由丰度最高的核素组成的同位素峰。如氢原子的平均原子量为1.00794,丰度最高的同位素,H的质量为1.00783。"
    },
    {
        "instruction":"已知信息：\n'A class of biomacromolecules that bind to hormones, neurotransmitters, drugs, or intracellular signaling molecules and can cause changes in cell function.'可被翻译为：药物靶标中一类能够同激素、神经递质、药物或细胞内的信号分子结合并能引起细胞功能变化的生物大分子。\n'In the recording devices of modern analytical instruments, there are signal attenuators, which are used to weaken the detector signal.'可被翻译为：在近代分析仪器的记录装置中都有信号衰减器，用此将检测器信号减弱的过程。\n\n根据上述已知信息，请将'Usually peptides, which can enhance or weaken the response of neurons to neurotransmitters and play a regulatory role.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一般为肽类，能增强或减弱神经元对神经递质反应，起调节作用。"
    },
    {
        "instruction":"已知信息：\n'Article 71 In any of the following circumstances for medical device distributing enterprises and user facility, in accordance with Article 68 of the Regulations for the Supervision and Administration of Medical Devices, the drug regulatory departments and the health administrative departments above the county level according to their respective responsibilities should order to make correction and give warning, and a  fine between 5,000 RMB and  20,000 RMB should be imposed if MAHs refused to make correction; in serious circumstances, the production shall be ordered to stop until the relevant certificates are revoked by the original issuing authority:'可被翻译为：第七十一条  医疗器械经营企业、使用单位有下列情形之一的，依照《医疗器械监督管理条例》第六十八条的规定，由县级以上药品监督管理部门和卫生行政部门依据各自职责责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款；情节严重的，责令停产停业，直至由发证部门吊销相关证明文件：\n'Article 73 In any of the following circumstances for MAHs, the drug regulatory departments above county level should order to make correction and give warning, and a fine between 5,000 RMB and 20,000 RMB should be imposed if MAHs refused to make correction:'可被翻译为：第七十三条  持有人有下列情形之一的，由县级以上药品监督管理部门责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款：\n\n根据上述已知信息，请将'Article 70 In any of the following circumstances for MAHs, in accordance with Article 68 of the Regulations for the Supervision and Administration of Medical Devices, the drug regulatory departments above the county level should order to make correction and give warning, and a fine between 5,000 RMB and  20,000 RMB should be imposed if MAHs refused to make correction; in serious circumstances, the production should be instructed to stop until the relevant certificates are revoked by the original issuing authority:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条  持有人有下列情形之一的，依照《医疗器械监督管理条例》第六十八条的规定，由县级以上药品监督管理部门责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款；情节严重的，责令停产停业，直至由发证部门吊销相关证明文件："
    },
    {
        "instruction":"已知信息：\n'Drugs that can selectively act on the cerebral cortex and have the effect of activating, protecting and restoring the function of nerve cells. Such as piracetam and vincristine.'可被翻译为：能选择性地作用于大脑皮质，对神经细胞具有激活、保护和恢复功能效应的药物。如吡拉西坦和长春胺等。\n'Drugs that inhibit recurrent episodes of brain dysfunction caused by abnormal firing of brain cells. According to its mechanism of action can be divided into: ① sodium channel regulator; ② gamma-aminobutyric acid regulator; ③ excitatory amino acid receptor antagonists and excitatory amino acid release regulators; ④ anti-absence seizure agents related to ethansuxamine (selective calcium channel blockers); ⑤ other drugs whose mechanisms are not well defined.'可被翻译为：抑制由脑细胞异常放电引起的脑功能障碍反复发作的药物。按其作用机制可分为：①钠通道调节剂；②γ-氨基丁酸调节剂；③兴奋性氨基酸受体拮抗剂和兴奋性氨基酸释放调节剂；④与乙琥胺有关的抗失神发作药（选择性钙通道阻滞剂）；⑤其他机制尚不明确的药物。\n\n根据上述已知信息，请将'A drug that excites the central nervous system function and improves brain activity function. According to the site of action can be divided into excitatory cerebral cortex drugs, such as xanthine derivatives, such as caffeine, theophylline; Excitatory medullary respiratory center drugs, such as nicoxal rice; Drugs that excite the spinal cord, such as strychnine; And intelligence-boosting drugs that promote brain cell metabolism and improve brain function, such as piracetam.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有兴奋中枢神经系统功能，提高脑活动功能的药物。按照作用部位可分为兴奋大脑皮质的药物，如黄嘌吟衍生物，如咖啡因、茶碱等；兴奋延髓呼吸中枢的药物，如尼可刹米等；兴奋脊髓的药物，如士的宁；促进脑细胞代谢、改善脑功能的智能促进药物如吡拉西坦等。"
    },
    {
        "instruction":"已知信息：\n'Antimicrobial drugs used to treat infections caused by pathogenic microorganisms such as bacteria, rickettsia, chlamydia, mycoplasma, spirochetes, fungi, etc. Excluded are drugs for treating tuberculosis, parasitic diseases, and various viral infections, as well as traditional Chinese medicine formulations with antibacterial properties.'可被翻译为：治疗细菌、支原体、衣原体、立克次体、螺旋体、真菌等病原微生物所致感染性疾病病原的药物，\n不包括治疗结核病、寄生虫病和各种病毒所致感染性疾病的药物以及具有抗菌作用的中药制剂。\n'A drug used to treat or prevent infections caused by various pathogens, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, worms, etc. They may be further classified according to their source and properties.'可被翻译为：治疗或预防各种病原体，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫、蠕虫等所致感染用的药物。根据来源和性质的不同可进一步分类。\n\n根据上述已知信息，请将'Drugs used to treat or prevent infections caused by pathogenic microorganisms, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, etc. Unlike anti-infective drugs, these drugs do not target worms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防致病微生物，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫等所致感染用的药物。与抗感染药的区别是本类药物的作用对象不包括蠕虫类。"
    },
    {
        "instruction":"已知信息：\n'An IVPT study can be sensitive and discriminating to differences in the rate and extent to which compounds applied on the skin from different formulations become available in and through it. Notably, unlike an IVRT study, differences in permeation that are observed in an IVPT study comparing a test versus reference product, if any, may correlate with and\/or be predictive of differences in bioavailability in vivo. The IVPT is routinely carried out to guide semi-solid topical formulation development.'可被翻译为：IVPT研究可以对不同配方的涂抹在皮肤上的化合物在皮肤内和通过皮肤获得的速率和程度的差异进行敏感和区分。值得注意的是，与IVRT研究不同的是，在IVPT研究中观察到的比较测试品与参考产品的渗透差异(如果有的话)可能与体内生物利用度差异相关和\/或预测了差异。IVPT通常用于指导半固体外用制剂的开发。\n'Appropriate alert levels and action limits should be set for the results of viable and total particle monitoring. The maximum total particle action limits are described in Table 5 and the maximum viable particle action limits are described in Table 6. However, more stringent action limits may be applied based on data trending, the nature of the process or as determined within the CCS. Both viable and total particle alert levels should be established based on results of cleanroom qualification tests and periodically reviewed based on ongoing trend data.'可被翻译为：对活性粒子和总微粒监测的结果应设置适当的警戒限和行动限。最大粒子总数行动限见表 5 ，最大活性粒 子行动限见表 6。然而，基于数据趋势分析、工艺性质或按照 CCS 中的规定，可以应用更严格的行动限。应根据洁净室确认测试的结果确定活性粒子和总微粒警戒限，并根据持续趋势数据定期回顾。\n\n根据上述已知信息，请将'The selection between IVRT or IVPT should be based on the intended objective(s) of the formulation assessment, as described in Table 2. Intrinsic experimental differences between the two methodologies are further described in Table 3.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IVRT或IVPT之间的选择应基于制剂评估的预期目标，如表2所示。表3进一步描述了两种方法内在的实验差异。"
    },
    {
        "instruction":"已知信息：\n'A description of the identified and unidentified impurities present in a new drug substance.'可被翻译为：对存在于某一新原料药中的已鉴定或未鉴定杂质的数量及含量。\n'Intermediates produced during the manufacture of a drug substance that can be used by downstream manufacturers for further processing into a drug substance.'可被翻译为：生产原料药过程中产生的可以被下游厂家用于进一步加工为原料药的中间产品。\n\n根据上述已知信息，请将'An impurity that theoretically can arise during manufacture or storage. It may or may not actually appear in the new drug substance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"按照理论推测在生产或储存过程中可能产生的杂质。其在新原料药中可能存在，也可能不存在。"
    },
    {
        "instruction":"已知信息：\n'The China Food and Drug Administration shall supervise the management of medical device recall nationwide.'可被翻译为：国家食品药品监督管理总局监督全国医疗器械召回的管理工作。\n'Overseas manufacturers of imported drugs who recall drugs abroad shall report the case to the State Food and Drug Administration promptly. In the case of recall inside China, the importer shall be responsible for implementing the recall according to these Provisions.'可被翻译为：进口药品的境外制药厂商在境外实施药品召回的，应当及时报告国家食品药品监督管理局；在境内进行召回的，由进口单位按照本办法的规定负责具体实施。\n\n根据上述已知信息，请将'The State Food and Drug Administration shall supervise the management of recall of drugs across the country.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家食品药品监督管理局监督全国药品召回的管理工作。"
    },
    {
        "instruction":"已知信息：\n'The minimum amount of energy required in a chemical reaction to travel from the ground state molecules of the reactants to the activated molecules. The difference between the average energy of the activated molecules and the average energy of all the reactant molecules.'可被翻译为：化学反应中由反应物基态分子到达活化分子所需的最小能量。即活化分子的平均能量与全部反应物分子平均能量之差。\n'Non-fat soluble or very little fat soluble substances, with the help of carrier proteins or channel proteins on the cell membrane, along the concentration gradient and\/or along the potential gradient (potential difference) of the transport process through the cell membrane.'可被翻译为：非脂溶性或脂溶性很小的物质，借助于细胞膜上的运载蛋白或通道蛋白的帮助，顺浓度梯度和（或）顺电位梯度（电位差）通过细胞膜的转运过程。\n\n根据上述已知信息，请将'An intermediate state occurring along a given reaction path. It is characterized by a higher potential energy than other states adjacent to it along that pathway.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"沿着一定反应途径所出现的一种中间状态。其特征是比该途径上与之相邻的其他状态有较高的势能。"
    },
    {
        "instruction":"已知信息：\n'The food and drug regulatory department shall issue a dated acceptance or rejection notice affixed with its special seal to indicate its acceptance or rejection of the in-vitro diagnostic reagent registration application.'可被翻译为：食品药品监督管理部门受理或者不予受理体外诊断试剂注册申请，应当出具加盖本部门专用印章并注明日期的受理或者不予受理的通知书。\n'If the provincial drug regulatory department accepts or rejects the application for first importation of crude drugs, it shall issue a Notice of Acceptance or Rejection; if the application is rejected, it shall state the reasons in written form.'可被翻译为：省级药品监督管理部门受理或者不予受理首次进口药材申请，应当出具受理或者不予受理通知书；不予受理的，应当书面说明理由。\n\n根据上述已知信息，请将'The food and drug regulatory department shall grant a dated acceptance or rejection notice affixed with its special seal to indicate its acceptance or rejection of the medical device registration application.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"食品药品监督管理部门受理或者不予受理医疗器械注册申请，应当出具加盖本部门专用印章并注明日期的受理或者不予受理的通知书。"
    },
    {
        "instruction":"已知信息：\n'In the process of the lot release of a specific product, the lot release institution may make a comprehensive evaluation according to the process and quality control maturity of the product variety and previous lot release and dynamically adjust the testing items and testing frequency in the registration specification of the product variety. Where there is any nonconforming item of the products subject to lot release, the lot release institution shall add the testing frequency on the corresponding item of the products of subsequent batches.'可被翻译为：批签发机构在对具体品种的批签发过程中，可以根据该品种的工艺及质量控制成熟度和既往批签发等情况进行综合评估，动态调整该品种注册标准中的检验项目和检验频次。批签发产品出现不合格项目的，批签发机构应当对后续批次产品的相应项目增加检验频次。\n'Article 29 For lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. The testing items and testing frequency for lot release of vaccines shall be dynamically adjusted according to the vaccine quality risk evaluation.'可被翻译为：第二十九条 疫苗批签发应当逐批进行资料审核和抽样检验。疫苗批签发检验项目和检验频次应当根据疫苗质量风险评估情况进行动态调整。\n\n根据上述已知信息，请将'In the process of the lot release of specific variety, the lot release institution may make a comprehensive evaluation according to the process and quality control maturity of the variety and previous lot release and dynamically adjust the testing items and testing frequency of the variety. Where there is any nonconforming item of the products subject to lot release, the lot release institution shall increase the testing frequency on the corresponding item of the products in subsequent batches.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发机构在对具体品种的批签发过程中，可以根据该品种的工艺及质量控制成熟度和既往批签发等情况进行综合评估，动态调整该品种的检验项目和检验频次。批签发产品出现不合格项目的，批签发机构应当对后续批次产品的相应项目增加检验频次。"
    },
    {
        "instruction":"已知信息：\n'Where an application for withdrawal of the lot release is required for such situations as that the test results fail to meet the provisions during the simultaneous lot release process, reasons shall be explained and the application may be withdrawn upon the approval of the lot release institution.'可被翻译为：同步批签发过程中出现检验结果不符合规定情况等需要申请撤回批签发的，应当说明理由，经批签发机构同意后方可撤回。\n'Article 28 If the lot release applicant applies for withdrawal of its lot release application, it shall provide the explanation, and may withdraw the application only upon approval by the lot release institution; the lot release applicant shall report such withdrawal to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government. If the lot release institution has confirmed through review that the dossiers show defects or the testing results do not comply with the requirements, the application shall not be withdrawn by the lot release applicant.'可被翻译为：第二十八条    批签发申请人申请撤回批签发的，应当说明理由，经批签发机构同意后方可撤回；批签发申请人应当向所在地省、自治区、直辖市药品监督管理部门报告批签发申请撤回情况。批签发机构已经确认资料审核提示缺陷、检验结果不符合规定的，批签发申请人不得撤回。\n\n根据上述已知信息，请将'If the lot release institution has confirmed through review that the dossier has defects or the testing results do not comply with the requirements, the application shall not be withdrawn by the lot release applicant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发机构已经确认资料审核提示缺陷、检验结果不符合规定的，批签发申请人不得撤回。"
    },
    {
        "instruction":"已知信息：\n'An instrument in chromatographic analysis that accumulates the electrical signals generated by the system over time.'可被翻译为：色谱分析仪器中按时间累积检测系统所产生电信号的仪器。\n'After the test is separated by the chromatographic column, the derivative reagent and auxiliary reaction liquid are added to the chromatographic system, and the chromatographic effluents are directly reacted in the system, and then the operation of the derivative reaction products is determined.'可被翻译为：待测物经色谱柱分离后，在色谱系统中加入衍生试剂及辅助反应液，与色谱流出组分直接在系统中进行反应，然后测定衍生反应产物的操作。\n\n根据上述已知信息，请将'In the chromatographic instrument, after the completion of the separation of the components, according to the qualitative and quantitative requirements of the chromatography, the original chromatographic signals and data are collected and processed, and the computer system is used to control the operation of the chromatographic instrument.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在色谱仪器中，完成了组分的色谱分离后，按照色谱定性、定量要求，对原始色谱信号和数据进行采集、处理，并控制色谱仪器的操作的计算机系统。"
    },
    {
        "instruction":"已知信息：\n'(9) there are other circumstances not in conformity with relevant regulations.'可被翻译为：（九）其他不符合有关规定的情形。\n'(5) Other circumstances where the cosmetics manufacturing license shall be cancelled as prescribed by laws and regulations.'可被翻译为：（五）法律法规规定应当注销化妆品生产许可的其他情形。\n\n根据上述已知信息，请将'9. Other circumstances that should not be passed as prescribed by laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9.法律法规规定的其他不应当通过的情形。"
    },
    {
        "instruction":"已知信息：\n'thin-layer chromatography'可被翻译为：薄层色谱法\n'preparative thin layer chromatography'可被翻译为：制备薄层色谱法\n\n根据上述已知信息，请将'A tool used in thin layer chromatography to analyze point samples. Micropipette (total capacity 10μl) or microsyringe is generally used to point samples.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"薄层色谱分析中点样用的工具。一般采用微量吸管（总容量10μl）或微量注射器来点样。"
    },
    {
        "instruction":"已知信息：\n'deflection point'可被翻译为：拐点\n'1.The storing of pharmaceutical products and materials up to their point of use.\n2.The storing of pharmaceutical products up to the point of use.\n3.The storing of medical products up to the point of use.'可被翻译为：1.储存:将药品和原料储存到其使用点\n2.将药品储存到使用点。\n3.将医疗产品储存至使用点。\n\n根据上述已知信息，请将'The concave point on the curve changes, that is, the point from concave up (down) to concave down (up). If the function representing the curve has a second continuous derivative, the point at which the second derivative changes sign is the inflection point.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"曲线上凹向改变的点，即由凹向上（下）变为凹向下（上）的点。若表示曲线的函数有二阶连续导数，则使二阶导数改变符号的点，就是拐点。"
    },
    {
        "instruction":"已知信息：\n'Usually refers to solid dosage forms of medicinal products such as tablets, capsules and powders to be taken orally.'可被翻译为：通常是指口服的片剂、胶囊、粉剂等药品的固体剂型。\n'oral solid dosage form'可被翻译为：口服固体剂型\n\n根据上述已知信息，请将'A solid dosage form that can be administered to patients in more than one manner, e.g. may be dispersed or taken orally as a whole.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可以一种以上方式给药给病人的固体剂型，例如，可分散或整体口服。"
    },
    {
        "instruction":"已知信息：\n'The hydroxide ion can be ionized in an aqueous solution, which can make the pH value of the solution greater than 7.'可被翻译为：在水溶液中能电离出氢氧根离子，可使溶液的pH值大于7的化合物。\n'The process by which an electrolyte forms freely moving cationic ions in an aqueous solution or molten state.'可被翻译为：电解质在水溶液或熔融状态下生成自由移动阴阳离子的过程。\n\n根据上述已知信息，请将'In an aqueous solution, hydrogen ions can be ionized, which can make the pH value of the solution less than 7 compounds.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在水溶液中能电离出氢离子，可使溶液的pH值小于7的化合物。"
    },
    {
        "instruction":"已知信息：\n'The operators of cosmetic e-commerce platform shall assume the responsibility for managing cosmetic marketers within the platform according to law, make daily inspection of the marketing behavior of the cosmetic marketers within the platform, urge the cosmetic marketers within the platform to perform obligations specified in the Regulations on Supervision and Administration of Cosmetics and these Provisions according to law. In case of discovering illegal marketing of cosmetics, the inspectors shall stop timely by necessary means of deleting, shielding and unlinking, etc. in accordance with the laws or with service agreement and trading provisions of the platform, and report to the drug regulatory department of the province, autonomous region or municipality directly under the central government of the place where it is located.'可被翻译为：化妆品电子商务平台经营者应当依法承担平台内化妆品经营者管理责任，对平台内化妆品经营者的经营行为进行日常检查，督促平台内化妆品经营者依法履行化妆品监督管理条例以及本办法规定的义务。发现违法经营化妆品行为的，应当依法或者依据平台服务协议和交易规则采取删除、屏蔽、断开链接等必要措施及时制止，并报告所在地省、自治区、直辖市药品监督管理部门。\n'If the operators of cosmetic e-commerce platform know or shall know that the cosmetic marketers in the platform are prohibited from engaging in manufacturing and marketing of cosmetics according to law, they shall not provide e-commerce platform services to such marketers.'可被翻译为：化妆品电子商务平台经营者知道或者应当知道平台内化妆品经营者被依法禁止从事化妆品生产经营活动的，不得向其提供电子商务平台服务。\n\n根据上述已知信息，请将'If the department in charge of drug supervision and administration requires the operators of cosmetic e-commerce platform to provide relevant information according to law due to the needs for supervision and inspection and case investigation, etc., the operator of cosmetics e-commerce platform shall provide assistance and cooperation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"负责药品监督管理的部门因监督检查、案件调查等工作需要，要求化妆品电子商务平台经营者依法提供相关信息的，化妆品电子商务平台经营者应当予以协助、配合。"
    },
    {
        "instruction":"已知信息：\n'(10) A medical device with measuring function, its class shall not be lower than class II.'可被翻译为：（十）具有计量测试功能的医疗器械，其分类应不低于第二类。\n'(8) A medical device supplied in sterile state, its class shall not be lower than class II.'可被翻译为：（八）以无菌形式提供的医疗器械，其分类应不低于第二类。\n\n根据上述已知信息，请将'(11) A medical device intended for the treatment of a certain disease, its class shall not be lower than class II.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）如果医疗器械的预期目的是明确用于某种疾病的治疗，其分类应不低于第二类。"
    },
    {
        "instruction":"已知信息：\n'Article 26 Undertaking of drug manufacturing shall comply with the GMP. A quality management system shall be established and improved for drug manufacturing, which gives into consideration all factors influencing drug quality, to ensure that the whole process of drug manufacturing continuously complies with statutory requirements.'可被翻译为：第二十六条 从事药品生产活动，应当遵守药品生产质量管理规范，建立健全药品生产质量管理体系，涵盖影响药品质量的所有因素，保证药品生产全过程持续符合法定要求。\n'Article 43 The undertaking of drug manufacturing shall comply with the GMP.A quality management system shall be established and improved for drug manufacturing, to ensure that the whole chain of drug manufacturing continuously complies with statutory requirements.'可被翻译为：第四十三条 从事药品生产活动，应当遵守药品生产质量管理规范，建立健全药品生产质量管理体系，保证药品生产全过程持续符合法定要求。\n\n根据上述已知信息，请将'Article 24 Engaging in drug manufacture activities shall comply with the GMP and the manufacturing process shall be in accordance with the national drug standards, drug registration specifications and the manufacturing process approved by drug regulatory departments. The site management file shall be submitted and continuously updated, the risk assessments and continuous improvements of the quality system operation shall be made to ensure a continuous compliance with statutory requirements throughout the whole process. Manufacturing and test records shall be complete and accurate. No fabrication or falsification is allowed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十四条 从事药品生产活动，应当遵守药品生产质量管理规范，按照国家药品标准、经药品监督管理部门核准的药品注册标准和生产工艺进行生产，按照规定提交并持续更新场地管理文件，对质量体系运行过程进行风险评估和持续改进，保证药品生产全过程持续符合法定要求。生产、检验等记录应当完整准确，不得编造和篡改。"
    },
    {
        "instruction":"已知信息：\n'(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;'可被翻译为：（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；\n'Article 92 Enterprises shall take records of drug sales. Sales records shall include the adopted name, strength, dosage form, lot number, expiry date, manufacturer, purchaser, sales quantity, unit price, amount and sales date of the drug. Special sales records shall be established for the direct transfer of drugs in accordance with Article 69 herein.'可被翻译为：第九十二条 企业应当做好药品销售记录。销售记录应当包括药品的通用名称、规格、剂型、批号、有效期、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。按照本规范第六十九条规定进行药品直调的，应当建立专门的销售记录。\n\n根据上述已知信息，请将'(IV) For dismantling sales, clean and sanitary package shall be used, on which the name, strength, quantity, usage, dosage, lot number, and expiry date of the drug, and name of the drug store shall be indicated;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）拆零销售应当使用洁净、卫生的包装，包装上注明药品名称、规格、数量、用法、用量、批号、有效期以及药店名称等内容；"
    },
    {
        "instruction":"已知信息：\n'Article 40 Any food and drug regulatory department, or lot release institution or its staff members that constitutes any of the following circumstances in the lot release work shall be ordered by its superior administrative authority or supervisory authority to make rectification, and administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第四十条 食品药品监督管理部门、批签发机构及其工作人员在批签发工作中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任：\n'Article 160 Any drug regulatory department or its staff members that violate the provisions of this Provisions and constitute any of the circumstances below shall be instructed by its superior administrative department or supervisory departments to make rectification. If the circumstances are serious, administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible in accordance with law:'可被翻译为：第一百六十条 药品监督管理部门及其工作人员违反本法的规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n\n根据上述已知信息，请将'Article 39 Any food and drug regulatory department, or lot release institution or its staff members that violate the provisions herein and in case of any of the circumstances below shall be ordered by its superior administrative authority or supervisory authority to make rectification. If the circumstances are serious, administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十九条 食品药品监督管理部门、批签发机构及其工作人员违反本办法规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分："
    },
    {
        "instruction":"已知信息：\n'Article 91 The clinical trial institution shall keep clinical trial documents for 10 years after the completion of the clinical trial, and the sponsor shall keep the clinical trial data until the medical device is out of use.'可被翻译为：第九十一条 临床试验机构应当保存临床试验资料至临床试验结束后10年。申办者应当保存临床试验资料至无该医疗器械使用时。\n'Article 90 The clinical trial institution, the investigator and the sponsor shall establish a basic document keeping system. The basic documents of the clinical trial are divided into three parts according to the clinical trial phases: documents in the preparation phase, documents in the implementation phase and documents after the termination or completion.'可被翻译为：第九十条 临床试验机构、研究者、申办者应当建立基本文件保存制度。临床试验基本文件按临床试验阶段分为三部分：准备阶段文件、进行阶段文件和终止或者完成后文件。\n\n根据上述已知信息，请将'Article 60 The clinical trial institutions shall properly keep the clinical trial records and basic documents as per the agreement with the sponsor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十条 临床试验机构应当按照与申办者的约定妥善保存临床试验记录和基本文件。"
    },
    {
        "instruction":"已知信息：\n'Article 8 Where any of the following circumstances exists, the food and drug regulatory departments can conduct an unannounced inspection for drugs and medical devices:'可被翻译为：第八条 有下列情形之一的，食品药品监督管理部门可以开展药品医疗器械飞行检查：\n'Article 3 China Food and Drug Administration shall be responsible for organizing and conducting the unannounced inspection of drugs and medical devices nationwide. Local food and drug regulatory departments at all levels shall be responsible for organizing and conducting the unannounced inspection of drugs and medical devices within their respective administrative areas.'可被翻译为：第三条 国家食品药品监督管理总局负责组织实施全国范围内的药品医疗器械飞行检查。地方各级食品药品监督管理部门负责组织实施本行政区域的药品医疗器械飞行检查。\n\n根据上述已知信息，请将'Article 34 The food and drug regulatory departments at all levels shall incorporate the costs for unannounced inspection of drugs and medical devices and related sampling and testing fees into annual budget, and shall provide sufficient guarantee as needed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 各级食品药品监督管理部门应当将药品医疗器械飞行检查所需费用及相关抽检费用纳入年度经费预算，并根据工作需要予以足额保障。"
    },
    {
        "instruction":"已知信息：\n'The limits for environmental monitoring of airborne particle concentration for each graded area are given in Table 5.'可被翻译为：各级别空气悬浮颗粒浓度环境监测限度见表 5。\n'Table 1: Maximum permitted total particle concentration for classification'可被翻译为：表 1：各级别允许的最大总微粒浓度\n\n根据上述已知信息，请将'Table 5: Maximum permitted total particle concentration for monitoring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"表 5：监测最大允许的总粒子浓度。"
    },
    {
        "instruction":"已知信息：\n'An ingested liquid preparation containing one or more pharmaceutical ingredients in water as a solvent.'可被翻译为：以水为溶剂含有一种或-种以上的药物成分的内服液体制剂。\n'Also known as \"liquid agent\". A liquid dispersion system in which the drug is dispersed in a certain form in a liquid medium for internal and external use.'可被翻译为：又称“液体药剂”。药物以一定的形式分散于液体介质中所制成的供内服和外用的液体分散体系。\n\n根据上述已知信息，请将'Also known as \"ingestion of liquid medicine\". A liquid preparation, such as a mixture, syrupy agent, or emulsion, for oral use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"内服液体药剂”。合剂、糖浆剂、乳剂等供口服的液体制剂。"
    },
    {
        "instruction":"已知信息：\n'A solution that allows the function and structure of red blood cells to remain normal when in contact with them.'可被翻译为：与红细胞接触时，可使红细胞功能和结构保持正常的溶液。\n'2. Electronic data collection system passes the system verification, and retains verification record. Set user management, role management and permission management for the computerized system, different personnel or roles have the unique logon rights. With audit track function, it can display the records of modification data and modification reason.'可被翻译为：2.电子数据采集系统经过系统验证， 并保存验证记录。计算机化系统设置用户管理、角色管理和权限管理， 不同人员或角色具有唯一登录权限。具有稽查轨迹功能，能够显示修改数据与修改原因的记录。\n\n根据上述已知信息，请将'After proper surface modification, the liposomes can avoid phagocytosis of reticuloendothelial system and prolong the time of circulating system in the body.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"表面经适当修饰后，可避免网状内皮系统吞噬，延长在体内循环系统时间的脂质体。"
    },
    {
        "instruction":"已知信息：\n'Article 129 Enterprises shall provide conditions for the personnel selling drugs under special management, drugs with special management requirements by the State, or refrigerated drugs to receive corresponding training, so that they can master relevant laws, regulations and professional knowledge.'可被翻译为：第一百二十九条 企业应当为销售特殊管理的药品、国家有专门管理要求的药品、冷藏药品的人员接受相应培训提供条件，使其掌握相关法律法规和专业知识。\n'Article 127 Personnel at all posts of enterprises shall have received pre-post training and on-the-job training on relevant laws and regulations as well as professional knowledge and skills of drugs to meet the requirements of the GSP.'可被翻译为：第一百二十七条 企业各岗位人员应当接受相关法律法规及药品专业知识与技能的岗前培训和继续培训，以符合本规范要求。\n\n根据上述已知信息，请将'Article 28 Personnel engaged in the storage and transportation of drugs under special management and refrigerated and frozen drugs shall have received the training on relevant laws and regulations and professional knowledge, and shall not take up their posts until passing the assessment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十八条 从事特殊管理的药品和冷藏冷冻药品的储存、运输等工作的人员，应当接受相关法律法规和专业知识培训并经考核合格后方可上岗。"
    },
    {
        "instruction":"已知信息：\n'A tablet coated with enteric-soluble coating material.'可被翻译为：用肠溶性包衣材料进行包衣的片剂。\n'The operation of coating the surface of the tablet with a suitable material.'可被翻译为：在片剂表面包裹上适宜材料的衣层的操作。\n\n根据上述已知信息，请将'The process of coating the surface of the tablet (core, plain) with a layer of enteric-soluble material.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在片剂（片芯、素片）表面包裹肠溶性材料层的过程。"
    },
    {
        "instruction":"已知信息：\n'The ratio of absorbance of the sample solution under different wavelength conditions. Generally used for differential or derivative spectrometry for content determination.'可被翻译为：样品溶液在不同波长条件下的吸光度的比值。一般用于鉴别或导数光谱法进行含量测定。\n'The use of tetrazonium salivary salt in a strong alkaline solution, can be reduced by reducing substances quantitative reduction to the principle of colored substances, through the determination of the absorbance of tetrazonium salivary reducing substance solution, the method of calculating the content of reduced substances.'可被翻译为：利用四氮唾盐在强碱性溶液中，可被还原性物质定量还原为有色物质的原理，通过测定四氮唾还原物溶液的吸光度，计算还原物质含量的方法。\n\n根据上述已知信息，请将'The absorbance of test solution and control solution is measured at two different wavelengths, and the difference of absorbance at two wavelengths (A4) is used as a quantitative basis to determine the content of the method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在两个不同的波长处测定供试品溶液和对照品溶液的吸光度，以两波长处吸光度的差值（A4）作为定量的依据来测定含量的方法。"
    },
    {
        "instruction":"已知信息：\n'(V) Carrying out acceptance inspection of drugs, and guiding and supervising the quality management in drug purchase, storage, maintenance, sales, return and transportation;'可被翻译为：（五）负责药品的验收，指导并监督药品采购、储存、养护、销售、退货、运输等环节的质量管理工作；\n'(XI) Being responsible for the audit of operation permission of computer system, and the establishment and update of basic data of quality management;'可被翻译为：（十一）负责计算机系统操作权限的审核和质量管理基础数据的建立及更新；\n\n根据上述已知信息，请将'1) To participate in quality management activities such as establishment of the quality system, self-inspection, external quality audit, validation, adverse drug reaction reporting and product recalls;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.参与企业质量体系建立、内部自检、外部质量审计、验证以及药品不良反应报告、产品召回等质量管理活动；"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory department under the State Council and lot release institutions shall promptly publish the results of the lot release of marketed vaccines for public reference.'可被翻译为：国务院药品监督管理部门、批签发机构应当及时公布上市疫苗批签发结果，供公众查询。\n'Article 21 The drug regulatory department under the State Council shall examine and approve the production process, quality control standards, package inserts and labels of vaccines during the approval process of the vaccine registration application.'可被翻译为：第二十一条 国务院药品监督管理部门在批准疫苗注册申请时，对疫苗的生产工艺、质量控制标准和说明书、标签予以核准。\n\n根据上述已知信息，请将'The drug regulatory department under the State Council shall publish the content of vaccine package inserts and labels on its websites in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国务院药品监督管理部门应当在其网站上及时公布疫苗说明书、标签内容。"
    },
    {
        "instruction":"已知信息：\n'Article 30 Cosmetic registrants and filing persons shall select ingredients that meet the requirements of laws, administrative regulations, mandatory national standards and technical specifications for cosmetic production, and shall be responsible for the safety of cosmetic ingredients they use. When applying for registration and filing for filing, the cosmetic registrant and filing person shall clarify the source of ingredients and relevant information on ingredient safety through the information service platform.'可被翻译为：第三十条 化妆品注册人、备案人应当选择符合法律、行政法规、强制性国家标准和技术规范要求的原料用于化妆品生产，对其使用的化妆品原料安全性负责。化妆品注册人、备案人申请注册、进行备案时，应当通过信息服务平台明确原料来源和原料安全相关信息。\n'Article 31 If cosmetic registrants and filing persons entrust cosmetic manufacturing, for domestic cosmetics, the entrustment shall be associated and confirmed by the cosmetic manufacturers through the information service platform when applying for registration or filing; for imported cosmetics, relevant documents demonstrating the entrustment shall be submitted by the cosmetic registrants or filing persons.'可被翻译为：第三十一条 化妆品注册人、备案人委托生产化妆品的，国产化妆品应当在申请注册或者进行备案时，经化妆品生产企业通过信息服务平台关联确认委托生产关系；进口化妆品由化妆品注册人、备案人提交存在委托关系的相关材料。\n\n根据上述已知信息，请将'Article 32 Cosmetic registrants and filing persons shall clarify the product standards that are implemented, and submit it to the drug regulatory department when applying for registration or filing for filing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 化妆品注册人、备案人应当明确产品执行的标准，并在申请注册或者进行备案时提交药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'Article 40    Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.'可被翻译为：第四十条 药品生产、经营企业违反本办法第二十条规定的，限期改正，给予警告；逾期不改正或者情节严重的，处以赠送药品货值金额二倍以下的罚款，但是最高不超过三万元。\n'Article 30    In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:'可被翻译为：第三十条 有下列情形之一的，责令限期改正，给予警告；逾期不改正的，处以五千元以上二万元以下的罚款：\n\n根据上述已知信息，请将'Article 35    Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十五条 违反本办法第十三条规定，药品生产、经营企业知道或者应当知道他人从事无证生产、经营药品行为而为其提供药品的，给予警告，责令改正，并处一万元以下的罚款，情节严重的，处一万元以上三万元以下的罚款。"
    },
    {
        "instruction":"已知信息：\n'With respect to vaccines that have serious adverse reactions or jeopardize human health due to other reasons, the drug regulatory department under the State Council shall revoke the drug registration certificates of such vaccines.'可被翻译为：对预防接种异常反应严重或者其他原因危害人体健康的疫苗，国务院药品监督管理部门应当注销该疫苗的药品注册证书。\n'(4) Where, according to provisions in Article 83 of the Drug Administration Law, drugs have uncertain efficacy and serious adverse reactions or are otherwise harmful to human health;'可被翻译为：（四）按照《药品管理法》第八十三条的规定，疗效不确切、不良反应大或者因其他原因危害人体健康的；\n\n根据上述已知信息，请将'(5) Where, according to the provisions in Article 61 of the Vaccine Administration Law, vaccines have serious adverse events following immunization or are otherwise harmful to human health as indicated by post-marketing evaluation;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）按照《疫苗管理法》第六十一条的规定，经上市后评价，预防接种异常反应严重或者其他原因危害人体健康的；"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing the Requirements for Change Items and Application Dossiers of Marketed Biological Products'可被翻译为：国家药监局关于发布《已上市生物制品变更事项及申报资料要求》的通告\n'NMPA Notice on Issuing the Requirements for Change Items of Marketed Traditional Chinese Medicines and Application Dossiers'可被翻译为：国家药监局关于发布《已上市中药变更事项及申报资料要求》的通告\n\n根据上述已知信息，请将'NMPA Notice on Issuing the Requirements for Change Items of Marketed Chemicals and Application Dossier'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布已上市化学药品变更事项及申报资料要求的通告"
    },
    {
        "instruction":"已知信息：\n'Article 26 The State implements lot release system for vaccines.'可被翻译为：第二十六条 国家实行疫苗批签发制度。\n'Article 22 The State implements strict access system for vaccine manufacturing.'可被翻译为：第二十二条 国家对疫苗生产实行严格准入制度。\n\n根据上述已知信息，请将'Article 76 The State implements the uniform release system for vaccine safety information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十六条 国家实行疫苗安全信息统一公布制度。"
    },
    {
        "instruction":"已知信息：\n'As far as practicable, equipment, fittings and services should be designed and installed so that operations, maintenance, and repairs can be performed outside the cleanroom. If maintenance has to be performed in the cleanroom, and the required standards of cleanliness and\/or asepsis cannot be maintained, then precautions such\nas restricting access to the work area to specified personnel, generation of clearly defined work protocols and maintenance procedures should be considered. Additional cleaning, disinfection and environmental monitoring should also be considered. If sterilisation of equipment is required, it should be carried out, wherever possible, after complete reassembly.'可被翻译为：设备及辅助装置和服务的设计和安装方式，应尽可能地使操作、维护和维修在洁净室外进行。如果必须在洁净室中进行维护，并且无法维持所要求的洁净和\/或无菌标准，则应当考虑预防措施，例如限制指定人员进入工作区，建立明确的工作方案和维护程序。还应考虑额外的清洁、消毒和环境监测。如果需要对设备进行灭菌，应尽可能在重新组装完成后灭菌\n'Article 63: Quality Control laboratories usually should be separated from production areas. Laboratories for the control of biological, microbiological and radioisotopes should also be separated from each other.'可被翻译为：第六十三条 质量控制实验室通常应当与生产区分开。生物检定、微生物和放射性同位素的实验室还应当彼此分开。\n\n根据上述已知信息，请将'Article 70: Maintenance workshops should as far as possible be separated from production areas. Whenever parts and tools are stored in the clean area, they should be kept in rooms or lockers reserved for that use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 维修间应当尽可能远离生产区。存放在洁净区内的维修用备件和工具，应当放置在专门的房间或工具柜中。"
    },
    {
        "instruction":"已知信息：\n'(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number.'可被翻译为：（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证编号或者备案编号。\n'(3) Name, residence, manufacturing address, contacts and production license number or filing number of medical device manufacturer. For contract manufacturing, name, address, manufacturing address, production license number or filing number of contracted manufacturer shall be also specified.'可被翻译为：（三）生产企业的名称、住所、生产地址、联系方式及生产许可证编号或者生产备案凭证编号，委托生产的还应当标注受托企业的名称、住所、生产地址、生产许可证编号或者生产备案凭证编号；\n\n根据上述已知信息，请将'(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证号或者备案编号；"
    },
    {
        "instruction":"已知信息：\n'(3) For clinical trials with patients as subjects, relevant medical records shall be recorded in the outpatient or inpatient medical record system. The specific time and person who gives informed consent shall be recorded in the medical history record.'可被翻译为：(3) 以患者为受试者的临床试验，相关医疗记录载入门诊或住院病历。病历中记录受试者知情同意的具体时间和人员。\n'(b) The items identified in paragraphs (a)(1), (a)(2), and (a)(3) of this section shall be subject to the same controls as for electronic records and shall be included as part of any human readable form of the electronic record (such as electronic display or printout).'可被翻译为：本节(a)(1), (a)(2), 和(a)(3)中明确的内容应采用电子记录相同的管理方式，且应作为易读电子记录（电子显示或打印输出）的一部分。\n\n根据上述已知信息，请将'(2) Where the electronic medical record has already been adopted in daily diagnosis and treatment, the clinical trials shall use electronic medical records.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) 日常诊疗已使用电子病历系统的，临床试验应使用电子病历。"
    },
    {
        "instruction":"已知信息：\n'A solvent (non-solvent) that is insoluble to the material is added to the solution of the drug and the material, causing phase separation, and the drug is wrapped into a sac or co-precipitation into a ball method.'可被翻译为：药物和材料的溶液中加入一种对材料不溶的溶剂（非溶剂），引起相分离，而将药物包裹成囊或共沉淀成球的方法。\n'The use of natural or synthetic polymer materials as carrier materials, so that the drug dissolved or\/and dispersed in the polymer material, the formation of a skeleton type of tiny spherical entity.'可被翻译为：利用天然或合成的高分子材料为载体材料，使药物溶解或\/和分散在高分子材料中，形成的骨架型微小球状实体。\n\n根据上述已知信息，请将'The insoluble drug is dispersed in the aqueous solution of the polymer material, and the coagulant is added to reduce the solubility of the polymer material to condense it into a sac.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"难溶性药物分散在高分子材料的水溶液中，加入凝聚剂以降低高分子材料溶解度使之凝聚成囊的方法。"
    },
    {
        "instruction":"已知信息：\n'1. Design qualification is to verify that the design of the premises, facilities and equipment is suitable for the intended use and in compliance with the Provisions;'可被翻译为：（一）设计确认应当证明厂房、设施、设备的设计符合预定用途和本规范要求；\n'Guidance on the requirements for specific training, knowledge and skills. Also gives guidance regarding the qualification of personnel.'可被翻译为：关于具体培训、知识和技能要求，以及关于人员资质确认的指导。\n\n根据上述已知信息，请将'General guidance regarding the specific needs for premises design and also guidance on the qualification of premises including the use of Barrier Technology.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"有关具体厂房设计需求的一般性指导，以及关于厂房确认的指导（包括屏障技术的使用）。"
    },
    {
        "instruction":"已知信息：\n'Article 53 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall deliver the review opinions, inspection reports and the application dossiers to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and notice the applicants.'可被翻译为：第五十三条 省、自治区、直辖市药品监督管理部门应当在规定的时限内将审查意见、核查报告以及申报资料送交国家食品药品监督管理局药品审评中心，并通知申请人。\n'Article 64 Drug testing institutes shall conduct sample testing according to the verified specifications, and within the specified timeline, provide testing reports to the Center for Drug Evaluation of the State Food and Drug Administration, and copy to the relevant drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government and the applicants.'可被翻译为：第六十四条 药品检验所应当依据核定的药品标准对抽取的样品进行检验，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，同时抄送相关省、自治区、直辖市药品监督管理部门和申请人。\n\n根据上述已知信息，请将'Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall deliver the review opinions, inspection reports and the application dossiers to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and notice the applicants.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省、自治区、直辖市药品监督管理部门应当在规定的时限内将审查意见、核查报告及申报资料送交国家食品药品监督管理局药品审评中心，并通知申请人。"
    },
    {
        "instruction":"已知信息：\n'A sample of a batch of starting material, packaging material, product contained in its primary packaging, or finished product that is stored for the purpose of being analysed, should the need arise. This may include storage in a suitable bulk container.'可被翻译为：一批起始原料、包装材料、包含在其主要包装中的产品或成品的样品，如果需要，为分析目的而储存。这可能包括储存在合适的散装容器中。\n'17.Stability Testing – sample storage conditions, missed sampling dates, etc.'可被翻译为：稳定性试验—样品存贮条件、错过取样日期等\n\n根据上述已知信息，请将'9. Product sampling: a representative sample is selected based on lot size as per USP <71> guidelines; quantity per container & units per batch, sample storage (time and temperature), sampling port sanitization or sterilization problems; be aware of skip lot testing on raw material.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"产品取样：按 USP<71>指南中的批量选择具有代表性的样品；每个包装&每批产品件数所取数量，样品存贮（时间和温度）、取样端口灭菌或消毒问题；了解原料的跳批检测"
    },
    {
        "instruction":"已知信息：\n'Medical costs directly related to the delivery of medical services. Such as the cost of diagnosis, treatment, and tests.'可被翻译为：与医疗服务的提供直接相关的医疗成本。如诊断、治疗、检查费。\n'The costs directly related to health care that are incurred specifically to provide a health care service.'可被翻译为：专为提供某医疗服务项目而发生的与医疗服务直接相关的成本。\n\n根据上述已知信息，请将'Non-medical costs directly related to the provision of medical services. Such as transportation costs for patients to hospitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与医疗服务的提供直接相关的非医疗成本。比如患者去医院的交通费。"
    },
    {
        "instruction":"已知信息：\n'In accordance with the results of adverse drug reaction assessment, to further guarantee the safety of people in the use of drug, the NMPA decided to revise such items as [Adverse reactions], [Contraindications]and [Precautions] in the package inserts of antiviral syrup, capsules, soft capsules, pills(concentrated pills), dropping pills, tablets, effervescent tablets, chewable tablet, oral liquid, and granules. The relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒说明书【不良反应】、【禁忌】和【注意事项】项进行统一修订。现将有关事项公告如下：\n'I. The marketing authorization holders of the said products shall, in accordance with the Provisions for Drug Registration and the revision requirements for the package insert (see Attachments 1 and 2) of antiviral syrup, capsules, soft capsules, pills (concentrated pills), dropping pills, tablets, effervescent tablets, chewable tablet, oral liquid and granules (both prescription drugs and OTC), file a report as such before December 27, 2021 to provincial medical products regulatory authority.'可被翻译为：一、上述药品的上市许可持有人均应依据《药品注册管理办法》等有关规定，按照抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒的处方药、非处方药说明书修订要求，于2021年12月27日前报省级药品监督管理部门备案。\n\n根据上述已知信息，请将'NMPA Announcement on Revising the Package Insert of Antiviral Syrup, Capsules, Soft Capsules, Pills (Concentrated Pills), Dropping Pills, Tablets, Effervescent Tablets, Chewable Tablet, Oral Liquid, And Granules'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于修订抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒药品说明书的公告"
    },
    {
        "instruction":"已知信息：\n'Article 64 Drugs shall be imported via the ports where drug importation is permitted, and drug importers shall file a record with the local drug regulatory department at the port. The drugs shall be released by customs on the basis of the Drug Import Note issued by the said departments and shall not release drugs for which no Drug Import Note has been issued.'可被翻译为：第六十四条 药品应当从允许药品进口的口岸进口，并由进口药品的企业向口岸所在地药品监督管理部门备案。海关凭药品监督管理部门出具的进口药品通关单办理通关手续。无进口药品通关单的，海关不得放行。\n'Article 3 Drugs shall be imported via the ports where drug importation is permitted by the State Council.'可被翻译为：第三条 药品必须经由国务院批准的允许药品进口的口岸进口。\n\n根据上述已知信息，请将'Article 11 An importer shall choose a port where drug importation is permitted as the port of delivery when signing a purchase contract. Drugs specified in Article 10 of the Provisions shall be imported via a port that is specially permitted by the State for such importation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十一条 进口单位签订购货合同时，货物到岸地应当从允许药品进口的口岸选择。其中本办法第十条规定情形的药品，必须经由国家特别批准的允许药品进口的口岸进口。"
    },
    {
        "instruction":"已知信息：\n'Machinery for the preparation of solid particles.'可被翻译为：可制备固体颗粒的机械。\n'The size of particles.'可被翻译为：颗粒的大小。\n\n根据上述已知信息，请将'The use of machinery to press the material powder into a certain diameter of the embryo sheet, and then broken into a certain size of particles.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"利用机械将物料粉末压制成一定直径的胚片，再破碎成一定大小颗粒的方法。"
    },
    {
        "instruction":"已知信息：\n'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the Entries of [contraindications], [adverse reactions] and [precautions] on the package inserts of nicotinic acid injections (including nicotinic acid injection and nicotinic acid for injection).'可被翻译为：进一步保障公众用药安全，2020年3月17日，国家药监局发布公告决定对烟酸注射剂（包括烟酸注射液、注射用烟酸）说明书【不良反应】、【禁忌】、【注意事项】项进行修订。\n'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions] and other Entries on the package inserts of Diclofenac Sodium Suppositories.'可被翻译为：为进一步保障公众用药安全，国家药监局于2020年3月17日发布公告，决定对双氯芬酸钠栓说明书【不良反应】、【注意事项】等项进行修订。\n\n根据上述已知信息，请将'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions] and other Entries on the package inserts of probucol.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步保障公众用药安全，2020年3月17日，国家药品监督管理局发布公告，决定对普罗布考说明书【不良反应】、【注意事项】等项进行修订。"
    },
    {
        "instruction":"已知信息：\n'According to the Provisions for Drug Importation, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing Principles and Standards for the Newly Establishment of Drug Import Ports, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing the Evaluation and Assessment Scheme for the Newly Establishment of Drug Import Ports, the Notice of the Comprehensive Department of National Medical Products Administration on Printing and Issuing the Evaluation Criteria for the Ports for the First Drug Importation and other relevant regulations, upon the on-site evaluation and assessment, the NMPA has approved the application of the Chongqing Municipal Medical Products Administration for adding the filing function for the first importation of chemicals, and this Announcement was hereby issued on February 2 as follows:'可被翻译为：根据《药品进口规定》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸原则和标准的通知》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸评价考核方案的通知》，《国家药品监督管理局综合司关于印发《药品首次进口口岸评审标准》及其他有关规定的通知》经现场评审评估，国家药品监督管理局批准重庆市药品监督管理局关于增加化学品首次进口备案功能的申请，于2月2日发布本公告如下:\n'I. Chongqing Municipal Medical Products Administration is approved to add the filling function for the first import of chemicals. As of the date of printing and issuing this Announcement, the Chongqing Municipal Medical Products Administration can handle the filing of the first importation of chemicals.'可被翻译为：一、同意重庆市药品监督管理局增加化学药品首次药品进口备案职能。自本公告印发之日起，重庆市药品监督管理局可办理化学药品首次药品进口备案手续。\n\n根据上述已知信息，请将'NMPA Announcement on Approval of Adding the Filing Function for the First Importation of Chemicals to the Chongqing Municipal Medical Products Administration'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于同意重庆市药品监督管理局增加化学药品首次药品进口备案职能的公告"
    },
    {
        "instruction":"已知信息：\n'When drugs are produced, packaged or prescribed, labels that meet the regulations should be affixed to the inner and outer packages of drugs; In order to guide patients to use the drug correctly, the pharmacist shall give written notification documents accompanying the drug.'可被翻译为：药品在生产、分装或处方调配时，将符合规定的标签贴在药品的内、外包装上；亦药师为指导患者正确使用药品，随药品所给予的书面告知文书。\n'(2) Changes to the content of drug packaging labels;'可被翻译为：（二）药品包装标签内容的变更；\n\n根据上述已知信息，请将'Article 16    Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十六条 药品的标签是指药品包装上印有或者贴有的内容，分为内标签和外标签。药品内标签指直接接触药品的包装的标签，外标签指内标签以外的其他包装的标签。"
    },
    {
        "instruction":"已知信息：\n'Where final containers are closed by fusion, e.g. Blow-Fill-Seal (BFS), Form-Fill-Seal (FFS), Small and Large Volume Parenteral (SVP & LVP) bags, glass or plastic ampoules, the critical parameters and variables that affect seal integrity should be evaluated, determined, effectively controlled and monitored during operations. Glass ampoules, BFS units and small volume containers (≤100 ml) closed by fusion should be subject to 100% integrity testing using validated methods. For large volume containers (>100 ml) closed by fusion, reduced sampling may be acceptable where scientifically justified and based on data demonstrating the consistency of the existing process, and a high level of process control. It should be noted that visual inspection is not considered as an acceptable integrity test method.'可被翻译为：当最终容器通过融合密封时，例如吹灌封（BFS）、成型-灌装-密封（FFS）、小容量注射剂和大容量注射剂（SVP&LVP）的袋子、玻璃或塑料安瓶瓶，应评估、确定影响密封完整性的关键参数和变量，并在操作过程中进行有效控制和监测。熔融密封的玻璃安瓿瓶、BFS 单元和小容量容器（≤100 ml）应使用经验证的方法进行 100%完整性测试。对于熔融密封的大容量容器（>100 ml），在经过科学论证并基于证明现有工艺可靠性和高水平工艺控制的数据的情况下，减少取样可能是可以接受的。值得注意的是，目检不被认为是可接受的完整性测试方法。\n'The size of monitoring samples taken using automated systems will usually be a function of the sampling rate  of the  system  used.  It  is  not necessary  for the  sample  volume  to  be  the  same  as  that  used  for  formal classification of cleanrooms and clean air equipment. Monitoring sample volumes should be justified.'可被翻译为：使用自动化系统监测时，采样量通常取决于系统的釆样速率。采样量不需要与洁净室和洁净空气设备的正式分级所用的采样量相同。采样量的合理性应经过论证。\n\n根据上述已知信息，请将'Samples of products using systems other than fusion should be taken and checked for integrity using\nvalidated methods. The frequency of testing should be based on the knowledge and experience of the container\nand closure systems being used. A scientifically justified sampling plan should be used. The sample size should be\nbased on information such as supplier management, packaging component specifications and process knowledge.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用非融合系统的产品应进行取样并使用经验证的方法检查其完整性。完整性检查的频率应基于所使用容器和密封系统的知识和经验。应使用经科学论证的取样计划。样本量应基于供应商管理、包装组件质量标准和工艺知识等信息。"
    },
    {
        "instruction":"已知信息：\n'Article 69 Where a drug MAH or drug manufacturer has failed to carry out manufacturing activities as per GMP requirements in any of the following circumstances and the circumstance belongs to the serious circumstances as specified in Article 126 under the Drug Administration Law, penalties shall be imposed according to law:'可被翻译为：第六十九条 药品上市许可持有人和药品生产企业未按照药品生产质量管理规范的要求生产，有下列情形之一，属于《药品管理法》第一百二十六条规定的情节严重情形的，依法予以处罚：\n'The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where adverse events occur shall promptly notify the relevant information to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.'可被翻译为：不良事件发生地省、自治区、直辖市药品监督管理部门应当及时向持有人所在地省、自治区、直辖市药品监督管理部门通报相关信息。\n\n根据上述已知信息，请将'Article 70 Where manufacturers and suppliers of excipients or primary packaging materials and container in direct contact with drug products do not comply with the quality management standards or relevant requirements established by the NMPA and cannot ensure the quality management system persistently complies with regulatory requirements, the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government shall impose punishments in accordance with Article 126 under the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 辅料、直接接触药品的包装材料和容器的生产企业及供应商未遵守国家药品监督管理局制定的质量管理规范等相关要求，不能确保质量保证体系持续合规的，由所在地省、自治区、直辖市药品监督管理部门按照《药品管理法》第一百二十六条的规定给予处罚。"
    },
    {
        "instruction":"已知信息：\n'The branch of Chinese pharmacy in which modern scholars conduct documentary research on ancient materia medica. Materia medica is the special name for medicine in ancient China (now called traditional Chinese medicine).'可被翻译为：现代学者对古代本草进行文献研究的中药学分支学科。本草是中国古代对药物的特称（现称中药）。\n'Under the guidance of the basic theories of traditional Chinese medicine and the use of modern scientific methods, the study of the interaction and laws between traditional Chinese medicine and the body.'可被翻译为：以中医药基本理论为指导，运用现代科学方法，研究中药和机体相互作用及规律的学科。\n\n根据上述已知信息，请将'The general name of the Chinese medicine discipline. The discipline of studying the basic theory of traditional Chinese medicine and the source, extraction, performance, efficacy and clinical application of various herbal pieces and proprietary Chinese medicines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"中药学科的统称。研究中药基本理论和各种药材饮片、中成药的来源、采制、性能、功效、临床应用等知识的学科。"
    },
    {
        "instruction":"已知信息：\n'Article 43 The food and drug regulatory department accepting the registration application shall forward the application materials to technical evaluation institution within 3 workdays from the date of acceptance.'可被翻译为：第四十三条 受理注册申请的食品药品监督管理部门应当自受理之日起3个工作日内将申报资料转交技术审评机构。\n'Article 33 The food and drug regulatory department accepting the registration application shall forward the application materials to technical evaluation institution within 3 workdays from the date of acceptance.'可被翻译为：第三十三条 受理注册申请的食品药品监督管理部门应当自受理之日起3个工作日内将申报资料转交技术审评机构。\n\n根据上述已知信息，请将'Article 27 After accepting the application for approval of clinical trials, China Food and Drug Administration shall forward the application documents to technical evaluation institution within 3 workdays from the date of application acceptance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 国家食品药品监督管理总局受理医疗器械临床试验审批申请后，应当自受理申请之日起3个工作日内将申报资料转交医疗器械技术审评机构。"
    },
    {
        "instruction":"已知信息：\n'All operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage, and distribution of APIs and related controls.'可被翻译为：包括物料接收，生产，包装，再分装，标识，再标识，质量控制，放行，贮藏和 API 的分发及其他相关控制的所有操作。\n'All operations involved in the production of a drug, including processing, compounding, formulating, filling, packaging, and labelling.'可被翻译为：药品生产过程中涉及的所有操作，包括加工、配制、配方、灌装、包装和标签。\n\n根据上述已知信息，请将'All operations involved in the preparation of an API from receipt of materials through processing and packaging of the API.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"指从原料到 API 的生产和包装的所有操作。"
    },
    {
        "instruction":"已知信息：\n'It is referred to as \"total anesthetics\". A drug that acts on the central nervous system and can reversibly cause loss of consciousness, sensations (mainly pain), and reflexes, and relaxes skeletal muscles, thus enabling surgery to proceed smoothly. Categories include inhalant anesthetics nitrous oxide and enflurane; Intravenous anesthetics, such as ketamine, etomidate, etc.'可被翻译为：简称“全麻药”。作用于中枢神经系统，能可逆性地引起意识、感觉（主要是痛觉）和反射消失、松弛骨骼肌，而使外科手术能顺利进行的药物。分类有吸入性麻醉药氧化亚氮、恩氟烷;静脉麻醉药，如氯胺酮、依托米酯等。\n'Some gases used in medicine and pharmaceuticals. Such as oxygen, carbon dioxide, ammonia, nitrous oxide, etc.'可被翻译为：应用于医疗及制药中的一些气体。如氧、二氧化碳、氨、氧化亚氮等。\n\n根据上述已知信息，请将'Any of a class of volatile liquids or gases inhaled through the airway that diffuse into the blood through the alveolar capillary membranes and reach the brain tissue, blocking synaptic transmission and causing general anesthesia. Commonly used drugs are: halothane, enflurane, isoflurane, nitrous oxide, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一类挥发性液体或气体，经气道吸入后由肺泡毛细血管膜弥散入血而到达脑组织，阻滞其突触传递功能，引起全身麻醉作用的药物。常用药物有：氟烷、恩氟烷、异氟烷、氧化亚氮等。"
    },
    {
        "instruction":"已知信息：\n'The receptor solution should be adequately mixed, typically by stirring at a constant and well-controlled speed throughout the experiment. The stirring speed or the flow rate should also be part of system qualification and is further described under Equipment.'可被翻译为：受体溶液应充分混合，通常在整个实验过程中以恒定和控制良好的速度搅拌。搅拌速度或流量也应是系统鉴定的一部分，并在设备中作进一步说明。\n'Note: Always use LRW as the diluent for the CSE standard serial dilutions.'可被翻译为：注：始终使用LRW作为CSE标准系列稀释液的稀释剂\n\n根据上述已知信息，请将'The field laboratories are encouraged to mix the reconstituted CSE for at least 5 minutes and for at least 1 minute between dilutions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励现场实验室将调配的CSE混合至少5分钟，每次稀释之间混合至少1分钟。"
    },
    {
        "instruction":"已知信息：\n'Article 42 If the lot release applicant provides false data or samples, or conceal major changes that will affect product quality and obtain the Certificate for Lot Release of Biological Products by fraud, a penalty shall be imposed in accordance with Article 123 of the Drug Administration Law.'可被翻译为：第四十二条    批签发申请人提供虚假资料或者样品，或者故意瞒报影响产品质量的重大变更情况，骗取生物制品批签发证明的，依照《药品管理法》第一百二十三条的规定予以处罚。\n'If the lot release applicant provides false data, materials, or samples, or engages in deceptive behaviors in the application for lot release of vaccines, a penalty shall be imposed in accordance with the provisions of Article 81 of the Vaccine Administration Law.'可被翻译为：申请疫苗批签发提供虚假数据、资料、样品或者有其他欺骗行为的，依照《疫苗管理法》第八十一条的规定予以处罚。\n\n根据上述已知信息，请将'Article 42 If the lot release applicant provides false data or samples, or conceal major changes that will affect product quality and obtain the Certificate for Lot Release of Biological Products by fraud, a penalty shall be imposed in accordance with Article 82 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十二条 批签发申请人提供虚假资料或者样品，或者故意瞒报影响产品质量的重大变更情况,骗取生物制品批签发证明的，依照《药品管理法》第八十二条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'可被翻译为：第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。\n'Appropriate maintenance procedures should be established based on risk, and include maintenance and inspection plans for items critical to unit sealing, integrity and sterility.'可被翻译为：应根据风险建立适当的维护程序，并包括对单元密封、完整性和无菌性至关重要的物品的维护和检查计划。\n\n根据上述已知信息，请将'Article 80: Preventive maintenance plans and procedures should be established, and the maintenance and repair activities should be recorded.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条 应当制定设备的预防性维护计划和操作规程，设备的维护和维修应当有相应的记录。"
    },
    {
        "instruction":"已知信息：\n'Drugs used to treat or prevent infections caused by pathogenic microorganisms, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, etc. Unlike anti-infective drugs, these drugs do not target worms.'可被翻译为：治疗或预防致病微生物，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫等所致感染用的药物。与抗感染药的区别是本类药物的作用对象不包括蠕虫类。\n'Antimicrobial drugs used to treat infections caused by pathogenic microorganisms such as bacteria, rickettsia, chlamydia, mycoplasma, spirochetes, fungi, etc. Excluded are drugs for treating tuberculosis, parasitic diseases, and various viral infections, as well as traditional Chinese medicine formulations with antibacterial properties.'可被翻译为：治疗细菌、支原体、衣原体、立克次体、螺旋体、真菌等病原微生物所致感染性疾病病原的药物，\n不包括治疗结核病、寄生虫病和各种病毒所致感染性疾病的药物以及具有抗菌作用的中药制剂。\n\n根据上述已知信息，请将'A drug used to treat or prevent infections caused by various pathogens, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, worms, etc. They may be further classified according to their source and properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防各种病原体，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫、蠕虫等所致感染用的药物。根据来源和性质的不同可进一步分类。"
    },
    {
        "instruction":"已知信息：\n'The highest amount of an analyte in a sample that can be quantitatively determined with pre_x0002_defined precision and accuracy'可被翻译为：样品中可通过预先定义的精密度和准确度进行定量测定的待测物最高浓度。\n'The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products.'可被翻译为：某一分析方法的定量限度是指在合适的准确性和精密度下，能够定量测定样品中被分析物的最低量。它是样品中含量下，能够定量测定样品中被分析物的最低量。它是样品中含量低的化合物定量测定的参数，特别适用于杂质和\/或降解产物的测定。\n\n根据上述已知信息，请将'The lowest amount of an analyte in a sample that can be quantitatively determined using a method with predefined precision and accuracy'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用预先定义其精密度和准确度的方法，使样品中的待测物可被定量测定的最低浓度。"
    },
    {
        "instruction":"已知信息：\n'Apply the principles and methods of sociology and behavioral science to study the discipline of human behavior in pharmaceutical practice.'可被翻译为：应用社会学和行为科学的原理和方法，研究药学实践中人的行为学科。\n'Article 9 CFDI and the institutions of drug evaluation, drug testing and others shall establish a joint mechanism for registration inspection, evaluation, and registration test, and strengthen communication, exchanges, and coordination to research and solve problems in the registration inspection work.'可被翻译为：第九条 核查中心与药品审评、药品检验等机构建立注册核查与审评、注册检验的工作衔接机制，并加强沟通和交流，共同协调、研究和解决注册核查工作中出现的问题。\n\n根据上述已知信息，请将'The subject that uses the theories and principles of ethics to explore and solve the problems of right and wrong, good and evil of human behavior in pharmaceutical work.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用伦理学的理论和原则探讨和解决药学工作中人类行为的是非、善恶问题的学科。"
    },
    {
        "instruction":"已知信息：\n'Article 33 The sponsor shall, before carrying out the drug clinical trial, submit the drug clinical trial protocol and other information on the drug clinical trial registry and information disclosure platform. During the drug clinical trial, the sponsor shall continually update the registered information and, after the drug clinical trial ends, submit results of the drug clinical trial and other related information. Information posted on the platform shall be disclosed to the public. The sponsor is responsible for the authenticity of registered information about the drug clinical trial.'可被翻译为：第三十三条 申办者应当在开展药物临床试验前在药物临床试验登记与信息公示平台登记药物临床试验方案等信息。药物临床试验期间，申办者应当持续更新登记信息，并在药物临床试验结束后登记药物临床试验结果等信息。登记信息在平台进行公示，申办者对药物临床试验登记信息的真实性负责。\n'Article 62 Before the clinical trial, the medical device clinical trial management department of the clinical trial institution shall coordinate with the sponsor to submit the application to the ethics committee and submit relevant documents according to the regulations.'可被翻译为：第六十二条 临床试验前，临床试验机构的医疗器械临床试验管理部门应当配合申办者向伦理委员会提出申请，并按照规定递交相关文件。\n\n根据上述已知信息，请将'Article 26 When the drug clinical trial application is approved, the sponsor shall formulate the corresponding drug clinical trial protocols and have them reviewed and approved by the ethics committee before carrying out the subsequent phases of clinical trial, and submit the corresponding protocols and supporting dossiers on the CDE website.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十六条 获准开展药物临床试验的，申办者在开展后续分期药物临床试验前，应当制定相应的药物临床试验方案，经伦理委员会审查同意后开展，并在药品审评中心网站提交相应的药物临床试验方案和支持性资料。"
    },
    {
        "instruction":"已知信息：\n'××××3 shall indicate the serial number of filing.'可被翻译为：××××3为备案流水号。\n'××××3 shall indicate the year of initial registration.'可被翻译为：××××3为首次注册年份；\n\n根据上述已知信息，请将'××××6 shall indicate the serial number of initial registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"××××6为首次注册流水号。"
    },
    {
        "instruction":"已知信息：\n'An apparatus for injecting liquid medicine.'可被翻译为：用以注射药液的器具。\n'A cylindrical device with a cannula-like nozzle, with or without a fixed needle and a movable piston, used for the administration, usually parenteral, of an accurately measured quantity of a liquid pharmaceutical form. The syringe may be prefilled, and can be for single-dose or multi- dose use.'可被翻译为：注射器一种圆柱形装置，有类似套管的喷嘴，有或没有固定的针和可移动的活塞，通常用于注射精确测量的液体药物形式该注射器可预先填充，可用于单剂或多剂使用。\n\n根据上述已知信息，请将'A hollow needle with a locking device intended for the administration of liquid pharmaceutical dosage forms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"带有锁定装置的空心针，用于给药液体药物剂型。"
    },
    {
        "instruction":"已知信息：\n'Article 36 The registrant, filing entity or contract manufacturer of medical devices shall, in accordance with relevant requirements of the state for implementing Unique Device Identification (UDI) of medical devices, carry out code assignment, data uploading, maintenance and updating, to guarantee the authenticity, accuracy, integrity and traceability of the information.'可被翻译为：第三十六条  医疗器械注册人、备案人、受托生产企业应当按照国家实施医疗器械唯一标识的有关要求，开展赋码、数据上传和维护更新，保证信息真实、准确、完整和可追溯。\n'Article 3  The UDI System of Medical Device mentioned in these Rules consists of the unique device identifier (UDI), UDI data carrier and unique device identification database (UDID).'可被翻译为：第三条 本规则所称医疗器械唯一标识系统，由医疗器械唯一标识、唯一标识数据载体和唯一标识数据库组成。\n\n根据上述已知信息，请将'The medical device distributors shall execute Unique Device Identification (UDI) system of medical devices in accordance with relevant regulations of the State.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械经营企业应当按照国家有关规定执行医疗器械唯一标识制度。"
    },
    {
        "instruction":"已知信息：\n'Male use to reduce the number of sperm until no sperm and achieve contraceptive purposes of the drug. Such as gossypol.'可被翻译为：男性应用后使精子数量减少直至无精子而达到避孕目的的药物。如棉酚。\n'Products applied topically to the skin.'可被翻译为：用于皮肤局部的药物。\n\n根据上述已知信息，请将'Male contraceptive, applied topically to kill sperm. Such as commonly used surfactants.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"男用避孕药，局部应用以杀灭精子。如常用的表面活性剂类药。"
    },
    {
        "instruction":"已知信息：\n'This guidance is intended to assist applicants who are submitting abbreviated new drug applications (ANDAs) for liquid-based and\/or other semisolid products applied to the skin, including integumentary and mucosal (e.g., vaginal) membranes, which are hereinafter called topical products.（注释2）Because of the complex route of delivery associated with these products, which are typically locally acting, and the potential complexity of certain formulations, topical products (other than topical solutions) are classified as complex products.（注释3）This guidance provides recommendations for in vitro release test (IVRT) studies that can be used to compare a proposed generic (test) topical product and its reference standard (RS) for the purpose of supporting a demonstration of bioequivalence (BE) to the reference listed drug (RLD). The reference standard ordinarily is the RLD.（注释4）'可被翻译为：本指南旨在帮助申请人提交用于皮肤的液体和\/或其他半固体产品的仿制药申请（ANDA），包括皮肤和粘膜（如阴道），以下简称“外用制剂”（注释2）。由于这些制剂通常局部起效，具有复杂递送途径和配方，外用制剂（外用溶液除外）通常称为复杂制剂（注释3）。本指南为拟申报的仿制药与其对照制剂（RS）的体外释放试验（IVRT）研究提供建议，以论证与参比制剂（RLD）的生物等效性（BE）。参比制剂通常简称为RLD。（注释4）\n'(1) Act means the Federal Food, Drug, and Cosmetic Act (secs. 201-903 (21 U.S.C. 321-393)).'可被翻译为：法案是指联邦视频、药品、化妆品法案\n\n根据上述已知信息，请将'The Federal Food, Drug, and Cosmetic Act (FD&C Act) generally requires an ANDA to contain, among other things, information to show that the proposed generic drug product 1) is the same as the RLD with respect to the active ingredient(s), conditions of use, route of administration, dosage form, strength, and labeling (with certain permissible differences) and 2) is bioequivalent to the RLD.（注释9）Thus, an ANDA will not be approved if the information submitted in the ANDA is insufficient to show that the test product is bioequivalent to the RLD.（注释10）'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《联邦食品、药品和化妆品法案》（FD&C法案）要求ANDA申请中应包含合适的信息，说明：1）仿制药与RLD相比，具有相同的活性成分、使用条件、给药途径、剂型、规格和说明书（允许存在一些差异）；2）与RLD生物等效（注释9）。因此，如果ANDA中提交的信息不足以证明自制制剂与RLD具有生物等效性，则ANDA将不予批准。（注释10）"
    },
    {
        "instruction":"已知信息：\n'Article 67 A drug manufacturer shall investigate the manufacturing processes, quality, stability, therapeutic effect and adverse reactions, etc. of a new drug in the observation period, and report annually to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, where it is located. Where a drug manufacturer fails to perform its duties in the observation period, the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall order it to make rectifications.'可被翻译为：第六十七条 药品生产企业应当考察处于监测期内的新药的生产工艺、质量、稳定性、疗效及不良反应等情况，并每年向所在地省、自治区、直辖市药品监督管理部门报告。药品生产企业未履行监测期责任的，省、自治区、直辖市药品监督管理部门应当责令其改正。\n'After receiving the report, the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device distributor or using unit is located shall, in a timely manner, inform the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located.'可被翻译为：医疗器械经营企业、使用单位所在地省、自治区、直辖市食品药品监督管理部门收到报告后，应当及时通报医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门。\n\n根据上述已知信息，请将'Article 68 Where institutions for drug manufacturing, distribution, use, testing or supervision find any critical quality problem, serious or unexpected adverse reaction of a new drug, they shall report to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government in time. Once receiving the report, the drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall organize prompt investigation, and report to the State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十八条 药品生产、经营、使用及检验、监督单位发现新药存在严重质量问题、严重或者非预期的不良反应时，应当及时向省、自治区、直辖市药品监督管理部门报告。省、自治区、直辖市药品监督管理部门收到报告后应当立即组织调查，并报告国家食品药品监督管理局。"
    },
    {
        "instruction":"已知信息：\n'2. The storage conditions of the test\/control articles should be in conformity with those specified in the study protocol or other supporting documents (such as instructions for use, certificates of analysis, etc.); records of monitoring storage conditions and handling unexpected events of the test\/control articles and their formulations during the study period should be retained completely;'可被翻译为：2.受试物\/对照品保存条件应符合试验方案或相关证明 性文件(如使用说明书、质检报告等)要求；应完整保留研 究期间受试物\/对照品及其制剂保存条件监测及异常情况处理记录；\n'2. In case of laboratory animals used in a study, there should be proper animal facilities for carrying out the study with the corresponding approval documentation for the use of laboratory animals; records of environmental monitoring of animal facilities and handling of unexpected events in the course of the study should be retained completely;'可被翻译为：2.涉及实验动物研究的，应具备符合研究要求的动物设 施，具有相应的实验动物使用许可证明；应完整保存研究期间动物设施环境控制数据及异常情况处理等记录；\n\n根据上述已知信息，请将'3. The storage conditions of the test\/control articles and their formulations, biological samples, study files and specimens, etc. should be in conformity with those specified in the study protocol, SOPs or other operational instructions; records of corresponding environmental monitoring and handling of unexpected events in the course of the study should be retained completely.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.受试物\/对照品及其配制制剂、生物样本、研究档案和 标本等储存保管条件应符合试验方案及机构 SOP或其他试验操作文件要求；应完整保存研究开展期间相应环境控制数据以及异常情况处理等记录。"
    },
    {
        "instruction":"已知信息：\n'The applicant shall be subject to inspection within the specified timeline.'可被翻译为：申请人应当在规定时限内接受核查。\n'Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) shall be responsible for overseas on-site inspection during lot release.'可被翻译为：国家药品监督管理局食品药品审核查验中心（以下简称核查中心）承担批签发过程中的境外现场检查等工作。\n\n根据上述已知信息，请将'(4) Time occupied during overseas inspection where overseas inspection is initiated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）启动境外核查的，境外核查所占用的时间。"
    },
    {
        "instruction":"已知信息：\n'The site where an enzyme molecule binds to a substrate and participates in a catalytic reaction.'可被翻译为：酶分子与底物结合并参与催化反应的部位。\n'Any of a class of organic substances found in very small amounts in the body that are essential for the maintenance of human life. It is an important active substance for maintaining human health.'可被翻译为：一类在体内含量极微的维持人体生命所必需的有机物质。是保持人体健康的重要活性物质。\n\n根据上述已知信息，请将'Any of several organic substances of small molecular weight that are loosely bound to enzyme proteins and are essential for catalytic activity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"某些为催化活性所必需的、与酶蛋白疏松结合的小分子量的有机物质。"
    },
    {
        "instruction":"已知信息：\n'Disease prevention and control institutions shall supply vaccines to immunization entities as required.'可被翻译为：疾病预防控制机构应当按照规定向接种单位供应疫苗。\n'Entities or individuals other than disease prevention and control institutions shall not supply vaccines to immunization entities, and immunization entities shall not accept such vaccines.'可被翻译为：疾病预防控制机构以外的单位和个人不得向接种单位供应疫苗，接种单位不得接收该疫苗。\n\n根据上述已知信息，请将'(3) distributing vaccine to immunization entities by any institution or individual other than disease prevention and control institutions;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）疾病预防控制机构以外的单位或者个人向接种单位供应疫苗；"
    },
    {
        "instruction":"已知信息：\n'Article 75 Where a drug included into the special review and approval procedure is considered to no longer meet the inclusion conditions, the special review and approval procedure for the drug shall be terminated, and the applicant shall be informed.'可被翻译为：第七十五条 对纳入特别审批程序的药品，发现其不再符合纳入条件的，应当终止该药品的特别审批程序，并告知申请人。\n'Article 71 During review, where it is found that a drug registration application included into the priority review and approval procedure does not meet the conditions for priority review and approval, the CDE shall terminate the priority review and approval procedure for the application, evaluate the application as per the normal review procedure and inform the applicant.'可被翻译为：第七十一条 审评过程中，发现纳入优先审评审批程序的药品注册申请不能满足优先审评审批条件的，药品审评中心应当终止该品种优先审评审批程序，按照正常审评程序审评，并告知申请人。\n\n根据上述已知信息，请将'Where an application is recalled by the applicant in the process of drug registration, the review and approval procedure is terminated henceforth.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品注册过程中申请人自行提出撤回申请的，其审批程序自行终止。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for supervision and administration of medical device distribution within their administrative areas.'可被翻译为：省、自治区、直辖市药品监督管理部门负责本行政区域的医疗器械经营监督管理工作。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the contract manufacturer is located shall be responsible for carrying out supervision and inspection of the contract manufacturer’s manufacturing activities, and if involving relevant conditions of the registrant, the drug regulatory department of the place where the registrant is located shall carry out supervision and inspection on the registrant.'可被翻译为：受托生产企业所在地省、自治区、直辖市药品监督管理部门负责对受托生产企业生产活动开展监督检查，涉及注册人相关情况的，应当由注册人所在地药品监督管理部门对注册人开展监督检查。\n\n根据上述已知信息，请将'The drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or contract manufacturer of the medical devices is located shall implement local supervision and administration responsibility, establish coordinated supervision and administration mechanism to strengthen communication on regulatory information and realize effective cohesion.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门应当分别落实属地监管责任，建立协同监管机制，加强监管信息沟通，实现监管有效衔接。"
    },
    {
        "instruction":"已知信息：\n'The time it takes for the plasma drug concentration to decrease by half after the distribution of the drug in the body reaches equilibrium.'可被翻译为：药物在体内分布达到平衡状态后血浆药物浓度降低一半所需的时间。\n'The time it takes for half the drug to be eliminated from the body is also the time it takes for the blood concentration to drop by half.'可被翻译为：药物从体内消除一半所需的时间，也是血药浓度下降一半的时间。\n\n根据上述已知信息，请将'The time it takes for the concentration of the drug in the plasma to drop by half.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"血浆中药物浓度下降一半所需的时间。"
    },
    {
        "instruction":"已知信息：\n'Article 77 Enterprises shall carry out sampling inspection for acceptance lot by lot for drugs of each arrival in accordance with the provisions on acceptance inspection, and the samples taken shall be representative:'可被翻译为：第七十七条 企业应当按照验收规定，对每次到货药品进行逐批抽样验收，抽取的样品应当具有代表性：\n'If it is deemed necessary to conduct sample inspection during the on-site inspection, the inspection team shall, with the approval of CFDI, take samples and seal them in accordance with the relevant requirements on drug sampling, and the sampling situation shall be described in the inspection report. The samples shall be sent to the drug testing institution for sample testing as required.'可被翻译为：现场核查过程中认为有必要进行样品检验的，经报核查中心同意后，核查组按照药品抽样的有关要求，抽取样品并封样，抽样情况应当在核查报告中进行描述；样品按要求送交药品检验机构进行样品检验。\n\n根据上述已知信息，请将'Article 57 The sampling referred to in the Procedures refers to the sampling, sample sealing and notified inspection conducted by the drug regulatory authority during the registration inspection process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十七条 本程序所指的抽样是指药品监督管理部门在注册核查过程中进行的取样、封样和通知检验。"
    },
    {
        "instruction":"已知信息：\n'In molecular orbitals, the highest occupied orbital and the lowest unoccupied orbital are collectively called.'可被翻译为：分子轨道中，最高占据轨道和最低未占轨道的统称。\n'A series of theoretical indices calculated by quantum chemistry to describe or mark the structure, conformational characteristics and reaction properties of molecules. The commonly used quantum chemical indices are: the highest occupied orbital energy and the lowest empty orbital energy, which are related to the electron transport properties of molecules; The non-electron transfer and non-locality of hypercogranulation, and the total molecular energy, which is often used in conformational analysis or reaction mechanism research.'可被翻译为：经量子化学计算得出的一系列描述或标志分子结构、构象特点和反应性能的理论指数。常用的量子化学指数有：与分子的电子传递特性有关的最高占有轨道能和最低空轨道能；标志分子的无电子转移和超共粒现象的非定域性和常用于构象分析或反应机理研究的分子总能量等。\n\n根据上述已知信息，请将'The highest energy orbital of the electron occupied molecular orbitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在电子占有的分子轨道中，能量最高的分子轨道。"
    },
    {
        "instruction":"已知信息：\n'Article 82 Where, in violation of the Provisions, a registration alteration of permission items for an in-vitro diagnostic reagent is not performed according to law, punishments shall be imposed according to the situation concerning not obtaining a medical device registration certificate in the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第八十二条 违反本办法规定，未依法办理体外诊断试剂注册许可事项变更的，按照《医疗器械监督管理条例》有关未取得医疗器械注册证的情形予以处罚。\n'Article 17 Drug research and development activities shall comply with the Good Laboratory Practice for Non-Clinical Studies (GLP) and the Good Clinical Practice (GCP), and the entire drug research and development process shall continuously comply with statutory requirements.'可被翻译为：第十七条 从事药品研制活动，应当遵守药物非临床研究质量管理规范、药物临床试验质量管理规范，保证药品研制全过程持续符合法定要求。\n\n根据上述已知信息，请将'Article 165 Where the Good Laboratory Practice for Non-Clinical Laboratory Studies or the Good Clinical Practice is not executed in the process of drug registration according to regulations, punishments shall be given in accordance with the provisions in Article 79 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百六十五条 在药品注册中未按照规定实施《药物非临床研究质量管理规范》或者《药物临床试验质量管理规范》的，依照《药品管理法》第七十九条的规定处罚。"
    },
    {
        "instruction":"已知信息：\n'The drug is placed in a closed screen with a screen cover and a receiver, and the device for grading the material is shaken and vibrated on the machine for a certain time.'可被翻译为：将药物置于具有筛盖和接受器的密闭筛中，在机器上摇动和振动一定时间以完成物料分级的装置。\n'NMPA Announcement on Revising the Package Insert of Antiviral Syrup, Capsules, Soft Capsules, Pills (Concentrated Pills), Dropping Pills, Tablets, Effervescent Tablets, Chewable Tablet, Oral Liquid, And Granules'可被翻译为：国家药监局关于修订抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒药品说明书的公告\n\n根据上述已知信息，请将'Under certain conditions, all drug dosage forms (tablets, pills, etc.) were disintegrated and passed the screen with the testing device prescribed by pharmacopeia'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以药典规定的检测装置在一定条件下测得药物剂型（片剂、丸剂等）全部崩解并通过筛"
    },
    {
        "instruction":"已知信息：\n'The Plate Method is the most commonly used USP <81> test. The Plate Method uses a solid \nmedium (agar) to demonstrate antibiotic activity (i.e. zones of inhibitions (ZOIs)). This method \nrequires the use of a five-point standard curve [S1] – [S5], median reference standard [S3], test \nantibiotic\/ unknown sample [U3], verified inoculum, stainless steel penicylinders and petri_x0002_plates containing growth agar. See Diagram 1 for an example of one independent test run for the \nPlate Method and placement of the standard curve and unknown sample onto triplicate agar \nplates.'可被翻译为：管碟法是最常使用的 USP<81>测试方法。管碟法使用固体培养基（琼脂）证明抗生素活性（即抑菌圈（ZOI））。该方法需要使用 5 点标准曲线【S1】-【S5】、中值标准品【S3】、供试抗生素\/未知样品【U3】、经过确认的接种物、不锈钢小管和含有生长琼脂的培养碟。参见图 1 中一次独立碟法测试及一式三份标准曲线和未知样品琼脂平板的放置示例。\n'The Tube Method further states: The percentage coefficient of determinations (%R2) for each \nstandard curve will be NLT 90% (i.e. correlation coefficient of NLT 0.950) and\n2) Absorbance values of the media reference standard [S3] are predetermined per antibiotic. \nRefer USP <81> for testing parameters and acceptable data requirements.'可被翻译为：浊度法还要求，每条标准曲线的测定百分比系数（%R2）应 NLT90%（即相关系数NLT0.950），且中值对照品【S3】的吸光度值要根据不同抗生素分别预先确定。参见USP<81>中检测参数和可接受数据要求。\n\n根据上述已知信息，请将'USP <81> states the following criteria for both the Plate and Tube Methods: 1) The calculated \npotency of the test antibiotic [U3] must be 80% to 125% of the median reference standard [S3] \n2) Relative standard deviation for all measured and calculated data is NMT 10% and 3) Testing \nis performed in triplicate over a period of three independent test runs. The Plate Method further \nstates: 1) The percentage coefficient of determinations (%R2) for each standard curve will be \nNLT 95% (i.e. correlation coefficient of NLT 0.9750) and 2) ZOIs for all media reference standard (S3 will measure between 14-16 mm). Refer to USP <81> for testing parameters and acceptable data requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"USP<81>要求管碟法和浊度法符合以下标准：（1）测试抗生素【U3】的计算效价必须为中值标准品【S3】的 80-125%，（2）所有测量数据和计算数据的相对标准偏差 NMT 10%，且（3）进行三次独立检测，每次测试一式三份样品。管碟法还要求：（1）每条标准曲线的测试百分比系数（%R2）NLT 95%（即相关系数 NLT 0.9750），且（2）所有中值标准品（S3）的 ZOI 应在 14-16mm。参见 USP<81>中检测参数和可接受数据要求。"
    },
    {
        "instruction":"已知信息：\n'(3) Class 3 chemical drugs are drugs manufactured by domestic applicants by imitating the original drugs that have been marketed overseas but not yet in China. They have identical active ingredients, dosage forms, specifications, indications, routes of administration, usage and dosage with those of the reference formulations, and have proven consistency of quality and efficacy with those of the reference formulations.'可被翻译为：（三）化学药品3类为境内生产的仿制境外已上市境内未上市原研药品的药品，具有与参比制剂相同的活性成份、剂型、规格、适应症、给药途径和用法用量，并证明质量和疗效与参比制剂一致。\n'(2) Class 2 chemical drugs, being modified new drugs, are optimized on the basis of known active ingredients, and shall have obvious clinical advantages over those before modification. Known active ingredients refer to the active ingredients of drugs that have been marketed in China or overseas. If such drugs meet the requirements of multiple conditions at the same time, such conditions shall be described at application.'可被翻译为：（二）化学药品2类为改良型新药，在已知活性成份基础上进行优化，应比改良前具有明显临床优势。已知活性成份指境内或境外已上市药品的活性成份。该类药品同时符合多个情形要求的，须在申报时一并予以说明。\n\n根据上述已知信息，请将'(5) Class 5 chemical drugs are drugs that have been marketed overseas and are under application for being marketed in China. Drugs manufactured in China and overseas are included. Among them, Class5.1 chemical drugs are original drugs and modified drugs, and the latter are optimized on the basis of known active ingredients, and shall have obvious clinical advantages over those before modification. Class 5.2 chemical drugs are generic drugs, whose quality and efficacy shall be proven to be consistent with those of the reference formulations, and whose technical requirements are the same as those of Class 3 and Class 4 chemical drugs. Generic drugs developed simultaneously at home and abroad but produced overseas shall be applied in accordance with Class5.2 chemical drugs. If clinical trials for such drugs are applied, the supporting documents for approval of marketing and sales can be exempted.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）化学药品5类为境外上市的药品申请在境内上市，包括境内外生产的药品。其中化学药品5.1类为原研药品和改良型药品，后者在已知活性成份基础上进行优化，应比改良前具有明显临床优势；化学药品5.2类为仿制药，应证明与参比制剂质量和疗效一致，技术要求与化学药品3类、4类相同。境内外同步研发的境外生产仿制药，应按照化学药品5.2类申报，如申报临床试验，不要求提供允许药品上市销售证明文件。"
    },
    {
        "instruction":"已知信息：\n'Isokinetic  sampling head - A sampling head designed to disturb the air as little as possible  so that the  same particles go into the nozzle as would have passed the area if the nozzle had not been there (i.e. the  sampling condition in which the mean velocity of the air entering the sample probe inlet is nearly the same (±20 percent) as the mean velocity of the airflow at that location).'可被翻译为：等速采样头：一种几乎不会扰乱空气的采样头、使进入管口的粒子与管口不存在时通过该区域的微粒相同，即，采样条件为进入样品探针入口处的空气流速与该位置气流的平均流速几乎相同(±20%）。\n'Air velocity test (Note: For grade B, C and D the air velocity test should be performed according to a risk assessment documented as part of the CCS. However, it is required for filling zones supplied with unidirectional airflow (e.g. when filling terminally sterilised products or background to grade A and RABS). For grades with non-unidirectional airflow, a measurement of recovery testing should replace velocity testing).'可被翻译为：风速测试（注：对于 B 级、C 级和 D 级，风速测试应按照风险评估的结果进行，并将该风险评估包含到CCS 中。但是，使用单向流的灌装区（例如，灌装最终灭菌产品时或 A 级和 RABS 的背景区）需要进行测试。对于非单向流的级别，应以自净测试代替风速测试）。\n\n根据上述已知信息，请将'A sampling head designed to disturb the air as little as possible so that the same particles go into the nozzle as would have passed the area if the nozzle had not been there (that is, the sampling condition in which the mean velocity of the air entering the sample probe inlet is nearly the same (± 20%) as the mean velocity of the airflow at that location).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种采样头，其设计目的是尽可能少地干扰空气，使进入喷嘴的颗粒与没有喷嘴时通过该区域的颗粒相同(即进入样品探头入口的空气的平均速度与该位置气流的平均速度几乎相同(±20%)的采样条件)。"
    },
    {
        "instruction":"已知信息：\n'(VI) Failing to take corresponding control measures according to the situation of adverse events and release to the public;'可被翻译为：（六）未根据不良事件情况采取相应控制措施并向社会公布的；\n'a detailed risk management plan;'可被翻译为：详细的风险管理计划；\n\n根据上述已知信息，请将'(6) fails to formulate a risk management plan after a drug goes to market; or'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）未制定药品上市后风险管理计划；"
    },
    {
        "instruction":"已知信息：\n'Article 67 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall establish and timely update the credit files of the registrant or the contract manufacturer of Class II and Class III medical devices within the jurisdiction area, the department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update the credit files of Class I medical device filing entity or the contract manufacturer within the jurisdiction area according to its duties.'可被翻译为：第六十七条  省、自治区、直辖市药品监督管理部门应当建立并及时更新辖区内第二类、第三类医疗器械注册人、受托生产企业信用档案，设区的市级负责药品监督管理的部门应当依法按照职责建立并及时更新辖区内第一类医疗器械备案人、受托生产企业信用档案。\n'Article 18 The third-party platform shall submit the enterprise name, legal representative, unified social credit identifier, website name, domain name and other information to the provincial drug regulatory department where the platform is located for filing. The provincial drug regulatory department shall publicize the filing information of the platform.'可被翻译为：第十八条 第三方平台应当将企业名称、法定代表人、统一社会信用代码、网站名称以及域名等信息向平台所在地省级药品监督管理部门备案。省级药品监督管理部门应当将平台备案信息公示。\n\n根据上述已知信息，请将'Article 68 The drug regulatory department shall record the varieties of the products manufactured by the enterprise in the credit file.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十八条  药品监督管理部门应当在信用档案中记录企业生产产品品种情况。"
    },
    {
        "instruction":"已知信息：\n'The molecule contains groups that can absorb UV-visible light and produce electronic transition structures.'可被翻译为：分子中含有能吸收紫外-可见光而产生电子跃迁结构的基团。\n'The phenomenon of enhanced absorption at the short wavelength end of the ultraviolet absorption spectrum. It is produced when the molecules are excited by ultraviolet light, and the electrons in the molecular orbit absorb the photons from the ground state to the excited state, generally located between 180 and 220nm.'可被翻译为：紫外吸收光谱中位于短波末端所出现的吸收增强的现象。是分子在紫外光激发下，分子轨道上的电子吸收了光子后由基态激发到激发态上而产生的，一般位于180~220nm之间。\n\n根据上述已知信息，请将'After absorbing a certain wavelength of infrared light, molecules transition from the ground state to the second or even the third excited state to produce infrared absorption bands.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分子吸收一定波长的红外光后，从基态跃迁到第二激发态甚至第三激发态产生的红外吸收带。"
    },
    {
        "instruction":"已知信息：\n'(1) name, model, specification, and quantity of the medical device;'可被翻译为：（一）医疗器械的名称、型号、规格、数量；\n'(1) The information of the investigational medical device, including name, model, specification, date of receipt, lot number or serial number;'可被翻译为：（一）所使用的试验用医疗器械的信息，包括名称、型号、规格、接收日期、批号或者系列号等；\n\n根据上述已知信息，请将'(1) name, model, specification, registration certificate number or filing number, quantity, unit price and amount of the medical devices;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）医疗器械的名称、型号、规格、注册证编号或者备案编号、数量、单价、金额；"
    },
    {
        "instruction":"已知信息：\n'(I) to verify, item by item, whether the materials submitted are complete and true;'可被翻译为：（一）逐项核查所报资料是否完整、真实；\n'4. Speciation- Record and copy the method of identification (i.e. API, Vitek, etc.). Determine if there were possible secondary contaminants that were not identified or recorded (check original plates, or isolates); verify accuracy of entry into the LIM system.'可被翻译为：物种形成—记录和复制鉴别方法（即 API，Vitek 等）。确定是否有可能未发现或记录二次污染（检查原始平板或分离物）；核查录入 LIMS 系统的数据准确性。\n\n根据上述已知信息，请将'7. Worksheets - Review possible falsification or incorrect entry onto worksheets or Laboratory LIM system.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"工作表—审核是否存在伪造或不正确录入记录或实验室 LIMS 系统的可能性"
    },
    {
        "instruction":"已知信息：\n'(1) failing to supply, receive, and purchase vaccines as required;'可被翻译为：（一）未按照规定供应、接收、采购疫苗；\n'(1) performing responsibility insufficiently, resulting in serious negative effects or heavy losses;'可被翻译为：（一）履行职责不力，造成严重不良影响或者重大损失；\n\n根据上述已知信息，请将'(7) having any other dereliction of duty in vaccine administration, resulting in serious negative effects or heavy losses.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（七）其他未履行疫苗监督管理职责的行为，造成严重不良影响或者重大损失。"
    },
    {
        "instruction":"已知信息：\n'The process of putting a new label on the material (see also labelling).'可被翻译为：将新标签贴在材料上的过程(参见标签)。\n'Provisions for Instructions and Labels of Medical Devices'可被翻译为：医疗器械说明书和标签管理规定\n\n根据上述已知信息，请将'(VI) Revising the instructions, labels and operating manual, etc.;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）修改说明书、标签、操作手册等；"
    },
    {
        "instruction":"已知信息：\n'The applicant shall be subject to inspection within the specified timeline.'可被翻译为：申请人应当在规定时限内接受核查。\n'Article 38 For the purpose of the Provisions, importer includes distribution enterprises, the consignee and the applicant for testing.'可被翻译为：第三十八条 本办法所称进口单位，包括经营单位、收货单位和报验单位。\n\n根据上述已知信息，请将'The consignee and the applicant for testing may be the same.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"收货单位和报验单位可以为同一单位。"
    },
    {
        "instruction":"已知信息：\n'Any adventitiously introduced materials (e.g., chemical, biochemical, or microbial species) not intended to be part of the manufacturing process of the drug substance or drug product.'可被翻译为：任何引入的非原液或成品生产工艺预期部分的外源性物质(如化学、生化物质或微生物)。\n'10. Reagents used for microorganism identification and medicine sensitivity experiment.'可被翻译为：10.用于微生物鉴别或者药敏试验的试剂；\n\n根据上述已知信息，请将'1. Microorganism culture medium (not applicable to microorganism identification and drug sensitivity testing).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.微生物培养基（不用于微生物鉴别和药敏试验）；"
    },
    {
        "instruction":"已知信息：\n'A thin-layer chromatography technique developed on the basis of the high separation efficiency obtained by using a homogeneous stationary phase of fine particles in the high performance liquid chromatography.'可被翻译为：参考高效液相色谱仪使用均一的微细颗粒固定相而得到高分离效率的基础上发展起来的一种薄层色谱技术。\n'The method of electrophoretic analysis using solid thin layer as support.'可被翻译为：以固体薄层为支持物进行电泳的分析方法。\n\n根据上述已知信息，请将'The stationary phase is spread on the solid in a uniform thin layer for separation and analysis method of chromatography.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将固定相在固体上铺成均匀薄层进行色谱的分离、分析方法。"
    },
    {
        "instruction":"已知信息：\n'Article 63 The drug regulatory departments shall, based on their responsibilities, supervise and inspect the medical device adverse event monitoring and re-evaluation carried out by MAHs and distributing enterprises, and supervise and inspect the medical device adverse event monitoring by user facility of medical device jointly with the health administrative departments at the same level.'可被翻译为：第六十三条  药品监督管理部门应当依据职责对持有人和经营企业开展医疗器械不良事件监测和再评价工作情况进行监督检查，会同同级卫生行政部门对医疗器械使用单位开展医疗器械不良事件监测情况进行监督检查。\n'Article 11 Health administrative departments of the State Council and health administrative departments at all levels shall be responsible for supervision and administration of user facility of medical device related to medical device adverse event monitoring, urge user facility of medical device to carry out relevant medical device adverse event monitoring work and organize inspection, strengthen  assessment of medical device adverse event monitoring, and take relevant control measures for medical device adverse events within their responsibility according to law.'可被翻译为：第十一条  国务院卫生行政部门和地方各级卫生行政部门负责医疗器械使用单位中与医疗器械不良事件监测相关的监督管理工作，督促医疗器械使用单位开展医疗器械不良事件监测相关工作并组织检查，加强医疗器械不良事件监测工作的考核，在职责范围内依法对医疗器械不良事件采取相关控制措施。\n\n根据上述已知信息，请将'Article 52 The drug regulatory departments and health administrative departments at all levels may entrust medical device inspection agencies with corresponding qualification to inspect the products involved in medical device adverse events when necessary. A medical device testing institution shall perform the test promptly and issue the test report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条  各级药品监督管理部门和卫生行政部门必要时可以将医疗器械不良事件所涉及的产品委托具有相应资质的医疗器械检验机构进行检验。医疗器械检验机构应当及时开展相关检验，并出具检验报告。"
    },
    {
        "instruction":"已知信息：\n'For imported medical devices, overseas registration applicants (filing applicants)shall apply for registration (handle the filling). For medical devices manufactured in China by overseas enterprises, domestic manufacturing enterprises shall apply for registration (handle the filing) as the registration applicants (filing applicants).'可被翻译为：进口医疗器械，应当由境外注册申请人（备案人）申请注册（办理备案）；境外企业在境内生产的医疗器械，应当由境内生产的企业作为注册申请人（备案人）申请注册（办理备案）。\n'The agent appointed by the overseas manufacturer of imported medical devices within the territory of China shall, in a timely manner, report relevant information of the recall of medical devices implemented only overseas to the China Food and Drug Administration; for any recall within the territory of China, the agent appointed within the territory of China shall organize and implement the recall in accordance with these Provisions.'可被翻译为：进口医疗器械的境外制造厂商在中国境内指定的代理人应当将仅在境外实施医疗器械召回的有关信息及时报告国家食品药品监督管理总局；凡涉及在境内实施召回的，中国境内指定的代理人应当按照本办法的规定组织实施。\n\n根据上述已知信息，请将'The medical device manufacturers mentioned in the preceding paragraph refer to the registrants or filing entities of the domestic medical device products, and the agents appointed by the overseas manufacturer of imported medical devices within the territory of China.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"前款所述医疗器械生产企业，是指境内医疗器械产品注册人或者备案人、进口医疗器械的境外制造厂商在中国境内指定的代理人。"
    },
    {
        "instruction":"已知信息：\n'Analytical equipment and tools used in sterility analysis and suitability should be cleaned and sterilized using a validated sterilization procedure. Commercially purchased equipment and tools should be labeled sterile and accompanied by a certificate of analysis for sterility.'可被翻译为：无菌分析和适用性中所用的分析仪器和工具应使用经验证的灭菌程序进行清洁和灭 菌。商业购买的设备和工具应贴上无菌标签，并附有无菌分析证书。\n'An uninoculated media and rinse fluid control are analyzed to ensure sterility at time of use.'可被翻译为：对未接种培养基和淋洗液控制进行分析，以确保使用时的无菌性。\n\n根据上述已知信息，请将'a. Review QC records for proper\/validated sterilization of all equipment and media used during the sterility test method: manifold\/ Steritest; rinse fluid, culture media, canister kits, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审核 QC 记录，查看无菌检测中所用的所有设备和培养基是否均有经过恰当\/经验证的灭菌：歧管\/ Steritest 检验系统；冲洗液、培养基、灌装配套工具等"
    },
    {
        "instruction":"已知信息：\n'The administrative department that examines and approves, supervises and penalizes the research, production, distribution and use of drugs according to law.'可被翻译为：依法对药品的研制、生产、经营、使用进行审批、监督及违法处罚的行政部门。\n'Where the party concerned has evidences that are sufficient to prove that it has no subjective fault, there shall be no administrative punishment. If there are separate provisions by laws and administrative regulations, such provisions shall prevail.'可被翻译为：当事人有证据足以证明没有主观过错的，不予行政处罚。法律、行政法规另有规定的，从其规定。\n\n根据上述已知信息，请将'The administrative body of drug supervision and administration. Supervision and inspection of the other party's compliance with laws, administrative regulations, administrative orders, decisions and measures in accordance with its statutory functions and powers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理的行政主体。依照法定职权，对行政相对方是否遵守法律、行政法规、行政命令、决定和措施所进行的监督检查。"
    },
    {
        "instruction":"已知信息：\n'Article 2 All medical devices sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'可被翻译为：第二条 在中华人民共和国境内销售、使用的医疗器械,应当按照本办法的规定申请注册或者办理备案。\n'Article 2  For medical devices sold and used within the territory of the People's Republic of China, their UDI system shall comply with the requirements of the Rules.'可被翻译为：第二条 在中华人民共和国境内销售、使用的医疗器械，其唯一标识系统应当符合本规则。\n\n根据上述已知信息，请将'Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。"
    },
    {
        "instruction":"已知信息：\n'The action of chemical or biological materials that can trigger the development of cancer.'可被翻译为：化学或生物材料可引发癌症发生的作用。\n'The DNA of some cells has been mutated, but the phenotype is still normal, which can enable the expression of various malignant traits of these cells and become the substance of true malignant cells.'可被翻译为：有些细胞DNA已突变，但表型仍正常，能使这些细胞的各种恶性性状得以表达，成为真正的恶性细胞的物质。\n\n根据上述已知信息，请将'A substance that does not react with DNA and may indirectly affect DNA and alter the genome to cause cells to become cancerous or cause cancer by promoting growth or enhancement.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不与DNA反应，可能间接影响DNA并改变基因组导致细胞癌变或通过促长，增强作用导致癌产生的物质。"
    },
    {
        "instruction":"已知信息：\n'1.Analysis of active pharmaceutical ingredients (APIs), pharmaceutical excipients, packaging material or pharmaceutical products according to the requirements of a pharmacopoeial monograph or a specification in an approved marketing authorization.\n2.A regime of testing to verify that a lot complies with the specification.'可被翻译为：1.活性药物成分(api)、药用辅料、包装材料或药品根据药典各论的要求或已批准上市许可的规范进行分析。\n2.一套测试制度，以验证产品是否符合规格。\n'GMP good manufacturing practices'可被翻译为：优良生产规范\n\n根据上述已知信息，请将'The evaluation of documentary evidence by a competent regulatory authority recognized by the national regulatory authority, for compliance with the required good practices (good manufacturing practices (GMP), good laboratory practices and good clinical practices) in support of marketing authorization and other regulatory decisions. Desk assessment may be performed in support of a new marketing authorization, or for routine GMP inspection (including in the frame of specified product(s) life-cycle management as required).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由国家监管机构认可的主管监管机构对文件证据的评估，以证明符合所需的良好规范(良好生产规范(GMP)、良好实验室规范和良好临床规范)，以支持上市许可和其他监管决定。案头评估可用于支持新的上市许可，或用于常规GMP检查(包括在所要求的指定产品生命周期管理框架内)。"
    },
    {
        "instruction":"已知信息：\n'CDE accepted 5,979 applications for registration of chemical drugs, of which107 were for NDAs, an increase of 43%compared with 2017; and 982 applications were for ANDAs (generic drugs), an increase of 79% compared with 2017. The details of the acceptance of registration application for various classes of chemical drugs are shown in Figure 2. The 2015-2018 acceptance of registration applications for clinical trial,marketing and consistency evaluation of chemical drugs is detailed in Figure 3.'可被翻译为：药审中心受理化药注册申请共5979件，其中受理化药NDA申请107件，较2017年增长了43%；受理仿制药上市申请（ANDA）982件，较2017年增长了79%。化药各类注册申请受理情况详见图2。2018年化药临床、上市和一致性评价注册申请受理情况与近三年比较详见图3。\n'CDE completed the review of registration applications for 6,624 chemical drugs, including 843 clinical applications (IND and confirmatory trial), 206 NDAs, and 2,353 ANDAs. See Figure 14 for details of the various registration applications for chemical drugs that have been reviewed.'可被翻译为：药审中心完成审评的化药注册申请6624件，其中完成化药临床申请（IND和验证性临床）共843件，完成化药NDA 206件，完成化药ANDA 2353件。完成审评的化药各类注册申请情况详见图14。\n\n根据上述已知信息，请将'Of the 8,077 drug registration applications accepted by CDE, 80.2% (6,475) of the total are chemical drugs applications in 2019. See Figure 1 for the acceptance of registration applications for various classes of drugs in 2016-2019.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药审中心受理的8077件药品注册申请中，化学药注册申请受理量为6475件，占2019年全部注册申请受理量的80.2%，2016-2019年各类药品注册申请受理情况详见图1。"
    },
    {
        "instruction":"已知信息：\n'The genetic information carried by the nucleotide sequence. A set of 64 triplet codons that encode the start and end of 20 amino acid and polypeptide chains.'可被翻译为：核昔酸序列所携带的遗传信息。编码20种氨基酸和多肽链起始及终止的一套64个三联体密码子。\n'The determination of the nucleotide sequence of the DNA molecule, that is, the sequence of the A, T, G, and C components of the DNA molecule. Common methods include Sanger - Courson method and Maxam - Gilbert method.'可被翻译为：对DNA分子的核昔酸排列顺序的测定，也就是测定组成DNA分子的A、T、G、C的排列顺序。常用的方法有桑格-库森法和马克萨姆-吉尔伯特法等。\n\n根据上述已知信息，请将'The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。"
    },
    {
        "instruction":"已知信息：\n'ensure that the necessary equipment for QC is available and qualified at the RU site. The equipment used by the RU during the analytical transfer should meet the appropriate specifications in order to ensure the requirements of the method or specification are met;'可被翻译为：确保QC具备所需的仪器，并经过确认。分析方法转移期间RU所用仪器应符合适当的标准，以确保满足方法要求或标准要求；\n'4.4. The assessment should further cover resources including personnel, premises, equipment and instruments, utilities, QC, documentation, computerized systems, qualification, validation and further HSE-related considerations including waste management.'可被翻译为：评估应进一步覆盖到资源方面，包括人员、设施、设备和仪器、公用系统、QC、文件、计算机化系统、确认和验证及与HSE有关的更多考量，包括三废管理。\n\n根据上述已知信息，请将'5.12. The SU should assess the suitability and degree of preparedness of the RU before transfer, with regard to premises, equipment and support services (e.g. purchasing and inventory control mechanisms and pharmaceutical quality system - QC procedures, documentation, computer validation, site validation, equipment qualification, water for pharmaceutical production and waste management).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"转移前SU应评估RU的在设施、设备和支持服务（例如采购和库存控制机制和药物质量体系—QC程序、文件、计算机验证、场所验证、设备确认、制药生产用水和三废管理）方面的适合度和准备就绪程度。"
    },
    {
        "instruction":"已知信息：\n'The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve.'可被翻译为：仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。\n'The interval between the upper and lower concentration (amounts) of analyte in the calibration standards (including these concentrations)'可被翻译为：校正标样中待测物的高、低浓度区间（包括两端浓度）。\n\n根据上述已知信息，请将'A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。"
    },
    {
        "instruction":"已知信息：\n'The potential to induce direct DNA damage through chemical reaction with DNA.'可被翻译为：通过与DNA发生化学反应直接诱导DNA损伤的潜在能力。\n'Not involving or derived from biology or living organisms.'可被翻译为：不涉及或来源于生物学或活的有机体的。\n\n根据上述已知信息，请将'Electrophilic compounds and their metabolites form covalent conjugates with DNA in living organisms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"亲电性化合物及其代谢产物和生物体内的DNA形成的共价结合物。"
    },
    {
        "instruction":"已知信息：\n'A reference stringent regulatory authority that agrees to provide outcomes of its regulatory expertise (especially assessment and inspection reports) to applicants\/authorization holders or inspected manufacturers, does not object to sharing of these documents with national medicines regulatory authorities and provides, under specified conditions in line with the principles of the Procedure, support to other parties involved in the Procedure.'可被翻译为：参考严格监管机构同意向申请人\/授权持有人或被检查制造商提供其监管专业知识的结果(特别是评估和检查报告)，不反对与国家药品监管机构共享这些文件，并在符合程序原则的规定条件下向程序涉及的其他各方提供支持。\n'Registration procedure in which assessment and national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities (reference SRAs) is facilitated and accelerated by sharing of detailed assessment and inspection outcomes generated by a reference SRA'可被翻译为：通过分享参考SRA产生的详细评估和检查结果，促进和加速了对经严格监管机构(参考SRA)批准的药品和疫苗进行评估和国家注册的注册程序\n\n根据上述已知信息，请将'A regulatory authority that agrees to provide outcomes of its regulatory expertise (especially assessment and inspection reports) to applicants\/authorization holders or inspected manufacturers; agrees to sharing of these documents with national regulatory authorities; and provides, under specified conditions in line with the principles of the Procedure, support to other parties involved in the Procedure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"同意向申请人\/授权持有人或被检查制造商提供其监管专业知识结果(特别是评估和检查报告)的监管机构;同意与国家监管机构共享这些文件;并在符合程序原则的特定条件下，向参与程序的其他各方提供支持。"
    },
    {
        "instruction":"已知信息：\n'Raw material controls - including in-process controls'可被翻译为：原辅料控制——包括过程控制\n'For materials, equipment, components and ancillary items that are not a direct or indirect product contact part\nand are necessary for aseptic processing but cannot be sterilised, an effective and validated disinfection and\ntransfer process should be in place. These items, once disinfected, should be protected to prevent recontamination.\nThese items, and others representing potential routes of contamination, should be included in the environmental\nmonitoring programme.'可被翻译为：对于不直接或间接接触产品，并且是无菌工艺所必需但不能灭菌的物料、设备、组件和辅助用品，应建立有效且经验证的消毒和转移程序。消毒后应采取保护措施，防止物品再污染。这些物品以及代表潜在污染途径的其它因素应包含在环境监测计划中。\n\n根据上述已知信息，请将'Alternatively, controls for these materials are accomplished as part of the \"system control\" for each manifold. This will also include membrane cutters, and other items that contact the product but cannot be individually controlled.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"或者，完成对这些材料的控制，作为每个歧管的“系统控制”的一部分。这还将 包括薄膜切割器和其他接触产品但无法单独控制的物品。"
    },
    {
        "instruction":"已知信息：\n'The extent to which the results of a particular study or systematic review can be extrapolated to other Settings.'可被翻译为：某种研究或者系统综述的结果能够外推于其他环境的程度。\n'The source data refers to the original records of clinical findings, observations and other activities in the clinical trial and all information of approved copies, which can be used for clinical trial reconstruction and evaluation.'可被翻译为：源数据，是指临床试验中的临床发现、观察和其他活动的原始记录以及其经核准的副本中的所有信息，可以用于临床试验重建和评价。\n\n根据上述已知信息，请将'The extent to which the findings of a clinical trial can be reliably extrapolated from the subjects who participated in the trial to a broader patient population and a broader range of clinical settings.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指将临床试验的发现从参与试验的受试者可靠地外推到更广泛的患者人群和临床环境的程度。"
    },
    {
        "instruction":"已知信息：\n'A method of assessing the level of air cleanliness against a specification for a cleanroom or clean air equipment by measuring the total particle concentration.'可被翻译为：根据洁净室或洁净空气设备的规格，通过测量总颗粒浓度来评估空气洁净度水平的一种方法。\n'Air filter with a filtration efficiency of more than 99.97% for dust particles with a particle size of 0.3nm. Can be used to filter dust smaller than Ijim.'可被翻译为：对粒径0.3nm尘粒的滤过效率在99.97%以上的空气滤过器。可用于滤除小于Ijim的尘埃。\n\n根据上述已知信息，请将'It mainly measures the size of dust particles in the air and counts the concentration, which is used to monitor the cleanliness of the air.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"主要测量空气中尘埃粒子的大小以及计数浓度，用于监测空气洁净度。"
    },
    {
        "instruction":"已知信息：\n'enzyme'可被翻译为：酶\n'A way of numeralizing the molecular structure, obtained by performing some kind of numerical operation on the matrix that characterizes the molecular diagram. It is used to describe the chemical structure and is related to the physical properties, thermodynamic parameters, chemical properties, and biological activities of a compound.'可被翻译为：分子结构数值化的一种方式，通过对表征分子图的矩阵实施某种数字运算而获得。用于描述化学结构，并且与化合物的物理性质、热力学参数、化学性能和生物活性等相关。\n\n根据上述已知信息，请将'A group of enzymes that catalyze the same chemical reaction but differ in molecular structure, physicochemical properties, and even immunological properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"催化作用的化学反应相同而分子结构、理化性质乃至免疫学性质不同的-组酶。"
    },
    {
        "instruction":"已知信息：\n'transformation'可被翻译为：转化\n'Identification of worst case conditions covering the relevant variables, such as container size and line speed, and\ntheir impact on the process. The outcome of the assessment should justify the variables selected.'可被翻译为：确定最差条件，并涵盖相关变量，例如容器尺寸和生产线速度以及它们对工艺的影响。评估的结果应证明选择的变量是合理的。\n\n根据上述已知信息，请将'For a given set of variables, a new set of variables is generated by mathematical transformation. These new variables are linear functions of the original set of variables, but the two new variables are unrelated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对给定的一组变量，通过数学变换生成新一组的变量，这些新变量是原来一组变量的线性函数，两个新变量之间却是互不关联的。"
    },
    {
        "instruction":"已知信息：\n'The addition of electrolyte in the suspension system increases the J potential of the surface of the particles, and the increase of electrostatic repulsion hinders the collision and aggregation of the particles, making the process of reducing the flocculation phenomenon.'可被翻译为：在混悬体系中加入电解质使微粒表面J电位升高，这时静电排斥力的增大阻碍了微粒间的碰撞聚集，使得絮凝现象减少的过程。\n'If the appropriate amount of electrolyte is added to the suspension, the J potential can be reduced to an appropriate degree, even if the repulsive force between the particles is slightly lower than the attractive force, at this time the particles gather into a loose flocculent aggregate, which can be restored to a uniform suspension by shaking, the added electrolyte is called a flocculant.'可被翻译为：混悬剂中如果加入适量的电解质，可使J电位降低到适当的程度，即使微粒间的排斥力稍低于吸引力，此时微粒聚集成疏松的絮状聚集体，经振摇可恢复成均匀的混悬剂，所加电解质称为絮凝剂。\n\n根据上述已知信息，请将'If the electrolyte is added to the suspension to increase the potential of the particle surface, the electrostatic repulsion hinders the collision between the particles and the aggregation, the flocculation state disappears, the added electrolyte is called the deflocculant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在混悬剂中因加入电解质使微粒表面的&电位升高，静电排斥力阻碍了微粒之间的碰撞聚集，絮凝状态消失，所加入的电解质称为反絮凝剂。"
    },
    {
        "instruction":"已知信息：\n'ophthalmic preparation'可被翻译为：眼用制剂\n'The semi-solid ophthalmic preparation is made of a sterile solution or a suspended paste, which is evenly mixed with a suitable substrate.'可被翻译为：由药物与适宜基质均匀混合，制成无菌溶液型或混悬型膏状的眼用半固体制剂。\n\n根据上述已知信息，请将'A pasteurized preparation for ophthalmic use made of medicine and a suitable substrate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物与适宜基质制成的供眼用的膏状灭菌制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 7: The manufacturer should be adequately resourced with competent personnel, suitable and sufficient premises, equipment and facilities for achieving its quality objective.'可被翻译为：第七条 企业应当配备足够的、符合要求的人员、厂房、设施和设备，为实现质量目标提供必要的条件。\n'1.This is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n2.A system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to good engineering practice only.'可被翻译为：1.这是一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据GEP进行设计和调试。\n2.一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据良好的工程实践进行设计和调试。\n\n根据上述已知信息，请将'The manufacturer has sufficient knowledge and expertise in relation to the products manufactured and the equipment, engineering and manufacturing methods employed that have an impact on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产商对所生产的产品以及对产品质量有影响的设备、工程和制造方法具备充分的知识和专业技能。"
    },
    {
        "instruction":"已知信息：\n'A certified, homogeneous substance used for specific chemical and physical tests. One or more properties of the chemical reference required in the test to be compared with the sample to be tested, and the chemical reference should be of an appropriate purity for its purpose.'可被翻译为：用于特定化学和物理检测的经过检定、性质均匀的物质。在检测中需要化学对照品的一个或多个性质与待测样品进行比较，化学对照品应具有满足其用途的适当纯度。\n'The documented process by which an analytical procedure (or method) is demonstrated to be suitable for its intended use.'可被翻译为：证明分析程序(或方法)适合其预期用途的形成文件的过程。\n\n根据上述已知信息，请将'1.The term chemical reference substances, as used in this text, refers to an authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use.\n2.An authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.本文所用的“化学对照物质”一词是指一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有足以满足其预期用途的纯度。\n2.一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有适合其预期用途的纯度。"
    },
    {
        "instruction":"已知信息：\n'Article 41 The undertaking of drug manufacturing shall be subject to approval by the local drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the central government, and shall obtain a Drug Manufacturing Certificate. No one may manufacture drugs without the certificate.'可被翻译为：第四十一条 从事药品生产活动，应当经所在地省、自治区、直辖市人民政府药品监督管理部门批准，取得药品生产许可证。无药品生产许可证的，不得生产药品。\n'(5) a drug manufacturer that conducts repackaging shall hold the Drug Manufacturing Certificate. To apply for repackaging of import unpackaged tablets and capsules, the manufacturer shall also hold the GMP certificate covering the dosage forms for repackaging; and'可被翻译为：（五）接受分包装的药品生产企业，应当持有《药品生产许可证》。进口裸片、胶囊申请在国内分包装的，接受分包装的药品生产企业还应当持有与分包装的剂型相一致的《药品生产质量管理规范》认证证书；\n\n根据上述已知信息，请将'Article 9 An entity which applies for port testing shall be an independent legal entity and hold the Drug Supply Certificate. A drug manufacturer shall hold the Drug Manufacturing Certificate to import the active pharmaceutical ingredients and intermediate (including pharmaceutical preparations for re-packaging within China) used for its own manufacture.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九条 报验单位应当是持有《药品经营许可证》的独立法人。药品生产企业进口本企业所需原料药和制剂中间体（包括境内分包装用制剂），应当持有《药品生产许可证》。"
    },
    {
        "instruction":"已知信息：\n'The infusion of nutrients into the patient's body by a completely non-gastrointestinal route. It is of great significance for the treatment of certain diseases, especially for critically ill patients who cannot be taken orally, playing a life-saving role.'可被翻译为：完全由非胃肠途径输入病人体内的营养。它对于某些疾病的治疗有着重要的意义，特别对于不能口服的危重病人，起到挽救生命的作用。\n'A diet formulated according to the nutrient requirements of the human body and with reference to the amino acid patterns of high-quality proteins such as human milk and eggs and nutrients such as sugars, fats, vitamins and inorganic salts.'可被翻译为：以人体营养素需要量为标准，并参照优质蛋白如人乳、鸡蛋等氨基酸模式和糖、脂肪、维生素、无机盐等营养素配制而成的膳食。\n\n根据上述已知信息，请将'A type of intravenous infusion. Clinical according to the needs of special conditions, the injection containing essential nutrients - amino acids, fats, carbohydrates, vitamins, trace elements, etc., is directly injected into the vein administration method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"静脉输液的一种。临床针对特殊病情需要，将含有人体必需的营养素--氨基酸、脂肪、碳水化合物、维生素、微量元素等的注射液直接注射入静脉的给药方法。"
    },
    {
        "instruction":"已知信息：\n'(IX) Break-bulk drugs whose outer packages have been removed shall be stored in a centralized manner;'可被翻译为：（九）拆除外包装的零货药品应当集中存放；\n'(VII) Storage of refrigerated drugs in business premises;'可被翻译为：（七）营业场所冷藏药品的存放；\n\n根据上述已知信息，请将'(VII) Break-bulk drugs: drugs with their packaging for transportation and storage removed;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（七）零货：拆除了用于运输、储藏包装的药品。"
    },
    {
        "instruction":"已知信息：\n'biochemical engineering'可被翻译为：生化工程\n'The cross discipline of chemical engineering and industrial manufacturing engineering. Based on pharmacy, biology, chemical engineering and technology, the research scope covers chemical drug synthesis and process, biological separation engineering, pharmaceutical engineering and equipment, preparation process design, quality control, etc.'可被翻译为：化学工程和工业制造工程学的交叉学科。以药学、生物学、化学工程与技术为基础，研究范围涉及化学药物合成和工艺、生物分离工程、制药工程与设备、制剂工艺设计、质量控制等。\n\n根据上述已知信息，请将'An important part of bioengineering, including substrate or nutrient solution preparation, pretreatment, transformation and product separation, refining and other engineering and technology. Generally, fermentation engineering, large-scale culture of plant and animal cells, enzyme engineering, biochemical reaction engineering, biological separation engineering (downstream engineering), biological functional components (such as enzyme electrodes, etc.) and the control and optimization of biological processes are included in biochemical engineering.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生物工程的重要组成部分，包括底物或营养液的准备、预处理、转化以及产品的分离、精制等工程和工艺。一般把发酵工程、动植物细胞的大规模培养、酶工程、生化反应工程、生物分离工程（下游工程）、生物功能元件（如酶电极等）以及生物过程中的控制和优化都包括在生化工程之内。"
    },
    {
        "instruction":"已知信息：\n'Action to eliminate the cause of a detected non-conformity or other undesirable situation. NOTE: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence. (ISO 9000:2005)'可被翻译为：为消除已发现的违规或其他非期望状况的原因(所采取)的措施。注:采取纠正措施是为了防止(事情)再次发生，而采取预防措施是为了防止(事情)发生。 (ISO 9000:2005)\n'1.Steps taken to eliminate the cause of existing nonconformities in order to prevent recurrence. The corrective action process tries to make sure that existing nonconformities and potentially undesirable situations do not happen again.\n2.Steps that are taken to eliminate the causes of existing nonconformities in order to prevent recurrence. The corrective action process tries to ensure that existing nonconformities and potentially undesirable situations do not happen again.'可被翻译为：1.为消除现有不合格的原因而采取的步骤，以防止不合格的再次发生。纠正措施过程试图确保已存在的不符合和潜在的不良情况不再发生。\n2.为消除现有不符合的原因，防止不符合再次发生而采取的步骤。纠正措施过程试图确保已存在的不符合和潜在的不期望情况不再发生。\n\n根据上述已知信息，请将'Any action that is taken to eliminate a nonconformity. However, corrections do not address causes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为消除不符合而采取的任何措施。然而，纠正不解决原因。"
    },
    {
        "instruction":"已知信息：\n'Article 39 After completion of a clinical trial, the applicant shall submit a clinical trial final report, a statistical analysis report and its database to the State Food and Drug Administration.'可被翻译为：第三十九条 申请人完成临床试验后，应当向国家食品药品监督管理局提交临床试验总结报告、统计分析报告以及数据库。\n'Article 36 The clinical trial institution shall respectively provide the clinical trial report after completing the clinical trial. The applicant or leading unit of clinical trial shall summarize the results of clinical trials and complete the final report according to the relevant technical guidelines.'可被翻译为：第三十六条 临床试验机构完成临床试验后，应当分别出具临床试验报告。申请人或者临床试验牵头单位根据相关技术指导原则，对临床试验结果进行汇总，完成临床试验总结报告。\n\n根据上述已知信息，请将'(4) the applicant shall submit a complete clinical trial report to the State Food and Drug Administration after the completion of a clinical trial; and'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）临床试验结束后，申请人应当将完整的临床试验报告报送国家食品药品监督管理局；"
    },
    {
        "instruction":"已知信息：\n'Article 41 For an accepted registration application, where there are evidences indicating that the registration application materials may be spurious, the food and drug regulatory department shall suspend the evaluation and approval process. After investigation, the food and drug regulatory department shall determine to continue the process or to reject the registration application in accordance with the investigation conclusion.'可被翻译为：第四十一条 对于已受理的注册申请，有证据表明注册申报资料可能虚假的，食品药品监督管理部门可以中止审批。经核实后，根据核实结论继续审查或者作出不予注册的决定。\n'Article 39 For accepted registration applications, where one of the following circumstances exists, the food and drug regulatory department shall decide to reject the application and notify the applicant:'可被翻译为：第三十九条 对于已受理的注册申请，有下列情形之一的，食品药品监督管理部门作出不予注册的决定，并告知申请人：\n\n根据上述已知信息，请将'Article 51 For an accepted registration application, where there are evidences indicating that the registration application materials may be spurious, the food and drug regulatory department shall suspend the evaluation and approval process. After investigation, the food and drug regulatory department shall determine to continue the process or to reject the registration application in accordance with the investigation conclusion.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十一条 对于已受理的注册申请，有证据表明注册申报资料可能虚假的，食品药品监督管理部门可以中止审批。经核实后，根据核实结论继续审查或者作出不予注册的决定。"
    },
    {
        "instruction":"已知信息：\n'The date of the first marketing authorisation for any product containing the active substance granted to any company in any country in the world.'可被翻译为：任何公司的任何含有活性物质的药品在世界上任何国家\/区域被首次批准上市销售的日期。\n'interventional clinical trial'可被翻译为：干预性临床试 验\n\n根据上述已知信息，请将'Date of first approval (or authorisation) for conducting an interventional clinical trial in any country.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"干预性临床试验在任何国家首次获准（或许可的）的日期。"
    },
    {
        "instruction":"已知信息：\n'Article 79 The investigator may, according to the needs of the clinical trial, authorize corresponding personnel to recruit subjects, communicate with the subjects, record the clinical data and manage the investigational medical device. The investigator shall carry out relevant training and form the corresponding document for the personnel authorized.'可被翻译为：第七十九条 研究者可以根据临床试验的需要，授权相应人员进行受试者招募、与受试者持续沟通、临床试验数据记录、试验用医疗器械管理等。研究者应当对其授权的人员进行相关的培训并形成相应的文件。\n'Article 70 The investigator is responsible for making medical decisions related to the clinical trial. When any adverse event related to the clinical trial occurs, the clinical trial institution and the investigator shall ensure that the subjects are in a timely manner provided with adequate treatment and solution. When the subjects develop complications which require treatment, the investigator shall promptly inform the subjects of the situation.'可被翻译为：第七十条 研究者负责作出与临床试验相关的医疗决定，在发生与临床试验相关的不良事件时，临床试验机构和研究者应当保证为受试者提供足够、及时的治疗和处理。当受试者出现并发疾病需要治疗和处理时，研究者应当及时告知受试者。\n\n根据上述已知信息，请将'Article 67 The investigator is responsible for recruiting subjects and talking with them or the guardians. The investigator shall explain to the subjects the details of the investigational medical device and details about the clinical trial, inform the subjects of possible benefits and known and foreseeable risks, and obtain signed and dated informed consent forms from the subjects or the guardians.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十七条 研究者负责招募受试者、与受试者或者其监护人谈话。研究者有责任向受试者说明试验用医疗器械以及临床试验有关的详细情况，告知受试者可能的受益和已知的、可以预见的风险，并取得受试者或者其监护人签字和注明日期的知情同意书。"
    },
    {
        "instruction":"已知信息：\n'The assessment and analysis of clinical data pertaining to a medical device to verify the clinical safety and performance of the device when used as intended by the manufacturer (7).'可被翻译为：评估和分析与医疗器械有关的临床数据，以验证器械在按制造商预期使用时的临床安全性和性能(7)。\n'Article 20 Clinical evaluation of medical devices refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.'可被翻译为：第二十条 医疗器械临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者适用范围进行确认的过程。\n\n根据上述已知信息，请将'The clinical data refers to the safety and performance information which is obtained from relevant literature or in the clinical use of medical device.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"临床数据，是指在有关文献或者医疗器械的临床使用中获得的安全性、性能的信息。"
    },
    {
        "instruction":"已知信息：\n'(VIII) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（八）其他不符合法律法规要求的。\n'9. Other circumstances that should not be passed as prescribed by laws and regulations.'可被翻译为：9.法律法规规定的其他不应当通过的情形。\n\n根据上述已知信息，请将'(VI) Other circumstances in noncompliance with the laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）其他不符合法律法规要求的。"
    },
    {
        "instruction":"已知信息：\n'As of June 1, 2021, prior to the issuance and implementation of relevant provisions on registration and filing supporting the new Regulations, medical device registrants and filing applicants shall continue to apply for registration and conduct filing in accordance with the current provisions. The requirements for clinical evaluation of medical devices shall be implemented in accordance with Article III of this Announcement. Medical products administration shall carry out the registration and filing in accordance with the currently specified procedures and time limits.'可被翻译为：自2021年6月1日起，在新《条例》配套的注册、备案相关规定发布实施前，医疗器械注册申请人、备案人继续按照现行规定申请注册和进行备案。有关医疗器械临床评价要求，按照本公告第三条执行。药品监督管理部门按照现行规定的程序和时限开展注册、备案相关工作。\n'In order to strengthen the supervision over medical device production, guarantee the safety and effectiveness of medical devices, and guide registrants, filing entities and contract manufacturers of medical devices to jointly manage the quality of contract manufacturing of medical devices, according to Paragraph 2 of Article 34 in the Regulations on Supervision and Administration of Medical Devices, the National Medical Products Administration organized to revise the Guidance for Preparation of Contract Manufacturing Quality Agreement of Medical Devices, which was issued on March 22, 2022.'可被翻译为：为加强医疗器械生产监管，保障医疗器械安全有效，指导医疗器械注册人、备案人与受托生产企业共同做好医疗器械委托生产质量管理工作，根据《医疗器械监督管理条例》第三十四条第二款规定，国家药品监督管理局组织制定了《医疗器械委托生产质量协议编制指南》，于2022年3月22日发布。\n\n根据上述已知信息，请将'In order to improve the normalization and scientificity of technical evaluation of medical devices and guide medical device registrants\/filing entities to prepare product technical requirements,in accordance with the Regulations on Supervision and Administration of Medical Devices, Provisions for Medical Device Registration and Filing and Provisions for Registration and Filing of In-vitro Diagnostic Reagents, the National Medical Products Administration has organized the revision of the Guidance for Compiling the Product Technical Requirements for Medical Devices, which was issued on February 8,2022.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为提高医疗器械技术审评的规范性和科学性，指导医疗器械注册人\/备案人编写产品技术要求，根据《医疗器械监督管理条例》及《医疗器械注册与备案管理办法》《体外诊断试剂注册与备案管理办法》的规定，国家药品监督管理局组织修订了《医疗器械产品技术要求编写指导原则》，并于2022年2月8日发布。"
    },
    {
        "instruction":"已知信息：\n'e. Sterile Whirl-pak® bags'可被翻译为：无菌 Whirl-pak®袋\n'd. Whirl-pak® bag Sterility Control: Include one unopened Whirl- pak® bag as a closed control.'可被翻译为：Whirl- pak®袋的无菌控制：放入一个未开封的 Whirl- pak®袋作为密封控制。\n\n根据上述已知信息，请将'5. Place the EM sample into a sterile Whirl-pak® bag and identify the bag immediately after.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将 EM 样品放入 Whirl-pak®无菌袋，然后立即对袋子进行标示。"
    },
    {
        "instruction":"已知信息：\n'For shuttle type equipment used for aseptic filling, the parison is open to the environment and therefore the areas where parison  extrusion, blow-moulding and  sealing take place  should meet grade A  conditions  at the critical zones. The filling environment should be designed and maintained to meet grade A conditions for viable and total particle limits both at rest and when in operation.'可被翻译为：对于用于无菌灌装的往复式设备，模具在环境中是开放的，因此进行模具挤出、吹塑和密封的关键区域应 符合 A 级条件。灌装环境应进行设计和维护，从而在静态和动态下均符合活性粒子和总微粒限度的 A 级条件。\n'Due to the generation of particles from polymer extrusion and cutting during operation, and the restrictive size of critical filling zones of BFS equipment, in operation monitoring of total particle for BFS equipment is not expected. However, data should be available to demonstrate that the design of the equipment ensures that critical zones of the filling process environment would meet grade A conditions in operation.'可被翻译为：由于操作过程中聚合物挤出和切割产生的微粒， 以及 BFS 设备关键灌装区的尺寸限制，预计不会对 BFS 设备的总微粒进行动态监测。但是，应有数据证明设备的设计可确保灌装工艺环境的关键区域在动态下满足 A 级条件。\n\n根据上述已知信息，请将'For rotary-type equipment used for aseptic filling, the parison is generally closed to the environment once formed, the filling environment within the parison should be designed and maintained to meet grade A conditions for viable and total particle limits both at rest and when in operation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于用于无菌灌装的旋转式设备，包材通常在成型后密闭于环境，包材内灌装环境的设计和维护应在静态和动态下均符合活性粒子和总微粒限度的 A 级条件。"
    },
    {
        "instruction":"已知信息：\n'orthogonal design'可被翻译为：正交设计\n'bracketing. An experimental design to test the extremes of, for example, dosage strength. The design assumes that the extremes will be representative of all the samples between the extremes.'可被翻译为：分组：对例如剂量的极端进行检测的实验设计。该设计假定极端情况代表了极端中间的所有样本。\n\n根据上述已知信息，请将'A design method to study multi-factors and multi-levels. It is to select some representative points from the comprehensive test according to the orthogonality, these representative points have the characteristics of \"uniform dispersion, uniform comparison\", orthogonal experimental design is the main method of fractional factorial design.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究多因素多水平的一种设计方法。它是根据正交性从全面试验中挑选出部分有代表性的点进行试验，这些有代表性的点具备了\"均匀分散，齐整可比”的特点，正交试验 设计是分式析因设计的主要方法。"
    },
    {
        "instruction":"已知信息：\n'Article 45 Drug registration inspection refers to the inspection of drug R&D and manufacturing site in order to verify the authenticity and consistency of the application dossiers and the conditions for commercial manufacturing of the drug to be marketed, and to check the compliance and data integrity of drug R&D; when necessary, inspection may be extended to the manufacturers, suppliers or other contracted organizations for chemical active drug ingredients, excipient and primary packaging materials and containers involved in the drug application dossiers.'可被翻译为：第四十五条 药品注册核查，是指为核实申报资料的真实性、一致性以及药品上市商业化生产条件，检查药品研制的合规性、数据可靠性等，对研制现场和生产现场开展的核查活动，以及必要时对药品注册申请所涉及的化学原料药、辅料及直接接触药品的包装材料和容器生产企业、供应商或者其他受托机构开展的延伸检查活动。\n'Article 27 The applicant shall coordinate with the relevant institutions of drug development, manufacturing, and registration applications and the involved manufacturers and suppliers of chemical raw materials, TCM materials, TCM decoction pieces and extracts, excipients, and packaging materials and container that directly contact drugs, or other entrusted institutions to accept on-site inspections as required, and when necessary, coordinate and organize part of the inspection-related personnel and materials to be inspected at designated locations.'可被翻译为：第二十七条 申请人应当协调与药品研制、生产、注册申请相关单位及所涉及的化学原料药、中药材、中药饮片和提取物、辅料及直接接触药品的包装材料和容器生产企业、供应商或者其他受托机构按要求接受现场核查，必要时协调组织部分核查相关人员和材料到指定地点接受核查。\n\n根据上述已知信息，请将'Article 3 Registration inspection is the inspection activity initiated by the Center for Drug Evaluation of NMPA (hereinafter referred to as CDE) to verify the authenticity and consistency of the drug registration application dossiers, and the commercial production conditions of the drug ,check the compliance, data  integrity, etc. on the development site and manufacturing site focusing on the development and manufacturing involved in the application dossiers of relevant registration applications; and, if necessary, extended inspection activities may be carried out to the manufacturers, suppliers or other contracted institutions of chemical active pharmaceutical ingredient, traditional Chinese medicine (TCM) materials, TCM decoction pieces and extracts, excipients, and packaging materials and containers that directly contact the drugs involved in drug registration applications.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条 注册核查是由国家药品监督管理局药品审评中心(以下简称药品审评中心)启动，为核实药品注册申报资料的真实性、一致性以及药品上市商业化生产条件，检查药品研制的合规性、数据可靠性等，围绕相关注册申请事项申报资料中涉及的研制和生产情况，对研制现场和生产现场开展的核查活动，以及必要时对药品注册申请所涉及的化学原料药、中药材、中药饮片和提取物、辅料及直接接触药品的包装材料和容器生产企业、供应商或者其他受托机构开展的延伸检查活动。"
    },
    {
        "instruction":"已知信息：\n'4. Qualification of Stirring\/Agitation\/Flow Rate: The stirring rate should be verified with a suitable device, such as a photo tachometer. For VDC, stirring rates in the range of 400–600 rpm are common. The stirring rate measured is typically applicable to the specific location where the stirring impeller is (e.g., a specific position in a rack that holds multiple VDC, or a specific stir plate). Stirring rate can be measured using a surrogate stir bar if the stir bar used in the diffusion cell is too small to obtain an accurate measurement. The paddle stirring rate for immersion cells of 50 or 100 rpm is common and should be verified and maintained during the test.'可被翻译为：4.（桨法）搅拌\/（搅拌子）搅拌\/流速的确认:搅拌速率应使用合适的设备进行验证，例如光转速计。对于VDC，搅拌速率范围在400-600 rpm是常见的。测量的搅拌速率通常适用于搅拌叶轮所在的特定位置(例如，在容纳多个VDC的机架中的特定位置，或特定的搅拌板)。如果扩散池中使用的搅拌子太小而无法获得准确的测量，则可以使用替代搅拌子来测量搅拌速率。浸没池的桨叶搅拌速率通常为50或100转\/分，在试验期间应加以验证和保持。\n'Mixing rate variation (e.g., slight change in stirring speed, as applicable)'可被翻译为：混合速率变化（如，轻微改变搅拌速率，如适用）\n\n根据上述已知信息，请将'4. Rate of stirring or agitation for VDCs or immersion cells, or the flow rate for FDCs, as applicable'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"VDCs或浸没池的搅拌或搅拌速率，或FDCs的流量，视情况而定"
    },
    {
        "instruction":"已知信息：\n'Article 99: Purified water and water for injection should be produced, stored and distributed in a manner that prevents microbial growth. Purified water can be circulated, and water for injection can be circulated at a temperature above 70℃.'可被翻译为：第九十九条 纯化水、注射用水的制备、贮存和分配应当能够防止微生物的滋生。纯化水可采用循环，注射用水可采用70℃以上保温循环。\n'Where WFI storage tanks are equipped with hydrophobic bacteria retentive vent filters, the filters should not be a source of contamination and the integrity of the filter tested before installation and after use. Controls should\nbe in place to prevent condensation formation on the filter (e.g. by heating).'可被翻译为：如果 WFI 储罐配有疏水性除菌过滤器，过滤器不应成为污染的来源，并应在安装前和使用后进行过滤器的完整性测试。应采取控制措施，防止在过滤器上形成冷凝水（例如加热）。\n\n根据上述已知信息，请将'Article 98: The materials of storage tanks and pipes for transport of purified water and water for injection should be non-toxical and corrosion resistant. The vent of storage tanks should be installed with non-fiber releasing hydrophobic microorganism retention filter. Dead legs should be avoided in the design and installation of pipelines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十八条 纯化水、注射用水储罐和输送管道所用材料应当无毒、耐腐蚀；储罐的通气口应当安装不脱落纤维的疏水性除菌滤器；管道的设计和安装应当避免死角、盲管。"
    },
    {
        "instruction":"已知信息：\n'Maximum operating pressure.'可被翻译为：最大工作压力。\n'closed system'可被翻译为：封闭的系统\n\n根据上述已知信息，请将'The maximum useful work that a closed system can perform under isothermal and isobaric conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"封闭系统在等温等压条件下可能做出的最大有用功。"
    },
    {
        "instruction":"已知信息：\n'(VI) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（六）其他不符合法律法规要求的。\n'9. Other circumstances that should not be passed as prescribed by laws and regulations.'可被翻译为：9.法律法规规定的其他不应当通过的情形。\n\n根据上述已知信息，请将'(VIII) Other circumstances in noncompliance with the laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（八）其他不符合法律法规要求的。"
    },
    {
        "instruction":"已知信息：\n'Article 41 If the lot release institution issues a false testing report when undertaking the lot release work, a penalty shall be imposed in accordance with Article 138 of the Drug Administration Law.'可被翻译为：第四十一条    批签发机构在承担批签发相关工作时，出具虚假检验报告的，依照《药品管理法》第一百三十八条的规定予以处罚。\n'Article 163 When undertaking testing for drug review and approval, a drug testing institute that issues a false certificate of analysis shall be punished in accordance with the provisions in Article 87 of the Drug Administration Law.'可被翻译为：第一百六十三条 药品检验所在承担药品审批所需要的检验工作时，出具虚假检验报告的，依照《药品管理法》第八十七条的规定处罚。\n\n根据上述已知信息，请将'Article 117 Where a drug testing institution undertaking testing for drug registration issues false testing reports, the case shall be handled according to Article 138 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百一十七条 药品检验机构在承担药品注册所需要的检验工作时，出具虚假检验报告的，按照《药品管理法》第一百三十八条处理。"
    },
    {
        "instruction":"已知信息：\n'The medium density of plasma lipoprotein is 0.95 ~ 1.006g\/cn? Is a lipoprotein. Is a very low density of plasma lipoproteins - lipoproteins, which can be determined by class separation of plasma lipoproteins by ultracentrifugation or electrophoresis.'可被翻译为：血浆脂蛋白中密度为0.95〜1.006g\/cn?的脂蛋白。是血浆脂蛋白中密度极低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。\n'Plasma lipoproteins have a density of 1.063-1.21g\/cm3. Is the higher density of the plasma lipoprotein - lipoprotein, light by ultracentrifugation or electrophoresis of plasma lipoprotein category separation to determine.'可被翻译为：血浆脂蛋白中密度为1.063-1.21g\/cm3的脂蛋白。是血浆脂蛋白中密度较高的-类脂蛋白，灯用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。\n\n根据上述已知信息，请将'The medium density of plasma lipoprotein is 1.006-1.063g\/cn? Is a lipoprotein. Is a lower density of plasma lipoprotein - lipoprotein, can be determined by ultra-fast centrifugation or electrophoresis of plasma lipoprotein class separation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"血浆脂蛋白中密度为1.006-1.063g\/cn?的脂蛋白。是血浆脂蛋白中密度较低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。"
    },
    {
        "instruction":"已知信息：\n'Article 29 Upon knowing of any ADE cluster, a drug manufacturer shall immediately carry out investigation to have a detailed understanding of the occurrence of ADE cluster, information of drug use, diagnosis and treatment of patients involved, and production, storage, distribution and previous similar adverse events of the drug, etc., complete the investigation report within 7 days, and submit it to the provincial drug regulatory department and the ADR monitoring institution where the manufacturer is located. At the same time, the drug manufacturer shall rapidly conduct self-inspection, analyze the cause of the events, suspend production, sales and use, recall relevant drugs when necessary, and report to the provincial drug regulatory department where it is located.'可被翻译为：第二十九条 药品生产企业获知药品群体不良事件后应当立即开展调查，详细了解药品群体不良事件的发生、药品使用、患者诊治以及药品生产、储存、流通、既往类似不良事件等情况，在7日内完成调查报告，报所在地省级药品监督管理部门和药品不良反应监测机构；同时迅速开展自查，分析事件发生的原因，必要时应当暂停生产、销售、使用和召回相关药品，并报所在地省级药品监督管理部门。\n'Article 17 Drug manufacturers, distributors and medical institutions shall cooperate with drug regulatory departments, health administrative departments and ADR monitoring institutions in investigating ADRs or ADE clusters and provide materials necessary for the investigation.'可被翻译为：第十七条 药品生产、经营企业和医疗机构应当配合药品监督管理部门、卫生行政部门和药品不良反应监测机构对药品不良反应或者群体不良事件的调查，并提供调查所需的资料。\n\n根据上述已知信息，请将'Article 27 Drug manufacturers, distributors and medical institutions shall, upon knowing or discovering ADE clusters, immediately report to the county-level drug regulatory departments, health administrative departments and ADR monitoring institutions where they are located by telephone or by fax; when necessary, they may report directly to authorities at a higher level; at the same time, a Form for Basic Information of ADE Clusters (see Attached Table 2) and a Form for ADR\/ADE Report for each case shall be filled out promptly and submitted via the national ADR monitoring information network.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 药品生产、经营企业和医疗机构获知或者发现药品群体不良事件后，应当立即通过电话或者传真等方式报所在地的县级药品监督管理部门、卫生行政部门和药品不良反应监测机构，必要时可以越级报告；同时填写《药品群体不良事件基本信息表》（见附表2），对每一病例还应当及时填写《药品不良反应\/事件报告表》，通过国家药品不良反应监测信息网络报告。"
    },
    {
        "instruction":"已知信息：\n'Article 21 The technical committee on medical device standardization that undertakes the medical device standards plan project shall be responsible for organizing the technical review of the proposed draft of the medical device standard. After the proposed draft passes the technical review, the draft for approval, implementation suggestions and relevant materials for medical device standards shall be submitted to the Center for Medical Device Standardization Administration for examination.'可被翻译为：第二十一条 承担医疗器械标准计划项目的医疗器械标准化技术委员会负责组织对医疗器械标准送审稿进行技术审查。审查通过后，将医疗器械标准报批稿、实施建议及相关资料报送医疗器械标准管理中心进行审核。\n'Article 12 China Food and Drug Administration shall, based on the demands of medical device standardization, establish technical committees on medical device standardization upon approval in accordance with laws.'可被翻译为：第十二条 国家食品药品监督管理总局根据医疗器械标准化工作的需要，经批准依法组建医疗器械标准化技术委员会。\n\n根据上述已知信息，请将'Article 32 The technical committees on medical device standardization shall conduct follow-up assessment on standards implementation. The Center for Medical Device Standardization Administration shall make statistical analysis on the implementation of mandatory standards based on the follow-up assessment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 医疗器械标准化技术委员会对标准的实施情况进行跟踪评价。医疗器械标准管理中心根据跟踪评价情况对强制性标准实施情况进行统计分析。"
    },
    {
        "instruction":"已知信息：\n'A list of coded values that are used to structure the xml coding within a message. These values do not carry source data that is being transmitted by \nthe message, i.e. they do not represent data contained in the content of a message, but instead are used to identify components of an xml file for \nparsing by an IT system receiving transmitted message. Usually they are not entered by an end user (for instance through a drop-down pick list such as \nused for coded elements), but are instead used by an implementing IT system to construct an xml message for export and transmission.'可被翻译为：在消息中构建XML编码的编码值列表。这些值不携带消息发送的源数据，即不表示包含在消息内容中的数据，而旨在标识 XML 文件的组件，以供接收传输消息的 IT 系统进行解析。通常，它们不是由最终用户输入的（例如，借助用于编码元素的下拉选择列表等），而是被实施应用的IT系统构建的用于导出和传输的XML消息。\n'A defined list of values and terms to be used for transmitting information on a topic in a specific field or element in a message. A code list will usually \nconsist of a value (the code) and a label (the term being coded).'可被翻译为：值或术语的定义列表，用于某一特定领域的一个主题或一则消息中元素的信息传输。编码列表通常由值（编码）和标签（被编码的术语）组成。\n\n根据上述已知信息，请将'A technical identifier that allows the transmission of coded values for which there is no ICH accessible master list of values. Namespaces identify the \nsource or domain of a coded value without providing the list of values to allow the code to be interpreted, i.e. namespaces identify the domain of an \nidentifier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种技术识别符，允许在无 ICH 可访问的主编码值列表时，传输编码值。命名空间对编码值的源或域进行标识，但不提供解读编码值的列表，即命名空间确认 \n标识符的域。"
    },
    {
        "instruction":"已知信息：\n'Article 39 MAHs shall, from the date of the first approval for registration or filing, complete the post-market periodic risk evaluation report in the previous year within 60 days after one full year. For those approved by the NMPA to be registered , the report shall be submitted to national monitoring agencies; for those approved to be registered at  drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government, the report shall be submitted to local provincial monitoring agencies. Periodic risk evaluation report of Class I medical devices shall be kept by MAHs for future reference.'可被翻译为：第三十九条  持有人应当自产品首次批准注册或者备案之日起，每满一年后的60日内完成上年度产品上市后定期风险评价报告。其中，经国家药品监督管理局注册的，应当提交至国家监测机构；经省、自治区、直辖市药品监督管理部门注册的，应当提交至所在地省级监测机构。第一类医疗器械的定期风险评价报告由持有人留存备查。\n'Article 59 Where drug regulatory departments at provincial level or above order to carry out re-evaluation, MAHs shall submit the re-evaluation plan and re-evaluation report to the corresponding drug regulatory departments and monitoring agencies before implementation of re-evaluation and within 30 days upon the completion of re-evaluation.'可被翻译为：第五十九条  省级以上药品监督管理部门责令开展再评价的，持有人应当在再评价实施前和再评价结束后30日内向相应药品监督管理部门及监测机构提交再评价方案和再评价报告。\n\n根据上述已知信息，请将'Article 58 In case of voluntarily carrying out medical device re-evaluation, MAHs shall develop re-evaluation plan. Where control measures are required through re-evaluation, MAHs shall submit the re-evaluation report within 15 days upon the formation of re-evaluation conclusion. For medical devices approved by the NMPA to be registered or filed shall submit the report to national monitoring agencies; MAHs of other medical devices shall submit the report to the provincial monitoring agencies where MAHs locate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条  持有人主动开展医疗器械再评价的，应当制定再评价工作方案。通过再评价确定需要采取控制措施的，应当在再评价结论形成后15日内，提交再评价报告。其中，国家药品监督管理局批准注册或者备案的医疗器械，持有人应当向国家监测机构提交；其他医疗器械的持有人应当向所在地省级监测机构提交。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Guidance for the Classification Defining of AI-Based Medical Software Products'可被翻译为：国家药监局关于发布人工智能医用软件产品分类界定指导原则的通告\n'In order to strengthen the supervision and administration of recombinant collagen products and promote the high-quality development of the industry, NMPA has organized to formulate the Principles for the Classification Defining of Recombinant Collagen Products, which was issued on April 13,2021.'可被翻译为：为进一步加强重组胶原蛋白类医疗产品监督管理，推动产业高质量发展，国家药监局组织制定了《重组胶原蛋白类医疗产品分类界定原则》，于2021年4月13日予公布。\n\n根据上述已知信息，请将'In order to strengthen the supervision and administration of AI-based medical software products and promote the high-quality development of the industry, the NMPA has organized to formulate the Principles for the Classification Defining of AI-Based Medical Software Products, which was issued on July 1.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步加强人工智能医用软件类产品监督管理，推动产业高质量发展，国家药监局组织制定了《人工智能医用软件产品分类界定指导原则》，并于7月1日发布。"
    },
    {
        "instruction":"已知信息：\n'A drug that corrects various low blood cells, resulting in different types of anemia. It can be divided into: ① to correct low red blood cells, such as iron, folic acid, vitamins or epotin; ② promote leukocyte proliferation, such as recombinant human granulocyte macrophage colony factors.'可被翻译为：纠正各种血细胞低下，所致不同类型贫血的药物。分为：①纠正红细胞低下，如铁剂、叶酸、维生素或依泊汀类；②促进白细胞增生，如重组人粒细胞巨噬细胞集落因子等。\n'Drugs that can lower blood ammonia. Mainly used to treat liver coma, drugs are glutamic acid, arginine, lactulose, etc.'可被翻译为：可以降低血氨的药物。主要用于治疗肝昏迷，药物有谷氨酸、精氨酸、乳果糖等。\n\n根据上述已知信息，请将'A class of drugs used to treat agranulocytosis. Includes drugs that promote leukocyte proliferation and metabolism, such as inosine, madder bisester, anisene, berberine, etc.; Some cytokines, such as mixostim, sargasstim, etc., can stimulate bone marrow to produce white blood cells for the adjuvant treatment of tumors.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于治疗粒细胞缺乏症的一类药物。包括促进白细胞增生和代谢的药物，如肌苷、茜草双酯、茴香烯、小檗胺等；一些细胞因子，如米格司亭、沙格司亭等可刺激骨髓生成白细胞，用于肿瘤的辅助治疗。"
    },
    {
        "instruction":"已知信息：\n'A uniform, stable mixture formed by the separation of one or more substances into another.'可被翻译为：一种或几种物质分散到另-种物质里，形成的均一的、稳定的混合物。\n'Mixing of two or more substances will result in a decrease in the melting point.'可被翻译为：两种或两种以上物质混合会导致熔点降低。\n\n根据上述已知信息，请将'When two or more substances are mixed, there is no repulsive separation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"两种或两种以上物质混合时，不产生相斥分离的现象。"
    },
    {
        "instruction":"已知信息：\n'The action of changing the packaging of the material.'可被翻译为：改变材料包装的动作。\n'Article 121: Packaging materials should be issued for use only by designated personnel according to operation procedures. Measures should be taken to prevent mixups and errors to ensure the correct use of packaging materials for drug production.'可被翻译为：第一百二十一条 包装材料应当由专人按照操作规程发放，并采取措施避免混淆和差错，确保用于药品生产的包装材料正确无误。\n\n根据上述已知信息，请将'Article 123: When the version of a printed packaging material is changed, actions should be taken to ensure that the correct version is used for production. It is recommended that the obsolete stencil plates be withdrawn and destroyed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百二十三条 印刷包装材料的版本变更时，应当采取措施，确保产品所用印刷包装材料的版本正确无误。宜收回作废的旧版印刷模版并予以销毁。"
    },
    {
        "instruction":"已知信息：\n'Article 38 For a medical device which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the food and drug regulatory department may require its applicant to further complete relevant work after the product is put on market, and specify the requirements on the medical device registration certificate.'可被翻译为：第三十八条 对用于治疗罕见疾病以及应对突发公共卫生事件急需的医疗器械，食品药品监督管理部门可以在批准该医疗器械注册时要求申请人在产品上市后进一步完成相关工作，并将要求载明于医疗器械注册证中。\n'(3) For an in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the registrant fails to complete items stated in medical device registration certificate within specified time as required by registration department upon approving such registration.'可被翻译为：（三）对用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，批准注册部门在批准上市时提出要求，注册人未在规定期限内完成医疗器械注册证载明事项的。\n\n根据上述已知信息，请将'Article 48 For a in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the food and drug regulatory department may require its applicant to further complete relevant work after the product is put on market, and specify the requirements on the medical device registration certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 对用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，食品药品监督管理部门可以在批准该体外诊断试剂注册时要求申请人在产品上市后进一步完成相关工作，并将要求载明于医疗器械注册证中。"
    },
    {
        "instruction":"已知信息：\n'Maximum filtration time\/total time filter is in contact with the fluid.'可被翻译为：最长过滤时间\/过滤器与液体的总接触时间。\n'Routine process  controls  should be  implemented to  ensure  adherence to validated  filtration parameters. Results of critical process parameters should be included in the batch record, including but not limited to the minimum time taken to filter a known volume of bulk  solution and pressure difference across the filter. Any significant difference from critical parameters during manufacturing should be documented and investigated.'可被翻译为：应实施常规工艺控制以确保符合经验证的过滤参数。关键工艺参数的结果应包含在批记录中，包括但不限 于过滤已知体积的待包装溶液所需的最短时间和过滤器两端的压差。生产过程中与关键参数的任何显着差异都应记录并调查。\n\n根据上述已知信息，请将'The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"过滤已知体积的待包装溶液所需时间以及过滤器两端的压差。"
    },
    {
        "instruction":"已知信息：\n'If the quantity is below 20,000 vials (including), take 1 product for sampling; if the quantity is below 50,000 vials (including), take 2 products for sampling; if the quantity is below 100,000 vials (including), take 3 products for sampling; if the quantity is more than 100,000 vials, take additional 1 product for sampling for every additional 100,000 vials, and the odd less than 100,000 shall be counted as 100,000.'可被翻译为：2万支（瓶）以下（含2万支），抽样1件；5万支（瓶）以下（含5万支），抽样2件；10万支（瓶）以下（含10万支），抽样3件；10万支（瓶）以上，每增加10万支（瓶）加抽1件，不足10万支（瓶）以10万支（瓶）计。\n'If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000.'可被翻译为：100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。\n\n根据上述已知信息，请将'Take 1 product for sampling for every 20,000 boxes (vials), and the odd less than 20,000 boxes (vials) shall be counted as 20,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"每2万盒（瓶），抽样一件，不足2万盒（瓶）的按2万盒（瓶）计。"
    },
    {
        "instruction":"已知信息：\n'(1) appoint a dedicated quality responsible person to independently undertake responsibilities for drug quality management;'可被翻译为：（一）配备专门质量负责人独立负责药品质量管理；\n'(1) failing to appoint a dedicated person in charge of quality to independently undertake drug quality management and supervise GMP implementation;'可被翻译为：（一）未配备专门质量负责人独立负责药品质量管理、监督质量管理规范执行；\n\n根据上述已知信息，请将'(1) appoint a qualified dedicated person who is independently in charge of drug quality management, to supervise the implementation of the GMP, ensure suitable in-process control and quality control and guarantee the compliance of drugs with national drug standards and drug registration specifications;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）配备专门质量负责人独立负责药品质量管理，监督质量管理规范执行，确保适当的生产过程控制和质量控制，保证药品符合国家药品标准和药品注册标准；"
    },
    {
        "instruction":"已知信息：\n'Drug regulatory departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for the vaccine administration within their respective administrative regions. Departments undertaking responsibilities for drug administration (hereinafter referred to as drug regulatory departments) of the people's governments of municipalities divided into districts and at county level shall undertake the administrative duties on vaccines within their respective administrative regions. The competent health departments of people's governments at or above the county level shall undertake the administration of immunization within their respective administrative regions. Other relevant departments of the people's governments at or above the county level shall undertake the administrative duties on vaccines within the scope of their respective responsibilities.'可被翻译为：省、自治区、直辖市人民政府药品监督管理部门负责本行政区域疫苗监督管理工作。设区的市级、县级人民政府承担药品监督管理职责的部门（以下称药品监督管理部门）负责本行政区域疫苗监督管理工作。县级以上地方人民政府卫生健康主管部门负责本行政区域预防接种监督管理工作。县级以上地方人民政府其他有关部门在各自职责范围内负责与疫苗有关的监督管理工作。\n'Article 8 The drug regulatory department under the State Council shall be responsible for drug administration nationwide. The relevant departments under the State Council shall be responsible for the related administrative work within the scope of their duties. The drug regulatory department under the State Council shall cooperate with relevant departments under the State Council in implementing national drug development programs and policies.'可被翻译为：第八条 国务院药品监督管理部门主管全国药品监督管理工作。国务院有关部门在各自职责范围内负责与药品有关的监督管理工作。国务院药品监督管理部门配合国务院有关部门，执行国家药品行业发展规划和产业政策。\n\n根据上述已知信息，请将'Article 8 The drug regulatory department under the State Council shall be responsible for the administration of vaccines nationwide. The competent health department under the State Council shall be responsible for the administration of immunization nationwide. Other relevant departments under the State Council shall be responsible for the administration of vaccines within the scope of their respective responsibilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八条 国务院药品监督管理部门负责全国疫苗监督管理工作。国务院卫生健康主管部门负责全国预防接种监督管理工作。国务院其他有关部门在各自职责范围内负责与疫苗有关的监督管理工作。"
    },
    {
        "instruction":"已知信息：\n'6.4. The quality system should ensure that:'可被翻译为：质量体系应确保：\n'12.37. The number of analysts involved in the transfer, from both SU and RU, should be defined and justified.'可被翻译为：从SU转移至RU过程中所涉及的化验员的数量应予以规定并说明理由。\n\n根据上述已知信息，请将'6.1. The SU and RU should each have an appropriately designed, clearly defined and documented quality system.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SU与RU应分别具备经过恰当设计、清楚规定和文件化的质量体系。"
    },
    {
        "instruction":"已知信息：\n'A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.'可被翻译为：药品的标签应当以说明书为依据，其内容不得超出说明书的范围，不得印有暗示疗效、误导使用和不适当宣传产品的文字和标识。\n'A mark affixed to the package of a drug to indicate the name, dosage form, dosage, usage, and other information.'可被翻译为：贴于药品包装上用于指示药物名称、剂型、装量、用法用量等信息的标志。\n\n根据上述已知信息，请将'Article 4    A drug label shall be printed on or affixed to the drug package, and no other written words, audio and\/or visual materials or other information are attached to introduce or publicize the product or the enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四条 药品包装必须按照规定印有或者贴有标签，不得夹带其他任何介绍或者宣传产品、企业的文字、音像及其他资料。"
    },
    {
        "instruction":"已知信息：\n'(IV) Post-marketing change approval documents;'可被翻译为：（四）上市后变更的批准证明性文件；\n'Drug approval numbers shall not change in the event of a post-marketing change of registration items.'可被翻译为：药品批准文号，不因上市后的注册事项的变更而改变。\n\n根据上述已知信息，请将'(IV)  Post-marketing change approval documents\/filing documents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）上市后变更的批准或者备案文件；"
    },
    {
        "instruction":"已知信息：\n'(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the in-vitro diagnostic reagent to be sold on the market.'可被翻译为：（一）申请人对拟上市销售体外诊断试剂的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；\n'(I) Cognitional changes of the safety and effectiveness of the medical device according to the development of scientific research;'可被翻译为：（一）根据科学研究的发展，对医疗器械的安全、有效有认识上改变的；\n\n根据上述已知信息，请将'(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the medical device to be sold on the market.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）申请人对拟上市销售医疗器械的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；"
    },
    {
        "instruction":"已知信息：\n'2. Swab corner crevices inside the HEPA Filtered work station.'可被翻译为：擦拭取样有 HEPA 过滤的工作站内的角落缝隙\n'Prior to product testing, the exterior of the unit container should be disinfected before transfer to the work station or HEPA filtered laminar flow hood. If the product container is not hermetically sealed do not soak the product container in a disinfection solution which may allow the ingress of bactericidal solution into the product.'可被翻译为：产品测试前，单元容器的外部应在转移到工作站或HEPA过滤层流罩之前进行消毒。 如果产品容器未密封，请勿将产品容器浸泡在消毒溶液中，否则灭菌溶液可能会渗 入产品中。\n\n根据上述已知信息，请将'5. Swab tables or benches within the controlled room where product container(s) or post sterilized product may be held outside of the HEPA filtered workstation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"擦拭取样控制室内但不在 HEPA 过滤工作台内，可能会放置产品容器或消毒后的产品的桌子或长凳"
    },
    {
        "instruction":"已知信息：\n'Cleanroom - A room designed, maintained, and controlled to prevent particle and microbial contamination of drug\nproducts. Such a room is assigned and reproducibly meets an appropriate air cleanliness level.'可被翻译为：洁净室：一种经设计、维护和控制以防止微粒和微生物污染药品的房间。这样的房间是指定的，可持续性地符合适当的空气洁净水平。\n'A room (or an area) with defined environmental control of particulate and microbial contamination, constructed, outfitted and used in such a way as to reduce the introduction, generation and retention of contaminants within the room or area.'可被翻译为：需要对环境中尘粒及微生物数量进行控制的房间（区域），其建筑结构、装备及其使用应当能够减少该区域内污染物的引入、产生和滞留。\n\n根据上述已知信息，请将'1.A room or area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n2.A room designed, maintained and controlled to prevent particle and microbial contamination of drug products. Such a room is assigned and reproducibly meets an appropriate air cleanliness level.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.对微粒和微生物污染有明确环境控制的房间或区域，其建造和使用方式可减少该区域内污染物的引入、产生和滞留。\n2.为防止药品被颗粒和微生物污染而设计、维护和控制的房间。这样的房间是指定的，并且可重复地满足适当的空气洁净度水平。"
    },
    {
        "instruction":"已知信息：\n'3. Dedicated facilities (e.g. a dedicated air handling system) and equipment must be used in production of β-lactam products and sex hormonal contraceptives, and their production areas must be strictly segregated from those of other products.'可被翻译为：（三）生产β－内酰胺结构类药品、性激素类避孕药品必须使用专用设施（如独立的空气净化系统）和设备，并与其他药品生产区严格分开。\n'2. Dedicated and self-contained premises, facilities and equipment must be used for the production of products with particular properties such as highly sensitizing products (e.g. penicillins) or biological preparations (e.g. Bacillus Calmette Guerin vaccine or any other products derived from live microorganisms). Dust generating operation areas in penicillin production should maintain relatively negative pressure, the exhaust air should be decontaminated as required, and the air outlet should be far away from the air inlet of other air-handling systems.'可被翻译为：（二）生产特殊性质的药品，如高致敏性药品（如青霉素类）或生物制品（如卡介苗或其他用活性微生物制备而成的药品），必须采用专用和独立的厂房、生产设施和设备。青霉素类药品产尘量大的操作区域应当保持相对负压，排至室外的废气应当经过净化处理并符合要求，排风口应当远离其他空气净化系统的进风口。\n\n根据上述已知信息，请将'4. Dedicated facilities (e.g. a dedicated air handling system) and equipment should be used for some hormonal, cytotoxic and highly potent chemical products. In exceptional cases, the principle of campaign working in the same facilities and equipment can be accepted provided that specific precautions are taken and the necessary validations are made.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）生产某些激素类、细胞毒性类、高活性化学药品应当使用专用设施（如独立的空气净化系统）和设备；特殊情况下，如采取特别防护措施并经过必要的验证，上述药品制剂则可通过阶段性生产方式共用同一生产设施和设备。"
    },
    {
        "instruction":"已知信息：\n'A class of pharmaceutical preparations that use certain physical or chemical methods to kill all living microbial propagules and buds.'可被翻译为：采用某种物理或化学方法杀灭所有活的微生物繁殖体和芽抱的一类药物制剂。\n'aseptic sampling techniques'可被翻译为：无菌取样技术\n\n根据上述已知信息，请将'A class of pharmaceutical preparations prepared by aseptic manipulation or aseptic techniques that do not contain any living microbial propagules or buds.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"采用无菌操作法或无菌技术制备的不含任何活的微生物繁殖体和芽抱的一类药物制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 75 Where, for a registered in-vitro diagnostic reagent, there exists a revocation situation in accordance with laws and regulations, or a registrant applies for revocation before the expiration of a registration certificate, the food and drug regulatory department shall revoke the registration certificate according to law and disclose to the society.'可被翻译为：第七十五条 已注册的体外诊断试剂有法律、法规规定应当注销的情形，或者注册证有效期未满但注册人主动提出注销的，食品药品监督管理部门应当依法注销，并向社会公布。\n'Article 54 Where it is required to extend the period of validity of the medical device registration certificate, the registrant shall submit application for registration renewal to the food and drug regulatory department six months before the expiration of period of validity and submit application documents according to corresponding requirements.'可被翻译为：第五十四条 医疗器械注册证有效期届满需要延续注册的，注册人应当在医疗器械注册证有效期届满6个月前，向食品药品监督管理部门申请延续注册，并按照相关要求提交申报资料。\n\n根据上述已知信息，请将'Article 65 Where, for a registered medical device, there exists a revocation situation in accordance with laws and regulations, or a registrant applies for revocation before the expiration of a registration certificate, the food and drug regulatory department shall revoke the registration certificate according to law and disclose to the society.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十五条 已注册的医疗器械有法律、法规规定应当注销的情形，或者注册证有效期未满但注册人主动提出注销的，食品药品监督管理部门应当依法注销，并向社会公布。"
    },
    {
        "instruction":"已知信息：\n'A multidimensional measure of health status. These include physical changes, functional changes, social activity, cognition, emotion, sleep and rest, energy and vitality, health awareness, and overall life satisfaction.'可被翻译为：健康状态的一种多维测量指标。包括生理变化、功能变化、社会活动、认知、情感、睡眠与休息、精力与活力、健康意识以及总的生活满意度等。\n'A method of measuring health status using four dimensions of mobility, physical activity, social ability, and disease symptoms.'可被翻译为：用行动能力、躯体活动能力、社交能力及疾病症状四个维度测量健康状态的一种方法。\n\n根据上述已知信息，请将'A measure of a patient's health outcome. The measurement extends beyond traditional mortality and morbidity to include measures of multiple dimensions such as physiology, functioning, social activity, cognition, emotion, sleep and rest, energy and activity, perceived health, and overall survival satisfaction.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种测量患者健康结果的指标。其测量范围超越了传统的死亡率和患病率，还包括生理、功能、社会活动、认知、情感、睡眠和休息、精力和活动、健康感知和总体生存满意度等多个维度的测量。"
    },
    {
        "instruction":"已知信息：\n'Article 32    In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated,  and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:'可被翻译为：第三十二条 有下列情形之一的，依照《药品管理法》第七十三条规定，没收违法销售的药品和违法所得，并处违法销售的药品货值金额二倍以上五倍以下的罚款：\n'Article 36    Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.'可被翻译为：第三十六条 药品生产、经营企业违反本办法第十四条规定的，按照《药品管理法》第八十二条的规定予以处罚。\n\n根据上述已知信息，请将'Article 43    Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十三条 违反本办法第二十二条规定非法收购药品的，按照《药品管理法》第七十三条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'The DNA sequence corresponding to mature mRNA, rRNA, or tRNA molecules in eukaryotic genes. Is the coding sequence.'可被翻译为：真核生物基因中与成熟mRNA、rRNA或tRNA分子相对应的DNA序列。为编码序列。\n'The expression vector which contains the coding sequence of the recombinant protein and the elements necessary for its expression.'可被翻译为：是含有重组蛋白的编码序列和它表达所需元件的表达载体。\n\n根据上述已知信息，请将'Non-coding nucleotide sequences that are adjacent to the 5' and 3' end of the coding sequence of the product which contain important elements that affect the transcription, translation, or stability of the coding sequence. These regions include, e.g., promoter, enhancer, and splicing sequences and do not include origins of replication and antibiotic resistance genes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是与产品编码序列的5'和3'末端相邻的非编码核苷酸序列,含有影响编码序列转录、翻译和稳定性的重要元件,包括启动子、增强子和剪接序列等区域,但不包括复制起点和抗生素耐药基因区域。"
    },
    {
        "instruction":"已知信息：\n'If the results do not meet this criterion, 4 additional tests (2 reference and 2 test) of 6 cells each should be performed, resulting in 12 additional slope determinations for each product tested. The T\/R slope ratios for all 18 slopes for each product tested are determined. All 324 individual T\/R slope ratios are ordered from the lowest to the highest. To pass this second stage testing, the 110th and 215th slope ratios, representing the 90% confidence interval, must be within the range of 75%–133.33%.'可被翻译为：如果结果不符合此标准，则应执行4个额外的测试(2个参考和2个测试)，每个测试6个单元，从而为每个测试产品进行12个额外的斜率测定。确认了每个测试样品的所有18个T\/R斜率比率。所有324个单独的T\/R斜率比从低到高排序。为了通过第二阶段的测试，代表90%置信区间的第110和215斜率比率必须在75%-133.33%的范围内。\n'The T\/R slope ratios are calculated for each test-to-reference combination of all pairs of T\/R slopes. This procedure is facilitated with a table where the values for the slopes for T are listed down the left side of the table and the slopes for R are listed across the top of the table. The T\/R slope ratios are then determined. See Table 1.'可被翻译为：计算每次试验相对于参考坡度的T\/R斜率比。该程序通过一个表格来实现，其中测试批次和参考批次的斜率值分别列在表格的左侧和顶部。然后确定T\/R斜率。见表1。\n\n根据上述已知信息，请将'After the T\/R ratios have been calculated, they are ordered from the lowest to the highest. The 8th and 29th T\/R ratios are identified and converted to percent (multiplied by 100). These values represent the 90% confidence interval for the ratio of test to reference release rates. To pass first stage testing, those ratios must be within the range of 75%–133.33%.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在计算出T\/R比后，它们按从低到高的顺序排列。识别第8和第29个T\/R比率并将其转换为百分比（乘以100）。这些值代表试验与参考释放率之比的90%置信区间。要通过第一阶段测试，这些比率必须在75%-133.33%的范围内。"
    },
    {
        "instruction":"已知信息：\n'Article 176 In case of identifying that a sold drug has serious quality issue, an enterprise shall immediately take measures to retrieve the drug, make records and report to the food and drug regulatory department.'可被翻译为：第一百七十六条 企业发现已售出药品有严重质量问题，应当及时采取措施追回药品并做好记录，同时向食品药品监督管理部门报告。\n'(V) Any drug identified with suspicious issues shall be locked and recorded in the computer system in time and notified to the quality management department for disposal;'可被翻译为：（五）发现有问题的药品应当及时在计算机系统中锁定和记录，并通知质量管理部门处理。\n\n根据上述已知信息，请将'Article 87 For drugs likely to have quality issues, measures of suspending the sales shall be taken immediately, and the drugs shall be locked in the computer system and reported to the quality management department for confirmation. With respect to drugs with quality issues, the following measures shall be taken:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十七条 对质量可疑的药品应当立即采取停售措施，并在计算机系统中锁定，同时报告质量管理部门确认。对存在质量问题的药品应当采取以下措施："
    },
    {
        "instruction":"已知信息：\n'An enclosure capable of being subject to reproducible interior biodecontamination, with an internal work zone meeting grade A conditions that provide uncompromised continuous isolation of its interior from the external environment (for example, surrounding cleanroom air and personnel). There are two major types of isolators:\n•□Closed isolator systems exclude external contamination of the isolator’s interior by accomplishing material transfer via aseptic connection to auxiliary equipment rather than use of openings to the surrounding environment. Closed systems remain sealed throughout operations.\n•□Open isolator systems are designed to allow for the continuous or semicontinuous ingress or egress of materials during operations through one or more openings. Openings are engineered (for example, using continuous overpressure) to exclude the entry of external contaminant into the isolator.'可被翻译为：能够进行可重复的内部生物净化的外壳，其内部工作区域满足A级条件，可将其内部与外部环境(例如，周围洁净室空气和人员)不受损害地连续隔离。隔离器主要有两种类型:\n•□闭式隔离器系统通过与辅助设备的无菌连接来完成物料转移，而不是使用对周围环境的开口，从而排除隔离器内部的外部污染。封闭系统在整个操作过程中保持密封。\n•□开放式隔离系统的设计允许物料在操作期间通过一个或多个开口连续或半连续地进入或流出。开口设计(例如，使用连续超压)以排除外部污染物进入隔离器。\n'Closed isolator  systems  exclude external  contamination of the  isolator's  interior by accomplishing material  transfer via aseptic connection to auxiliary equipment, rather than use of openings to the surrounding environment.Closed systems remain sealed throughout operations.'可被翻译为：密闭隔离器系统通过与辅助设备的无菌连接而不是对周围环境开放来完成物料转移，从而阻断外部污染物进入隔离器内部。密闭系统在整个操作中保持密封。\n\n根据上述已知信息，请将'Open isolator systems are designed to allow for the continuous or semi-continuous ingress and\/or egress of materials  during  operations  through  one  or  more  openings.  Openings  are  engineered  (e.g.  using  continuous overpressure) to exclude the entry of external contaminant into the isolator.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"开放隔离器系统的设计允许操作过程中物料通过一个或多个开口连续或半连续进出。开口的设计（如使用连续过压）可以阻断外部污染进入隔离器。"
    },
    {
        "instruction":"已知信息：\n'An establishment or institution that is subcontracting particular work or services to a different institution and sets up a contract defining the duties and responsibilities of each side.'可被翻译为：将特定的工作或服务分包给另一个机构，并订立合同规定双方的义务和责任的机构或机构。\n'The use of contract laboratories, not applicable under normal circumstances, in conformity with the principles of contract analysis detailed in Chapter 11, can be accepted for particular reasons, but this should be stated in the certificate of analysis.'可被翻译为：企业通常不得进行委托检验，确需委托检验的，应当按照第十一章中委托检验部分的规定，委托外部实验室进行检验，但应当在检验报告中予以说明。\n\n根据上述已知信息，请将'An establishment or institution that performs particular work or services under a contract for a different institution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据合同为另一机构提供特定工作或服务的机构或机构。"
    },
    {
        "instruction":"已知信息：\n'good manufacturing practices (gmp)'可被翻译为：良好生产规范(GMP)\n'Article 185: Operation procedures should be established to differentiate production batches, and the differentiations of production batches should achieve homogenous quality and property of the product within the same batch.'可被翻译为：第一百八十五条 应当建立划分产品生产批次的操作规程，生产批次的划分应当能够确保同一批次产品质量和特性的均一性。\n\n根据上述已知信息，请将'Commercial-scale production process verification batches and on-site inspection dynamic production batches if needs should be organized on the planned commercial production line in accordance with the requirements of Good Manufacturing Practice of Medical Products (GMP); in principle, the batches should be consistent with the planned commercial production batches.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"商业规模生产工艺验证批次和必要的现场核查动态生产批次，应当在拟定的商业化生产线上按照药品生产质量管理规范的要求组织生产；其批量原则上应当与拟定的商业化生产批量一致。"
    },
    {
        "instruction":"已知信息：\n'A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.'可被翻译为：一种物理、化学、生物或微生物性质或特性，应在适当的限制、范围或分布范围内，以确保所需的产品质量。\n'Critical Quality Attribute – a physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to assure the desired product quality. (Q8(R2))'可被翻译为：关键质量属性——一种物理、化学、生物学或微生物学属性或特征，其应在一个合适的限度、范围或分布内，以确保 符合预期 的产品质量。（Q8 R2）\n\n根据上述已知信息，请将'A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"指产品的物理、化学、生物或微生物性质或特征，应在适当的限度、范围或分布之内，以确保预期的产品质量。"
    },
    {
        "instruction":"已知信息：\n'Article 70 Personnel of the drug regulatory departments that abuse their powers, neglect their duties, engage in malpractice for personal gains in violation of these Provisions shall receive disciplinary punishment according to law.'可被翻译为：第七十条  药品监督管理部门工作人员违反本办法规定，滥用职权、玩忽职守、徇私舞弊的，依法给予处分。\n'Article 150 Where drug supervision and administration officers abuse their powers, engage in malpractice for personal gains, or neglect their duties, they shall be punished in accordance with the law.'可被翻译为：第一百五十条 药品监督管理人员滥用职权、徇私舞弊、玩忽职守的，依法给予处分。\n\n根据上述已知信息，请将'Article 80 Officers from the drug regulatory department who abuse their powers, neglect their duties, or engage in malpractice for personal gains violating provisions of these Provisions, shall be given sanctions in accordance with the law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条  药品监督管理部门工作人员违反本办法规定，滥用职权、玩忽职守、徇私舞弊的，依法给予处分。"
    },
    {
        "instruction":"已知信息：\n'expert knowledge'可被翻译为：专家知识\n'Article 17 CFDI shall establish an expert consultation system if needs and seek for expert opinions on major and difficult issues during the registration inspection process.'可被翻译为：第十七条 核查中心根据工作需要建立专家咨询制度，在注册核查过程中就重大疑难问题听取专家意见。\n\n根据上述已知信息，请将'A method of soliciting opinions from people with specific expertise. Often in a group setting, the aim is to use expert experience to make a quick assessment when certain variables are difficult to obtain.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"向具有特定专业知识的人征求意见的方法。通常采用小组座谈的方式,其目的在于当某些变量难以获得时,利用专家经验做出快速评估。"
    },
    {
        "instruction":"已知信息：\n'A tablet having a two - or multi-layer structure. Each layer may contain different drugs or excipients, may perform different functions, or avoid changes in compatibility between different drugs, etc.'可被翻译为：具有两层或多层结构的片剂。各层可含不同的药物或辅料，可发挥不同的功能，或避免不同药物间的配伍变化等。\n'A layer of material coated during the coating process in order to smooth out the edges of the tablet and facilitate the coating operation.'可被翻译为：包衣过程中，为了消除片剂棱角并有利于包衣操作而包上的一层物质。\n\n根据上述已知信息，请将'Also known as \"scratch tablet\". A tablet in which dividing lines are marked on the surface of the tablet during production. In order to facilitate the patient to cut into half or even 1\/4 pieces.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"划痕片”。生产过程中在片剂表面划出分割线的片剂。以方便患者切割成半片乃至1\/4片。"
    },
    {
        "instruction":"已知信息：\n'(II) Equipped with the organization and personnel corresponding to the products to carry out relevant works of medical device adverse event monitoring;'可被翻译为：（二）配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作；\n'(II) Failing to be equipped with the organization and personnel corresponding to the scale of business or use to carry out relevant works of medical device adverse event monitoring as required;'可被翻译为：（二）未按照要求配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作的；\n\n根据上述已知信息，请将'(II) Be equipped with the organization or personnel adapted to the scale of the business or use to carry out relevant works of medical device adverse event monitoring;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作；"
    },
    {
        "instruction":"已知信息：\n'Article 20 Where the change management category of circumstances of change has been specified in laws, regulations or technical guidelines, MAHs shall generally determine the change management category in accordance with relevant provisions.'可被翻译为：第二十条 变更情形在法律、法规或技术指导原则中已明确变更管理类别的，持有人一般应当根据有关规定确定变更管理类别。\n'Article 27 The reporting category shall be managed by the MAHs in accordance with the relevant requirements for change management, which shall be indicated in the annual report.'可被翻译为：第二十七条 报告类变更应当由持有人按照变更管理的有关要求进行管理，在年度报告中载明。\n\n根据上述已知信息，请将'Article 22 MAHs may adjust the change management category according to the management and production technology changes, and implement the change as per the adjusted change management category upon approval or filing, or report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条 持有人可以根据管理和生产技术变化对变更管理类别进行调整，并按照调整后的变更管理类别经批准、备案后实施或报告。"
    },
    {
        "instruction":"已知信息：\n'Test materials beyond those used in the current Chinese Pharmacopoeia, including excipients i n preparations, special chromatographic columns, special reagents, and laboratory supplies, etc.'可被翻译为：超出现行版《中国药典》标准中使用的实验材料，包括制剂中的辅料、特殊色谱柱、特殊试剂、实验用品等\n'(II)  Whether the raw materials and auxiliaries, bacterial strains\/seeds, viral strains\/seeds and cells used for production are consistent with those approved by the NMPA;'可被翻译为：（二）生产用原辅材料、菌种、毒种、细胞等是否与国家药品监督管理局批准的一致；\n\n根据上述已知信息，请将'Test materials beyond those used in the current Chinese Pharmacopoeia, including excipients i n preparations, special chromatographic columns, special reagents, cell strains for assay, bacterial strains, and laboratory supplies, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"超出现行版《中国药典》标准中使用的实验材料，包括制剂中的辅料、特殊色谱柱、特殊试剂、检定用细胞株和菌毒种、实验用品等。"
    },
    {
        "instruction":"已知信息：\n'If the cosmetics manufactured by the cosmetic manufacturer do not belong to the classification units of the licensed items stated on the License for manufacturing of cosmetics, but the manufacturer relocates the premises without licensing, or fails to obtain renewal of the license for manufacturing of cosmetics at the expiration of the validity period, it shall be deemed that the manufacturer engages in manufacturing of cosmetics without licensing.'可被翻译为：化妆品生产企业生产的化妆品不属于化妆品生产许可证上载明的许可项目划分单元，未经许可擅自迁址，或者化妆品生产许可有效期届满且未获得延续许可的，视为未经许可从事化妆品生产活动。\n'(2) the License is not renewed upon expiration of the valid term;'可被翻译为：（二）有效期届满未延续的；\n\n根据上述已知信息，请将'(3) Cosmetics Manufacturing License is not renewed upon expiration;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）化妆品生产许可证有效期届满未申请延续的；"
    },
    {
        "instruction":"已知信息：\n'Persons who use closed systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records, and to ensure that the signer cannot readily repudiate the signed record as not genuine. Such procedures and controls shall include the following:'可被翻译为：使用封闭系统来生成、修改、维护或传送电子记录的人员应采用能够保证真实性、完整性、以及必要时的机密性的规程和管理方式，以确保签名者不能轻易否认签名的非真实记录。规程和管理的内容应包括：\n'Persons who use electronic signatures based upon use of identification codes in combination with passwords shall employ controls to ensure their security and integrity. Such controls shall include:'可被翻译为：同时使用识别码和密码的电子签名应给予管理以确保其安全性和完整性，管理内容应包括：\n\n根据上述已知信息，请将'Persons who use open systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, as appropriate, the confidentiality of electronic records from the point of their creation to the point of their receipt. Such procedures and controls shall include those identified in 11.10, as appropriate, and additional measures such as document encryption and use of appropriate digital signature standards to ensure, as necessary under the circumstances, record authenticity, integrity, and confidentiality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用开放式系统来生成、修改、维护或传送电子记录的人员应采用能够保证记录从创建点至接收点的真实性、完整性以及必要时的机密性的规程和个人管理方式，必要时应包括11.10中明确的内容，以及额外的措施，例如文档加密和运用相应的数字签名标准以确保记录必要的真实性、完整性和保密性。"
    },
    {
        "instruction":"已知信息：\n'Article 54 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-issue the medical device registration certificate within 20 workdays.'可被翻译为：第五十四条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。\n'Article 21 In the event that a drug MAH or manufacturer has lost the Drug Manufacturing Certificate, they may apply to the original issuing authority for a replacement of the Certificate. The original issuing authority shall issue the replacing Drug Manufacturing Certificate with the same previously authorized contents within 10 days. The information such as Certificate number and valid term specified on the replacing Certificate shall be the same as that specified on the original Certificate.'可被翻译为：第二十一条 药品生产许可证遗失的，药品上市许可持有人、药品生产企业应当向原发证机关申请补发，原发证机关按照原核准事项在十日内补发药品生产许可证。许可证编号、有效期等与原许可证一致。\n\n根据上述已知信息，请将'Article 45 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-grant the medical device registration certificate within 20 workdays.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十五条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。"
    },
    {
        "instruction":"已知信息：\n'NMPA Issues 5 Technical Review Guidances for the Registration of Tendon and Ligament Fixation Systems and Others'可被翻译为：国家药监局关于发布肌腱韧带固定系统等5项注册技术审查指导原则的通告\n'NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire'可被翻译为：国家药监局关于发布一次性使用乳腺定位丝注册技术审查等6项注册技术审查指导原则的通告\n\n根据上述已知信息，请将'NMPA Announcement on Issuing 5 Technical Review Guidances for Registration'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布5项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'e. Validation and security of computerized or automated processes'可被翻译为：计算机化或自动化流程的验证和安全保护\n'computerized system validation'可被翻译为：计算机化系统验证\n\n根据上述已知信息，请将'h. Process validation, including validation and security of computerized or automated processes (i.e. simulation studies)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"工艺验证，包括计算机化或自动化工艺的验证和安全保护（即模拟研究）"
    },
    {
        "instruction":"已知信息：\n'The CCS should consider all aspects of contamination control with ongoing and periodic review resulting in updates within the pharmaceutical quality system as appropriate. Changes to the systems in place should be\nassessed for any impact on the CCS before and after implementation.'可被翻译为：CCS 应考虑污染控制的所有方面，并进行持续、定期的回顾，酌情更新药品质量体系。现行体系如有变更，应在实施前后评估对 CCS 的任何影响。\n'The aseptic process should be clearly defined. The risks associated with the aseptic process, and any\nassociated requirements, should be identified, assessed and appropriately controlled. The site's CCS should clearly\ndefine the acceptance criteria for these controls, requirements for monitoring and the review of their effectiveness.\nMethods and procedures to control these risks should be described and implemented. Accepted residual risks\nshould be formally documented.'可被翻译为：无菌工艺应被明确定义。无菌工艺相关风险以及任何相关要求应被识别、评估并适当控制。工厂的 CCS应明确规定这些控制的可接受标准、监测要求及其有效性审核。应描述并执行控制这些风险的方法和程序。可接受的残留风险应形成正式记录。\n\n根据上述已知信息，请将'A Contamination Control Strategy (CCS) should be implemented across the facility in order to define all critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures employed to manage risks to medicinal product quality and safety. The\ncombined strategy of the CCS should establish robust assurance of contamination prevention. The CCS should be actively reviewed and, where appropriate, updated and should drive continual improvement of the manufacturing and control methods. Its effectiveness should form part of the periodic management review. Where existing control systems are in place and are appropriately managed, these may not require replacement but should be referenced in the CCS and the associated interactions between systems should be understood.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"污染控制策略（CCS）应在整个设施内实施，从而明确所有关键控制点，并评估所有用于管理药品质量和安全风险的控制措施（设计，程序性、技术性和组织性措施）和监测措施的有效性。CCS 的综合策略应建立起强有力的污染预防保障。应积极回顾并适当更新 CCS，并应推动生产和控制方法的持续改进。CCS 的有效性应成为定期管理回顾的一部分。如果控制系统已经建立并得到了妥善管理，则这些系统可能不需要更换，但应在 CCS 中提及，并应了解系统之间在相关方面的相互作用。"
    },
    {
        "instruction":"已知信息：\n'Article 24    The drug name in insert sheets and labels shall conform to the nomenclature principles on the adopted name in China and trade name of drug announced by the State Food and Drug Administration, and shall be consistent with those appeared in the approval documents of the drug.'可被翻译为：第二十四条 药品说明书和标签中标注的药品名称必须符合国家食品药品监督管理局公布的药品通用名称和商品名称的命名原则，并与药品批准证明文件的相应内容一致。\n'Article 108 For the registration application of a non-prescription drug, the insert sheet and package label shall comply with the relevant regulations on non-prescription drugs.'可被翻译为：第一百零八条 非处方药的注册申请，其药品说明书和包装标签应当符合非处方药的有关规定。\n\n根据上述已知信息，请将'Article 142 The name, insert sheet and label of any drug for which the registration is applied, shall comply with the provisions of the State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百四十二条 申请注册药品的名称、说明书和标签应当符合国家食品药品监督管理局的规定。"
    },
    {
        "instruction":"已知信息：\n'The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVRT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior to, or during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. IVRT membranes can be presoaked with receptor solution prior to assembling in the diffusion cell or equilibrated with the receptor solution in situ within the diffusion cell prior to dosing (e.g., for 30 min at a membrane temperature of 32°) depending upon the method.'可被翻译为：在IVRT开始运行之前，系统应在预定的实验条件下适当地平衡。在实验前或实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。IVRT膜在装配于扩散池之前可以用受体溶液预浸泡，或者在给药之前用扩散池内的受体溶液原位平衡(例如，在32°的膜温度下30分钟)，具体取决于方法。\n'The receptor compartment of the Model A VDC should be filled with receptor solution that is equilibrated to the target temperature (typically 32° or 37°) during the preparation and dosing of the membrane in the cell top assembly. The stirrers can be run during this period to speed up temperature stabilization. The receptor solution temperature should be measured and ensured to be within ±1° of the target temperature prior to mounting the cell top assembly. The stirrers can be run to help speed up temperature stabilization.'可被翻译为：A型VDC的受体室应充满受体溶液，在池体顶部组装膜的制备和给药过程中，受体溶液应平衡到目标温度(通常为32°或37°)。在此期间可以运行搅拌子以加速温度稳定。在安装池体顶部组件之前，应测量并确保受体溶液温度在目标温度的±1°范围内。搅拌子可以运行，以帮助加快温度稳定。\n\n根据上述已知信息，请将'The system should be equilibrated, and the temperature should be measured at the membrane. The membrane should be within ±1° of the target temperature (typically 32° or 37°) prior to applying the dosage form. The stirrers should be turned on during the equilibration period.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"系统应平衡，并在膜处测量温度。在上样之前，膜应在目标温度(通常为32°或37°)的±1°范围内。在平衡期间应打开搅拌子搅拌。"
    },
    {
        "instruction":"已知信息：\n'The legal representative and the principal responsible person of a drug manufacturer shall be fully responsible for the drug manufacturing activities.'可被翻译为：药品生产企业的法定代表人、主要负责人对本企业的药品生产活动全面负责。\n'Article 28 The legal representative and the principal of a drug MAH shall be fully responsible for drug quality and fulfill the following responsibilities:'可被翻译为：第二十八条 药品上市许可持有人的法定代表人、主要负责人应当对药品质量全面负责，履行以下职责：\n\n根据上述已知信息，请将'Article 29 The legal representative and principal of a drug manufacturer shall be responsible for drug manufacturing of the company in all aspects and perform the following duties:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 药品生产企业的法定代表人、主要负责人应当对本企业的药品生产活动全面负责，履行以下职责："
    },
    {
        "instruction":"已知信息：\n'drug synthesis'可被翻译为：药物合成\n'functional group'可被翻译为：官能团\n\n根据上述已知信息，请将'In designing the synthetic route of the target molecule, a logical reasoning analysis method conforming to the principle of organic synthesis is adopted. The target molecule is converted reasonably (including functional group tautometry, functional group addition, functional group removal, connection, etc.) or divided to produce molecular fragments and new target molecules. The latter is then repeatedly converted or segmented until readily available reagents are obtained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在设计目标分子的合成路线时，采用的一种符合有机合成原理的逻辑推理分析法。将目标分子经过合理的转换（包括官能团互变，官能团加成，官能团脱去、连接等）或分割，产生分子碎片和新的目标分子。后者再重复进行转换或分割，直至得到易得的试剂为止。"
    },
    {
        "instruction":"已知信息：\n'Article 4 The generic names of medical devices shall be in Chinese and conform to the norms of the standard spoken and written Chinese language.'可被翻译为：第四条 医疗器械通用名称应当使用中文，符合国家语言文字规范。\n'Article 7    Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.'可被翻译为：第七条 药品说明书和标签应当使用国家语言文字工作委员会公布的规范化汉字，增加其他文字对照的，应当以汉字表述为准。\n\n根据上述已知信息，请将'Article 9 Text in the instructions and labels of medical devices shall be in Chinese, and the use of Chinese shall meet the national general rules for language and words. Other languages are optional in the instructions and labels of medical devices, but the Chinese version shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九条 医疗器械说明书和标签文字内容应当使用中文，中文的使用应当符合国家通用的语言文字规范。医疗器械说明书和标签可以附加其他文种，但应当以中文表述为准。"
    },
    {
        "instruction":"已知信息：\n'These are drugs that can be sold from licensed dealers without professional supervision and without prescriptions. These drugs are suitable for self-medication for minor diseases and symptoms.'可被翻译为：这些药物可以在没有专业监督和处方的情况下从有执照的经销商那里出售。这些药物适合小病小症的自我药疗。\n'These are drugs supplied only in licensed pharmacies on the presentation of signed prescriptions issued by a licensed and registered medical practitioner, licensed and\/or registered dentist (for dental treatment only), and\/or licensed and\/or registered veterinarian (for animal treatment only), and the supply and dispensing of these drugs must be carried out by a pharmacist or under the supervision of a pharmacist. Prescription drugs are further subdivided into controlled drugs (narcotic drugs and psychotropic substances) and non- controlled drugs.'可被翻译为：这些药物仅在持牌药房供应，需出示由持牌和注册医生、持牌和\/或注册牙医(仅用于牙科治疗)和\/或持牌和\/或注册兽医(仅用于动物治疗)签发的签名处方，并且这些药物的供应和配药必须由药剂师或在药剂师的监督下进行。处方药又进一步细分为管制药物(麻醉药品和精神药物)和非管制药物。\n\n根据上述已知信息，请将'These are drugs authorized to be sold only in licensed pharmacies under the supervision of licensed or registered pharmacists; they may be sold without a prescription.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这是指在持牌或注册药剂师的监督下，只能在持牌药房销售的药物;可以在没有处方的情况下销售。"
    },
    {
        "instruction":"已知信息：\n'Article 148 The drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall complete the check of drug development conditions and raw data, the review of application dossiers, sampling, the notice to drug testing institutes for conducting testing for drug registration, the submission of review opinions, inspection report and application dossiers to the State Food and Drug Administration, and the notice to the applicant of the review opinions within 30 days starting from the date an application is accepted.'可被翻译为：第一百四十八条 省、自治区、直辖市药品监督管理部门应当在受理申请后30日内完成对研制情况及原始资料的核查、对申报资料的审查、抽取样品、通知药品检验所进行注册检验、将审查意见和核查报告连同申请人的申报资料一并报送国家食品药品监督管理局等工作，同时将审查意见通知申请人。\n'Article 11 Provincial drug control institutions shall, within 30 days upon the receipt of test samples and related materials, complete the sample testing, issue the testing report of imported drugs to the applicants, and submit it to the provincial drug regulatory department. Where it is necessary to extend the testing time due to characteristics of varieties or testing items, the duration and reasons of the extension shall be reported to provincial drug regulatory department in written form and notified to the applicants.'可被翻译为：第十一条 省级药品检验机构收到检验样品和相关资料后，应当在30日内完成样品检验，向申请人出具进口药材检验报告书，并报送省级药品监督管理部门。因品种特性或者检验项目等原因确需延长检验时间的，应当将延期的时限、理由书面报告省级药品监督管理部门并告知申请人。\n\n根据上述已知信息，请将'Provincial drug regulatory departments shall strengthen the supervision and administration, complete the review on the notified materials within 30 days upon the completion of filing according to the risk characteristics and safety credit of the filing change items, and may carry out inspection and testing when necessary.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省级药品监管部门应当加强监管，根据备案变更事项的风险特点和安全信用情况，自备案完成之日起30日内完成对备案资料的审查，必要时可实施检查与检验。"
    },
    {
        "instruction":"已知信息：\n'A substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be:—obtained from an officially recognized source;\n—prepared by independent synthesis;\n—obtained from existing production material of high purity; or\n—prepared by further purification of existing production material.'可被翻译为：经大量分析试验证明为真实材料的物质，应具有高纯度。该标准可以是:-从官方认可的来源获得;\n-独立合成制备;\n-从现有的高纯度生产材料中获得;或\n-通过进一步提纯现有生产材料制备。\n'reference substance'可被翻译为：对照品\n\n根据上述已知信息，请将'A high-purity non-standard substance provided by a pharmaceutical reference substance development institution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由药品标准物质研制机构提供的高纯度非标准物质。"
    },
    {
        "instruction":"已知信息：\n'electrophoretogram'可被翻译为：电泳图\n'Method for electrophoretic analysis using paper as a support.'可被翻译为：以纸为支持物进行电泳的分析方法。\n\n根据上述已知信息，请将'Recording of zoned electrophoretic patterns. The form or the electrophoretic carrier itself or a scan of it.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"区带电泳图形的记录。其形式或电泳载体本身或为对它的扫描图。"
    },
    {
        "instruction":"已知信息：\n'An auxiliary material used to reduce friction between particles and improve material flow.'可被翻译为：降低颗粒间摩擦、改善物料流动性的辅料。\n'5. The name, batch number and actually used quantities of each kind of packaging materials;'可被翻译为：（五）每一包装材料的名称、批号和实际使用的数量。\n\n根据上述已知信息，请将'An additive used to reduce the adhesion of raw materials to the die. It is a kind of lubricant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于减轻原料对冲模的黏附作用的添加剂。为润滑剂的一种。"
    },
    {
        "instruction":"已知信息：\n'Article 147 Where an enterprise establishes a warehouse, it shall ensure that the inner walls and ceiling of the warehouse are smooth and clean, the floor is flat and the doors and windows have a tight structure; and there are reliable safety protection, anti-theft and other measures.'可被翻译为：第一百四十七条 企业设置库房的，应当做到库房内墙、顶光洁，地面平整，门窗结构严密；有可靠的安全防护、防盗等措施。\n'Article 49: Interior surfaces (walls, floors and ceilings) of a clean area should be smooth, free from cracks, open joints and dust retention, and should not shed particulate matter, and should permit easy and effective cleaning and, if necessary, disinfection.'可被翻译为：第四十九条 洁净区的内表面（墙壁、地面、天棚）应当平整光滑、无裂缝、接口严密、无颗粒物脱落，避免积尘，便于有效清洁，必要时应当进行消毒。\n\n根据上述已知信息，请将'(II) The warehouse has smooth interior walls and ceiling as well as flat floor with tight structure of door and window;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）库房内墙、顶光洁，地面平整，门窗结构严密；"
    },
    {
        "instruction":"已知信息：\n'first-time donor'可被翻译为：第一次捐赠\n'A person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.'可被翻译为：在同一血库按最低时间间隔定期捐献血液、血液成分或血浆的人。\n\n根据上述已知信息，请将'A donor whose blood or plasma is tested for the first time for infectious disease markers in a blood establishment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"首次在血液机构进行血液或血浆传染病标志物检测的献血者。"
    },
    {
        "instruction":"已知信息：\n'Where pre-marketing GMP inspection is necessary, the CFDI shall coordinate the relevant drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government to implement the inspection concurrently with the drug registration inspection of the manufacturing site. The administrative requirements for pre-marketing GMP inspection shall be stipulated by the Provisions for Drug Manufacturing Supervision and Administration.'可被翻译为：需要上市前药品生产质量管理规范检查的，由药品核查中心协调相关省、自治区、直辖市药品监督管理部门与药品注册生产现场核查同步实施。上市前药品生产质量管理规范检查的管理要求，按照药品生产监督管理办法的有关规定执行。\n'(3) For varieties having passed GMP compliance inspection for manufacturing conditions of the products, the drug regulatory departments of related provinces, autonomous regions and municipalities directly under the Central Government shall decide whether or not to carry out pre-marketing GMP inspection according to risk management principles.'可被翻译为：（三）已通过与生产该药品的生产条件相适应的药品生产质量管理规范符合性检查的品种，相关省、自治区、直辖市药品监督管理部门根据风险管理原则决定是否开展上市前的药品生产质量管理规范符合性检查。\n\n根据上述已知信息，请将'Article 52 The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government may, as needed for supervision and administration, carry out pre-marketing GMP compliance inspection on drug marketing authorization applicants holding Drug Manufacturing Certificate and its contract manufacturer as required below:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 省、自治区、直辖市药品监督管理部门根据监管需要，对持有药品生产许可证的药品上市许可申请人及其受托生产企业，按以下要求进行上市前的药品生产质量管理规范符合性检查："
    },
    {
        "instruction":"已知信息：\n'The inspection records of incoming goods shall be kept till 2 years after expiration of valid term of the medical device; if there is no valid term for such medical device, the records shall be kept for no less than 5 years. The inspection records of incoming implantable medical devices shall be kept permanently.'可被翻译为：进货查验记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械进货查验记录应当永久保存。\n'The sales records shall be kept till 2 years after expiration of valid term of the medical devices; if there is no valid term for such medical devices, the records shall be kept for no less than 5 years. The sales records of implantable medical devices shall be kept permanently.'可被翻译为：销售记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械销售记录应当永久保存。\n\n根据上述已知信息，请将'Article 22 MAHs, medical device distributing enterprises as well as user facility shall establish and keep medical device adverse event monitoring records. The records shall be kept until 2 years upon shelf life expiration of medical devices; for those without shelf life label, the record-keeping period shall not be less than 5 years. The monitoring records of implantable medical devices shall be kept permanently, and medical institutions shall keep them in accordance with the relevant provisions for medical records.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条  持有人、经营企业、使用单位应当建立并保存医疗器械不良事件监测记录。记录应当保存至医疗器械有效期后2年；无有效期的，保存期限不得少于5年。植入性医疗器械的监测记录应当永久保存，医疗机构应当按照病例相关规定保存。"
    },
    {
        "instruction":"已知信息：\n'Prior to beginning a test procedure an environment blank must be prepared and tested according to ORA-LAB.019. After passing results have been obtained the instrument can now be used to perform the test procedure.'可被翻译为：在开始检测程序之前，必须根据ORA-LAB.019制备和检测一份环境空白。在得 到合格结果之后，可使用该仪器执行检测程序。\n'The test Apparatus is described in USP<788> with additional information found in USP<1788> .'可被翻译为：USP<788>中描述了检测仪器，更多信息参见USP<1788>。\n\n根据上述已知信息，请将'Prior to initiating the test sequence with a specimen, a blank determination is required and must be carried out according to USP<788> . The environmental blank must meet the requirements set forth in USP <788>in order to initiate testing of the specimen.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在开始样本检测序列之前，应根据USP<788>进行空白检测。环境空白必须符合USP<788>中所设定的要求方可开始样本检测。"
    },
    {
        "instruction":"已知信息：\n'Article 105: Materials and products should be transported in a manner to protect their quality. Where special requirements are needed, the transportation conditions should be verified.'可被翻译为：第一百零五条 物料和产品的运输应当能够满足其保证质量的要求，对运输有特殊要求的，其运输条件应当予以确认。\n'1.An area within the facility in which specific environmental facility conditions and procedures are defined, controlled, and monitored to prevent degradation or cross-contamination of the product.\n2.An area within the facility in which specific procedures and environmental parameters, including viable and nonviable particles, are defined, controlled and monitored to prevent degradation, contamination or cross-contamination of the product.'可被翻译为：1.设施内的一个区域，在该区域内，特定的环境设施条件和程序被定义、控制和监测，以防止产品的降解或交叉污染。\n2.设施内特定程序和环境参数(包括活的和非活的颗粒)被定义、控制和监测以防止产品降解、污染或交叉污染的区域。\n\n根据上述已知信息，请将'environmental conditions or any special requirement needed for the facility or equipment depending on the nature of the product to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"准备转移的产品特性所决定的设施或设备所需的环境条件和所有特殊要求。"
    },
    {
        "instruction":"已知信息：\n'Exposure during gestation to physical and chemical factors that can cause offspring malformations.'可被翻译为：在妊娠期接触能引起子代畸形的物理化学因素。\n'Exogenous physical and chemical factors cause all toxicity before and after implantation until the end of the organ-forming period.'可被翻译为：外源性物理化学因素造成孕体着床前后一直到器官形成期结束的所有毒性。\n\n根据上述已知信息，请将'Exposure to exogenous physical and chemical factors during gestation (before birth) causes structural deformities in offspring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在妊娠期（出生前）接触外源性物理化学因素，引起后代结构畸形的作用。"
    },
    {
        "instruction":"已知信息：\n'In chromatographic analysis, a quantitative method is performed by comparing the chromatographic peak area or peak height of the reference and the test.'可被翻译为：在色谱分析中，一种通过对照品和供试品色谱峰面积或峰高的比较进行定量的方法。\n'To measure the normal chromatographic peak and abnormal chromatographic peak index.'可被翻译为：为衡量正常色谱峰与不正常色谱峰的指标。\n\n根据上述已知信息，请将'The method uses the percentage of the chromatographic peak area of each component in the total peak area of a multi-component sample for chromatographic quantification. Usually used only for the examination of the substance in question.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种利用多组分样品中各组分的色谱峰面积占总峰面积的百分比进行色谱定量的方法。通常仅用于有关物质检查。"
    },
    {
        "instruction":"已知信息：\n'Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.'可被翻译为：第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。\n'Article 4 The State encourages the research and development of new drugs and adopts the special review and approval with respect to innovative drugs, new drugs for serious and life-threatening diseases and to address unmet medical needs and drugs.'可被翻译为：第四条 国家鼓励研究创制新药，对创制的新药、治疗疑难危重疾病的新药实行特殊审批。\n\n根据上述已知信息，请将'Article 8 The State encourages the research and innovation of medical devices, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of medical devices and promotes the development of medical device industry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八条 国家鼓励医疗器械的研究与创新，对创新医疗器械实行特别审批，促进医疗器械新技术的推广与应用，推动医疗器械产业的发展。"
    },
    {
        "instruction":"已知信息：\n'(1) The test sample analysis is conducted according to the analysis plan, the preprocessing and testing method of the samples in the analysis batch are consist with the method validation, and the plasma concentration data is consistent with that in the application dossier.'可被翻译为：(1) 试验样品分析按照分析计划执行， 分析批中样品预处理的过程和检测方法与方法学验证一致， 血药浓度数据与申报资料一致。\n'(4) Samples introduced into all the instruments are recorded in the original records, and investigation and analysis are conducted for abnormal circumstances occurred during the process of sample analysis, consist with the application dossier.'可被翻译为：(4) 所有在仪器中进样的样品均记录在原始记录中， 并对样品分析过程中出现的异常情况进行调查和分析， 与申报资料一致。\n\n根据上述已知信息，请将'(5) If there is residual during the process of test sample analysis, evaluate the impact on the concentration of the test sample and carry out specific measures, consist with the application dossier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) 试验样品分析过程中如有残留， 对试验样品浓度的影响进行评估并采取具体措施， 与申报资料一致。"
    },
    {
        "instruction":"已知信息：\n'1. All changes of starting materials used for the product, especially those materials from new suppliers;'可被翻译为：（一）产品所用原辅料的所有变更，尤其是来自新供应商的原辅料；\n'1.A general term used to denote starting materials (active pharmaceutical ingredients and excipients), reagents, solvents, process aids, intermediates, packaging materials and labelling materials.\n2.A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n3.A term used to denote starting materials, process aids, intermediates, active pharmaceutical ingredients, packaging and labelling materials.'可被翻译为：1.用于表示起始原料(活性药物成分和赋形剂)、试剂、溶剂、工艺助剂、中间体、包装材料和标签材料的总称。\n2.用于表示原材料(起始原料、试剂、溶剂)、工艺助剂、中间体、原料药以及包装和标签材料的通用术语。\n3.用于表示起始原料、工艺助剂、中间体、活性药物成分、包装和标签材料的术语。\n\n根据上述已知信息，请将'(i) A review of starting materials including packaging materials used in the product, especially those from new sources and in particular the review of supply chain traceability of active substances;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(i) 对产品中使用的原材料包括包装材料进行回顾，特别是新供应商的包装材料，以及贵活性物质的供应链追溯性的回顾；"
    },
    {
        "instruction":"已知信息：\n'Article 51 ADR monitoring institutions at all levels shall conduct statistical analysis on the ADR reporting and monitoring data received and provide feedback in appropriate forms.'可被翻译为：第五十一条 各级药品不良反应监测机构应当对收到的药品不良反应报告和监测资料进行统计和分析，并以适当形式反馈。\n'(I) Undertake the collection, evaluation, feedback and reporting of ADR reporting and monitoring data nationwide, and set up and maintain the national information network for ADR monitoring;'可被翻译为：（一）承担国家药品不良反应报告和监测资料的收集、评价、反馈和上报，以及全国药品不良反应监测信息网络的建设和维护；\n\n根据上述已知信息，请将'Article 52 The National Center for ADR Monitoring shall release ADR warning information in a timely manner based on results of comprehensive analysis and evaluation on ADR reporting and monitoring data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 国家药品不良反应监测中心应当根据对药品不良反应报告和监测资料的综合分析和评价结果，及时发布药品不良反应警示信息。"
    },
    {
        "instruction":"已知信息：\n'Article 26 Medical device testing institutions shall have the relevant qualification of medical device testing, and perform testing within their specified testing scope. It shall carry out pre-evaluation of the product technical requirements. The pre-evaluation opinions together with the medical device registration testing report shall be submitted to the applicant.'可被翻译为：第二十六条 医疗器械检验机构应当具有医疗器械检验资质、在其承检范围内进行检验，并对申请人提交的产品技术要求进行预评价。预评价意见随注册检验报告一同出具给申请人。\n'(2) having the institutions, full-time testing personnel and equipment capable of meeting the quality testing requirements for the medical devices manufactured;'可被翻译为：（二）有能对生产的医疗器械进行质量检验的机构或者专职检验人员以及检验设备；\n\n根据上述已知信息，请将'For the medical devices having not included in the testing scope of any medical device testing institutions, the corresponding registration department shall designate a testing institution which has the capability to conduct the testing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尚未列入医疗器械检验机构承检范围的医疗器械，由相应的注册审批部门指定有能力的检验机构进行检验。"
    },
    {
        "instruction":"已知信息：\n'A class of stability tests designed to accelerate the chemical degradation or physical change of an active drug substance or preparation through the use of exceptional storage conditions.'可被翻译为：通过使用超常的贮存条件来加速活性原料药或制剂的化学降解或物理变化的一类稳定性试验。\n'Records of the test\/control articles on stability, batch number, purity, specification, quantity, physical and chemical characteristics, storage conditions, expiration date, etc. should be retained completely;'可被翻译为：受试物与对照品的稳定性、批号、纯度含量、规格、数量、理化特征、保存条件、有效期等记录完整；\n\n根据上述已知信息，请将'A stability test performed under conditions close to the actual storage of the drug to provide a basis for establishing the expiration date of the drug.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在接近药品实际贮存条件下进行的，为制定药物的有效期提供依据的稳定性试验。"
    },
    {
        "instruction":"已知信息：\n'National medical device varieties under intensive surveillance shall be determined according to the medical device registration, adverse event monitoring, supervisory inspection and testing and based on risk degree and product use.'可被翻译为：国家医疗器械重点监测品种应当根据医疗器械注册、不良事件监测、监督检查、检验等情况，结合产品风险程度和使用情况确定。\n'(4) The status of use or the effects generated of medical devices, according to their different structural characteristics, whether are in contact with human body and patterns of use, include:'可被翻译为：（四）根据不同的结构特征、是否接触人体以及使用形式，医疗器械的使用状态或者其产生的影响包括以下情形：\n\n根据上述已知信息，请将'The risk degree of a medical device shall be determined comprehensively according to the intended purpose, structural characteristics, pattern of use, status of use as well as whether the device is body contacting.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械风险程度，应当根据医疗器械的预期目的，通过结构特征、使用形式、使用状态、是否接触人体等因素综合判定。"
    },
    {
        "instruction":"已知信息：\n'Article 60 Where the management classification of a filed medical device is adjusted, the filing entity shall apply to the food and drug regulatory department for cancellation of the original filing. Where the management classification is adjusted to a class II or class III medical device, the filing entity shall apply for registration in accordance with the Provisions.'可被翻译为：第六十条 已备案的医疗器械管理类别调整的，备案人应当主动向食品药品监督管理部门提出取消原备案；管理类别调整为第二类或者第三类医疗器械的，按照本办法规定申请注册。\n'For a newly developed in-vitro diagnostic reagent not yet listed in the classification catalogue, the applicant may directly apply for a class III in-vitro diagnostic reagent registration, or, after determining the class of the product in accordance with the classification rules and applying for class confirmation to the China Food and Drug Administration, apply for registration or for filing.'可被翻译为：对新研制的尚未列入体外诊断试剂分类目录的体外诊断试剂，申请人可以直接申请第三类体外诊断试剂产品注册，也可以依据分类规则判断产品类别向国家食品药品监督管理总局申请类别确认后，申请产品注册或者办理产品备案。\n\n根据上述已知信息，请将'Article 70 Where the management classification of a filed in-vitro diagnostic reagent is adjusted, the filing entity shall apply to the food and drug regulatory department for cancellation of the original filing. Where the management classification is adjusted to a class II or class III in-vitro diagnostic reagent, the filing entity shall apply for registration in accordance with the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 已备案的体外诊断试剂管理类别调整的，备案人应当主动向食品药品监督管理部门提出取消原备案；管理类别调整为第二类或者第三类体外诊断试剂的，按照本办法规定申请注册。"
    },
    {
        "instruction":"已知信息：\n'For all product types, follow current USP methodology in , with the following additional instructions.'可被翻译为：所有产品类型应遵循中现行USP方法和以下附加说明。\n'Follow the current edition of the USP for the amount of sample to be tested.'可被翻译为：样本量执行USP现行版本要求。\n\n根据上述已知信息，请将'For all product types, follow current USP<51> methodology in chapter , with the following additional instructions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有的产品类型均需遵守现行USP<51>的方法，和以下附加说明。"
    },
    {
        "instruction":"已知信息：\n'The selection of the monitoring system should take into account any risk presented by the materials used in the manufacturing operation (e.g. those involving live organisms, powdery products or radiopharmaceuticals) that may give rise to biological, chemical or radiation hazards.'可被翻译为：监测系统的选择应考虑生产操作中使用的可能导致生物、化学或放射性危害的物料所带来的任何风险（例如涉及活微生物的物料，粉末物料或放射性物料）。\n'Article 244: When changes involve key quality factors such as starting materials, immediate packaging materials, manufacturing process, major equipment, etc., the quality of at least the first three batches produced after the change should be evaluated. If the change has potential impact on the shelf life, stability studies should also be conducted.'可被翻译为：第二百四十四条 改变原辅料、与药品直接接触的包装材料、生产工艺、主要生产设备以及其他影响药品质量的主要因素时，还应当对变更实施后最初至少三个批次的药品质量进行评估。如果变更可能影响药品的有效期，则质量评估还应当包括对变更实施后生产的药品进行稳定性考察。\n\n根据上述已知信息，请将'The determination of key materials should comprehensively take into account of the quality risk of the drugs produced by the manufacturer, the materials consumption and the impact on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"主要物料的确定应当综合考虑企业所生产的药品质量风险、物料用量以及物料对药品质量的影响程度等因素。"
    },
    {
        "instruction":"已知信息：\n'Design compounds with expected pharmacological effects, improve the screening hit rate, and find new effective structure types by using the law of drug structure-activity relationship under the premise of reducing the workload of synthesis and screening, and obtain new drugs with high efficiency, low toxicity and easy to administer.'可被翻译为：设计预期药理作用的化合物，提高筛选命中率，在减少合成及筛选工作量的前提下，运用药物构效关系规律，寻找新的显效结构类型，获得高效低毒便于给药的新药的途径和方法。\n'Chemical products with simple chemical structure as the starting material, through a series of chemical reactions and physical processing process to produce drugs.'可被翻译为：以化学结构简单的化工产品为起始原料，经过一系列化学反应和物理处理过程制得药物的过程。\n\n根据上述已知信息，请将'Through chemical structure modification and in vitro and in vivo pharmacological and toxicological evaluation, the process of further discovering the derivative of the lead compound series with excellent efficacy, safety and pharmacokinetic properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过化学结构改造，并经体外和体内药理毒理方法评价，进一步发现先导化合物系列中，其药效、安全性、药动学特性优良的衍生物的过程。"
    },
    {
        "instruction":"已知信息：\n'x-ray diffraction of powder'可被翻译为：X 射线粉末衍射\n'x-ray diffraction of single crystal'可被翻译为：X 射线单晶衍射\n\n根据上述已知信息，请将'The X-ray diffraction method using powder crystal or polycrystal as the sample.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"采用粉末状晶体或多晶体为试样的X射线衍射法。"
    },
    {
        "instruction":"已知信息：\n'For the registrant, filing entity and distributor of medical devices with bad credit records, the drug regulatory departments shall increase the supervision and inspection frequency, and impose heavier punishment on dishonest behaviors according to law.'可被翻译为：对有不良信用记录的医疗器械注册人、备案人和经营企业，药品监督管理部门应当增加监督检查频次，依法加强失信惩戒。\n'Article 66 For drug MAHs and manufacturers with bad credit records, drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government shall increase the supervision and inspection frequency and may impose joint punishment according to national regulations.'可被翻译为：第六十六条 省、自治区、直辖市药品监督管理部门对有不良信用记录的药品上市许可持有人、药品生产企业，应当增加监督检查频次，并可以按照国家规定实施联合惩戒。\n\n根据上述已知信息，请将'Drug regulatory departments shall establish a credit record system for the vaccine MAHs and their responsible persons and include them into the national credit information sharing platform, release information of their serious loss of honesty according to regulations and impose joint punishment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理部门应当建立疫苗上市许可持有人及其相关人员信用记录制度，纳入全国信用信息共享平台，按照规定公示其严重失信信息，实施联合惩戒。"
    },
    {
        "instruction":"已知信息：\n'In the DNA double strand, the strand that is not used to transcribe mRNA.'可被翻译为：DNA双链中，不用于转录mRNA的那条链。\n'A replication model of double-stranded deoxyribonucleic acid (DNA) in which each single strand is used as a template for the synthesis of a new strand after the separation of the parental double strand. Thus, when replication is complete, there will be two daughter DNA molecules, each with the same nucleotide sequence as the parent molecule.'可被翻译为：一种双链脱氧核糖核酸（DNA）的复制模型，其中亲代双链分离后，每条单链均作为新链合成的模板。因此，复制完成时将有两个子代DNA分子，每个分子的核昔酸序列均与亲代分子相同。\n\n根据上述已知信息，请将'The strand of a DNA double that is used to transcribe mRNA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"DNA双链中，用于转录mRNA的那条链。"
    },
    {
        "instruction":"已知信息：\n'Some product types should not be pooled. Two examples are drug products that have an initial low MVD (see discussion above of “adjusted MVD”) and products that are manufactured as a suspension, because sample aliquot homogeneity may present significant interference issues.'可被翻译为：有些产品类型不可混合取样。2个例子是初始MVD较低（参见上述“调整后的 MVD”）的药品和作为混悬液生产的药品，因为样品等分均匀性可能呈现出重大 干扰问题。\n'1.Subjecting an in-process or bulk process intermediate (final biological bulk intermediate) or final product of a single batch to an alternate manufacturing process due to a failure to meet predetermined specifications. Reworking is an unexpected occurrence and is not pre- approved as part of the marketing authorization.\n2.Subjecting an intermediate or API that does not conform to standards or specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g. recrystallizing with a different solvent).'可被翻译为：1.由于未能达到预定的规格，使制程或散装工艺中间体(最终生物散装中间体)或单个批次的最终产品采用替代生产工艺。返工是一种意外事件，不作为上市许可的一部分预先批准。\n2.对不符合标准或规范的中间体或API进行一个或多个不同于既定生产工艺的加工步骤，以获得质量可接受的中间体或API(例如，用不同的溶剂重结晶)。\n\n根据上述已知信息，请将'FDA does not recommend pooling in-process samples from different in- process stages of the manufacturing process because it may be difficult to ensure the homogeneity of these materials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"FDA不建议对生产工艺中不同中控步骤的中控样品进行合并，因为可能难以确保这 些物料的均一性。"
    },
    {
        "instruction":"已知信息：\n'Annexes: 1. Requirements for registration of medical excipients (Interim)(omitted)'可被翻译为：附件：1.药用辅料登记资料要求（试行）（略）\n'Raw materials and excipients packaging materials, and etc.'可被翻译为：指原料、辅料和包装材料等。\n\n根据上述已知信息，请将'4. Basic requirements for the annual report of medicinal raw materials, excipients and pharmaceutical packaging materials (omitted)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.药用原辅料、药包材年度报告基本要求（略）"
    },
    {
        "instruction":"已知信息：\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。\n'Article 24 If the lot release institution believes that relevant data in the application dossiers needs to be verified or supplemented, it shall notify the lot release applicant of supplementing data in writing and specify the time limit for reply.'可被翻译为：第二十四条 批签发机构认为申请资料中的有关数据需要核对或者补充的，应当书面通知批签发申请人补正资料，并明确回复时限。\n\n根据上述已知信息，请将'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料之日起即为受理。"
    },
    {
        "instruction":"已知信息：\n'Person(s) who direct and control an organization at the highest levels and who have the authority and responsibility to mobilize resources within the organization. In NRAs, the terms “senior management” or “top management” can be used interchangeably.'可被翻译为：在组织最高层指导和控制组织的人，他们有权力和责任在组织内调动资源。在国家注册机构中，术语“高级管理人员”或“最高管理人员”可以互换使用。\n'Management system to direct and control a pharmaceutical company with regard to quality. (ICH Q10 based upon ISO 9000:2005)'可被翻译为：为在质量方面指导和控制制药公司而建立的管理体系。(ICH Q10 依据 ISO 9000:2005)\n\n根据上述已知信息，请将'Person(s) who direct and control a company or site at the highest levels with the authority and responsibility to mobilise resources within the company or site. (ICH Q10 based in part on ISO 9000:2005)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在最高级别上指导和控制一个公司或工厂、具有权力和责任在公司或工厂内部调动资源 的人员。 (ICH Q10 部分依据 ISO 9000:2005)"
    },
    {
        "instruction":"已知信息：\n'Prior to use in the test, the labeled LAL reagent sensitivity must be confirmed. Prepare a control standard endotoxin dilution series having at least four concentrations equivalent to 2 λ, λ, 0.5 λ, and 0.25 λ. Inoculate four replicates from each control standard endotoxin tube with equal amounts of reconstituted lysate per manufacturer’s recommendation. Multiple dilution series are not required. The geometric mean of the endpoints must be within the limits of labeled claim. The acceptable variation is one half (0.5 λ) to two times (2 λ) the labeled sensitivity (λ).'可被翻译为：LAL试剂用于检测之前，必须确认其灵敏度。制备一套标准内毒素对照稀释液，至 少有4个等同于2 λ、λ、0.5 λ和0.25 λ的浓度。根据生产商的建议从每个标准内毒 素对照管接种出4个相同等数量的复溶裂解液。不需要多个稀释系列。终点的等比 中数（几何平均数）必须在标称的限度内。可接受变异为标示灵敏度（λ）的0.5-2 倍（0.5 λ-2 λ）\n'A collaborated method prepared by an ORS laboratory is available for extraction of endotoxin from devices and may be used if necessary. Analytical verification of the final version should be conducted by the responsible laboratory. The ORS laboratory protocol is summarized below for convenience.'可被翻译为：ORS实验室起草了一份协作方法，用于从医疗器械中萃取内毒素，必要时可使用之。 应由责任实验室对最终版本的分析方法进行确认。方便起见，将ORS实验室方案总结 如下：\n\n根据上述已知信息，请将'NOTE: Adjust the final endotoxin value taking into account the volume of the rinse solution used in the extraction procedure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"注：调整最终内毒素值时要考虑提取程序所用淋洗溶液的体积。"
    },
    {
        "instruction":"已知信息：\n'The period in which the bacteria are inoculated into the fermentation medium and begin to grow and reproduce under suitable culture conditions.'可被翻译为：产生菌接种至发酵培养基后，在合适的培养条件下，开始生长和繁殖的时期。\n'The liquid in which the microorganisms are inoculated into the liquid medium for a period of time and then metabolized to synthesize the bacteria and secrete the products.'可被翻译为：微生物接种到液体培养基培养一段时间后，经微生物代谢合成菌体及分泌产物的液体。\n\n根据上述已知信息，请将'The period in which the seeds or bacteria grown on the solid medium are transferred to the liquid medium for culture, so that they can multiply into a large number of mycelia or bacteria.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将在固体培养基上培养出的抱子或菌体转入到液体培养基中培养，使其繁殖成大量菌丝或菌体的时期。"
    },
    {
        "instruction":"已知信息：\n'Article 7 Where units and individuals discover any medical device adverse event, they have the right to report to authorities of drug supervision and administration (hereinafter referred to as drug regulatory departments) or monitoring agencies.'可被翻译为：第七条  任何单位和个人发现医疗器械不良事件，有权向负责药品监督管理的部门（以下简称药品监督管理部门）或者监测机构报告。\n'Article 28 The food and drug regulatory departments shall supervise and inspect the implementation of medical device mandatory standards and the registered or filed product technical requirements by medical device enterprises.'可被翻译为：第二十八条 食品药品监督管理部门对医疗器械企业实施医疗器械强制性标准以及经注册或者备案的产品技术要求的情况进行监督检查。\n\n根据上述已知信息，请将'Article 29 Any unit or individual have the right to report to the food and drug regulatory departments misbehaviors that violate the medical device mandatory standards and registered or filed product technical requirements. Departments receiving such reports shall take proper actions in accordance with regulations in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 任何单位和个人有权向食品药品监督管理部门举报或者反映违反医疗器械强制性标准以及经注册或者备案的产品技术要求的行为。收到举报或者反映的部门，应当及时按规定作出处理。"
    },
    {
        "instruction":"已知信息：\n'(2) not publicizing at the acceptance place the information that shall be publicized by la]w;'可被翻译为：（二）不在受理场所公示依法应当公示的材料的；\n'(2) The enterprise's eligibility as an entity is terminated according to law;'可被翻译为：（二）企业主体资格被依法终止的；\n\n根据上述已知信息，请将'(II) Not publicizing on the institution's website or at the acceptance place the information that should be publicized according to law;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）不在本机构网站或者申请受理场所公示依法应当公示的材料的；"
    },
    {
        "instruction":"已知信息：\n'Article 93 Anyone who fabricates or spreads false information about vaccine safety, or picks quarrels and provokes troubles in immunization entities, thus constituting an act violating public security regulations shall be subject to public security punishment by the public security departments according to law.'可被翻译为：第九十三条 编造、散布虚假疫苗安全信息，或者在接种单位寻衅滋事，构成违反治安管理行为的，由公安机关依法给予治安管理处罚。\n'Article 87 Where any disease prevention and control institution or immunization entity is under any of the following circumstances in violation of this Law, the competent health department of the people's government at or above the county level shall order to make rectification, give a warning, and confiscate the illegal income; and in serious circumstances, impose sanctions of a warning and up to  dismissal on the main responsible person, directly responsible persons and other directly responsible personnel according to law, and order the responsible medical personnel to suspend practice activities for more than one year and less than eighteen months; and for serious consequence, give an expulsion to the main responsible person and executive in charge and other directly responsible personnel according to law, and responsible medical and health personnel shall be revoked of business certificate by original issuing department:'可被翻译为：第八十七条 违反本法规定，疾病预防控制机构、接种单位有下列情形之一的，由县级以上人民政府卫生健康主管部门责令改正，给予警告，没收违法所得；情节严重的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至撤职处分，责令负有责任的医疗卫生人员暂停一年以上十八个月以下执业活动；造成严重后果的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分，由原发证部门吊销负有责任的医疗卫生人员的执业证书：\n\n根据上述已知信息，请将'Relevant competent departments shall impose sanctions according to law on a newspaper, journal, radio, television, internet website or any other media where they fabricate or disseminate any false information about vaccine safety, and on the main responsible person, executive in charge and other directly responsible personnel.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"报纸、期刊、广播、电视、互联网站等传播媒介编造、散布虚假疫苗安全信息的，由有关部门依法给予处罚，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予处分。"
    },
    {
        "instruction":"已知信息：\n'Article 84 The registration shall not be renewed in any of the following circumstances:'可被翻译为：第八十四条 有下列情形之一的，不予再注册：\n'(2) the re-registration is not allowed according to provisions in Article 126 of the Provisions;'可被翻译为：（二）按照本办法第一百二十六条的规定不予再注册的；\n\n根据上述已知信息，请将'(2) Where registration shall not be renewed according to these Provisions;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）按照本办法规定不予再注册的；"
    },
    {
        "instruction":"已知信息：\n'In the sequence of peptide or protein, the amino group and the carboxyl group between amino acids are dehydrated to form a bond, so the amino acid in the peptide or protein molecule is not a complete amino acid and is called residue.'可被翻译为：在肽或蛋白质的序列中，氨基酸之间的氨基和竣基脱水成键，因此肽或蛋白质分子中的氨基酸已不是完整的氨基酸，被称为残基。\n'Also called \"p-aminobenzenesulfonic acid\". A compound prepared by the reaction of aniline with concentrated sulfuric acid at 180 7.'可被翻译为：又称\"对氨基苯磺酸\"。由苯胺和浓硫酸在180七反应制得的化合物。\n\n根据上述已知信息，请将'A protein compound consisting of a non-protein group of cogroups bound to an amino acid sequence. The non-protein portion of which is nucleic acid is called riboprotein, lipid compound is called lipoprotein, polysaccharide is called glycoprotein, and flavin riboxylic acid is called flavin protein.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由非蛋白质基团的辅基结合于氨基酸序列上组成的蛋白质类化合物。其非蛋白质部分是核酸的称为核蛋白，是类脂化合物的称为脂蛋白，是多糖的称为糖蛋白，是黄素核昔酸的称为黄素蛋白。"
    },
    {
        "instruction":"已知信息：\n'The online drug sales enterprises shall keep complete records of qualification documents and electronic transactions of the suppliers. The online drug retailers selling prescription drugs shall also keep records of prescriptions, online pharmaceutical services, etc. The relevant records shall be kept for not less than 5 years, and not less than 1 year after the expiration of the drug.'可被翻译为：药品网络销售企业应当完整保存供货企业资质文件、电子交易等记录。销售处方药的药品网络零售企业还应当保存处方、在线药学服务等记录。相关记录保存期限不少于5年，且不少于药品有效期满后1年。\n'The third-party platform shall strengthen the examination, manage the drug information display, prescription examination, drug sales and delivery, and other behaviors of the online drug sales enterprises settled on the platform, and urge them to strictly perform their legal obligations.'可被翻译为：第三方平台应当加强检查，对入驻平台的药品网络销售企业的药品信息展示、处方审核、药品销售和配送等行为进行管理，督促其严格履行法定义务。\n\n根据上述已知信息，请将'Article 21 The third-party platform shall keep the information on drug display, transaction records, complaints and reports, and other relevant information. The storage period shall not be less than 5 years, and not less than 1 year after the expiration of the drug. The third-party platform shall ensure the authenticity and integrity of relevant materials, information, and data, and provide convenience for the settled online drug sales enterprises to save their own data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十一条 第三方平台应当保存药品展示、交易记录与投诉举报等信息。保存期限不少于5年，且不少于药品有效期满后1年。第三方平台应当确保有关资料、信息和数据的真实、完整，并为入驻的药品网络销售企业自行保存数据提供便利。"
    },
    {
        "instruction":"已知信息：\n'Article 48 The National Center for ADR Monitoring shall conduct comprehensive analysis on serious ADR reports received quarterly, extract and evaluate safety information that needs attention, propose risk management measures, and promptly report to the SFDA and the Ministry of Health.'可被翻译为：第四十八条 国家药品不良反应监测中心应当每季度对收到的严重药品不良反应报告进行综合分析，提取需要关注的安全性信息，并进行评价，提出风险管理建议，及时报国家食品药品监督管理局和卫生部。\n'For death cases, the provincial ADR monitoring institutions where the event occurs and where the drug manufacturer is located shall analyze and evaluate the event based on the investigation report in a timely manner, conduct on-site investigation when necessary, and report the evaluation results to the provincial drug regulatory departments and health administrative departments and the National Center for ADR Monitoring.'可被翻译为：对死亡病例，事件发生地和药品生产企业所在地的省级药品不良反应监测机构均应当及时根据调查报告进行分析、评价，必要时进行现场调查，并将评价结果报省级药品监督管理部门和卫生行政部门，以及国家药品不良反应监测中心。\n\n根据上述已知信息，请将'Article 47 Provincial ADR monitoring institutions shall conduct comprehensive analysis on ADR reports received quarterly, extract and evaluate safety information that needs attention, propose risk management measures, and promptly report to drug regulatory departments and health administrative departments at the provincial level and the National Center for ADR Monitoring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条 省级药品不良反应监测机构应当每季度对收到的药品不良反应报告进行综合分析，提取需要关注的安全性信息，并进行评价，提出风险管理建议，及时报省级药品监督管理部门、卫生行政部门和国家药品不良反应监测中心。"
    },
    {
        "instruction":"已知信息：\n'Article 46 Where major interest relationship between the applicant and others is directly involved in the application for medical device registration, the food and drug regulatory department shall inform the applicant and the interested party of their right to apply for a hearing in accordance with laws, regulations and other provisions of China Food and Drug Administration. During the process of reviewing the application for medical device registration, if the food and drug regulatory department believes there are major licensing issues concerning public interests, it shall make a public announcement and hold a hearing.'可被翻译为：第四十六条 医疗器械注册申请直接涉及申请人与他人之间重大利益关系的，食品药品监督管理部门应当告知申请人、利害关系人可以依照法律、法规以及国家食品药品监督管理总局的其他规定享有申请听证的权利；对医疗器械注册申请进行审查时，食品药品监督管理部门认为属于涉及公共利益的重大许可事项，应当向社会公告，并举行听证。\n'Article 41 To apply for in-vitro diagnostic reagent registration, the applicant shall submit application materials to the food and drug regulatory department in accordance with relevant requirements.'可被翻译为：第四十一条 申请体外诊断试剂注册，申请人应当按照相关要求向食品药品监督管理部门报送申报资料。\n\n根据上述已知信息，请将'Article 56 Where major interest relationship between the applicant and others is directly involved in the application for in-vitro diagnostic reagent registration, the food and drug regulatory department shall inform the applicant and the interested party of their right to apply for a hearing in accordance with laws, regulations and other provisions of China Food and Drug Administration. During the process of reviewing the application for in-vitro diagnostic reagent registration, if the food and drug regulatory department believes there are major licensing issues concerning public interests, it shall make a public announcement and hold a hearing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十六条 体外诊断试剂注册申请直接涉及申请人与他人之间重大利益关系的，食品药品监督管理部门应当告知申请人、利害关系人依照法律、法规以及国家食品药品监督管理总局的有关规定享有申请听证的权利；对体外诊断试剂注册申请进行审查时，食品药品监督管理部门认为属于涉及公共利益的重大许可事项，应当向社会公告，并举行听证。"
    },
    {
        "instruction":"已知信息：\n'An antibiotic whose molecule contains three common double bonds.'可被翻译为：分子中含有三个共瓶双键的抗生素。\n'macrolide antibiotics'可被翻译为：大环内酯类抗生素\n\n根据上述已知信息，请将'The 3-position of the tetradecyclic macrolide is converted into a keto-based antibiotic.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"十四元环大环内酯的3-位转变为酮基的抗生素。"
    },
    {
        "instruction":"已知信息：\n'Methods and parameters for integrity testing of 100% of all filled containers (see paragraph 8.22).'可被翻译为：所有已灌装容器 100%完整性测试的方法和参数（参见第 8.22 节）。\n'The performance of the pre- and post-use integrity testing for sterilising grade filters (see paragraph 8.87).'可被翻译为：除菌级过滤器的使用前后完整性测试的性能（参见第 8.87 节）。\n\n根据上述已知信息，请将'Methods and parameters for integrity testing of filled containers (see paragraph 8.22).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"已灌装容器完整性测试的方法和参数（参见第 8.22 节）。"
    },
    {
        "instruction":"已知信息：\n'Article 55 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall determine inspection frequency based on the drug varieties, dosage form, regulation categories, taking into account overall national situation of drug safety, drug safety risk warning information, major drug safety events and related investigations and handling information as well as the previous inspections, monitoring of adverse reactions, complaints and whistle-blowing.'可被翻译为：第五十五条 省、自治区、直辖市药品监督管理部门应当根据药品品种、剂型、管制类别等特点，结合国家药品安全总体情况、药品安全风险警示信息、重大药品安全事件及其调查处理信息等，以及既往检查、检验、不良反应监测、投诉举报等情况确定检查频次：\n'Article 6 The drug regulatory departments of the provinces, autonomous regions, and municipalities directly under the Central Government are responsible for the following administrative tasks pertaining to drug registration within their respective administrative regions:'可被翻译为：第六条 省、自治区、直辖市药品监督管理部门负责本行政区域内以下药品注册相关管理工作：\n\n根据上述已知信息，请将'The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government may adjust the inspection frequency depending on the practical situation of drug manufacturing supervision within respective administrative regions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省、自治区、直辖市药品监督管理部门可以结合本行政区域内药品生产监管工作实际情况，调整检查频次。"
    },
    {
        "instruction":"已知信息：\n'(20) The drug regulatory authorities of the provinces (autonomous regions and municipalities) shall strengthen the supervision and inspection of drug\/preparation enterprises (Drug Marketing Authorization Holder) within their respective administrative regions, supervise and urge drug\/preparation enterprises(Drug Marketing Authorization Holder)to perform supplier audit responsibility for APIs, pharmaceutical excipients and pharmaceutical packaging materials.'可被翻译为：（二十）各省（区、市）药品监督管理局应加强对本行政区域内药品制剂生产企业（药品上市许可持有人）的监督检查，督促药品制剂生产企业（药品上市许可持有人）履行原料药、药用辅料和药包材的供应商审计责任。\n'II. Drug marketing authorization holders and drug registration applicants shall actively prepare for the implementation of the Good Pharmacovigilance Practice, establish and continuously improve the pharmacovigilance system and conduct pharmacovigilance activities in a standardized manner.'可被翻译为：二、药品上市许可持有人和药品注册申请人应当积极做好执行《药物警戒质量管理规范》的准备工作，按要求建立并持续完善药物警戒体系，规范开展药物警戒活动。\n\n根据上述已知信息，请将'IV. All the provincial medical products administration shall supervise and urge the drug marketing authorization holders within their respective administrative areas to actively make preparations, cooperate with relevant publicity and interpretation, supervise and guide drug marketing authorization holders to implement the Good Pharmacovigilance Practice as required by strengthening routine inspection and other activities, and in a timely manner collect and feedback relevant questions and comments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、各省级药品监督管理部门应当督促本行政区域内的药品上市许可持有人积极做好相关准备工作，配合做好有关宣贯和解读，通过加强日常检查等工作监督和指导药品上市许可持有人按要求执行《药物警戒质量管理规范》，及时收集和反馈相关问题和意见。"
    },
    {
        "instruction":"已知信息：\n'Article138 An applicant shall select representative samples for drug registration specifications study.'可被翻译为：第一百三十八条 申请人应当选取有代表性的样品进行标准的研究工作。\n'Except for special regulations and requirements, the quantity of drug samples required for sampling generally shall be three times of the quantity required for testing. The remaining samples after testing, except for the retained samples for future reference, shall be returned to the applicant for testing.'可被翻译为：除特殊规定与要求外，一般为检验用量的三倍。检验后剩余样品除留样备查外，应当退回报验单位。\n\n根据上述已知信息，请将'Article 133 An applicant shall provide the relevant data, samples and reference standards, or assist in sampling, which are required for the testing for drug registration. The amount of samples shall be three times the amount used for testing and, for biological products, manufacturing record for the relevant batches of products shall also be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百三十三条 申请人应当提供药品注册检验所需要的有关资料、报送样品或者配合抽取检验用样品、提供检验用标准物质。报送或者抽取的样品量应当为检验用量的3倍；生物制品的注册检验还应当提供相应批次的制造检定记录。"
    },
    {
        "instruction":"已知信息：\n'a. Carefully remove the lid of RODAC plate or loosen the cap on the Hycheck slide tube. \nTake care not to touch the agar surface.\nNote: Examine agar for contamination and or dehydration'可被翻译为：小心取下 RODAC 碟的盖子或松开 Hycheck 滑管的盖子。小心不要接触琼脂培养基表面\n注：检查琼脂是否被污染或脱水\n'b. Gently but firmly touch the RODAC agar surface against the area being sampled, exert moderate, even, vertical pressure and then carefully replace lid. Avoid using rubbing motions of the plate at the sample site as this may break the agar.'可被翻译为：将 RODAC 碟用于取样的琼脂表面轻轻但牢固地接触被取样的表面，垂直均匀按压，取下，小心地重新盖上盖子。避免碟表面与取样面摩擦，因为可能会使琼脂裂开。\n\n根据上述已知信息，请将'c. When using Hycheck press down on the spike to bend the paddle at the hinge line gently lowering the slide and press the agar to the surface with firm and even pressure. Repeat this step using the 2nd agar surface on an area adjacent to the initial test site. \nReplace slide in container and close tightly.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用 Hycheck 取样条时，以尖头为着力点，手持盖按压，让取样条在折线处向下弯曲，垂直均匀地将培养基表面压在被取样表面。翻转，将反面培养基同样操作，从第一个取样点的邻近表面取样。将培养基条放回瓶中，盖紧。"
    },
    {
        "instruction":"已知信息：\n'The active drug ingredients and excipients for the manufacture of drug products shall meet the requirements for pharmaceutical use and relevant requirements in the corresponding GMP. The primary packaging materials and container in direct contact with drug products shall meet the requirements for pharmaceutical use and the standards for ensuring human health and safety.'可被翻译为：生产药品所需的原料、辅料，应当符合药用要求以及相应的生产质量管理规范的有关要求。直接接触药品的包装材料和容器，应当符合药用要求，符合保障人体健康、安全的标准。\n'Article 43 When evaluating a drug registration application, the CDE conducts bundling review of the chemical active drug ingredients, excipients and primary packaging materials and containers of the drug product. Where supplementary dossiers are needed, the drug product applicant or the enterprise that registers chemical active drug ingredients, excipients and primary packaging materials and containers shall be required to provide supplementary dossiers in compliance with relevant procedures. When necessary, extended inspection on enterprises of chemical active drug ingredients, excipients and primary packaging materials and containers may be proposed based on risks.'可被翻译为：第四十三条 药品审评中心在审评药品制剂注册申请时，对药品制剂选用的化学原料药、辅料及直接接触药品的包装材料和容器进行关联审评，需补充资料的，按照补充资料程序要求药品制剂申请人或者化学原料药、辅料及直接接触药品的包装材料和容器登记企业补充资料，可以基于风险提出对化学原料药、辅料及直接接触药品的包装材料和容器企业进行延伸检查。\n\n根据上述已知信息，请将'When preparing drug preparations, medical institutions shall perform their duties in accordance with the approved process, and the required active drug ingredients, excipients, and packaging materials shall comply with medicinal requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗机构配制制剂，应当按照经核准的工艺进行，所需的原料、辅料和包装材料等应当符合药用要求。"
    },
    {
        "instruction":"已知信息：\n'Article 287: A contract should be drawn up between the contract giver and the contract acceptor which specifies their respective responsibilities relating to the manufacture and control of the product. Technical aspects of the contract should be drawn up by competent persons with suitable knowledge in the pharmaceutical technology, analysis and the provisions. All arrangements for manufacture and analysis must be in accordance with the drug registration requirements and agreed by both parties.'可被翻译为：第二百八十七条 委托方与受托方之间签订的合同应当详细规定各自的产品生产和控制职责，其中的技术性条款应当由具有制药技术、检验专业知识和熟悉本规范的主管人员拟订。委托生产及检验的各项工作必须符合药品生产许可和药品注册的有关要求并经双方同意。\n'Article 278: To ensure the product quality of contract manufacture, and the accuracy and reliability of contract analysis, there must be a written contract between the contract giver and the contract acceptor, which clearly establishes the duties of each party, and covers the manufacture and\/or analysis arranged under contract and any technical arrangements made in connection with it.'可被翻译为：第二百七十八条 为确保委托生产产品的质量和委托检验的准确性和可靠性，委托方和受托方必须签订书面合同，明确规定各方责任、委托生产或委托检验的内容及相关的技术事项。\n\n根据上述已知信息，请将'Article 279: All arrangements for contract manufacture and analysis including any proposed changes in technical or other arrangements should be in accordance with the drug manufacturing licensing and registration requirements for the product concerned.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百七十九条 委托生产或委托检验的所有活动，包括在技术或其他方面拟采取的任何变更，均应当符合药品生产许可和注册的有关要求。"
    },
    {
        "instruction":"已知信息：\n'In metrology absorptiometry, a data processing method used for multi-component analysis.'可被翻译为：在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。\n'The application of multivariate statistical techniques to analyse complex process data with potentially correlated variables. (Ph. Eur.)'可被翻译为：应用多变量统计技术分析具有潜在相关变量的复杂工艺数据。\n\n根据上述已知信息，请将'A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。"
    },
    {
        "instruction":"已知信息：\n'The phenomenon in which the aqueous solubility of some insoluble drugs can be increased without reducing their biological activity when a third substance is added.'可被翻译为：当加入第三种物质时可增加一些难溶性药物的水中溶解度而不降低其生物活性的现象。\n'An auxiliary solvent that increases the solubility of the drug in the main solvent.'可被翻译为：能提高药物在主溶剂中溶解度的辅助溶剂。\n\n根据上述已知信息，请将'The phenomenon in which the solubility of a drug in a mixture of two solvents in a certain ratio is greater than that in any single solvent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在混合溶剂中两溶剂在某一比例时，药物的溶解度比在任一单纯溶剂中的溶解度均大的现象。"
    },
    {
        "instruction":"已知信息：\n'(1) products with unreasonable risks that may cause hazards to human health and life safety under normal use;'可被翻译为：（一）正常使用情况下存在可能危及人体健康和生命安全的不合理风险的产品；\n'A substance that is present in the matrix that may affect the quantification of an analyte.'可被翻译为：在基质中存在的可能影响待测物定量的物质。\n\n根据上述已知信息，请将'A product or substance that may present a substantial risk of injury, to health or to the environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可能对健康或环境造成重大伤害风险的产品或物质。"
    },
    {
        "instruction":"已知信息：\n'I. On June 24, 2020, the government website of NMPA has released a new version of drug registration application software for applicants.'可被翻译为：一、2020年6月24日，国家药监局政府网站将发布供申请人使用的新版药品注册申报软件。\n'NMPA Issued the Notice on Enabling the New Version of the Drug Production License and other Certificates'可被翻译为：国家药监局综合司关于启用新版《药品生产许可证》等许可证书的通知\n\n根据上述已知信息，请将'III. From July 1, 2020, NMPA will enable a new version of related system for drug registration. Drug registrants are advised to download the latest version of the application software, and submit registration application as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"三、2020年7月1日起，国家药监局将启用新版药品注册相关系统，请药品注册申请人注意下载最新版申报软件，按要求提交注册申请。"
    },
    {
        "instruction":"已知信息：\n'NMPA Notice on Launching the Cosmetic Ingredient Safety Information Registration Platform'可被翻译为：国家药监局关于化妆品原料安全信息登记平台上线通知\n'After the launch of the Cosmetic Ingredient Safety Information Registration Platform, cosmetics registrants, filing applicants and persons in charge within the territory of China can still fill out and submit the safety information document of ingredients issued by raw material manufacturers through the Information Service Platform for Registration and Filing of Cosmetics, or fill in the safety information document of ingredients associated with the ingredients submission code generated by the platform.'可被翻译为：化妆品原料安全信息登记平台上线后，化妆品注册人、备案人、境内责任人仍可以通过化妆品注册备案信息服务平台填报原料生产商出具的原料安全信息文件，也可以填写化妆品原料安全信息登记平台生成的原料报送码关联原料安全信息文件。\n\n根据上述已知信息，请将'In order to implement the Provisions for the Registration and Filing of Cosmetics, Provisions for the Registration or Filing Dossier of Cosmetics and other regulatory documents, NMPA organized to establish the Cosmetic Ingredient Safety Information Registration Platform. Since 9 A.M. on December 31, 2021, cosmetic ingredient manufacturers or their authorized enterprises can log in to this platform to report information related to the safety of ingredients. Domestic users may log in to the platform directly through the \"Cosmetic Ingredient Safety Information Registration Platform\" module at NMPA Online Service Hall (https:\/\/zwfw.nmpa.gov.cn); and overseas users need to set up an account at the \"Cosmetic Ingredient Safety Information Registration Platform” (http:\/\/ciip.nifdc.org.cn) before login.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为贯彻落实《化妆品注册备案管理办法》《化妆品注册备案资料管理规定》等法规文件，国家药监局组织建立了化妆品原料安全信息登记平台，自2021年12月31日上午9时起，化妆品原料生产商或其授权企业可以登陆该平台报送原料安全相关信息。境内用户直接通过国家药监局网上办事大厅（https:\/\/zwfw.nmpa.gov.cn）的“化妆品原料安全信息登记平台”模块进行登陆；境外用户需在“化妆品原料安全信息登记平台”（http:\/\/ciip.nifdc.org.cn）开通账号后登陆。"
    },
    {
        "instruction":"已知信息：\n'The range of blood concentrations within which drug efficacy can be produced without unacceptable toxicity, or the range of dosage and frequency of administration that should be considered in the course of prolonged treatment.'可被翻译为：能产生药效而不出现不可接受毒性的血药浓度范围，或进行长时间治疗时应考虑的给药剂量和频度范围。\n'median lethal dose(ld50)'可被翻译为：半数致死剂量\n\n根据上述已知信息，请将'The ratio of median lethal dose to median effective dose. A large therapeutic index indicates high curative effect and relatively safe drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"半数致死量与半数有效量的比值。治疗指数大表示疗效高、用药比较安全。"
    },
    {
        "instruction":"已知信息：\n'In 2019, the National ADR Monitoring Network received 1.514 million copies of ADR\/ADE Report Form. From 1999 to 2019, the National ADR Monitoring Network received an accumulative total of 15.19 million copies of the ADR\/ADE Report Form (See Figure 1).'可被翻译为：2019年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》151.4万份。1999年至2019年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1,519万份（图1）。\n'In 2018, the National ADR Monitoring Network received 1.499 million copies of the Report on Adverse Drug Reactions\/Events. From 1999 to 2018, the National ADR Monitoring Network received a total of 13.68 million copies of the ADRs \/ ADEs Report Forms (Figure 1).'可被翻译为：2018年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》149.9万份。1999年至2018年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1368万份（图1）。\n\n根据上述已知信息，请将'In 2020, the China National ADR Monitoring Network received 1.676 million copies of ADR\/ADE Reports. From 1999 to 2020, the National ADR Monitoring Network received a total of 16.87 million copies of ADR\/ADE Reports.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2020年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》167.6万份。1999年至2020年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1,687万份。"
    },
    {
        "instruction":"已知信息：\n'(V)  Production is approved to resume after ordered production suspension for violation of relevant laws and regulations;'可被翻译为：（五）因违反相关法律法规被责令停产后经批准恢复生产的；\n'Article 48 Where a patent dispute arises during the registration review or after approval, it shall be dealt with according to relevant laws and regulations.'可被翻译为：第四十八条 注册申请审查过程中及批准后发生专利权纠纷的，应当按照有关法律、法规的规定处理。\n\n根据上述已知信息，请将'(3) Time occupied during suspension of the review and approval procedures where the review and approval procedures are suspended in accordance with laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）根据法律法规的规定中止审评审批程序的，中止审评审批程序期间所占用的时间；"
    },
    {
        "instruction":"已知信息：\n'In 2020, the total number of registered grassroots users increased by 10.03% compared with the previous year. Among them, the registered grassroots users of registrants, distributors and using units have increased by 38.31%, 11.52% and 3.24% compared with the previous year, respectively.'可被翻译为：2020年，注册基层用户总数比上年增长10.03%。其中，注册人注册基层用户比上年增长38.31%，经营企业和使用单位的注册基层用户分别比上年增长11.52%和3.24%。\n'In 2018, the total number of registered grassroots users increased by 8.87% over2017. It shows that the scope of monitoring of adverse events of medical devices in China has been expanding. Among them, the registered grassroots users of manufacturers,distributors and user units have increased by 16.44%, 11.59% and 4.97% over 2017,respectively (Figure 5) .'可被翻译为：2018年，注册基层用户总数比2017年增长8.87%。显示我国医疗器械不良事件监测范围不断扩大。其中，生产企业、经营企业和使用单位的注册基层用户分别比2017年增长16.44%、11.59%和4.97%(图5)。\n\n根据上述已知信息，请将'In 2019, the total number of registered grassroots users increased by 15.69 percent over the previous year. Among them, the registered grassroots users of registrants, distributors and user units have increased by 41.92 percent, 24.22 percent and 2.28 percent over 2017, respectively.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年，注册基层用户总数比上年增长15.69%。其中，注册人注册基层用户比上年增长41.92%，经营企业和使用单位的注册基层用户分别比上年增长24.22%和2.28%。"
    },
    {
        "instruction":"已知信息：\n'Review and approval for drug registration applications'可被翻译为：药品注册申请审评审批情况\n'Evaluation studies that evaluate, analyze, and interpret the proportions, costs, and reasonableness of drug use in order to evaluate the irrational use of drugs, prevent adverse drug interactions, and optimize the rational use of drugs.'可被翻译为：评价、分析和解释药物使用的比例、成本和合理性，以评估药物的不合理使用，防止药物不良相互作用及优化药品的合理使用的评价研究。\n\n根据上述已知信息，请将'A technical evaluation of the reasonableness and controllability of drug registration criteria. Such as the review of imported drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对药品注册标准的合理性和可控性进行的技术评价。比如进口药品复核。"
    },
    {
        "instruction":"已知信息：\n'Article 45 The sponsor shall be responsible for the safety of investigational medical device in clinical trial. When finding it may affect the safety of the subjects or the implementation of the trial may change the approval of the ethics committee for the continuation of the trial, the sponsor shall immediately notify all clinical trial institutions and investigators and make corresponding handling.'可被翻译为：第四十五条 申办者对试验用医疗器械在临床试验中的安全性负责。当发现可能影响受试者安全或者试验实施可能改变伦理委员会对继续试验的批准情况时，申办者应当立即通知所有临床试验机构和研究者，并作出相应处理。\n'Article 21 When conducting a drug clinical trial, details such as the clinical trial objective and risks shall be truthfully stated and explained to the trial subjects or their guardians, an informed consent letter signed voluntarily by the trial subject or their guardian shall be obtained, and effective measures shall be taken to protect the lawful rights and interests of the trial subjects.'可被翻译为：第二十一条 实施药物临床试验，应当向受试者或者其监护人如实说明和解释临床试验的目的和风险等详细情况，取得受试者或者其监护人自愿签署的知情同意书，并采取有效措施保护受试者合法权益。\n\n根据上述已知信息，请将'Article 17 The sponsor of vaccine clinical trials shall design the clinical trial protocol, establish the safety monitoring and evaluation system for clinical trials, prudently select subjects, appropriately set up subject population and age groups, and take effective measures based on risk levels to protect legal interests of subjects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十七条 疫苗临床试验申办者应当制定临床试验方案，建立临床试验安全监测与评价制度，审慎选择受试者，合理设置受试者群体和年龄组，并根据风险程度采取有效措施，保护受试者合法权益。"
    },
    {
        "instruction":"已知信息：\n'On November 29, 2019, NMPA issued the Announcement on Issues Pertaining to the Implementation of the Drug Administration Law of the People's Republic of China (2019 No. 103), which reads as follows:'可被翻译为：2019年11月29日，国家药监局发布了关于贯彻实施《中华人民共和国药品管理法》有关事项的公告（2019No.103），其内容如下：\n'NMPA Issued the Announcement on Issues Pertaining to the Implementation of the Newly Revised Provisions for the Supervision and Administration of Drug Production'可被翻译为：国家药监局关于实施新修订《药品生产监督管理办法》有关事项的公告\n\n根据上述已知信息，请将'NMPA Issued the Announcement on Issues Pertaining to the Implementation of the Drug Administration Law of the People's Republic of China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于贯彻实施《中华人民共和国药品管理法》有关事项的公告"
    },
    {
        "instruction":"已知信息：\n'(1) site master files and the materials in connection with any change;'可被翻译为：（一）药品生产场地管理文件以及变更材料；\n'Article 74 Site master file refers to a summary document of drug production activities prepared by a drug manufacturer, which is a part of the files in the manufacturer's quality management system. The requirements for site master files will be defined separately.'可被翻译为：第七十四条 场地管理文件，是指由药品生产企业编写的药品生产活动概述性文件，是药品生产企业质量管理文件体系的一部分。场地管理文件有关要求另行制定。\n\n根据上述已知信息，请将'New document format introduced to replace the product dossier and site master file.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"引入新的文档格式，以取代产品档案和站点主文件。"
    },
    {
        "instruction":"已知信息：\n'The technique of manipulating genes at the molecular level to alter the genetic characteristics of a species. For example, the operation of introducing the foreign gene into the recipient cell after recombination in vitro, so that the gene can be copied, transcribed, translated and expressed in the recipient cell.'可被翻译为：在分子水平上对基因进行操作，以达到改变物种遗传特征的技术总称。如将外源基因通过体外重组后导入受体细胞内，使这个基因能在受体细胞内复制、转录、翻译表达的操作。\n'A method of searching for specific biosynthetic genes by means of genetic engineering such as mutation complementation, resistance gene probe and homologous gene probe.'可被翻译为：利用突变互补、抗性基因探针以及同源基因探针等基因工程手段寻找特异的生物合成基因的方法。\n\n根据上述已知信息，请将'An experimental technique in which a specific gene in the genome is altered by site-specific homologous recombination of DNA in order to study the function of the gene in vivo. It builds on the achievements of embryonic stem cell technology and homologous recombination technology, and promotes the further development of related technologies. It is widely used in the research of gene function, the development of animal models of human diseases and the improvement of genetic material of economic animals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过DNA定点同源重组，改变基因组中的某一特定基因，从而在生物活体内研究此基因功能的实验技术。它建立在胚胎干细胞技术和同源重组技术成就的基础上，并促进了相关技术的进一步发展。广泛应用于基因功能研究、人类疾病动物模型的研制以及经济动物遗传物质的改良等方面。"
    },
    {
        "instruction":"已知信息：\n'(IV) A copy of the packing list, bill of lading and shipping invoice;'可被翻译为：（四）装箱单、提运单和货运发票复印件；\n'Article 98 At the time of ex-warehousing of drugs, the accompanying sheet (bill) stamped with the original special seal for drug ex-warehousing of enterprises shall be attached.'可被翻译为：第九十八条 药品出库时，应当附加盖企业药品出库专用章原印章的随货同行单（票）。\n\n根据上述已知信息，请将'(IV) Model of relevant seal and the accompanying sheet (bill);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）相关印章、随货同行单（票）样式；"
    },
    {
        "instruction":"已知信息：\n'The transfer of partially closed containers to a lyophilizer should be undertaken under grade A conditions at all times and handled in a manner designed to minimize direct operator intervention. Technologies such as conveyor systems or portable transfer systems (e.g. clean air transfer carts, portable unidirectional airflow workstations) should be used to ensure that the cleanliness of the  system used to transfer the partially closed containers is maintained. Alternatively, where supported by validation, trays closed in grade A and not reopened whilst in the grade B area may be used to protect partially stoppered vials (e.g. appropriately closed boxes).'可被翻译为：将半封闭容器转移到冻干机时，应始终在 A 级条件下进行，并且采用可以最大程度减少操作员直接干预的 传递方式。应使用诸如传送带系统或便携式转移系统（例如，洁净空气传输车，便携式单向流工作台）等 技术，以确保维持用于转移部分密闭容器的系统的洁净度。或者，在经过验证的情况下，在 A 级密封且在B 级区时不再重新打开的托盘可用于保护半压塞的西林瓶（例如，适当密封的箱子）。\n'The loading pattern within the lyophilizer should be specified and documented.'可被翻译为：应规定并记录冻干机的装载方式。\n\n根据上述已知信息，请将'Utensils used during loading and unloading of the lyophilizer (e.g. trays, bags, placing devices, tweezers) should be sterile.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"冻干机装载和卸载过程中使用的器具（例如托盘、袋子、定位装置、镶子）应为无菌状态。"
    },
    {
        "instruction":"已知信息：\n'This programme is typically comprised of the following elements:'可被翻译为：本计划通常包括以下内容：\n'5.5. The SU should provide criteria and information on inherent risks, hazards and critical steps associated with the process, product or procedure to be transferred. This may serve as a basis for the risk assessment exercise.'可被翻译为：SU应提供准备转移的工艺、产品或方法相关的固有风险、危害和关键步骤的标准和信息。这可作为风险评估活动的基础。\n\n根据上述已知信息，请将'5.14. A training programme should be implemented covering various topics, including those specific to the process, product or procedure to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应针对准备转移的工艺、产品和程序执行专门的不同主题培训。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems'可被翻译为：国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance over medical device registration, and further improve the quality of registration review, NMPA has organized to formulate the Technical Review Guidance for the Registration of Disposable Breast localization Wire, Technical Review Guidance for the Registration of Dural(Spinal) Patches, Technical Review Guidance for the Registration of Customized and Personalized Equivalent Models of Bone Implants, Technical Review Guidance for the Registration of Finite Element Analysis Data of Orthopedic Metal Implants, Guidance for Clinical Trials of Hernia Repair Meshes, and Guidance for Animal Study of Bioabsorbable Coronary Artery Drug-Eluting Stents, and they were issued on July 7, 2020.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《一次性使用乳腺定位丝注册技术审查指导原则》《硬脑（脊）膜补片注册技术审查指导原则》《定制式个性化骨植入物等效性模型注册技术审查指导原则》《骨科金属植入物有限元分析资料注册技术审查指导原则》《疝修补补片临床试验指导原则》《生物可吸收冠状动脉药物洗脱支架动物实验研究指导原则》，现予发布。\n\n根据上述已知信息，请将'NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布一次性使用乳腺定位丝注册技术审查等6项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'drug advertisement'可被翻译为：药品广告\n'Article 107 Drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government shall perform routine GLP and GCP inspections of drug non-clinical safety evaluation and research institutes, drug clinical trial organizations and other research institutions to ensure their continuous compliance with statutory requirements. The NMPA may initiate supervision and inspection of drug non-clinical safety evaluation and research institutes, drug clinical trial organizations and other research institutions as needed.'可被翻译为：第一百零七条 省、自治区、直辖市药品监督管理部门应当组织对辖区内药物非临床安全性评价研究机构、药物临床试验机构等遵守药物非临床研究质量管理规范、药物临床试验质量管理规范等情况进行日常监督检查，监督其持续符合法定要求。国家药品监督管理局根据需要进行药物非临床安全性评价研究机构、药物临床试验机构等研究机构的监督检查。\n\n根据上述已知信息，请将'No unscientific, categorical assertion, or guarantee of described function or safety may be included in drug advertisements. No names or images of government departments, research institutions, and academic institutions, or of experts, scholars, physicians, pharmacists and patients may be used as evidence for drug advertising.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品广告不得含有表示功效、安全性的断言或者保证；不得利用国家机关、科研单位、学术机构、行业协会或者专家、学者、医师、药师、患者等的名义或者形象作推荐、证明。"
    },
    {
        "instruction":"已知信息：\n'The term applied to third party attestation related to a conformity assessment body conveying formal demonstration of its competence to carry out specific conformity assessment tasks (2).'可被翻译为：该术语适用于与合格评定机构有关的第三方认证，该机构正式证明了其执行特定合格评定任务的能力(2)。\n'1.The term biowaiver is applied to a regulatory drug approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.\n2.The term biowaiver is applied to a regulatory pharmaceutical product approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.'可被翻译为：1.当档案(申请)基于等效性证据而不是通过体内等效性试验获得批准时，术语生物豁免适用于监管药物批准过程。\n2.当档案(申请)基于等效性证据而不是通过体内等效性试验获得批准时，术语生物豁免适用于监管药品批准过程。\n\n根据上述已知信息，请将'1.The final review and formal approval of a validation or revalidation, followed by approval of a process for routine use.\n2.The term applied to third party attestation related to products, processes, systems or persons (2).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.确认或再确认的最终审查和正式批准，随后批准常规使用的过程\n2.该术语适用于与产品、过程、体系或人员相关的第三方认证(2)。"
    },
    {
        "instruction":"已知信息：\n'Samples of products using systems other than fusion should be taken and checked for integrity using\nvalidated methods. The frequency of testing should be based on the knowledge and experience of the container\nand closure systems being used. A scientifically justified sampling plan should be used. The sample size should be\nbased on information such as supplier management, packaging component specifications and process knowledge.'可被翻译为：使用非融合系统的产品应进行取样并使用经验证的方法检查其完整性。完整性检查的频率应基于所使用容器和密封系统的知识和经验。应使用经科学论证的取样计划。样本量应基于供应商管理、包装组件质量标准和工艺知识等信息。\n'b. Validation of Growth-Based Rapid Microbiological Methods for Sterility Testing of Cellular and Gene Therapy Products (draft guidance, 2\/2008)'可被翻译为：基于生长快速微生物方法用于细胞和基因治疗产品无菌检测的验证（2008 年 2月，草案）\n\n根据上述已知信息，请将'c. Guidance for Industry- Container and Closure system Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products (2\/2008)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"行业指南—容器和密闭器系统完整性测试替代无菌检测，作为无菌药品的稳定性试验方案的一部分（2008 年 2 月）"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products'可被翻译为：国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance of medical device registration and further improve the quality of registration review, the NMPA organized to formulate the Guidance (Revision 2020) for Technical Review of Clinical Evaluation of Equivalent Devices of Medical Magnetic Resonance Imaging Systems which was issued on January 27, 2021.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了《医用磁共振成像系统同品种临床评价技术审查指导原则（2020年修订版）》，并于2021年1月27日发布。\n\n根据上述已知信息，请将'In order to strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, the NMPA has organized to formulate 2 technical review guidelines for registration including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products, which are hereby promulgated on January 15, 2021.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则，于2021年1月15日予以发布。"
    },
    {
        "instruction":"已知信息：\n'The substance is dissolved in the solvent, the combination of solvent molecules and solute molecules or ions, etc., makes the solute change its original state and generate solvent compounds.'可被翻译为：物质在溶剂中溶解，溶剂分子与溶质分子或离子等的相互结合，使溶质改变了原来的状态而生成的溶剂化合物。\n'The binding between the drug and the protein is in homeostasis, a phenomenon in which the drug molecule with strong binding force to the protein replaces the drug molecule that is already bound to albumin but has weak binding force.'可被翻译为：药物与蛋白质之间的结合处于动态平衡，与蛋白结合力强的药物分子将已经与白蛋白结合、但结合力弱的药物分子置换出来的现象。\n\n根据上述已知信息，请将'The solvation layer of the colloidal particles is heated or other soluble compounds are added! 1 (it and the original loss of solvent has a strong binding force) under the conditions, the solvation layer is weakened, resulting in the phenomenon of colloidal condensation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"溶胶胶粒的溶剂化层在受热或加入其他溶齐!1（它和原失溶剂有较强的结合力）的条件下，溶剂化层被削弱，导致胶体聚沉的现象。"
    },
    {
        "instruction":"已知信息：\n'Article 58 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall organize to conduct on-site inspections of the drug research and development conditions and raw data, make preliminary review of the submitted dossiers, and provide review opinions within five days from the date it accepts an application. For the other drugs except biological products, samples of three production batches shall also be collected for testing, and a notice of specifications verification shall be issued to the drug testing institute.'可被翻译为：第五十八条 省、自治区、直辖市药品监督管理部门应当自受理申请之日起5日内组织对临床试验情况及有关原始资料进行现场核查，对申报资料进行初步审查，提出审查意见。除生物制品外的其他药品，还需抽取3批样品，向药品检验所发出标准复核的通知。\n'Article 24 When carrying out on-site sampling, the drug control institute of port shall impose close inspection on the actual condition of the imported drugs upon arrival, make sampling records, and fill in the Record of Sampling for Import Drugs.'可被翻译为：第二十四条 口岸药品检验所现场抽样时，应当注意核查进口品种的实际到货情况，做好抽样记录并填写《进口药品抽样记录单》。\n\n根据上述已知信息，请将'Article 63 When carrying out on-site inspection, the drug regulatory department can make sample testing as needed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条  药品监督管理部门开展现场检查时，可以根据需要进行抽查检验。"
    },
    {
        "instruction":"已知信息：\n'Pharmaceutical professional and technical personnel who have passed the national unified examination, obtained the Qualification Certificate of Licensed Pharmacists and have been registered to practice in the units that produce, distribute and use drugs.'可被翻译为：经全国统一考试合格，取得《执业药师资格证书》并经注册登记，在药品生产、经营、使用单位中执业的药学专业技术人员。\n'Article 126 Personnel engaged in quality management, acceptance inspection and purchase shall have academic qualifications in pharmacy or medicine, biology, chemistry or other related disciplines or have professional and technical titles in pharmacy. Personnel engaged in the quality management, acceptance inspection and purchase of Prepared Slices shall have a degree of technical school or above, or a primary professional and technical title or above in traditional Chinese medicine.'可被翻译为：第一百二十六条 质量管理、验收、采购人员应当具有药学或者医学、生物、化学等相关专业学历或者具有药学专业技术职称。从事中药饮片质量管理、验收、采购人员应当具有中药学中专以上学历或者具有中药学专业初级以上专业技术职称。\n\n根据上述已知信息，请将'Pharmaceutical professional and technical personnel who have received academic education in pharmacy and are engaged in drug dispensing, preparation, testing, production and other work, and have been recognized as qualified according to law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"受过药学专业学历教育，从事药物调剂、制备、检定、生产等工作，并依法经资格认定的药学专业技术人员。"
    },
    {
        "instruction":"已知信息：\n'Article 71 If any serious adverse event in the clinical trial occurs, the investigator shall immediately give appropriate treatment measures to the subjects, at the same time report in writing to the relevant medical device clinical trial management department of the clinical trial institution, and notify the sponsor through the department by a written notice. The medical device clinical trial management department shall report in writing to the corresponding ethics committee and the local food and drug administration department and the competent health and family planning department of the province, autonomous region or municipality where the clinical trial institution is located within 24 hours. For death events, the clinical trial institution and the investigator shall provide the ethics committee and the sponsor with all the information needed.'可被翻译为：第七十一条 在临床试验中出现严重不良事件的，研究者应当立即对受试者采取适当的治疗措施，同时书面报告所属的临床试验机构医疗器械临床试验管理部门，并经其书面通知申办者。医疗器械临床试验管理部门应当在24小时内书面报告相应的伦理委员会以及临床试验机构所在地省、自治区、直辖市食品药品监督管理部门和卫生计生主管部门。对于死亡事件，临床试验机构和研究者应当向伦理委员会和申办者提供所需要的全部资料。\n'The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where adverse events occur shall promptly notify the relevant information to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.'可被翻译为：不良事件发生地省、自治区、直辖市药品监督管理部门应当及时向持有人所在地省、自治区、直辖市药品监督管理部门通报相关信息。\n\n根据上述已知信息，请将'Article 41 If any serious adverse event occurs during the clinical trial, the investigators shall report to the drug regulatory departments of the relevant provinces, autonomous regions or municipalities directly under the Central Government and the State Food and Drug Administration and notify the applicant within 24 hours, and report to the ethic committee in time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十一条 临床试验过程中发生严重不良事件的，研究者应当在24小时内报告有关省、自治区、直辖市药品监督管理部门和国家食品药品监督管理局，通知申请人，并及时向伦理委员会报告。"
    },
    {
        "instruction":"已知信息：\n'Tablets coated with sucrose as the main coating material.'可被翻译为：以蔗糖为主要包衣材料进行包衣的片剂。\n'A tablet coated with enteric-soluble coating material.'可被翻译为：用肠溶性包衣材料进行包衣的片剂。\n\n根据上述已知信息，请将'The core material of medicated tablets is coated with sucrose as the main material. To protect the drug or cover up the bad odor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以蔗糖为主要材料对含药片剂芯材进行包覆的操作。以保护药物或掩盖不良嗅味。"
    },
    {
        "instruction":"已知信息：\n'Article 123 The quality management department or quality management personnel of enterprises shall fulfill the following responsibilities:'可被翻译为：第一百二十三条 企业应当设置质量管理部门或者配备质量管理人员，履行以下职责：\n'Article 134 Enterprises shall take measures to ensure that the personnel at all the posts can correctly understand the quality management documents to ensure their effective implementation.'可被翻译为：第一百三十四条 企业应当采取措施确保各岗位人员正确理解质量管理文件的内容，保证质量管理文件有效执行。\n\n根据上述已知信息，请将'Article 12 Enterprises shall have all their employees involved in quality management. Personnel of all departments and posts shall correctly understand and perform their duties and assume corresponding quality responsibilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十二条 企业应当全员参与质量管理。各部门、岗位人员应当正确理解并履行职责，承担相应质量责任。"
    },
    {
        "instruction":"已知信息：\n'The work area for opening the unit container should be either a HEPA filtered laminar flow hood or an alternate controlled environment to safeguard the exposure of open media and product to either environmental or personnel contamination.'可被翻译为：打开单元容器的工作区应该是一个 HEPA 过滤层流罩或一个替代的受控环境，以保 护打开的介质和产品暴露在环境或人员污染中。\n'1. All processing of swabs must be aseptically performed within a HEPA Filtered II Biological Safety Cabinet (BSC) or HEPA Filtered Laminar Flow Hood (LFH) with an air classification at the same rating or better than that from which the swab was collected'可被翻译为：拭子处理必须在 HEPA 过滤 II 级生物安全柜（BSC）或 HEPA 过滤层流罩（LFH）内无菌操作，其中的空气级别应该等于或优于擦拭取样点。\n\n根据上述已知信息，请将'Aseptically open containers and perform weighing procedures in a laminar flow hood or biological safety cabinet if possible.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如可能的话，在无菌条件下打开容器，在层流罩中或生物安全柜中称重。"
    },
    {
        "instruction":"已知信息：\n'Filled APS units should be incubated without unnecessary delay to achieve the best possible recovery of potential contamination. The selection of the incubation conditions and duration should be scientifically justified and validated to provide an appropriate level of sensitivity of detection of microbial contamination.'可被翻译为：培养已灌装 APS 单元应避免延迟，以尽确保达到潜在微生物的最高回收率。培养条件和培养时长的选择应经过科学论证，并进行验证以提供适当水平的微生物污染检测灵敏度。\n'The number of units processed (filled) for APS should be sufficient to effectively simulate all activities that are representative of the aseptic manufacturing process. Justification for the number of units to be filled should be clearly captured in the CCS. Typically, a minimum of 5000 to 10000 units are filled. For small batches (e.g. those under 5000 units), the number of containers for APS should at least equal the size of the production batch.'可被翻译为：APS 的加工（灌装）单元的数量应足以有效模拟代表无菌生产工艺的所有活动。应在 CCS 中明确记录待 灌装数量的合理性。通常，至少灌装 5000 至 10000 个单元。对于小批量（例如 5000 单元以下），APS 的容器数量应至少等于生产批次的数量。\n\n根据上述已知信息，请将'All APS runs should be fully documented and include a reconciliation of units processed (e.g. units filled, incubated  and  not   incubated).  Justification   for  filled  and  non-incubated  units   should  be   included  in  the documentation. All interventions performed during the APS should be recorded, including the start and end time of each intervention and the involved person. All microbial monitoring data as well as other testing data should be recorded in the APS batch record.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有 APS 运行应完整记录，并包括已处理单元的物料平衡（例如已灌装、已培养和未培养的单元）。已灌 装和未培养的单元的说明应包含在文件中。在 APS 过程中进行的所有干预操作都应进行记录，包括每次干预的开始和结束时间以及涉及的人员。所有微生物监测数据以及其它检测数据应记录在 APS 批记录中。"
    },
    {
        "instruction":"已知信息：\n'(3) Where safety and effectiveness of the medical device can be demonstrated through the analysis and assessment made on the basis of the data obtained from clinical trial or application of a medical device of the same variety.'可被翻译为：（三）通过对同品种医疗器械临床试验或者临床使用获得的数据进行分析评价，能够证明该医疗器械安全、有效的。\n'(7) condition of carrying out adverse events monitoring and reevaluation, and collection and evaluation of information on product safety risks;'可被翻译为：（七）开展不良事件监测、再评价以及产品安全风险信息收集与评估等情况；\n\n根据上述已知信息，请将'(II) The analysis and evaluation of monitoring data are reinforced for product risks mining and promoting the safety of medical devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(二）夯实监测数据分析评价，挖掘产品风险促进用械安全"
    },
    {
        "instruction":"已知信息：\n'A group of hardware components and associated software, designed and assembled to perform a specific function or group of functions.'可被翻译为：旨在执行一种特定功能或一组特定功能的一组软硬件组合。\n'For short, \"metabolism\". A general term for all ordered chemical changes in an organism, including both material metabolism and energy metabolism.'可被翻译为：简称\"代谢”。生物体内全部有序化学变化的总称，包括物质代谢和能量代谢两个方面。\n\n根据上述已知信息，请将'A general term for the design and construction of computer systems, including technical infrastructure, information (data), and applications.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"计算机系统设计和构建的一般术语，包括技术基础设备、信息（数据）和应用程序。"
    },
    {
        "instruction":"已知信息：\n'(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;'可被翻译为：（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；\n'4. Records of formulating, storage, use, return and disposal of narcotic drugs and modeling reagents (drugs) used in the study should be retained completely.'可被翻译为：4.应完整保留研究所需毒麻药品、造模试剂(药品)等的配制、保存、使用、返还或废弃等记录。\n\n根据上述已知信息，请将'3. There are records retained for the receipt, storage, distribution, use, recovery, return and unused disposal of investigational medicinal products (such as authorized destruction).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.试验用药品的接收、贮存、分发、使用、回收、退还及未使用药品的处置(如授权销毁) 等环节留有记录。"
    },
    {
        "instruction":"已知信息：\n'One of the two substances with a high specific affinity between each other is used as the stationary phase, using different degrees of affinity with the stationary phase, so that the composition and impurities are separated by chromatography.'可被翻译为：将相互间具有高度特异亲和性的两种物质之一作为固定相，利用与固定相不同程度的亲和性，使成分与杂质分离的色谱法。\n'A polysaccharide chiral stationary phase using cellulose and amylose derived from different functional groups as stationary phases.'可被翻译为：一种利用不同官能团衍生化的纤维素和直链淀粉作为固定相的多聚糖手性固定相。\n\n根据上述已知信息，请将'In the analysis of complex component samples containing different functional groups by column chromatography, often a single component of the stationary phase can not achieve the purpose of complete separation, and must use a multi-component stationary phase.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在用柱色谱分析含有不同功能团的复杂组分样品时，往往单一组分的固定相不能达到全分离的目的，而必须采用多组分的固定相。"
    },
    {
        "instruction":"已知信息：\n'Article 70 The investigator is responsible for making medical decisions related to the clinical trial. When any adverse event related to the clinical trial occurs, the clinical trial institution and the investigator shall ensure that the subjects are in a timely manner provided with adequate treatment and solution. When the subjects develop complications which require treatment, the investigator shall promptly inform the subjects of the situation.'可被翻译为：第七十条 研究者负责作出与临床试验相关的医疗决定，在发生与临床试验相关的不良事件时，临床试验机构和研究者应当保证为受试者提供足够、及时的治疗和处理。当受试者出现并发疾病需要治疗和处理时，研究者应当及时告知受试者。\n'Article 61 The investigator who is responsible for the clinical trial shall meet the following conditions:'可被翻译为：第六十一条 负责临床试验的研究者应当具备下列条件：\n\n根据上述已知信息，请将'The investigator refers to the person who is responsible for implementing the clinical trial in a clinical trial institution. Where the trial is carried out by a group of personnel in a clinical trial institution, the investigator shall be the person who is in charge of the group, also known as the principal investigator.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究者，是指在临床试验机构中负责实施临床试验的人。如果在临床试验机构中是由一组人员实施试验的，则研究者是指该组的负责人，也称主要研究者。"
    },
    {
        "instruction":"已知信息：\n'Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。\n'Article 2 All in-vitro diagnostic reagents sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'可被翻译为：第二条 在中华人民共和国境内销售、使用的体外诊断试剂，应当按照本办法的规定申请注册或者办理备案。\n\n根据上述已知信息，请将'Article 2 All medical devices sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 在中华人民共和国境内销售、使用的医疗器械,应当按照本办法的规定申请注册或者办理备案。"
    },
    {
        "instruction":"已知信息：\n'The process of artificially manipulating the genetic material of an organism so that it is modified or altered.'可被翻译为：对生物体的遗传物质进行人为的操作，使之发生修饰和改变的过程。\n'The technique of introducing artificially isolated and modified genes into the genome of an organism and causing heritable modification of the traits of the organism due to the expression of the imported genes.'可被翻译为：将人工分离和修饰过的基因导入到生物体基因组中，由于导入基因的表达，引起生物体性状的可遗传性修饰的技术。\n\n根据上述已知信息，请将'The technique or method of synthesizing new compounds by replacing, adding, or deleting genes involved in the synthase of an organism's metabolic product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过对参与生物体某种代谢产物合成酶的基因进行替换、添加以及删除等操作，使其合成新的化合物的技术或方法。"
    },
    {
        "instruction":"已知信息：\n'A fluid whose shear stress (t) is proportional to the shear velocity (Q). Its flow properties can be expressed by the formula: t=ηD, where the proportional coefficient η is called the viscosity coefficient. For Newton fluids, the viscosity is constant at a certain temperature and does not change with the shear rate.'可被翻译为：切应力（t）与切变速度（Q）成正比的流体。其流动性质可用公式表示：t=ηD,式中的比例系数η称为黏滞系数。对于牛顿流体，黏度在一定温度下是常数，不随切变速度而变。\n'The viscosity of a liquid varies at different shear rates.'可被翻译为：不同的剪切速率下有不同的黏度。\n\n根据上述已知信息，请将'The fluids that do not conform to Newton's formula mainly include polymer solutions and colloidal solutions. The ratio of shear stress and shear velocity of non-Newtonian fluid G\/D) is called the apparent viscosity, which is commonly expressed by %. Apparent viscosity is not only a function of temperature, but is also related to shear velocity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不符合牛顿公式的流体，主要有高分子溶液及胶体溶液等。非牛顿流体的切应力与切变速度的比值G\/D）称为表观黏度，常用%表示。表观黏度不仅是温度的函数，而且与切变速度有关。"
    },
    {
        "instruction":"已知信息：\n'The opening and closing of an ion channel is regulated by the potential difference between the two sides of the membrane.'可被翻译为：通道的开闭受膜两侧电位差调控的离子通道。\n'The difference in pressure between two points, such as the pressure difference between an \nenclosed space and an independent reference point, or the pressure difference between two \nenclosed spaces.'可被翻译为：两点之间的压差，如安之间的压差\n封闭空间与独立参考点之间的压力差，或两者之间的压力差\n封闭的空间。\n\n根据上述已知信息，请将'The potential difference between the two sides of the membrane due to the different types (or concentrations) of electrolytes leads to ion migration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"膜两侧因电解质种类（或浓度）不同而导致离子迁移时所产生的电位差。"
    },
    {
        "instruction":"已知信息：\n'(xi) Complaints about products are examined, the causes of quality defects investigated and appropriate measures taken in respect of the defective products and to prevent reoccurrence.'可被翻译为：(xi) 调查导致药品投诉和质量缺陷的原因，并采取措施，防止类似质量缺陷再次发生\n'Article 8: Quality Assurance is a part of the quality management system. The manufacturer should establish the Quality Assurance system with the support of a complete documentation system to ensure its effective operation.'可被翻译为：第八条 质量保证是质量管理体系的一部分。企业必须建立质量保证系统，同时建立完整的文件体系，以保证系统有效运行。\n\n根据上述已知信息，请将'2. To investigate causes related to the product, process and quality assurance system;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）调查与产品、工艺和质量保证系统有关的原因。"
    },
    {
        "instruction":"已知信息：\n'The personnel accessing grade A and B areas should be trained for aseptic gowning and aseptic behaviours.\nCompliance with aseptic gowning procedures should be confirmed by assessment and periodic reassessment at\nleast annually, and should involve both visual and microbial assessment (using monitoring locations such as\ngloved fingers, forearms, chest and hood (facemask \/ forehead). See paragraph 9.30 for the expected limits). The\nunsupervised access to the grade A and grade B areas where aseptic operations are or will be conducted should be\nrestricted to appropriately qualified personnel, who have passed the gowning assessment and have participated in\na successful APS.'可被翻译为：进入 A 级和 B 级区的人员应接受无菌更衣和无菌行为的培训。应通过评估和至少每年定期再评估来确认符合无菌更衣程序，并应包括目检和微生物评估（使用戴手套的手指、前臂、胸部和头罩（口罩\/额头）等监测位置。预期限度参见 9.30 节）。对于正在或即将进行无菌操作的 A 级和 B 级区，无监督进入应仅限于经过适当资质确认、已通过更衣评估并参与过成功的 APS 的人员。\n'gowning qualification'可被翻译为：净化服资格\n\n根据上述已知信息，请将'Personnel gowning qualification should be performed by any analyst that enters the aseptic clean room. Personnel gowning qualification must consist of:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"进入无菌洁净室的任何分析员都应进行人员更衣资格确认。人员更衣资格必须包 括："
    },
    {
        "instruction":"已知信息：\n'The systematic application of quality management policies, procedures, and practices to the tasks of assessing, controlling, communicating, and reviewing risk. (ICH Q9)'可被翻译为：系统地应用质量管理策略、程序和规范进行风险的评估、控制、沟通和回顾。（ICH Q9）\n'1.A systematic process for the assessment, control, communication and review of risks to the quality of the product across the product’s life cycle.\n2.Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product life- cycle.'可被翻译为：1.在整个产品生命周期内对产品质量风险进行评估、控制、沟通和审查的系统过程。\n2.质量风险管理是对药品在整个生命周期内的质量风险进行评估、控制、沟通和评审的系统过程。\n\n根据上述已知信息，请将'A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是一套系统的、基于充分的科学知识和质量风险管理的研发方法，从预先确定的目标出发，强调对产品和工艺的理解以及工艺控制。"
    },
    {
        "instruction":"已知信息：\n'8. The application dossier is inconsistent with the original record, and has an impact on the result evaluation;'可被翻译为：8.申报资料与原始记录不一致且影响结果评价；\n'2. All original records should be recorded truthfully, promptly, accurately, completely and traceably, and the results should be consistent with those in the application dossiers; the changes made in the records should not obscure the original entry, and the person who made the change should sign and date with the reason for change;'可被翻译为：2.各项原始记录应真实、及时、准确、完整、可追溯，且 结果与申报资料一致；记录修改不得覆盖原有数据痕迹，并标注修改人、修改日期和修改理由；\n\n根据上述已知信息，请将'6. The application dossiers are inconsistent with the original records and affect the evaluation results;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6.申报资料与原始记录不一致且影响结果评价；"
    },
    {
        "instruction":"已知信息：\n'The total amount of one or more enzymes of a microbial cell that convert one compound into another.'可被翻译为：微生物细胞的一种或多种酶将一种化合物转变为另一种化合物的总量。\n'Convert the actual number of years of survival in one or a series of identified conditions of less than full health to the number of years of survival in full health.'可被翻译为：将一个或一系列已确定的非完全健康状态下的实际生存年数折算成完全健康状态下的生存年数。\n\n根据上述已知信息，请将'A series of reactions in which microorganisms, under the action of a series of biosynthetases, convert nutrients into final products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"微生物在其体内一系列生物合成酶作用下，将营养成分转变为终产物所经历的一系列反应过程。"
    },
    {
        "instruction":"已知信息：\n'A discipline that uses modern organic synthesis, structural analysis, physical organic chemistry, molecular biology, cell biology, and molecular pharmacology as means to discover small organic molecules with important biological activities and study their interactions with biological macromolecules.'可被翻译为：以现代有机合成、结构分析、物理有机化学、分子生物学、细胞生物学、分子药理学为手段，发现具有重要生物活性的有机小分子并研究其与生物大分子相互作用的学科。\n'A compound capable of forming a complex ion with a metal ion.'可被翻译为：能与金属离子形成络合离子的化合物。\n\n根据上述已知信息，请将'The interdisciplinary study of metal-containing biomolecules (e.g., metalloenzymes) and metal-biomolecular interactions (e.g., metal ion channels, metal drugs).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"无机化学与生物化学的交叉学科，主要研究含金属的生物分子（如金属酶）、金属与生物分子的相互作用（如金属离子通道、金属药物）等。"
    },
    {
        "instruction":"已知信息：\n'For a newly developed in-vitro diagnostic reagent not yet listed in the classification catalogue, the applicant may directly apply for a class III in-vitro diagnostic reagent registration, or, after determining the class of the product in accordance with the classification rules and applying for class confirmation to the China Food and Drug Administration, apply for registration or for filing.'可被翻译为：对新研制的尚未列入体外诊断试剂分类目录的体外诊断试剂，申请人可以直接申请第三类体外诊断试剂产品注册，也可以依据分类规则判断产品类别向国家食品药品监督管理总局申请类别确认后，申请产品注册或者办理产品备案。\n'Where a class III medical device registration is directly applied for, China Food and Drug Administration shall determine the class according to its risk degree. Where a domestic medical device is determined as class II, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the province, autonomous region or municipality directly under the central government where the applicant is located, for evaluation and approval. Where a medical device is determined as class I, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the city consists of its districts where the applicant is located, for filing.'可被翻译为：直接申请第三类医疗器械注册的，国家食品药品监督管理总局按照风险程度确定类别。境内医疗器械确定为第二类的，国家食品药品监督管理总局将申报资料转申请人所在地省、自治区、直辖市食品药品监督管理部门审评审批；境内医疗器械确定为第一类的，国家食品药品监督管理总局将申报资料转申请人所在地设区的市级食品药品监督管理部门备案。\n\n根据上述已知信息，请将'Where a class III in-vitro diagnostic reagent registration is directly applied for, China Food and Drug Administration shall determine the class based on its risk degree. Where a domestic in-vitro diagnostic reagent is determined as class II, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the province, autonomous region, or municipality directly under the central government where the applicant is located for evaluation and approval. Where a domestic in-vitro diagnostic reagent is determined as class I, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the city consisting of districts where the applicant is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"直接申请第三类体外诊断试剂注册的，国家食品药品监督管理总局按照风险程度确定类别。境内体外诊断试剂确定为第二类的，国家食品药品监督管理总局将申报资料转申请人所在地省、自治区、直辖市食品药品监督管理部门审评审批；境内体外诊断试剂确定为第一类的，国家食品药品监督管理总局将申报资料转申请人所在地设区的市级食品药品监督管理部门备案。"
    },
    {
        "instruction":"已知信息：\n'regulatory impact analysis'可被翻译为：监管影响分析\n'The State formulates development planning and industry policies for the vaccine industry to support development and structural optimization of the vaccine industry, and encourages scale and intensive production and constant improvement on the production process and quality of vaccines.'可被翻译为：国家制定疫苗行业发展规划和产业政策，支持疫苗产业发展和结构优化，鼓励疫苗生产规模化、集约化，不断提升疫苗生产工艺和质量水平。\n\n根据上述已知信息，请将'Process of examining the probable impacts of a proposed regulation and of alternative policies to assist the policy development process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审查拟议法规和替代政策可能产生的影响，以协助政策制定过程的过程。"
    },
    {
        "instruction":"已知信息：\n'Secondly, scientific evaluation is reinforced to timely deal with risk warning signals. We established and improved the working mechanism of daily monitoring, weekly summarization and quarterly analysis. At the same time, we paid close attention to the domestic and foreign regulatory dynamics in close integration with our actual clinical medication practice, and continuously strengthened the analysis and evaluation of the ADR report data. According to the evaluation outputs, we timely released pharmacovigilance information. In 2019, we issued the Announcement on the Cessation of Production, Sale and Use of Furazolidone containing Compound Preparations, as well as 27 Announcements on the revision of drug package inserts, and 12 volumes of Pharmacovigilance Express. The functions of the early warning management platform were further optimized to realize early detection, response, investigation, and disposal of early warning signals to ensure effective protection of drug safety for the public.'可被翻译为：二是加强科学评价，及时处置风险预警信号。建立健全日监测、周汇总、季度分析工作机制，同时密切关注国内外监管动态，紧密结合临床用药实际，不断强化对药品不良反应报告数据的分析评价。根据评价结果，及时发布药品安全警示信息。2019年发布停止含呋喃唑酮复方制剂生产销售使用公告，发布药品说明书修订公告27期，发布《药物警戒快讯》12期。继续优化预警管理平台功能，对预警信号做到早发现、早应对、早调查、早处置，切实保障公众用药安全。\n'In 2018, the evaluation and disposal of risk signals for the monitoring of adverse events in medical devices were carried out in depth.We've strengthened the daily monitoring,early warning analysis and quarterly summary of national medical device adverse event reports. Based on the risk conditions,3 issues of Medical Device Adverse Event Information Notification and 6 Medical Device Pharmacovigilance Expresses were issued throughout the year. The intensive monitoring of adverse events in medical devices 13th Five-Year Plan continued to advance. The National Center for ADR Monitoring has organized inspections on key surveillance work. The relevant undertaking units proactively collected monitoring data to dig deeper into the risks of medical devices, and the relevant work saw steady progress.'可被翻译为：2018年，医疗器械不良事件监测风险信号评价处置工作深入开展。强化对全国医疗器械不良事件报告的日常监测、预警分析及季度汇总，根据发现的风险情况，全年共发布《医疗器械不良事件信息通报》3期、《医疗器械警戒快讯》6期。“十三五”医疗器械不良事件重点监测工作持续推进。国家药品不良反应监测中心组织对重点监测工作进行督查，相关承担单位主动收集监测数据，深入挖掘医疗器械风险，工作进展顺利。\n\n根据上述已知信息，请将'Second, conduct in-depth safety evaluation and timely address risk warning signals.Based on monitoring data analysis and evaluation results, in 2018, we've released a total of 33 announcements on the revision of drug package inserts; mandated the cessation of production, sales and use of Pyrithioxine Injections, Composite Terfenadine Tablets, Sulfisomidiae Tablets and Terfenadine, Ibuprofen and Pseudoephedrine Capsules, and issued 12volumes of Pharmacovigilance Express.We continued to optimize the early warning system and timely handled more than 150highly concerned ADR-events clustering signals, focusing on early detection, early response, early investigation and early disposal to ensure safety of public drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二是深入开展安全性评价，及时处置风险预警信号。根据监测数据分析评价结果，2018年共发布药品说明书修订公告33期、停止吡硫醇注射剂、特酚伪麻片、磺胺索嘧啶片和特洛伪麻胶囊生产销售使用、发布《药物警戒快讯》12期。继续优化预警系统，对重点关注的150余个药品不良反应事件聚集性信号及时进行处置，做到早发现、早应对、早调查、早处置，保障公众用药安全。"
    },
    {
        "instruction":"已知信息：\n'Validated loading patterns should be established for all sterilisation processes and load patterns should be subject to periodic revalidation. Maximum and minimum loads should also be considered as part of the overall load validation strategy.'可被翻译为：所有灭菌工艺都应建立经验证的装载模式，并且装载模式应定期进行再验证。最大装载和最小装载也应视为装载验证策略的一部分。\n'Samples of products using systems other than fusion should be taken and checked for integrity using\nvalidated methods. The frequency of testing should be based on the knowledge and experience of the container\nand closure systems being used. A scientifically justified sampling plan should be used. The sample size should be\nbased on information such as supplier management, packaging component specifications and process knowledge.'可被翻译为：使用非融合系统的产品应进行取样并使用经验证的方法检查其完整性。完整性检查的频率应基于所使用容器和密封系统的知识和经验。应使用经科学论证的取样计划。样本量应基于供应商管理、包装组件质量标准和工艺知识等信息。\n\n根据上述已知信息，请将'The validity of the sterilizing process should be reviewed and verified at scheduled intervals based on risk.\nHeat sterilization cycles should be revalidated with a minimum frequency of at least annually for load patterns\nthat are considered worst case. Other load patterns should be validated at a frequency justified in the CCS.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据风险按照预定的时间间隔审核和确认灭菌工艺的有效性。对于被认为是最差条件的装载模式，应至少每年一次定期开展加热灭菌周期的再验证。其它装载模式应以 CCS 中论证的频率进行验证。"
    },
    {
        "instruction":"已知信息：\n'The products subject to lot release shall be manufactured as per the process approved by the CFDA. Enterprises shall be responsible for the authenticity of the materials, records and data generated during the production and testing processes of the products subject to lot release. The materials for lot release shall be reviewed, signed and issued by the Qualified Person of the enterprise.'可被翻译为：批签发产品应当按照食品药品监管总局核准的工艺生产。企业对批签发产品生产、检验等过程中形成的资料、记录和数据的真实性负责。批签发资料应当经企业质量受权人审核并签发。\n'Article 12 For each variety subject to the application for lot release, the lot release applicant shall establish an independent template for the summary of the production and testing records of lot release, which shall be submitted to the NIFDC for verification and then be distributed after approval to the lot release institution and the applicant by the NIFDC. In case of a revision of the verified template for the summary of the production and testing records of lot release required, the lot release applicant shall submit an application to the NIFDC. The template shall not be changed until verified by the NIFDC.'可被翻译为：第十二条    对拟申请批签发的每个品种，批签发申请人应当建立独立的批签发生产及检验记录摘要模板，报中检院核定后，由中检院分发给批签发机构和申请人。批签发申请人需要修订已核定的批签发生产及检验记录摘要模板的，应当向中检院提出申请，经中检院核定后方可变更。\n\n根据上述已知信息，请将'Lot release products shall be manufactured in accordance with the approved process and shall conform to the national drug standards and drug registration standards. The entire production process shall comply with the Good Manufacture Practice for Pharmaceutical Products. MAHs shall establish a complete production quality management system and continuously strengthen the management of deviation. MAHs shall be responsible for the authenticity of the materials, records and data generated during the production, testing and relevant processes of the lot release products. Lot release materials shall be reviewed, signed and issued by the qualified person of the MAHs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发产品应当按照经核准的工艺生产，并应当符合国家药品标准和药品注册标准。生产全过程应当符合药品生产质量管理规范的要求。药品上市许可持有人应当建立完整的生产质量管理体系，持续加强偏差管理。药品上市许可持有人对批签发产品生产、检验等过程中形成的资料、记录和数据的真实性负责。批签发资料应当经药品上市许可持有人的质量受权人审核并签发。"
    },
    {
        "instruction":"已知信息：\n'Test Organism, Inoculum Preparation and Standardization'可被翻译为：微生物检测，接种准备和标定\n'The original strain used for breeding.'可被翻译为：用于育种的原始菌株。\n\n根据上述已知信息，请将'A standard strain used for microbiological assays and other tests.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于微生物测定和其他检查用的标准菌株。"
    },
    {
        "instruction":"已知信息：\n'Document specifying the quality management system of an organisation. (ISO 9000:2005)'可被翻译为：详细说明一个组织的质量管理体系的文件。(ISO 9000:2005)\n'1.Overall intentions and direction of an organization related to quality as formally expressed by senior management.\n2.A brief statement that describes the organization’s purpose, overall intentions and strategic direction; provides a framework for quality objectives; and includes a commitment to meet applicable requirements.\n3.A brief statement that describes the organization’s purpose, overall intentions and strategic direction; provides a framework for quality objectives; and includes a commitment to meet applicable requirements.'可被翻译为：1.由高级管理层正式表达的与质量有关的组织的总体意图和方向。\n2.一份描述组织宗旨、总体意图和战略方向的简短声明;提供质量目标的框架;并包括满足适用要求的承诺。\n3.一份描述组织宗旨、总体意图和战略方向的简短声明;提供质量目标的框架;并包括满足适用要求的承诺。\n\n根据上述已知信息，请将'1.A handbook that describes the various elements of the system for assuring the quality of the test results generated by a laboratory.\n2.A handbook that describes the various elements of the quality management system for assuring the quality of the test results generated by a laboratory (see Part one, sections 2.1–2.2).\n3.A document that includes the quality policy and objectives and describes the various elements of the QMS.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.描述保证实验室产生的检测结果质量的系统的各种要素的手册。\n2.描述质量管理体系各种要素的手册，以保证实验室产生的检测结果的质量(见第一部分2.1-2.2节)。\n3.包括质量方针和目标并描述质量管理体系各要素的文件。"
    },
    {
        "instruction":"已知信息：\n'(V) The sales of drugs under special management and drugs with special management requirements by the State;'可被翻译为：（五）特殊管理的药品和国家有专门管理要求的药品的销售；\n'Article 170 The sales of drugs under special management and those with special management requirements of the State shall be carried out in strict accordance with the relevant national provisions.'可被翻译为：第一百七十条 销售特殊管理的药品和国家有专门管理要求的药品，应当严格执行国家有关规定。\n\n根据上述已知信息，请将'(V) Management of drugs under special management and drugs with special management requirements by the State;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）特殊管理的药品和国家有专门管理要求的药品的管理；"
    },
    {
        "instruction":"已知信息：\n'Article 155 This Law shall go into effect as of December 1, 2019.'可被翻译为：第一百五十五条 本法自2019年12月1日起施行。\n'Note: The statistics period of this report is from January 1, 2019 to December 31, 2019.'可被翻译为：注：本报告的数据统计自2019年1月1日至2019年12月31日。\n\n根据上述已知信息，请将'Article 100 This Law shall be effective as of December 1, 2019.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百条 本法自2019年12月1日起施行。"
    },
    {
        "instruction":"已知信息：\n'(2) have the premises, facilities, and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施和卫生环境；\n'(2) having the premises, facilities, equipment and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施、设备和卫生环境；\n\n根据上述已知信息，请将'(2) have the premises, equipment, warehouses, and hygienic environment required for drug distribution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）有与所经营药品相适应的营业场所、设备、仓储设施和卫生环境；"
    },
    {
        "instruction":"已知信息：\n'oil-in-water emulsion'可被翻译为：水包油乳剂\n'An emulsion made by further dispersing colostrum of oil in water (o\/w) or water in oil (W\/O) in an oil phase (O\/W\/O) or water phase (W\/O\/W) for emulsification.'可被翻译为：将水包油(o\/w)或油包水(W\/O)的初乳进一步分散在油相(O\/W\/O)或水相(W\/O\/W)中进行乳化所制成的乳剂。\n\n根据上述已知信息，请将'Ointments made from oil-in-water (O\/W) emulsion matrix and water-soluble matrix.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由水包油（O\/W）乳剂基质及水溶性基质制备而成的软膏。"
    },
    {
        "instruction":"已知信息：\n'(7) cooperate with the drug regulatory departments in extended inspection of the drug MAH and related parties;'可被翻译为：（七）配合药品监督管理部门对药品上市许可持有人及相关方的延伸检查；\n'Article 292: The contract should define that the contract acceptor has the obligation to accept the inspection conducted by drug regulatory department.'可被翻译为：第二百九十二条 委托检验合同应当明确受托方有义务接受药品监督管理部门检查。\n\n根据上述已知信息，请将'(5) Cooperating with the supervision and inspection of the drug regulatory department.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）配合药品监督管理部门的监督检查工作。"
    },
    {
        "instruction":"已知信息：\n'The inspection records of incoming goods shall be kept till 2 years after expiration of valid term of the medical device; if there is no valid term for such medical device, the records shall be kept for no less than 5 years. The inspection records of incoming implantable medical devices shall be kept permanently.'可被翻译为：进货查验记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械进货查验记录应当永久保存。\n'Article 22 MAHs, medical device distributing enterprises as well as user facility shall establish and keep medical device adverse event monitoring records. The records shall be kept until 2 years upon shelf life expiration of medical devices; for those without shelf life label, the record-keeping period shall not be less than 5 years. The monitoring records of implantable medical devices shall be kept permanently, and medical institutions shall keep them in accordance with the relevant provisions for medical records.'可被翻译为：第二十二条  持有人、经营企业、使用单位应当建立并保存医疗器械不良事件监测记录。记录应当保存至医疗器械有效期后2年；无有效期的，保存期限不得少于5年。植入性医疗器械的监测记录应当永久保存，医疗机构应当按照病例相关规定保存。\n\n根据上述已知信息，请将'The sales records shall be kept till 2 years after expiration of valid term of the medical devices; if there is no valid term for such medical devices, the records shall be kept for no less than 5 years. The sales records of implantable medical devices shall be kept permanently.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"销售记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械销售记录应当永久保存。"
    },
    {
        "instruction":"已知信息：\n'(2) Assisting the registrants and filing persons in carrying out cosmetic adverse reaction monitoring, safety monitoring and reporting of new cosmetic ingredients;'可被翻译为：（二）协助注册人、备案人开展化妆品不良反应监测、化妆品新原料安全监测与报告工作；\n'(1) In the name of the registrants and filing persons, handling the registration and filing of cosmetics and new cosmetic ingredients;'可被翻译为：（一）以注册人、备案人的名义，办理化妆品、化妆品新原料注册、备案；\n\n根据上述已知信息，请将'(3) Assisting the registrants and filing persons in implementing the recall of cosmetics and new cosmetic ingredients;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）协助注册人、备案人实施化妆品、化妆品新原料召回工作；"
    },
    {
        "instruction":"已知信息：\n'Sterile  filtration  of liquids  should be validated  in  accordance with relevant Pharmacopeia requirements. Validation can be grouped by different strengths or variations of a product but should be done under worst-case conditions. The rationale for grouping should be justified and documented.'可被翻译为：液体的除菌过滤应按照相关药典要求进行验证。验证可以根据产品的不同规格或种类进行分组，但应在最差条件下进行。分组的基本依据应经过论证并用文件记录。\n'Assess and document the risks associated with the duration of filter use for the sterile filtration process for a given fluid.'可被翻译为：评估并记录与给定液体除菌过滤工艺中过滤器的使用时间相关的风险。\n\n根据上述已知信息，请将'Conduct and document effective validation and qualification studies to demonstrate that the duration of filter use for a given  sterile  filtration process and for a given  fluid does not compromise performance of the final sterilising grade filter or filtrate quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"执行有效的验证和确认研究并进行记录，以证明给定液体和给定除菌过滤工艺中过滤器的使用时间不会影响最终除菌级过滤器的性能或滤液质量。"
    },
    {
        "instruction":"已知信息：\n'The CFDA shall, in accordance with the needs of lot release work, in a timely manner announce the selection criteria and conditions for added lot release institutions and the product varieties added by the lot release institutions.'可被翻译为：食品药品监管总局根据批签发工作需要，适时公布新增批签发机构及批签发机构扩增批签发品种的遴选标准和条件。\n'Article 37 The NMPA shall establish a unified IMS, where it can publish information on the lot release institutions and relevant adjustments, decision on handling major issues, provide the lot release applicants with the searchable progress and conclusions of lot release, and disclose the products approved for lot release for public inquiries.'可被翻译为：第三十七条   国家药品监督管理局建立统一的生物制品批签发信息平台，公布批签发机构及调整情况、重大问题处理决定等信息，向批签发申请人提供可查询的批签发进度、批签发结论，及时公布已通过批签发的产品信息，供公众查询。\n\n根据上述已知信息，请将'Article 36 The CFDA shall establish a unified Information Management System for Lot Release, release the determination and adjustment by the lot release institutions and provide the lot release applicants with the searchable progress and conclusions of lot release, and summarize and disclose the lot release conclusion of the products with the lot release completed and handling decision of major issues and other information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十六条 食品药品监管总局建立统一的批签发信息管理系统，公布批签发机构确定及调整情况，向批签发申请人提供可查询的批签发进度、批签发结论，汇总公开已完成批签发的产品批签发结论以及重大问题处理决定等信息。"
    },
    {
        "instruction":"已知信息：\n't-test'可被翻译为：t检验\n'The difference in pressure between two points, such as the pressure difference between an \nenclosed space and an independent reference point, or the pressure difference between two \nenclosed spaces.'可被翻译为：两点之间的压差，如安之间的压差\n封闭空间与独立参考点之间的压力差，或两者之间的压力差\n封闭的空间。\n\n根据上述已知信息，请将'A statistical test to determine whether the difference between two means is significant by applying T-distribution theory to infer the probability of the difference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应用t分布理论推断差异发生的概率，从而判定两个平均数的差异是否显著的一种统计学检验方法。"
    },
    {
        "instruction":"已知信息：\n'In a redundant filtration system (where a second redundant sterilising grade filter is present as a backup but the sterilising process is validated as only requiring one filter), post-use integrity test of the primary sterilising grade filter should be performed and if demonstrated to be integral, then a post-use integrity test of the redundant (backup) filter is not necessary. However, in the event of a failure of the post-use integrity test on the primary filter, post-use integrity test  on the  secondary (redundant) filter  should be performed, in conjunction with an investigation and risk assessment to determine the reason for the primary filter test failure.'可被翻译为：对于冗余过滤系统（存在第二个冗余除菌级过滤器作为备用过滤器，但灭菌工艺验证时仅用一个过滤器）， 应进行主除菌级过滤器的使用后完整性测试，如果证明该过滤器是完整的，则不需要对冗余（备用）过滤 器进行使用后完整性测试。但如果主过滤器的使用后完整性测试失败，应对二级（冗余）过滤器进行使用后完整性测试，同时进行调查和风险评估，确定主过滤器测试失败的原因。\n'Methods and parameters for integrity testing of filled containers (see paragraph 8.22).'可被翻译为：已灌装容器完整性测试的方法和参数（参见第 8.22 节）。\n\n根据上述已知信息，请将'The performance of the pre- and post-use integrity testing for sterilising grade filters (see paragraph 8.87).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除菌级过滤器的使用前后完整性测试的性能（参见第 8.87 节）。"
    },
    {
        "instruction":"已知信息：\n'Stereoisomers that are mirror images of each other.'可被翻译为：互为镜像关系的立体异构体。\n'The phenomenon of being physical objects and mirror images of each other but not overlapping.'可被翻译为：互为实物与镜像而不可重叠的现象。\n\n根据上述已知信息，请将'For stereoisomers that have two or more asymmetric centers in a molecule and whose molecules are not mirror images of each other.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于分子中具有两个或多个不对称中心，并且其分子不互为镜像关系的立体异构体。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory departments shall conduct supervision and inspection on the vaccine quality during the process of the vaccine development, manufacture, storage, transportation, and immunization. The competent health departments shall conduct supervision and inspection on the implementation of the immunization planning system and immunization activities according to law.'可被翻译为：药品监督管理部门依法对疫苗研制、生产、储存、运输以及预防接种中的疫苗质量进行监督检查。卫生健康主管部门依法对免疫规划制度的实施、预防接种活动进行监督检查。\n'(I) Personnel engaged in quality management shall have a degree of technical school in pharmacy, or college degree or above in medicine, biology and chemistry, or primary professional and technical title or above in pharmacy;'可被翻译为：（一）从事质量管理工作的，应当具有药学中专或者医学、生物、化学等相关专业大学专科以上学历或者具有药学初级以上专业技术职称；\n\n根据上述已知信息，请将'For the dispatch of vaccines, there shall be at least two professionals especially responsible for the quality management and acceptance inspection of vaccines. Professionals shall have a bachelor's degree or above and intermediate professional and technical title or above in preventive medicine, pharmacy, microbiology or medicine, and have working experiences in vaccine management or techniques for more than 3 years.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从事疫苗配送的，还应当配备2名以上专业技术人员专门负责疫苗质量管理和验收工作。专业技术人员应当具有预防医学、药学、微生物学或者医学等专业本科以上学历及中级以上专业技术职称，并有3年以上从事疫苗管理或者技术工作经历。"
    },
    {
        "instruction":"已知信息：\n'Sonicate the test containers for 60 minutes (wattage range 150 – 480 watts) at 37°C ±1°C. Do not sonicate more tubes than can be vortexed within 15 minutes of completion of the sonication. Make sure the water in the sonicator covers the rinse solution in the 20 x 150 mm tubes. Do not allow the water in the sonicator to exceed 38°C.'可被翻译为：37°C ±1°C 超声测试容器60分钟（功率150-480瓦）。在超声处理完成后的15 分钟内，超声处理的管数不要超过可以涡旋的管数。确保超声装置里面的水覆盖20 x 150 mm试管中的淋洗溶液。不要让超声装置中的水温超过38°C。\n'Place all pieces into the 20 x 150 mm tube containing 15 mL of preheated (37°C ±1°C) 0.01% SLS rinse solution.'可被翻译为：将所有小片放入装有15ml预热（37°C ±1°C）0.01%SLS淋洗液的20 x 150 mm 试管。\n\n根据上述已知信息，请将'Vortex the tubes for 30 – 60 seconds or until all pieces of the device are immersed in the rinse solution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"涡旋震摇试管30-60秒钟或直到器械的所有小块均浸入淋洗液。"
    },
    {
        "instruction":"已知信息：\n'In a prescribed release medium, the drug is released slowly and at a non-constant rate as required, and the frequency of administration is reduced by half or somewhat than that of the ordinary preparation compared with the corresponding ordinary preparation, and the patient's compliance is significantly increased.'可被翻译为：在规定释放介质中，按要求缓慢地非恒速释放药物，与相应的普通制剂比较，给药频率比普通制剂减少一半或给药频率比普通制剂有所减少，且能显著增加患者的顺应性的制剂。\n'In the prescribed release medium, the drug is slowly released at or near a constant rate as required, and compared with the corresponding ordinary preparation, the frequency of administration is reduced by half or the frequency of administration is reduced compared with the ordinary preparation, the blood concentration is more stable than the sustained release preparation, and can significantly increase the patient's compliance.'可被翻译为：在规定释放介质中，按要求缓慢地恒速或接近恒速释放药物，与相应的普通制剂比较，给药频率比普通制剂减少一半或给药频率比普通制剂有所减少，血药浓度比缓释制剂更加平稳，且能显著增加患者的顺应性的制剂。\n\n根据上述已知信息，请将'Capsules that slowly release the drug at a non-constant rate or near constant rate in water or a prescribed release medium.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在水中或规定的释放介质中缓慢地以非恒速或接近恒速释放药物的胶囊剂。"
    },
    {
        "instruction":"已知信息：\n'electronic signatures'可被翻译为：电子签名\n'(2) Persons using electronic signatures shall, upon agency request, provide additional certification or testimony that a specific electronic signature is the legally binding equivalent of the signer's handwritten signature.'可被翻译为：应FDA要求人们在使用电子签名时，应提供一份明确电子签名与签字者手写签名具有同等的法律效力的附加的证明书或证据。\n\n根据上述已知信息，请将'(7) Electronic signature means a computer data compilation of any symbol or series of symbols executed, adopted, or authorized by an individual to be the legally binding equivalent of the individual's handwritten signature.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"电子签名系指与手写签名具有相同法律效力，且由一个个体签署、采纳或授权的符号或一系列符号的计算机数据编制。"
    },
    {
        "instruction":"已知信息：\n'Article 94 The drug registration timeline mentioned in these Provisions is the longest time needed for drug registration acceptance, review, inspection, testing, approval, etc. The timeline for priority review and approval procedures shall be implemented in accordance with relevant provisions on priority review and approval.'可被翻译为：第九十四条 本办法所规定的时限是药品注册的受理、审评、核查、检验、审批等工作的最长时间。优先审评审批程序相关工作时限，按优先审评审批相关规定执行。\n'If it is included in the priority evaluation and approval procedures, the time limit for registration inspection is 80 days.'可被翻译为：纳入优先审评审批程序的，注册核查工作时限为80日。\n\n根据上述已知信息，请将'Article 14 Priority shall be given to registration inspection of the drugs in special approval procedures and priority evaluation and approval procedures.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 特别审批程序、优先审评审批程序的品种，予以优先安排注册核查。"
    },
    {
        "instruction":"已知信息：\n'Article 49 Enterprises engaged in storage and transportation of refrigerated and frozen drugs shall be equipped with the following facilities and equipment:'可被翻译为：第四十九条 储存、运输冷藏、冷冻药品的，应当配备以下设施设备：\n'(II) Packaging and sealing of refrigerated or frozen drugs shall be completed in refrigerated environment;'可被翻译为：（二）应当在冷藏环境下完成冷藏、冷冻药品的装箱、封箱工作；\n\n根据上述已知信息，请将'Article 99 Specially-assigned personnel shall be responsible for the operations such as packaging and loading of refrigerated or frozen drugs, which shall conform to the following requirements:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十九条 冷藏、冷冻药品的装箱、装车等项作业，应当由专人负责并符合以下要求："
    },
    {
        "instruction":"已知信息：\n'The process by which a drug is transported from one side of a biofilm to the other side of a biofilm with a higher concentration.'可被翻译为：药物从浓度低的一侧生物膜向浓度高的一侧的转运过程。\n'The transmembrane transport of a drug from one side with a high concentration to the other side with a low concentration.'可被翻译为：药物从浓度高的一侧向浓度低的一侧的跨膜转运。\n\n根据上述已知信息，请将'The process by which a non-fat-soluble small molecule is transported from one side of the biofilm to the other with the help of special membrane proteins.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"非脂溶性小分子物质，在特殊膜蛋白质帮助下，由高浓度向低浓度一侧转运的过程。"
    },
    {
        "instruction":"已知信息：\n'In order to strengthen the supervision and administration of cosmetics labels, standardize the use of cosmetics labels and protect the legitimate rights and interests of consumers, according to the Regulations for the Supervision and Administration of Cosmetics, NMPA has drafted the Measures for the Administration of Cosmetics Labels (hereinafter referred to as the Measures),which are hereby promulgated. On May 31, matters related to implementation of the Measures are hereby announced as follows:'可被翻译为：为加强化妆品标签监督管理，规范化妆品标签使用，保障消费者合法权益，依据《化妆品监督管理条例》，国家药监局组织起草了《化妆品标签管理办法》（以下简称《办法》），现予公布。现就《办法》实施有关事宜公告如下：\n'Announcement of National Medical Products Administration and National Intellectual Property Administration on the Issuance of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (Interim)'可被翻译为：国家药监局 国家知识产权局关于发布《药品专利纠纷早期解决机制实施办法（试行）》的公告\n\n根据上述已知信息，请将'NMPA Announcement on Issuance and Implementation of the Measures for the Administration of Cosmetics Labels'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布实施《化妆品标签管理办法》的公告"
    },
    {
        "instruction":"已知信息：\n'Where a drug distributor fails to report suspected adverse drug reactions as required, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to production suspension for rectification and be fined not less than RMB 50,000 but not more than RMB 500,000.'可被翻译为：药品经营企业未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，责令停产停业整顿，并处五万元以上五十万元以下的罚款。\n'Where a medical institution fails to report suspected adverse drug reactions, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to a fine of not less than RMB 50,000 but not more than RMB 500,000.'可被翻译为：医疗机构未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，处五万元以上五十万元以下的罚款。\n\n根据上述已知信息，请将'Article 134 Where a drug MAH fails to monitor adverse drug reactions or report suspected adverse drug reactions as required, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to production suspension and be fined not less than RMB 100,000 but not more than RMB 1,000,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百三十四条 药品上市许可持有人未按照规定开展药品不良反应监测或者报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，责令停产停业整顿，并处十万元以上一百万元以下的罚款。"
    },
    {
        "instruction":"已知信息：\n'On November 29, 2019, approved by the State Council, the Leading Group for Deepening the Reform of the Medical and Health System Issued the Notice on Several Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement &Use of Drugs as a Breakthrough in order to implement the decisions and plans of the CPC central Committee and the State Council on deepening the reform of the medical and health care systems and promote the interlocked reform of healthcare, health insurance, and pharmaceuticals. The Notice pointed out that it is necessary to promote the interlocked reform of healthcare, health insurance, and pharmaceuticals, magnify the effects of reform, and better address the problems complicating medical services to the people, the following policies and measures shall be implemented, covering 15 aspects:'可被翻译为：为贯彻落实党中央、国务院关于深化医药卫生体制改革的决策部署，推动各地加大力度持续深化医疗、医保、医药联动改革，2019年11月29日，经国务院同意，国务院深化医药卫生体制改革领导小组发布《关于以药品集中采购和使用为突破口 进一步深化医药卫生体制改革的若干政策措施》。通知指出要促进医疗、医保、医药联动，放大改革效应，更好推动解决群众看病就医问题。\n'1. Deepening the reform of state-led centralized procurement and use of drugs'可被翻译为：一、全面深化国家组织药品集中采购和使用改革\n\n根据上述已知信息，请将'The State Council's Leading Group for Deepening the Reform of the Medical and Health System Issued the Notice on Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement & Use of Drugs as a Breakthrough'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国务院深化医药卫生体制改革领导小组印发关于以药品集中采购和使用为突破口进一步深化医药卫生体制改革若干政策措施的通知"
    },
    {
        "instruction":"已知信息：\n'Article 82 Where an enterprise directly transfers the drugs in accordance with Article 69 herein, it may entrust the purchaser to conduct drug acceptance inspection. The purchaser shall conduct acceptance inspection on the drugs in strict accordance with the GSP and establish special acceptance inspection records for the directly transferred drugs. On the day of acceptance inspection, relevant information of acceptance inspection records shall be transmitted to the directly transferring enterprise.'可被翻译为：第八十二条 企业按本规范第六十九条规定进行药品直调的，可委托购货单位进行药品验收。购货单位应当严格按照本规范的要求验收药品，并建立专门的直调药品验收记录。验收当日应当将验收记录相关信息传递给直调企业。\n'Article 98 At the time of ex-warehousing of drugs, the accompanying sheet (bill) stamped with the original special seal for drug ex-warehousing of enterprises shall be attached.'可被翻译为：第九十八条 药品出库时，应当附加盖企业药品出库专用章原印章的随货同行单（票）。\n\n根据上述已知信息，请将'Where an enterprise directly transfers drugs in accordance with Article 69 herein, the supplier shall issue two copies of the same accompanying sheet (bill) at the time of ex-warehousing of the directly transferred drugs which shall be respectively sent to the directly transferring enterprise and the purchaser. The contents of the accompanying sheet (bill) shall comply with the requirements of Paragraph 2 of Article 73 herein and also indicate the name of the directly transferring enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"企业按照本规范第六十九条规定直调药品的，直调药品出库时，由供货单位开具两份随货同行单（票），分别发往直调企业和购货单位。随货同行单（票）的内容应当符合本规范第七十三条第二款的要求，还应当标明直调企业名称。"
    },
    {
        "instruction":"已知信息：\n'A substance that changes the genetic information of a strain by physical action.'可被翻译为：通过物理作用使菌种发生遗传信息改变的物质。\n'A type of physical mutagen. The genetic information of the strain is altered by exposure to ultraviolet light.'可被翻译为：物理诱变剂的一种。用紫外线进行照射使菌种发生遗传信息改变。\n\n根据上述已知信息，请将'A substance that causes the genetic information of a strain to be altered by chemical action.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过化学作用使菌种发生遗传信息改变的物质。"
    },
    {
        "instruction":"已知信息：\n'Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.'可被翻译为：对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。\n'Article 67 For a conditionally approved drug, where the MAH fails to complete the studies as required within the specified timeline or fails to prove that the benefits outweigh risks, the NMPA shall handle the matter in accordance with the law until the Drug Approval License is revoked.'可被翻译为：第六十七条 对附条件批准的药品，持有人逾期未按照要求完成研究或者不能证明其获益大于风险的，国家药品监督管理局应当依法处理，直至注销药品注册证书。\n\n根据上述已知信息，请将'Where further study is required when a vaccine's registration application is approved, the vaccine MAH shall complete the study within the prescribed time limit; where the study fails to be completed on time or fails to prove that the benefits outweigh the risks, the drug regulatory department under the State Council shall take actions in accordance with law up to revoke the vaccine's registration certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对批准疫苗注册申请时提出进一步研究要求的疫苗，疫苗上市许可持有人应当在规定期限内完成研究；逾期未完成研究或者不能证明其获益大于风险的，国务院药品监督管理部门应当依法处理，直至注销该疫苗的药品注册证书。"
    },
    {
        "instruction":"已知信息：\n'2. Relative standard deviation for all measured (i.e. millimeters or absorbance) and calculated \ndata (e.g. averages) is NMT 10%; and,'可被翻译为：所有测量所得（即毫米或吸光度）和计算所得数据（例如平均值）的相对标准偏差\n不得过 10%，且\n'2) Relative standard deviation for all measured and calculated data is NMT 10% and'可被翻译为：所有测量和计算所得数据的相对标准偏差应 NMT 10%，且\n\n根据上述已知信息，请将'Relative standard deviation for all measured (i.e. millimeters or absorbance) and calculated data (e.g. averages) is NMT 10%; and,'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有测量值（即，mm或吸光度）的相对标准偏差和计算所得数据（例如平均值） NMT10%；且"
    },
    {
        "instruction":"已知信息：\n'2) To be responsible for product release and to ensure that the production and testing of each batch of released products are in accordance with the related regulations, the registration requirements and specifications;'可被翻译为：2.承担产品放行的职责，确保每批已放行产品的生产、检验均符合相关法规、药品注册要求和质量标准；\n'Article 23 The legal representative and principal responsible person of vaccine MAHs shall have good credit records, and personnel in key positions such as the responsible person for manufacturing management, the responsible person for quality management and the quality authorized person shall have relevant professional background and work experience.'可被翻译为：第二十三条 疫苗上市许可持有人的法定代表人、主要负责人应当具有良好的信用记录，生产管理负责人、质量管理负责人、质量受权人等关键岗位人员应当具有相关专业背景和从业经历。\n\n根据上述已知信息，请将'1.A person responsible for the release of batches of finished product for sale. In certain countries the batch documentation of a batch of finished product must be signed by an authorized person from the production department and the batch test results by an authorized person from the quality control department for batch release.\n2.A person (among key personnel of a manufacturing establishment) responsible for the release of batches of finished products for sale.\n3.The person recognized by the national regulatory authority as having the responsibility for ensuring that each batch of finished product has been manufactured, tested and approved for release in compliance with the laws and regulations in force in that country.\n4.A person (among key personnel of a manufacturing establishment) responsible for the release of batches of finished products for sale. In some good manufacturing practice (GMP) guides and legal texts, the term qualified person is used to describe analogous functions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.负责放行成批销售的成品的人。在某些国家，一批成品的批文件必须由生产部门的授权人员签字，批检测结果必须由质量控制部门的授权人员签字才能批放行。\n2.负责放行成批成品供销售的人员(在制造企业的关键人员中)。\n3.经国家监管机构认可的负责确保每批成品的生产、检测和放行符合该国现行法律法规的人员。\n4.负责放行成批成品供销售的人员(在制造企业的关键人员中)。在一些良好生产规范(GMP)指南和法律文本中，“合格人员”一词用于描述类似的功能。"
    },
    {
        "instruction":"已知信息：\n'Article 77 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall organize to conduct on-site inspections of the drug research and development conditions as well as raw data, and production site inspections according to the manufacturing processes and quality specifications provided by the applicant, and take samples of three consecutive batches of products, and send to the drug testing institutes for testing within five days starting from the date they accept an application.'可被翻译为：第七十七条 省、自治区、直辖市药品监督管理部门应当自受理申请之日起5日内组织对研制情况和原始资料进行现场核查，并应当根据申请人提供的生产工艺和质量标准组织进行生产现场检查，现场抽取连续生产的3批样品，送药品检验所检验。\n'Article 12 If the drug regulatory authorities of a province, autonomous region, or municipality directly under the Central Government determine that it is necessary to conduct Pre-market inspection of Good Manufacturing Practice of Medical Products (GMP) during the Manufacturing Site Inspection period, CFDI shall coordinate the drug regulatory authorities of the relevant province, autonomous region, or municipality directly under the Central Government to implement the inspection simultaneously with Manufacturing Site Inspection.'可被翻译为：第十二条 对于省、自治区、直辖市药品监督管理部门确定需要在生产现场核查期间开展上市前药品生产质量管理规范符合性检查的，核查中心协调相关省、自治区、直辖市药品监督管理部门与生产现场核查同步实施。\n\n根据上述已知信息，请将'Article 117 For supplementary applications of drug manufacturing technology transfer, altering formula or manufacturing process that may affect product quality, etc., the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall organize production site inspection, according to the attachment of the Letter of Approval for Drug Registration or the verified manufacturing process. Drug testing institutes shall conduct testing on samples of three batches of product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百一十七条 对药品生产技术转让、变更处方和生产工艺可能影响产品质量等的补充申请，省、自治区、直辖市药品监督管理部门应当根据其《药品注册批件》附件或者核定的生产工艺，组织进行生产现场检查，药品检验所应当对抽取的3批样品进行检验。"
    },
    {
        "instruction":"已知信息：\n'Integrity testing of the product filling lines and filtration systems (as relevant).'可被翻译为：产品灌装线和过滤系统的完整性测试（如相关）。\n'(ix) A review of adequacy of any other previous product process or equipment corrective actions;'可被翻译为：(ix)对任何以前产品工艺或设备纠正措施的充分性进行回顾；\n\n根据上述已知信息，请将'If the system is flushed or integrity tested in-situ with a fluid other than the product, appropriate actions are taken to avoid any deleterious effect on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果使用产品之外的其他液体冲洗系统或进行在线完整性测试，应釆取适当措施避以免对产品质量的任何有害影响。"
    },
    {
        "instruction":"已知信息：\n'One of the mass spectrometry samplers. It is mainly used for solid samples and high boiling point liquid samples. Place the microgram (Rg) measure sample at the bottom of the capillary tube with closed end and insert it into the top of the injector rod.'可被翻译为：质谱进样器之一。主要用于固体样品及高沸点液体样品的进样。将微克(Rg)量样品置于末端封闭的毛细管底部，插入进样杆顶端。\n'laser desorption mass spectrometry'可被翻译为：激光解吸质谱法\n\n根据上述已知信息，请将'One of the mass spectrometry sampler. It consists of a valve, a storage tank and a pinhole leak.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"质谱进样器之一。由阀、贮槽和针孔漏组成。"
    },
    {
        "instruction":"已知信息：\n'(1) No application for registration renewal has been submitted prior to expiration of the term of validity;'可被翻译为：（一）有效期届满未提出再注册申请的；\n'Article 19 For a drug patented in China, applicants other than the patentee may submit the application for registration two years prior to the expiry date of the patent. The State Food and Drug Administration shall review the drug application in accordance with the Provisions, and after the expiry date of the patent, check and issue the drug approval number, Import Drug License or a Pharmaceutical Product License if the application conforms with the provisions.'可被翻译为：第十九条 对他人已获得中国专利权的药品，申请人可以在该药品专利期届满前2年内提出注册申请。国家食品药品监督管理局按照本办法予以审查，符合规定的，在专利期满后核发药品批准文号、《进口药品注册证》或者《医药产品注册证》。\n\n根据上述已知信息，请将'(1) the application for re-registration is not made prior to the expiry date;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）有效期届满前未提出再注册申请的；"
    },
    {
        "instruction":"已知信息：\n'Any untoward medical occurrence that at any dose: \n- results in death, \n- is life-threatening, \n- requires inpatient hospitalization or prolongation of existing hospitalization, \n- results in persistent or significant disability\/incapacity, or \n- is a congenital anomaly\/birth defect (see the ICH Guideline for Clinical Safety Data Management: \nDefinitions and Standards for Expedited Reporting).[ICH E6(R1)]'可被翻译为：在任何剂量下发生的任何不良医疗事件：\n- 导致死亡\n- 危及生命\n- 需要住院治疗或延长现有住院治疗\n- 导致永久的或严重的残疾或功能损失，或\n- 治疗现有住院治疗永久的或严重的残疾或功能损失先天性异常\/出生缺陷\n（见 ICH 指导原则临床安全数据管理：加速报告的定义和标准）。[ICH E6 (R1) ]\n'Medical events that may not be immediately life -threatening or result in death or  hospitalisation, but may jeopardise the patient or may require intervention to prevent serious  outcomes; these events require medical and scientific judgement and fall under the expedited  reporting rules (see ICH E2A).'可被翻译为：可能不会立即危及生命、死亡或住院，但可能危害患者或可能需要干预以预防严重后果的医学事件；这些事件需要医学判断，符 合快速报告规则的类别（参见ICH E2A）。\n\n根据上述已知信息，请将'Any untoward medical occurrence that at any dose: - results in death,   - is life -threatening,   - requires inpatient hospitali sation or prolongation of existing hospitali sation,   - results in persistent or significant disability\/incapacity,   or  - is a congenital anomaly\/birth defect   (see ICH E2A and ICH E6 ).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在任何剂量下发生的以下任何不良医学事件：\n- 导致死亡，\n- 危及生命，\n- 需要住院或者延长住院时间，\n- 导致永久性或显著的残疾\/功能丧失，\n或- 先天性异常\/出生缺陷\n（参见ICH E2A和ICH E6）。"
    },
    {
        "instruction":"已知信息：\n'Where any violation by a medical institution defined in the preceding paragraph is identified by the drug regulatory department, the case shall be transferred to the health administrative department at the same level for handling.'可被翻译为：药品监督管理部门发现医疗机构有前款规定行为之一的，应当移交同级卫生行政部门处理。\n'In the case of failures to stop manufacture, sales, distribution, use and recall of vaccines as the preceding paragraph, the drug regulatory departments and the health departments at or above the county level shallr to stop manufacture, sales, distribution, use and recall of such vaccines according to their respective responsibilities.'可被翻译为：未依照前款规定停止生产、销售、配送、使用或者召回疫苗的，县级以上人民政府药品监督管理部门、卫生健康主管部门应当按照各自职责责令停止生产、销售、配送、使用或者召回疫苗。\n\n根据上述已知信息，请将'In case of identifying any using unit having violations specified in preceding paragraph, the drug regulatory departments shall transfer the case to the health administrative departments at the same level for disposition.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理部门发现使用单位有前款规定行为的，应当移交同级卫生行政部门处理。"
    },
    {
        "instruction":"已知信息：\n'If the substance to be tested has many components or is under special circumstances, the substance can adopt the indication name related to the product or other substitute names.'可被翻译为：如果被测物组分较多或者有其他特殊情况，可以采用与产品相关的适应症名称或者其他替代名称。\n'A liquid preparation for use by anal injection into the rectum.'可被翻译为：经肛门灌入直肠使用的液体制剂。\n\n根据上述已知信息，请将'2. Use the reference preparation substitute for the test preparation, use the test preparation substitute for the reference preparation or use product purchased in the market substitute for self-developed investigational drug, or otherwise use false investigational drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.以参比制剂替代试验制剂、以试验制剂替代参比制剂或者以市场购买药品替代自行研制的试验用药品， 以及以其他方式使用虚假试验用药品；"
    },
    {
        "instruction":"已知信息：\n'Most IVPT experiments report skin flux and the total cumulative amount of drug that has permeated into the receptor solution (or as a percentage of drug from the total applied dose). Depending on the purpose of the study, an evaluation of drug tissue distribution (amounts in the stratum corneum, viable epidermis, and dermis) and total mass balance may provide additional insights.'可被翻译为：大多数IVPT实验报告皮肤通量和渗透到受体溶液中的药物总累积量(或药物占总应用剂量的百分比)。根据研究的目的，对药物组织分布(角质层、活表皮和真皮层中的药物量)和总质量平衡的评估可能会提供额外的见解。\n'Full mass balance requires more intensive bioanalytical method development to ensure that the drug(s) of interest are efficiently extracted from each sample matrix type, such as cotton swabs used to remove the excess of formulation present on the skin surface at the end of the experiment, tape strips used to remove stratum corneum, and homogenized viable epidermis and dermis.'可被翻译为：完全的质量守衡需要更深入的生物分析方法开发，以确保从每种样品基质类型中有效地提取感兴趣的药物，例如在实验结束时用于去除皮肤表面过量配方的棉签，用于去除角质层的胶带，以及均质活表皮和真皮层。\n\n根据上述已知信息，请将'Full mass balance results are generally reported as percentage of drug(s) in each compartment (e.g., stratum corneum, viable epidermis, dermis and receptor solution) relative to the total amount applied at the beginning of the experiment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"全质量守衡结果通常报告为每个部分(例如角质层、活表皮、真皮层和受体溶液)中药物相对于实验开始时施用的总量的百分比。"
    },
    {
        "instruction":"已知信息：\n'metabolism'可被翻译为：新陈代谢\n'To reflect the physiological and biochemical metabolism changes in the process of fermentation of organisms.'可被翻译为：反映生物体发酵过程中生理生化代谢变化的检测数据。\n\n根据上述已知信息，请将'For short, \"metabolism\". A general term for all ordered chemical changes in an organism, including both material metabolism and energy metabolism.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"简称\"代谢”。生物体内全部有序化学变化的总称，包括物质代谢和能量代谢两个方面。"
    },
    {
        "instruction":"已知信息：\n'(1) Employ at least two distinct identification components such as an identification code and password.'可被翻译为：至少采用两种不同的识别方式，例如识别码和密码。\n'(b) Ensuring that identification code and password issuances are periodically checked, recalled, or revised (e.g., to cover such events as password aging).'可被翻译为：保证定期检查、收回或修订识别码和密码（例如，解决密码老化）。\n\n根据上述已知信息，请将'(a) Maintaining the uniqueness of each combined identification code and password, such that no two individuals have the same combination of identification code and password.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"保持每一组的识别码和密码的唯一性，即不存在两个个体拥有同组识别码和密码的现象。"
    },
    {
        "instruction":"已知信息：\n'Article 75 To apply for the registration of a generic drug, the applicant shall fill the Application Form for Drug Registration, submit relevant dossiers and apply for production site inspection to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the applicant is located.'可被翻译为：第七十五条 申请仿制药注册，应当填写《药品注册申请表》，向所在地省、自治区、直辖市药品监督管理部门报送有关资料和生产现场检查申请。\n'A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.'可被翻译为：药品经营企业应当按照《药品经营许可证》许可的经营范围经营药品。\n\n根据上述已知信息，请将'Article 73 The applicant applying for registration of a generic drug shall be a drug manufacturer. The applied drug shall be within the production scope specified in the Drug Manufacturing Certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十三条 仿制药申请人应当是药品生产企业，其申请的药品应当与《药品生产许可证》载明的生产范围一致。"
    },
    {
        "instruction":"已知信息：\n'The APS should assess all aseptic operations performed subsequent to the sterilisation and decontamination\ncycles of materials utilised in the process to the point where the container is sealed.'可被翻译为：APS 应评估从工艺所用物料的灭菌和清洁后到容器密封之间进行的所有无菌操作。\n'filling machine'可被翻译为：灌装机\n\n根据上述已知信息，请将'Interventions requiring cessation of filling and\/or extrusion, moulding and sealing and, where required, re-sterilisation of the filling machine should be clearly defined and described in the filling procedure, and included in the APS as relevant (see paragraphs 9.34, 9.35 and 9.36).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"要求停止灌装和\/或挤出、模塑和密封，以及必要时灌装机再灭菌的干预措施，应在灌装程序中明确规定和描述，并包括在 APS 中（如相关）（参见第 9.34 、9.35 和 9.36 节）。"
    },
    {
        "instruction":"已知信息：\n'Drugs that constrict blood vessels and raise blood pressure. Divided into two categories according to their effects: (1) adrenergic receptor agonists, such as epinephrine, norepinephrine, dopamine, ephedrine, mehydroxyamine, etc., can raise blood pressure and can be used in the early stage of shock; (2) Angiotensin amines, that is, pressors and their derivatives, such as phrenopressin.'可被翻译为：使血管收缩而升高血压的药物。按其作用分为两类：①肾上腺素受体激动药，如肾上腺素、去甲肾上腺素、多巴胺、麻黄素、间羟胺等，可以升高血压，可用于休克早期；②血管紧张素胺，即增压素及其衍生物，如苯赖加压素。\n'A class of peptides that have strong effects such as constricting blood vessels and stimulating the secretion of aldosterone by the adrenal cortex. Angiotensinogen is changed to angiotensin I by renin and then to angiotensin n by angiotensin-converting enzyme, which plays an important role in blood pressure regulation and the cause of hypertension.'可被翻译为：一类具有极强的收缩血管和刺激肾上腺皮质分泌醛固酮等作用的肽类物质。血管紧张素原在肾素作用下变为血管紧张素I,然后在血管紧张素转化酶作用下又变为血管紧张素n,在血压调节和高血压病因中起重要作用。\n\n根据上述已知信息，请将'Medications used to correct low blood pressure, such as shock. These include alpha-agonist epinephrines and angiotensin amines that directly contraindicate blood vessels.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用以纠正血压过低(如休克)的治疗药物。包括具有α激动作用的肾上腺素类和直接收缩血管的血管紧张素胺。"
    },
    {
        "instruction":"已知信息：\n'drug information for consumer'可被翻译为：消费者用药信息\n'Information to the user provided on the package label or in the patient information leaflet.'可被翻译为：在包装标签或患者信息单张上提供给用户的信息。\n\n根据上述已知信息，请将'Drug information provided to the patient (consumer) in plain language and manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以通俗的语言和方式，向患者（消费者）提供的药物信息。"
    },
    {
        "instruction":"已知信息：\n'(4) If the application materials are incomplete or do not meet the requirements for format examination, the notification on correcting and supplementing materials of amendments shall be sent to the applicant on the spot or within five days, with all the content needs to be corrected or supplemented at one time. The application materials shall be deemed as accepted since the date of submission if there is no notification after the timeline.'可被翻译为：（四）申请材料不齐全或者不符合形式审查要求的，应当当场或者在五日内发给申请人补正材料通知书，一次性告知申请人需要补正的全部内容，逾期不告知的，自收到申请材料之日起即为受理；\n'Article 60 Where the application materials for change of registry items conform to the requirements, the food and drug regulatory department shall issue the medical device registration alteration document within 10 workdays. Where the application materials are not complete or do not meet the requirements for preliminary review, the food and drug regulatory department shall inform the applicant one-off of all the supplements to be completed.'可被翻译为：第六十条 登记事项变更资料符合要求的，食品药品监督管理部门应当在10个工作日内发给医疗器械注册变更文件。登记事项变更资料不齐全或者不符合形式审查要求的，食品药品监督管理部门应当一次告知需要补正的全部内容。\n\n根据上述已知信息，请将'(III) Where the application materials are incomplete or do not meet the preliminary review requirements, the applicants shall be informed one-off of all the supplements or corrections required within 5 workdays. Where the application is not informed, the application shall be deemed as accepted from the date the application materials are received.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）申报资料不齐全或者不符合形式审查要求的，应当在5个工作日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申报资料之日起即为受理；"
    },
    {
        "instruction":"已知信息：\n'burden of disease'可被翻译为：疾病负担\n'The total number of healthy years lost from onset to death. Years of life lost due to premature death and years of life lost due to disability due to disease are often used to measure the burden of disease.'可被翻译为：从发病到死亡所损失的全部健康年。包括因早亡所致的寿命损失年和疾病所致伤残引起的寿命损失年两部分，经常用于测量疾病负担。\n\n根据上述已知信息，请将'The socio-economic and population health effects of disease. It includes two aspects: epidemiological burden and economic burden of disease.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"疾病对社会经济及人群健康的影响。包括疾病的流行病学负担和经济负担两个方面。"
    },
    {
        "instruction":"已知信息：\n'solubility'可被翻译为：溶解度\n'Excipients in this Law refer to the vehicles and additives used for drug manufacturing and prescription dispensing.'可被翻译为：本法所称辅料，是指生产药品和调配处方时所用的赋形剂和附加剂。\n\n根据上述已知信息，请将'information on solubility of active ingredients, excipients and vehicles;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"活性成分、辅料和载体的溶解度信息；"
    },
    {
        "instruction":"已知信息：\n'Article 56 The State implements a compensation system for adverse reactions of immunization. Where, during or after the immunization process, a vaccine recipient suffers from harm including death, severe disability, organ and tissue damage, etc., compensation shall be given thereto if these conditions are adverse reactions of immunization or the possibility cannot be ruled out. The scope of compensation is subject to catalogue management, and shall be adjusted based on the actual situations.'可被翻译为：第五十六条 国家实行预防接种异常反应补偿制度。实施接种过程中或者实施接种后出现受种者死亡、严重残疾、器官组织损伤等损害，属于预防接种异常反应或者不能排除的，应当给予补偿。补偿范围实行目录管理，并根据实际情况进行动态调整。\n'Before administering vaccines, medical and healthcare professionals shall, in accordance with the prescribed guidance for immunization, examine the vaccine recipient's health status, immunization contraindication, check the immunization certificate, examine the appearance, lot number and expiration date of the vaccine and syringe, and verify the recipient's name and age and the vaccine's name, specifications, dose, injection site and route of administration. Vaccine administration shall only take place after confirmation of information on the recipient, the immunization certificate and the vaccine to be administered.'可被翻译为：医疗卫生人员在实施接种前，应当按照预防接种工作规范的要求，检查受种者健康状况、核查接种禁忌，查对预防接种证，检查疫苗、注射器的外观、批号、有效期，核对受种者的姓名、年龄和疫苗的品名、规格、剂量、接种部位、接种途径，做到受种者、预防接种证和疫苗信息相一致，确认无误后方可实施接种。\n\n根据上述已知信息，请将'Article 52 An adverse reaction of immunization is an adverse drug reaction that causes damage to the vaccine recipient's body tissue, organ and functions during or following the standard process of administering a qualified vaccine, for which no party involved is at fault.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 预防接种异常反应，是指合格的疫苗在实施规范接种过程中或者实施规范接种后造成受种者机体组织器官、功能损害，相关各方均无过错的药品不良反应。"
    },
    {
        "instruction":"已知信息：\n'Drugs that do not require a prescription from a medical practitioner or assistant medical practitioner and that consumers can judge, purchase and use on their own.'可被翻译为：不需要凭执业医师和执业助理医师处方，消费者可以自行判断、购买和使用的药品。\n'These are drugs authorized to be sold only in licensed pharmacies under the supervision of licensed or registered pharmacists; they may be sold without a prescription.'可被翻译为：这是指在持牌或注册药剂师的监督下，只能在持牌药房销售的药物;可以在没有处方的情况下销售。\n\n根据上述已知信息，请将'These are drugs that can be sold from licensed dealers without professional supervision and without prescriptions. These drugs are suitable for self-medication for minor diseases and symptoms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这些药物可以在没有专业监督和处方的情况下从有执照的经销商那里出售。这些药物适合小病小症的自我药疗。"
    },
    {
        "instruction":"已知信息：\n'Standardized Generalized Markup Language. An ISO standard for describing structured information in a platform independent manner.'可被翻译为：标准通用标记语言。以平台无关的方式描述结构化信息的 ISO 标准。\n'Human readable information (HRI) means direct recognition of code by human eyes matching with the medium of machine readable information.'可被翻译为：人工识读，是指与机器识读媒介相对应的，可由人眼直接识别的编码信息。\n\n根据上述已知信息，请将'American Standard Code for Information Interchange. A specification for representing text as computer-readable information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"美国信息交换标准代码。将文本表示为计算机可读的信息规范。"
    },
    {
        "instruction":"已知信息：\n'An intervention that is an integral part of the aseptic process and is required for set-up, routine operation or monitoring (for example, aseptic assembly, container replenishment or environmental sampling). Inherent interventions are required by procedure or work instruction for the execution of the aseptic process.'可被翻译为：是无菌工艺的一个组成部分，是设置、常规操作或监控所必需的干预(例如，无菌装配、容器补充或环境取样)。固有干预措施是无菌工艺执行的程序或作业指导书所要求的。\n'Inherent and corrective interventions representative of the routine process should be performed in a manner and\nfrequency similar to that during the routine aseptic process.'可被翻译为：代表常规工艺的固有性和纠正性干预措施应以与常规无菌工艺类似的方式和频率进行。\n\n根据上述已知信息，请将'Inherent interventions - An intervention that is an integral part of the aseptic process and is required for either set-up,  routine  operation  and\/or  monitoring  (e.g.  aseptic  assembly,  container  replenishment,  environmental sampling). Inherent interventions are required by procedure or work instruction for the execution of the aseptic process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"固有性干预：无菌工艺不可或缺的、在组装、常规操作和\/或监测（例如无菌装配、容器补充、环境采样）中必须要进行的干预措施。关于无菌工艺执行的程序或工作指令要求固有干预。"
    },
    {
        "instruction":"已知信息：\n'To produce intermediates of certain products.'可被翻译为：生产某些产品的中间产物。\n'A complex formed when the molecules of one compound are wholly or partially enclosed in a molecular cavity of another compound.'可被翻译为：由-种化合物分子全部或部分包入另一种化合物分子腔中形成的络合物。\n\n根据上述已知信息，请将'Something else, such as another compound, that is produced in the process of making one thing, such as a compound.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在制作生产某种物品（如某化合物）时附带产生的另外物品（如另一化合物）."
    },
    {
        "instruction":"已知信息：\n'Article 76  Where the drug regulatory departments, health administrative departments and monitoring agencies at all levels and their staff fail to fulfill   responsibilities in accordance with regulations, they shall be penalized in accordance with Article 72 and Article 74 of the Regulations for the Supervision and Administration of Medical Devices.'可被翻译为：第七十六条  各级药品监督管理部门、卫生行政部门、监测机构及其工作人员，不按规定履行职责的，依照《医疗器械监督管理条例》第七十二条和第七十四条的规定予以处理。\n'Article 67 For violation of relevant requirements in the Good Supply Practice for medical devices, the drug regulatory departments shall order rectification within prescribed time limit; if safety and effectiveness of medical device products are influenced, punishment shall be imposed as stipulated in Article 86 of the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第六十七条  违反医疗器械经营质量管理规范有关要求的，由药品监督管理部门责令限期改正；影响医疗器械产品安全、有效的，依照医疗器械监督管理条例第八十六条的规定处罚。\n\n根据上述已知信息，请将'Article 18 Where the instructions and labels fail to comply with the Provisions, punishment shall be imposed by the food and drug regulatory departments at or above the county level according to stipulations of Article 67 of Regulations on Supervision and Administration of Medical Devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十八条 说明书和标签不符合本规定要求的，由县级以上食品药品监督管理部门按照《医疗器械监督管理条例》第六十七条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'A distribution procedure to ensure that the oldest stock is distributed and\/or used before a newer and identical stock item is distributed and\/or used.'可被翻译为：一种分配程序，以确保在分发和\/或使用较新的和相同的库存项目之前分发和\/或使用最旧的库存。\n'A distribution procedure to ensure that the stock with the earliest expiry date is distributed and\/or utilized before an identical stock item with a later expiry date is distributed and\/or utilized.'可被翻译为：一种分配程序，以确保具有最早到期日的库存在具有较晚到期日的相同库存被分配和\/或使用之前被分配和\/或使用。\n\n根据上述已知信息，请将'A distribution procedure to ensure that the oldest stock is distributed and\/or utilized before a newer and identical stock item is distributed and\/or utilized.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种分配程序，以确保较旧的库存在较新的和相同的库存项目分发和\/或使用之前被分发和\/或使用。"
    },
    {
        "instruction":"已知信息：\n'area under the concentration-time curve'可被翻译为：浓度-时间曲线下面积\n'When steady-state plasma concentration is reached, the area under the plasma concentration curve is divided by the quotient of the dosing interval during one dose interval.'可被翻译为：血药浓度达稳态时，在一个剂量间隔时间内，血药浓度一时间曲线下面积除以给药间隔时间的商值。\n\n根据上述已知信息，请将'1.Area Under the Curve\n2.Area under the concentration versus time curve'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"曲线下面积；血药浓度-时间曲线下面积"
    },
    {
        "instruction":"已知信息：\n'Drugs that dilate the function of the pupil. Such as atropine, homatropine, topicamide, etc., often used for fundus examination and optometry.'可被翻译为：有扩大瞳孔功能的药物。如阿托品、后马托品、托吡卡胺等，常用于眼底检查和验光。\n'It is also called \"anticholinesterase drug\". A drug that inhibits the activity of cholinesterase, preventing the hydrolysis of acetylcholine (Ach) released by cholinergic nerve endings and enhancing its M - and N-like effects. According to the rate of hydrolysis after binding to cholinesterase (AchE), it can be divided into two classes: ① reversible cholinesterase inhibitors, such as neostigmine and physostigmine; ② Refractory cholinesterase inhibitors, such as organophosphate esters. Acetylcholinesterase inhibitors that can enter the center, such as galantamine, rivanstigmine, Donepezil, etc., can be used for Alzheimer's disease as symptomatic treatment.'可被翻译为：又称\"抗胆碱酯酶药\"。能抑制胆碱酯酶的活性，使胆碱能神经末梢释放的乙酰胆碱(Ach)免遭水解而加强其M和N样作用的药物。根据与胆碱酯酶(AchE)结合后水解速度的快慢，可分为两类：①易逆性胆碱酯酶抑制药，如新斯的明和毒扁豆碱；②难逆性胆碱酯酶抑制药，如有机磷酸酯类。可进入中枢的乙酰胆碱酯酶抑制药，如加兰他敏、利凡斯的明，多奈哌齐等，可用于阿尔茨海默痴呆症，作为症状性治疗。\n\n根据上述已知信息，请将'The drugs that can make the pupil shrink and the intraocular pressure drop after the application of local eye drops are mostly paracoleceptive agents. Including M receptor agonists and cholinesterase inhibitors, such as pilocarpine, physostigmine, etc., for glaucoma.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"局部滴眼应用后能使瞳孔缩小、眼压下降的药，多为拟副交感受神经药。包括M受体激动药及胆碱酯酶抑制药，如毛果芸香碱、毒扁豆碱等，用于青光眼。"
    },
    {
        "instruction":"已知信息：\n'Article 25 The registrant, filing entity, and contract manufacturer of medical devices shall, in compliance with the requirements of the Good Manufacturing Practice for medical devices, establish and improve the quality management system commensurate with the medical devices manufactured and maintain its effective operation, organize manufacturing in strict accordance with the registered or filed technical specifications for the products, and ensure that the medical devices released from the factory meet the mandatory standards and registered or filed technical specifications for the products.'可被翻译为：第二十五条  医疗器械注册人、备案人、受托生产企业应当按照医疗器械生产质量管理规范的要求，建立健全与所生产医疗器械相适应的质量管理体系并保持其有效运行，并严格按照经注册或者备案的产品技术要求组织生产，保证出厂的医疗器械符合强制性标准以及经注册或者备案的产品技术要求。\n'The legal representative and principal responsible person of the registrant, the filing entity and the contract manufacturer shall assume full responsibility for quality and safety of cosmetics.'可被翻译为：化妆品注册人、备案人、受托生产企业的法定代表人、主要负责人对化妆品质量安全工作全面负责。\n\n根据上述已知信息，请将'Article 27 The registrant, filing entity or contract manufacturer of medical devices shall designate a management representative. The management representative is entrusted by the legal representative or principal responsible person with establishing, implementing and maintaining effective operation of the quality management system, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条  医疗器械注册人、备案人、受托生产企业应当配备管理者代表。管理者代表受法定代表人或者主要负责人委派，履行建立、实施并保持质量管理体系有效运行等责任。"
    },
    {
        "instruction":"已知信息：\n'Manual aseptic processing— An aseptic process where the operator manually compounds, fills, places and \/or seals an open container with sterile product.'可被翻译为：手动无菌工艺：操作人员手动配制、灌装、放置和\/或密封无菌产品敞口容器的无菌工艺。\n'Sterile Product - For purpose of this guidance, sterile product refers to one or more of the  sterilised elements exposed to aseptic conditions and ultimately making up the sterile active substance or finished sterile product. These elements include the containers, closures, and components of the finished drug product. Or, a product that is rendered sterile by a terminal sterilisation process.'可被翻译为：无菌产品：在本指南中，无菌产品指的一种或多种经灭菌、暴露于无菌条件下并最终制成无菌原料药或无 菌成品制剂的要素。这些要素包括容器、密封件和成品制剂的成分。或者，是指通过最终灭菌工艺灭菌的产品。\n\n根据上述已知信息，请将'An aseptic process whereby the operator manually compounds, fills, places or seals an open container with sterile product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"操作人员用无菌产品手动配制、填充、放置或密封一个开放容器的无菌过程。"
    },
    {
        "instruction":"已知信息：\n'In 2019, the total number of registered grassroots users increased by 15.69 percent over the previous year. Among them, the registered grassroots users of registrants, distributors and user units have increased by 41.92 percent, 24.22 percent and 2.28 percent over 2017, respectively.'可被翻译为：2019年，注册基层用户总数比上年增长15.69%。其中，注册人注册基层用户比上年增长41.92%，经营企业和使用单位的注册基层用户分别比上年增长24.22%和2.28%。\n'In 2018, the total number of registered grassroots users increased by 8.87% over2017. It shows that the scope of monitoring of adverse events of medical devices in China has been expanding. Among them, the registered grassroots users of manufacturers,distributors and user units have increased by 16.44%, 11.59% and 4.97% over 2017,respectively (Figure 5) .'可被翻译为：2018年，注册基层用户总数比2017年增长8.87%。显示我国医疗器械不良事件监测范围不断扩大。其中，生产企业、经营企业和使用单位的注册基层用户分别比2017年增长16.44%、11.59%和4.97%(图5)。\n\n根据上述已知信息，请将'In 2020, the total number of registered grassroots users increased by 10.03% compared with the previous year. Among them, the registered grassroots users of registrants, distributors and using units have increased by 38.31%, 11.52% and 3.24% compared with the previous year, respectively.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2020年，注册基层用户总数比上年增长10.03%。其中，注册人注册基层用户比上年增长38.31%，经营企业和使用单位的注册基层用户分别比上年增长11.52%和3.24%。"
    },
    {
        "instruction":"已知信息：\n'sedimentation'可被翻译为：沉降\n'An aerosol made by dispersing solid particles of a drug in a projectile. Its content is a suspended liquid, and the solid particles of the drug are ejected in a haze as the ejector evaporates.'可被翻译为：将药物的固体微粒分散在抛射剂中制成的气雾剂。其内容物属于混悬型液体，喷射时随着抛射剂的挥发药物的固体微粒以烟雾状喷出。\n\n根据上述已知信息，请将'The act of continuous settling of solid particles suspended in a liquid.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"悬浮在液体中的固体颗粒的连续沉降的行为。"
    },
    {
        "instruction":"已知信息：\n'Sub culture SCD broth to general growth medium and incubate aerobically. Streak one plate; incubate aerobically at 22.5 ± 2.5 ºC.'可被翻译为：转接种SCD肉汤至通用生长培养基，并在有氧情况下培养。划线转接种一个培养 碟，在22.5 ± 2.5 ºC有氧情况下培养。\n'Incubation period for THIO and SCD:'可被翻译为：THIO 和 SCD的培养时间\n\n根据上述已知信息，请将'All streaked plates are incubated for a period at least as long as required for growth in original isolation media (THIO or SCD) not to exceed seven days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有划线平板均培养原始分离培养基（THIO或SCD）生长所要求的相同时长，但不 得超过7天。"
    },
    {
        "instruction":"已知信息：\n'Key Points and Determination Principles for Drug Registration Inspection(Drug Clinical Trials)(Trial)'可被翻译为：药品注册核查要点与判定原则(药物临床试验)(试行)\n'In order to ensure the quality of drug registration inspection and to unify the scope of inspection and determination standards, in accordance with the Drug Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and other laws and regulations and related guidelines, the Key Points and Determination Principles of Drug Registration Inspection (Pharmacological and Toxicological study) (Trial) is hereby formulated.'可被翻译为：为保证药品注册核查质量，统一核查范围和判定标准， 根据《中华人民共和国药品管理法》《药品注册管理办法》等 法律法规及相关指导原则，特制定《药品注册核查要点与判定原则(药理毒理学研究)(试行)》。\n\n根据上述已知信息，请将'2.《Key Points and Determination Principles of Drug Registration Inspection(Pharmacological and Toxicological Study)(Trial)》'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. 药品注册核查要点与判定原则（药理毒理学研究）（试行）"
    },
    {
        "instruction":"已知信息：\n'pepsin chiral stationary phase'可被翻译为：胃蛋白酶手性固定相\n'A protein chiral stationary phase covalently bonded by human serum albumin to a diol activated silica gel support using silica gel as a carrier. Used in protein analysis.'可被翻译为：以硅胶为载体，由人血清白蛋白与双醇激活硅胶担体共价键合的一种蛋白质手性固定相。用于蛋白质分析。\n\n根据上述已知信息，请将'A chiral stationary phase of protein prepared by N, v-dissuccinimide binding pepsin to aminopropyl silica gel.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由N,V-二琥珀酰亚胺酯将胃蛋白酶结合在胺丙基硅胶上制备的一种蛋白质手性固定相。"
    },
    {
        "instruction":"已知信息：\n'IV. Under the leadership of the provincial Party Committee and the provincial government, the relevant administrative departments of each province should cooperate with and assist the people's government of the place of origin of Chinese crude drugs to achieve regulated development of Chinese crude drugs, such as improving the working mechanism for high-quality development of Chinese crude drugs industry; formulating the development plan for Chinese medicine materials industry; refining the incentive policies to promote the regulated development of Chinese crude drugs; establishing a standing book and credit archives for TCM manufacturers and their manufacturing bases to implement dynamic supervision; and establishing an information platform for regulated manufacturing and traceability for Chinese crude drugs. Provinces with a better basis for regulated and intensive manufacturing of Chinese crude drugs are encouraged to study and formulate implementation rules based on the actual development of Chinese crude drugs in the areas under their jurisdiction, and make active exploration and promotion, so as to accumulate experiences for further promotion of the GAP.'可被翻译为：四、各省相关管理部门在省委省政府领导下，配合和协助中药材产地人民政府做好中药材规范化发展工作，如完善中药材产业高质量发展工作机制；制定中药材产业发展规划；细化推进中药材规范化发展的激励政策；建立中药材生产企业及其生产基地台账和信用档案，实施动态监管；建立中药材规范化生产追溯信息化平台等。鼓励中药材规范化、集约化生产基础较好的省份，结合本辖区中药材发展实际，研究制定实施细则，积极探索推进，为本规范的深入推广积累经验。\n'Article 6 The drug regulatory departments shall strengthen cooperation with relevant departments, give full play to the role of industry organizations and other institutions, promote the construction of credit system, and promote social co-governance.'可被翻译为：第六条 药品监督管理部门应当与相关部门加强协作，充分发挥行业组织等机构的作用，推进信用体系建设，促进社会共治。\n\n根据上述已知信息，请将'VI. The relevant administrative departments of each province should strengthen cooperation to form a joint force, jointly promote the regulated, standardized and intensive development of Chinese crude drugs, enhance publicity and training according to their responsibilities, and promote the implementation of the GAP. The relevant administrative departments of each province should strengthen the routine supervision during the implementation. In case identifying any major problems or suggestions on the improvement of major policies, please report to the corresponding management department of the State intime.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"六、各省相关管理部门应加强协作，形成合力，共同推进中药材规范化、标准化、集约化发展，按职责强化宣传培训，推动本规范落地实施。加强实施中日常监管，如发现存在重大问题或者有重大政策完善建议的，请及时报告国家相应的管理部门。"
    },
    {
        "instruction":"已知信息：\n'Imported starting materials should comply with importation regulations.'可被翻译为：进口原辅料应当符合国家相关的进口管理规定。\n'Article 61 Cosmetics of which the last process touching the contents completes in China are domestic products, and those that completes overseas are imported products. Those that completes in Taiwan, Hong Kong SAR and Macau SAR shall be regulated by the reference of imported products.'可被翻译为：第六十一条 化妆品最后一道接触内容物的工序在境内完成的为国产产品，在境外完成的为进口产品，在中国台湾、香港和澳门地区完成的参照进口产品管理。\n\n根据上述已知信息，请将'For products used in conjunction or combination products that apply for registration or file for filing under one product name, if any of the last process touching the contents are produced overseas, the set shall be regulated as imported products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以一个产品名称申请注册或者进行备案的配合使用产品或者组合包装产品，任何一剂的最后一道接触内容物的工序在境外完成的，按照进口产品管理。"
    },
    {
        "instruction":"已知信息：\n'Article 24 If the lot release institution believes that relevant data in the application dossiers needs to be verified or supplemented, it shall notify the lot release applicant of supplementing data in writing and specify the time limit for reply.'可被翻译为：第二十四条 批签发机构认为申请资料中的有关数据需要核对或者补充的，应当书面通知批签发申请人补正资料，并明确回复时限。\n'The lot release institution, under the premise of guaranteeing independence of dossier review, sample test and other technical review work, may communicate with the lot release applicant about specific problems requiring explanation in the lot release process.'可被翻译为：批签发机构在保证资料审核和样品检验等技术审查工作独立性的前提下，可就批签发过程中需要解释的具体问题与批签发申请人进行沟通。\n\n根据上述已知信息，请将'Article 24 The lot release institution, under the premise of guaranteeing independence of dossier review, sample testing and other technical review work, may communicate with the lot release applicant about specific issues requiring explanation in the lot release process. Verification can be carried out through telephone communication, written notice and other forms, and on-site verification can be carried out if necessary. If it is necessary for the lot release applicant to provide explanations or supplement materials, a written notice shall be given and the time limit for reply shall be specified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十四条    批签发机构在保证资料审核和样品检验等技术审查工作独立性的前提下，可就批签发过程中需要解释的具体问题与批签发申请人进行沟通核实。核实工作可通过电话沟通、书面通知等形式进行，必要时可开展现场核实。需要批签发申请人提供说明或者补充资料的，应当书面通知，并明确回复时限。"
    },
    {
        "instruction":"已知信息：\n'finished pharmaceutical product (FPP). A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more active pharmaceutical ingredients (APIs). In some cases, it may be in combination with a medical device.'可被翻译为：制剂成品（FPP） 经过了所有生产步骤包括包装在最终容器中并贴上标签的产品。一种FPP可包括一种或多种API。有时可能会与医疗器械的组合。\n'A product which has undergone all stages of production, including packaging in its final container.'可被翻译为：已完成所有生产操作步骤和最终包装的产品。\n\n根据上述已知信息，请将'A product that has undergone all stages of production, including packaging in its ﬁnal container and labelling. A finished pharmaceutical product may contain one or more APIs. In some cases, it may be in combination with a medical device.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经过所有生产阶段的产品，包括最终容器的包装和标签。药品成品可能含有一种或多种原料药。在某些情况下，它可能与医疗器械结合使用。"
    },
    {
        "instruction":"已知信息：\n'For a filed medical device, the food and drug regulatory department shall make filing certificates according to the format in relevant requirements and publish the information from the filing information form for medical device on their website.'可被翻译为：对备案的医疗器械，食品药品监督管理部门应当按照相关要求的格式制作备案凭证，并将备案信息表中登载的信息在其网站上予以公布。\n'Article 69 For a filed in-vitro diagnostic reagent, where the contents set forth in the filing information form for in-vitro diagnostic reagent changed, the filing entity shall submit a description of the change and related supporting documents to the original filing department and apply for change of filing. Where the filing materials meet the formal requirements, the food and drug regulatory department shall put the changes in the information of changes, and file a record.'可被翻译为：第六十九条 已备案的体外诊断试剂，备案信息表中登载内容及备案的产品技术要求发生变化的，备案人应当提交变化情况的说明及相关证明文件，向原备案部门提出变更备案信息。备案资料符合形式要求的，食品药品监督管理部门应当将变更情况登载于变更信息中，将备案资料存档。\n\n根据上述已知信息，请将'For a filed in-vitro diagnostic reagent, the food and drug regulatory department shall make filing certificates according to the format in relevant requirements and publish the information from the filing information form for medical device on their website.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对备案的体外诊断试剂，食品药品监督管理部门应当按照相关要求的格式制作备案凭证，并将备案信息表中登载的信息在其网站上予以公布。"
    },
    {
        "instruction":"已知信息：\n'For the filing of class I in-vitro diagnostic reagent, the filing entity may submit the product self-testing report.'可被翻译为：办理第一类体外诊断试剂备案的，备案人可以提交产品自检报告。\n'To apply for filing of import class I medical devices, the filing entity shall submit the filing documents to China Food and Drug Administration.'可被翻译为：进口第一类医疗器械备案，备案人向国家食品药品监督管理总局提交备案资料。\n\n根据上述已知信息，请将'For the filing of class I medical device, the filing entity may submit the product self-testing report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"办理第一类医疗器械备案的，备案人可以提交产品自检报告。"
    },
    {
        "instruction":"已知信息：\n'Due to the conformation of the molecule leads to the influence on the physical properties, chemical reaction characteristics and biological activity.'可被翻译为：由于分子的构象导致对物理特性、化学反应特征和生物活性的影响。\n'ground state'可被翻译为：基态\n\n根据上述已知信息，请将'According to the conformation distribution of the ground state and transition state of a compound, the influence on the physical and chemical behavior and biological activity of the compound is studied.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据一个化合物的基态、过渡态的构象分布，研究对该化合物物理、化学行为和生物活性的影响。"
    },
    {
        "instruction":"已知信息：\n'The entire process of a new drug from laboratory research to marketing and expansion of clinical application. It involves many disciplines such as pharmacy, pharmacology, toxicology, drug analysis, pharmacodynamics and clinical medicine.'可被翻译为：新药从实验室研究到上市、扩大临床应用的整个过程。涉及药剂学、药理学、毒理学、药物分析、药物动力及临床医学等诸多学科。\n'Article 21 Pre-clinical drug study for drug registration application includes drug synthetic processes, extraction methods, physical and chemical properties, purity, selection of dosage form, screening of formula, preparing processes, testing methods, quality specifications, stability, pharmacology, toxicology and animal pharmacokinetics, etc. For traditional Chinese medicine preparations, in addition to the above-mentioned items, pre-clinical drug study also includes the study in the source of the crude drugs, and of their pre-treatment and processing, etc. For biological products, it also includes study on the source, quality specifications, storage conditions, biological characteristics and genetic stability of the starting materials such as bacterial and viral seeds\/strains, cell lines, bio-tissues, and immunological study, etc.'可被翻译为：第二十一条 为申请药品注册而进行的药物临床前研究，包括药物的合成工艺、提取方法、理化性质及纯度、剂型选择、处方筛选、制备工艺、检验方法、质量指标、稳定性、药理、毒理、动物药代动力学研究等。中药制剂还包括原药材的来源、加工及炮制等的研究；生物制品还包括菌毒种、细胞株、生物组织等起始原材料的来源、质量标准、保存条件、生物学特征、遗传稳定性及免疫学的研究等。\n\n根据上述已知信息，请将'A series of laboratory studies carried out to prepare a proposed new drug for clinical trials. It includes synthetic process, extraction method, physicochemical properties and purity, prescription screening, preparation process, test method, quality index, stability, pharmacology and toxicology, animal pharmacokinetics, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为拟开发的新药用于临床试验而开展的一系列实验室研究工作的总称。包括合成工艺、提取方法、理化性质及纯度、处方筛选、制备工艺、检验方法、质量指标、稳定性、药理毒理、动物药动学等。"
    },
    {
        "instruction":"已知信息：\n'Article 58 If in violation of Paragraph 1 of Article 17, Article 18 and Paragraph 1 of Article 19 of these Provisions, the cosmetic manufacturer changes its licensing conditions, or needs to change the items stated on the License, but fails to apply for changes as the drug regulatory department issued former license shall order it to make rectification, give warning to it, and impose a fine of not less than RMB 10,000 and not more than RMB 30,000.'可被翻译为：第五十八条 违反本办法第十七条、第十八条第一款、第十九条第一款，化妆品生产企业许可条件发生变化，或者需要变更许可证载明的事项，未按规定申请变更的，由原发证的药品监督管理部门责令改正，给予警告，并处1万元以上3万元以下罚款。\n'Article 60 If in violation of Paragraph 3 of Article 42 of these Provisions, the organizer of a trade fair fails to report the basis information on the trade fair to the department in charge of drug supervision and administration where it is located as required, the department in charge of drug supervision and administration shall order it to make rectification and give warning to it; if refusing to making rectification, the department shall impose a fine of not less than RMB 5,000 and not more than RMB 30,000.'可被翻译为：第六十条 违反本办法第四十二条第三款，展销会举办者未按要求向所在地负责药品监督管理的部门报告展销会基本信息的，由负责药品监督管理的部门责令改正，给予警告；拒不改正的，处5000元以上3万元以下罚款。\n\n根据上述已知信息，请将'If in violation of Paragraph 2 of Article 19 of these Provisions, the person in charge of quality and safety and the reserved contact information are changed, without reporting to related department as required, the drug regulatory department issued former license shall order the applicant to make rectification; if refusing to make rectification, the department shall give warning, and impose a fine of not more than RMB 5,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"违反本办法第十九条第二款，质量安全负责人、预留的联系方式发生变化，未按规定报告的，由原发证的药品监督管理部门责令改正；拒不改正的，给予警告，并处5000元以下罚款。"
    },
    {
        "instruction":"已知信息：\n'The crude drug importers shall be the marketing authorization holders (MAHs) of Chinese patent medicines, manufacturers of TCMs and drug distributors with the business scope covering Chinese crude drugs or Prepared Slices within the territory of China.'可被翻译为：药材进口单位，应当是中国境内的中成药上市许可持有人、中药生产企业，以及具有中药材或者中药饮片经营范围的药品经营企业。\n'I. The GAP is applicable to the whole process management of regulated manufacturing of Chinese crude drugs by Chinese crude drugs manufacturers, and is the basic requirement of regulated manufacturing and management of Chinese crude drugs. The Chinese crude drugs in the GAP refer to the medicinal raw materials derived from medicinal plants, medicinal animals and other resources and used for the manufacturing of prepared slices of Chinese crude drugs and preparations after standardized planting (including ecological planting, wild cultivation and imitated wild cultivation), breeding, harvesting and processing in the manufacturing place.'可被翻译为：一、本规范适用于中药材生产企业规范生产中药材的全过程管理，是中药材规范化生产和管理的基本要求。本规范涉及的中药材是指来源于药用植物、药用动物等资源，经规范化的种植（含生态种植、野生抚育和仿野生栽培）、养殖、采收和产地加工后，用于生产中药饮片、中药制剂的药用原料。\n\n根据上述已知信息，请将'Chinese crude drugs manufacturers in this announcement include planting and breeding specialized cooperatives or cooperatives with the nature of an enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本公告所指中药材生产企业包括具有企业性质的种植、养殖专业合作社或联合社。"
    },
    {
        "instruction":"已知信息：\n'An indicator of statistical analysis that shows how closely two phenomena are related to each other.'可被翻译为：说明两个现象之间相互关系密切程度的统计分析指标。\n'The quantitative relationship between the structure of a series of compounds and their biological activity is investigated using theoretical calculations and statistical analysis methods.'可被翻译为：利用理论计算和统计分析方法研究系列化合物结构与生物活性之间所存在的定量关系。\n\n根据上述已知信息，请将'A method of statistical analysis that determines a quantitative relationship of interdependence between two or more variables.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"确定两种或两种以上变数间相互依赖的定量关系的一种统计分析方法。"
    },
    {
        "instruction":"已知信息：\n'Article 73 Prescriptions dispensed by pharmacists or other drug professionals who are qualified in accordance with the law shall be checked, and no drugs listed in the prescriptions may be changed or substituted without authorization. The pharmacists shall refuse to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.'可被翻译为：第七十三条 依法经过资格认定的药师或者其他药学技术人员调配处方，应当进行核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。\n'Article 58 Drug distributors shall retail drugs properly and include an accurate description of dosage and administration and precautions. Prescriptions for dispensing shall be checked, and no drugs listed in the prescription may be changed or substituted without authorization. Requests to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.'可被翻译为：第五十八条 药品经营企业零售药品应当准确无误，并正确说明用法、用量和注意事项；调配处方应当经过核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。\n\n根据上述已知信息，请将'(I) Prescription can be dispensed only after being audited by licensed pharmacists. The drugs listed in the prescription shall not be altered or substituted without authorization. The dispensing of prescriptions with incompatibility or overdose shall be refused; however, those may be dispensed after being corrected or re-signed by the prescriber. After the dispensing of prescription, the drugs can be sold only after being checked;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）处方经执业药师审核后方可调配；对处方所列药品不得擅自更改或者代用，对有配伍禁忌或者超剂量的处方，应当拒绝调配，但经处方医师更正或者重新签字确认的，可以调配；调配处方后经过核对方可销售。"
    },
    {
        "instruction":"已知信息：\n'Article 39 Any food and drug regulatory department, or lot release institution or its staff members that violate the provisions herein and in case of any of the circumstances below shall be ordered by its superior administrative authority or supervisory authority to make rectification. If the circumstances are serious, administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law:'可被翻译为：第三十九条 食品药品监督管理部门、批签发机构及其工作人员违反本办法规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n'Article 162 Any drug regulatory department that constitutes any of the following circumstances in the process of drug registration shall be instructed by its superior administrative department or supervisory departments to make rectification, and administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible by law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第一百六十二条 药品监督管理部门在药品注册过程中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任：\n\n根据上述已知信息，请将'Article 40 Any food and drug regulatory department, or lot release institution or its staff members that constitutes any of the following circumstances in the lot release work shall be ordered by its superior administrative authority or supervisory authority to make rectification, and administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law; if a crime is committed, criminal liabilities shall be investigated by law:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十条 食品药品监督管理部门、批签发机构及其工作人员在批签发工作中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任："
    },
    {
        "instruction":"已知信息：\n'Article 49 During the drug review process, where on-site inspection is needed due to the circumstances such as the authenticity of the application dossiers is in doubt or reports with confirmed evidence are received, the CDE shall initiate for-cause inspection and, when necessary, sampling and testing shall be performed.'可被翻译为：第四十九条 药品审评中心在审评过程中，发现申报资料真实性存疑或者有明确线索举报等，需要现场检查核实的，应当启动有因检查，必要时进行抽样检验。\n'(2) when the application dossier is found false in the process of registration, and the applicant cannot prove the authenticity thereof;'可被翻译为：（二）在注册过程中发现申报资料不真实，申请人不能证明其申报资料真实的；\n\n根据上述已知信息，请将'Article 58 During the drug review and inspection process, where it is found that the authenticity of the application dossier is in doubt or reports with confirmed evidence are received, when necessary, sampling and testing shall be performed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条 在药品审评、核查过程中，发现申报资料真实性存疑或者有明确线索举报，或者认为有必要进行样品检验的，可抽取样品进行样品检验。"
    },
    {
        "instruction":"已知信息：\n'Numerical factor used in a quantitative risk assessment to represent or allow for the extrapolation, uncertainty, or variability of an observed exposure concentration and its associated health outcome in a particular laboratory species or exposed population to an exposure concentration for the target population (for example, from animals to human patients and short-term exposure to chronic exposure) that would be associated with the same delivered dose. Adjustment factors can also be used when dealing with clinical data, e.g.  when a study population is not representative of the general population.'可被翻译为：定量风险评估中使用的数值因子，用于表示或允许在特定实验室物种或暴露人群中观察到的暴露浓度及其相关健康结果的外推、不确定性或可变性，这些暴露浓度将与相同的给药剂量相关(例如，从动物到人类患者以及从短期暴露到慢性暴露)。在处理临床数据时也可以使用调整因子，例如，当研究人群不能代表一般人群时。\n'Since humans are more sensitive to the toxic reactions of most chemical poisons than animals, there are many uncertainties in the process of extrapolating the results of animal experiments to humans, which will cause errors. Especially in mg\/kg body weight to indicate the dose is even more so, so in the calculation, the experimental animal should not observe the harmful effect dose or observed harmful effect of the lowest dose to reduce a certain multiple to correct the error, to ensure safety.'可被翻译为：由于人对于大多数化学毒物的毒性反应要比动物敏感，在把动物实验结果向人外推的过程中，存在许多不确定因素，会造成误差。尤其是以mg\/kg体重表示剂量时更是如此，故在计算时，应该把实验动物的未观察到的有害作用剂量或观察到的有害作用的最低剂量缩小一定倍数来校正误差，确保安全。\n\n根据上述已知信息，请将'A factor set to eliminate the uncertainties involved in determining the adverse effects of an evaluated chemical on a large population by extrapolating data from animal trials to humans, or from small-population surveys. It is used to establish standards for the control of chemicals to ensure the safety of exposed populations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在以动物试验数据外推到人，或以小范围人群调查结果判断所评价的化学品对大范围人群的有害作用时，为排除所涉及的不确定因素而设定的系数。用于制定化学品控制标准，以保证接触人群的安全。"
    },
    {
        "instruction":"已知信息：\n'NMPA Issued the Administrative Measures for Drug Quality Sampling Inspection'可被翻译为：国家药监局关于印发药品质量抽查检验管理办法的通知\n'To strengthen medical device administration and standardize the sampling inspection of medical device quality, NMPA has organized the revision of and released on March 13, 2020 the Administrative Measures for Sampling Inspection of Medical Device Quality. The Administrative Regulations on Quality Supervision and Sampling Inspection of Medical Devices (CFDA Department of Medical Device Supervision [2013] No. 212) and the Work Procedures for National Medical Device Sampling Inspection (CFDA General Office [2014] No. 213) issued by the former China Food and Drug Administration shall be repealed simultaneously.'可被翻译为：为加强医疗器械监督管理，规范医疗器械质量抽查检验工作，国家药监局于2020年3月13日组织修订并发布了《医疗器械质量抽查检验管理办法》。原国家食品药品监督管理总局发布的《医疗器械质量监督抽查检验管理规定》（食药监械监〔2013〕212号）和《国家医疗器械抽查检验工作程序》（食药监办〔2014〕213号）同时废止。\n\n根据上述已知信息，请将'NMPA Issued the Administrative Measures for Sampling Inspection of Medical Device Quality'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于印发医疗器械质量抽查检验管理办法的通知"
    },
    {
        "instruction":"已知信息：\n'Article 27 If the registrant or filing entity of medical devices sells its registered and filed medical devices at its domicile or manufacturing address, it does not need to apply for Medical Device Distribution License or filing, but shall meet the prescribed distribution conditions; if it stores and sells the medical devices in other places, it shall apply for Medical Device Distribution License or filing as stipulated.'可被翻译为：第二十七条  医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存并销售医疗器械的，应当按照规定办理医疗器械经营许可或者备案。\n'Class III medical device distribution shall be subject to licensing management; Class II medical device distribution shall be subject to filing management, while Class I medical device distribution could be carried out without licensing or filing.'可被翻译为：经营第三类医疗器械实行许可管理，经营第二类医疗器械实行备案管理，经营第一类医疗器械不需要许可和备案。\n\n根据上述已知信息，请将'Medical device sold by its registrant and filing applicant at their residence or manufacturing site may not apply for medical device distribution licensing or filing, but shall comply with the specified distribution conditions; for Class II and Class III medical devices stored and sold at other sites, application for medical device distribution licensing or filing shall be made as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存、销售第二、三类医疗器械的，应当按照规定办理医疗器械经营许可或者备案。"
    },
    {
        "instruction":"已知信息：\n'The process by which one or more blood components are selectively obtained from a donor by withdrawing whole blood, separating it by centrifugation and\/or filtration into its components, and returning those not required to the donor.'可被翻译为：从献血者身上选择性地提取一种或多种血液成分的过程，通过离心和\/或过滤将其分离到其成分中，并将不需要的成分返回给献血者。\n'The liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and\/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.'可被翻译为：从含有抗凝剂的容器中收集的血液中分离细胞成分后，或在单采过程中通过抗凝血的连续过滤和\/或离心分离，用于进一步生产的人体血液的液体部分。\n\n根据上述已知信息，请将'The procedure whereby a single donation of blood is collected in an anticoagulant and\/or stabilizing solution, under conditions designed to minimize microbial contamination, cellular damage and\/or coagulation activation of the resulting blood donation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单次献血的血液在抗凝和\/或稳定溶液中收集的过程，在设计的条件下尽量减少微生物污染、细胞损伤和\/或由此产生的献血的凝血激活。"
    },
    {
        "instruction":"已知信息：\n'Article 1 These Provisions are formulated in accordance with the Standardization Law of the People's Republic of China, the Regulations for the Implementation of the Standardization Law of the People's Republic of China and the Regulations for the Supervision and Administration of Medical Devices as well as other laws and regulations to promote progress in science and technology, ensure the safety and effectiveness of medical devices, improve health care and enhance medical device standards administration.'可被翻译为：第一条 为促进科学技术进步，保障医疗器械安全有效，提高健康保障水平，加强医疗器械标准管理，根据《中华人民共和国标准化法》《中华人民共和国标准化法实施条例》和《医疗器械监督管理条例》等法律法规，制定本办法。\n'Article 2 The registration and filing activities of cosmetics and new cosmetic ingredients and their supervision and administration within the territory of the People's Republic of China shall comply with these Provisions.'可被翻译为：第二条 在中华人民共和国境内从事化妆品和化妆品新原料注册、备案及其监督管理活动，适用本办法。\n\n根据上述已知信息，请将'Article 3 The formulation and revision, implementation, supervision and administration of medical device standards within the territory of the People’s Republic of China shall conform to laws, administrative regulations and these Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条 在中华人民共和国境内从事医疗器械标准的制修订、实施及监督管理，应当遵守法律、行政法规及本办法的规定。"
    },
    {
        "instruction":"已知信息：\n'(II) Class II products'可被翻译为：（二）第二类产品\n'(I) Class I products'可被翻译为：（一）第一类产品\n\n根据上述已知信息，请将'Products not clearly defined as class I and class III products are class II products, mainly including:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除已明确为第一类、第三类的产品，其他为第二类产品，主要包括："
    },
    {
        "instruction":"已知信息：\n'ai-acid glycoprotein chiral stationary phase'可被翻译为：5酸性糖蛋白手性固定相\n'cellulose-based chiral stationary phase'可被翻译为：纤维素型手性固定相\n\n根据上述已知信息，请将'A chiral stationary phase of polymers prepared by coating phase and bonding phase of photoactive amino acids or pipercoic acid as chiral selective factors, which is mainly used for the analysis of amino acids and their derivatives.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以光活性氨基酸或哌可酸作为手性选择因子的涂渍相和键合相制备的，主要用于氨基酸及其衍生物分析的一种高聚物手性固定相。"
    },
    {
        "instruction":"已知信息：\n'pharmaceutical marketing'可被翻译为：医药营销学\n'Apply the principles and methods of sociology and behavioral science to study the discipline of human behavior in pharmaceutical practice.'可被翻译为：应用社会学和行为科学的原理和方法，研究药学实践中人的行为学科。\n\n根据上述已知信息，请将'An applied discipline that applies marketing principles, methods, and strategies to the study of the characteristics and needs of the pharmaceutical market, and how to provide pharmaceutical products and services to meet those needs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应用市场营销学原理、方法和策略，研究医药市场特征、需求，以及如何提供医药产品和服务满足需求的一门应用性学科。"
    },
    {
        "instruction":"已知信息：\n'The additive or synergistic effect produced by the combination of drugs with identical properties of action.'可被翻译为：作用性质相同药物的联合应用，产生的相加或协同效应。\n'In the analysis of variance, if a measurement result is affected by multiple factors at the same time, the sum of the squares of the total deviation is equal to the sum of the squares of the experimental error and the deviation formed by various factors, the total degree of freedom is equal to the sum of the degrees of freedom, the total variance is equal to the sum of the variance of each part, which is called addivity.'可被翻译为：在方差分析中，如果-个测定结果同时受到多个因素的影响，总偏差平方和等于实验误差与各因素所形成的偏差平方和之总和，总自由度等于各项自由度之和，总方差等于各部分方差之和，此称为加和性。\n\n根据上述已知信息，请将'The action of two or more drugs is equal to the sum of the separate actions of each chemical compound.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"两种以上药物作用等于每一种化合物质单独作用的总和。"
    },
    {
        "instruction":"已知信息：\n'A WHO-type certificate of the form described in Guidelines for implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Geneva,World Health Organization, 1998.'可被翻译为：在国际贸易中流通的药品质量WHO认证计划实施指南中所述形式的世卫组织类型证书。日内瓦，世界卫生组织，1998年。\n'2. WHO guidelines on good manufacturing practices for pharmaceutical products: main principle. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: forty-eighth report. Geneva: World Health Organization; 2014: Annex 2 (WHO Technical Report Series, No. 986; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/TRS986annex2.p df? ua=1, accessed 30 November 2020).'可被翻译为：WHO 药品GMP指南：总则，WHO TRS986附录2，2014\n\n根据上述已知信息，请将'A certificate of pharmaceutical product of the type defined in the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce* .\n\n*World Health Organization. WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Geneva, World Health Organization, 2000 WHO\/EDM\/QSM\/2000.2.\n(http:\/\/www.who.int\/medicines\/organization\/qsm\/activities\/drugregul\/certification\/certifschemes. html).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在国际贸易中流通的药品质量世界卫生组织认证计划中定义的药品类型的证书*。\n\n*世界卫生组织。在国际贸易中流通的药品质量世界卫生组织认证计划。日内瓦，世界卫生组织，2000年，世界卫生组织\/EDM\/QSM\/2000.2。\n(http:\/\/www.who.int\/medicines\/organization\/qsm\/activities\/drugregul\/certification\/certifschemes。html)。"
    },
    {
        "instruction":"已知信息：\n'A location within the aseptic processing area in which product and critical surfaces are exposed to the environment.'可被翻译为：无菌加工区内产品和关键表面暴露在环境中的位置。\n'The design of the technology and processes used should ensure appropriate conditions are maintained in the critical zone to protect the exposed product during operations.'可被翻译为：所用技术和工艺的设计应确保在关键区域维持适当的条件，从而保护操作期间暴露的产品。\n\n根据上述已知信息，请将'Critical zone - A location within the aseptic processing area in which product and critical surfaces are exposed to the environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"关键区：位于无菌工艺区内的、产品和关键表面暴露于其中的位置。"
    },
    {
        "instruction":"已知信息：\n'A drug that excites the central nervous system function and improves brain activity function. According to the site of action can be divided into excitatory cerebral cortex drugs, such as xanthine derivatives, such as caffeine, theophylline; Excitatory medullary respiratory center drugs, such as nicoxal rice; Drugs that excite the spinal cord, such as strychnine; And intelligence-boosting drugs that promote brain cell metabolism and improve brain function, such as piracetam.'可被翻译为：具有兴奋中枢神经系统功能，提高脑活动功能的药物。按照作用部位可分为兴奋大脑皮质的药物，如黄嘌吟衍生物，如咖啡因、茶碱等；兴奋延髓呼吸中枢的药物，如尼可刹米等；兴奋脊髓的药物，如士的宁；促进脑细胞代谢、改善脑功能的智能促进药物如吡拉西坦等。\n'The antagonistic action is mainly, and there is a certain intrinsic activity, that is, the effect of activating the receptor.'可被翻译为：以拮抗作用为主，还有一定内在活性，即激动受体的效应的药物。\n\n根据上述已知信息，请将'Drugs that can selectively act on the cerebral cortex and have the effect of activating, protecting and restoring the function of nerve cells. Such as piracetam and vincristine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"能选择性地作用于大脑皮质，对神经细胞具有激活、保护和恢复功能效应的药物。如吡拉西坦和长春胺等。"
    },
    {
        "instruction":"已知信息：\n'Article 48 In accordance with degree of risks of the products and enterprise, the drug regulatory department shall make graded management of the registrant, filing entity or contract manufacturer of medical devices as well as dynamic adjustment.'可被翻译为：第四十八条  药品监督管理部门依据产品和企业的风险程度，对医疗器械注册人、备案人、受托生产企业实行分级管理并动态调整。\n'Article 4 Medical device distribution is subject to classified management in accordance with their degree of risks.'可被翻译为：第四条  按照医疗器械风险程度，医疗器械经营实施分类管理。\n\n根据上述已知信息，请将'Article 47 The drug regulatory departments shall implement classified and graded management and make dynamic adjustment in accordance with quality management of the medical device distributors and degree of risk of the distributed medical device products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条  药品监督管理部门根据医疗器械经营企业质量管理和所经营医疗器械产品的风险程度，实施分类分级管理并动态调整。"
    },
    {
        "instruction":"已知信息：\n'Article 63 Terms used in these Provisions are defined as follows:'可被翻译为：第六十三条 本办法下列用语的含义：\n'Glossary'可被翻译为：术语表\n\n根据上述已知信息，请将'Article 312: Glossary:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三百一十二条 本规范下列术语（按汉语拼音排序）的含义是："
    },
    {
        "instruction":"已知信息：\n'Review and re-check results shall be fed back to MAHs. In case of any objection to the evaluation results of MAHs, MAHs may be required to carry out re-evaluation again.'可被翻译为：审核和复核结果应当反馈持有人。对持有人的评价结果存在异议的，可以要求持有人重新开展评价。\n'Where the drug regulatory departments have objection to the re-evaluation conclusions by MAHs, which shall, in accordance with the requirements by drug regulatory departments, re-confirm the re-evaluation conclusions and carry out re-evaluation.'可被翻译为：药品监督管理部门对持有人开展的再评价结论有异议的，持有人应当按照药品监督管理部门的要求重新确认再评价结果或者重新开展再评价。\n\n根据上述已知信息，请将'Article 55 In case of any of following situations, MAHs shall voluntarily carry out re-evaluation and take corresponding measures based on re-evaluation conclusions:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十五条  有下列情形之一的，持有人应当主动开展再评价，并依据再评价结论，采取相应措施："
    },
    {
        "instruction":"已知信息：\n'Article 5    The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.'可被翻译为：第五条 药品说明书和标签的文字表述应当科学、规范、准确。非处方药说明书还应当使用容易理解的文字表述，以便患者自行判断、选择和使用。\n'Section 3  Drug Name, Insert Sheet and Label'可被翻译为：第三节 药品名称、说明书和标签\n\n根据上述已知信息，请将'The applicant shall be responsible for making the drug insert sheet and label scientific, standard and accurate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申请人应当对药品说明书和标签的科学性、规范性与准确性负责。"
    },
    {
        "instruction":"已知信息：\n'Article 28 If a medical device manufacturer violates laws, regulations and rules and causes defects in the marketed medical devices, administrative penalties shall be imposed according to law. For the manufacturer who has taken recall measures to initiatively eliminate or reduce the harmful consequences, the food and drug regulatory department shall impose a lighter or mitigated penalty according to the Law of the People's Republic of China on Administrative Penalty; for the manufacturer who has committed minor violations and made prompt corrections but has not caused any serious consequences, the punishment shall be exempted.'可被翻译为：第二十八条 医疗器械生产企业因违反法律、法规、规章规定造成上市医疗器械存在缺陷，依法应当给予行政处罚，但该企业已经采取召回措施主动消除或者减轻危害后果的，食品药品监督管理部门依照《中华人民共和国行政处罚法》的规定给予从轻或者减轻处罚；违法行为轻微并及时纠正，没有造成危害后果的，不予处罚。\n'Severe and well-placed punishment for serious violations of the law'可被翻译为：严惩重处违法 落实处罚到人\n\n根据上述已知信息，请将'Article 75 MAHs, distributing enterprises and user facility report, investigate, evaluate and dispose medical device adverse events in accordance with the requirements of the Provisions to proactively eliminate or reduce serious consequence, they shall impose a lighter or mitigated punishment for the relevant violations in accordance with Law of the People's Republic of China on Administrative Penalties, and impose no punishment for those having mild violations and making timely correction without causing serious consequences but are not exempt from other legal liabilities according to laws.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十五条  持有人、经营企业、使用单位按照本办法要求报告、调查、评价、处置医疗器械不良事件，主动消除或者减轻危害后果的，对其相关违法行为，依照《中华人民共和国行政处罚法》的规定从轻或者减轻处罚。违法行为轻微并及时纠正，没有造成危害后果的，不予处罚，但不免除其依法应当承担的其他法律责任。"
    },
    {
        "instruction":"已知信息：\n'Cephalin that eliminates the acyl group on 7-amides.'可被翻译为：消去7-位酰胺基上酰基的头抱菌素。\n'penicillin'可被翻译为：青霉素\n\n根据上述已知信息，请将'Penicillin with the elimination of the 6-amide-superacyl group.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"消去6-位酰胺基上酰基的青霉素。"
    },
    {
        "instruction":"已知信息：\n'The monitoring  of grade A  should  demonstrate the maintenance  of aseptic processing  conditions  during critical operations. Monitoring should be performed at locations posing the highest risk of contamination to the sterile  equipment  surfaces,  containers,  closures  and  product.  The  selection  of  monitoring  locations  and  the orientation and positioning of sampling devices should be justified and appropriate to obtain reliable data from the critical zones.'可被翻译为：A 级区的监测应证明在关键操作中都维持了无菌工艺条件。监测位置应为对无菌设备表面、容器、密封件 和产品造成最高污染风险的位置。监测位置的选择以及取样装置的定位和放置应证明合理，适合从关键区域获取可靠的数据。\n'The unwrapping, assembly and preparation of sterilised equipment, components and ancillary items with\ndirect or indirect product contact should be treated as an aseptic process and performed in grade A with a grade B background. The filling line set-up and filling of the sterile product should be treated as an aseptic process and\nperformed in grade A with a grade B background. Where an isolator is used, the background should be in\naccordance with paragraph 4.20'可被翻译为：与产品直接或间接接触的已灭菌设备、组件和辅助用品的拆包、装配和准备应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。无菌产品的灌装线组装和灌装应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。当使用隔离器时，背景应符合 4.20 节的规定\n\n根据上述已知信息，请将'Note 1: It should be noted that the types of monitoring methods listed in the table above are examples and other methods can be used provided they meet the intent of providing information across the whole of the critical process where product may be contaminated (e.g. aseptic line set-up, aseptic processing, filling and lyophilizer\nloading).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"注 1：应注意，上表中列出的监测方法类型是示例，可以使用其它方法，只要这些方法满足相同目的，即在产品可能被污染是提供整个关键工艺过程的信息（例如无菌生产线组装、无菌工艺、灌装和冻干机上料）。"
    },
    {
        "instruction":"已知信息：\n'The sum total of the complete set of genes contained in an individual or cell.'可被翻译为：个体或细胞所含的全套基因的总和。\n'The sum of all aspects of a system that implements quality policy and ensures that quality objectives are met. (ICH Q10)'可被翻译为：实现质量方针和确保质量目标系统的全方面的总和。（ICH Q10）\n\n根据上述已知信息，请将'The sum of all the genes carried by all the individuals of a population.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一个种群全部个体所带有的全部基因的总和。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory department may require the drug manufacturer, distributor and user to stop selling and using the drug immediately if necessary.'可被翻译为：必要时，药品监督管理部门可以要求药品生产企业、经营企业和使用单位立即停止销售和使用该药品。\n'Article 46 Immediate packaging materials and containers shall meet the requirements for medicinal use and the standards for ensuring human health and safety.'可被翻译为：第四十六条 直接接触药品的包装材料和容器，应当符合药用要求，符合保障人体健康、安全的标准。\n\n根据上述已知信息，请将'Where the immediate packaging materials and containers are not up to standard, the drug regulatory department shall order a stop to the use of the materials and containers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对不合格的直接接触药品的包装材料和容器，由药品监督管理部门责令停止使用。"
    },
    {
        "instruction":"已知信息：\n'Changes in compatibility between drugs that are not conducive to application and treatment under certain conditions.'可被翻译为：在一定条件下，产生的不利于应用和治疗的合用药物之间的配伍变化。\n'When the drugs are compatible, chemical reactions occur, and the drugs have different degrees of deterioration or failure, reducing the efficacy or increasing side effects.'可被翻译为：药物配伍时，发生化学反应，而使药物产生不同程度的变质或失效，降低疗效或增加副作用。\n\n根据上述已知信息，请将'Physical properties change when drugs are compatible, so that they can not meet the requirements of the preparation, reduce the efficacy or increase side effects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物配伍时发生的物理性质改变，因而得不到符合要求的制剂、降低疗效或增加副作用。"
    },
    {
        "instruction":"已知信息：\n'(i) This part does not apply to records required to be established or maintained by part 117 of this chapter. Records that satisfy the requirements of part 117 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第117部分要求建立或维护的记录。符合本章第117部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'(n) This part does not apply to records required to be established or maintained by subpart O of part 1 of this chapter. Records that satisfy the requirements of subpart O of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第1部分的O部分要求建立或维护的记录。符合本章第1部分的O部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n\n根据上述已知信息，请将'(o) This part does not apply to records required to be established or maintained by part 121 of this chapter. Records that satisfy the requirements of part 121 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本部分不适用于根据本章第121部分要求建立或维护的记录。符合本章第121部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。"
    },
    {
        "instruction":"已知信息：\n'In accordance with the \"Regulations on the Trial Implementation of Professional Titles for Health Technical Personnel,\" individuals who have obtained qualifications for pharmaceutical technical positions include Chief Pharmacist, Deputy Chief Pharmacist, Supervising Pharmacist, Pharmacist, and Pharmacy Technician.'可被翻译为：按照《卫生技术人员职务试行条例》规定，取得药学专业技术职务任职资格人员，包括主任药师、\n副主任药师、主管药师、药师和药士。\n'Chapter VII Responsibilities of Clinical Trial Institution and Investigator'可被翻译为：第七章 临床试验机构和研究者职责\n\n根据上述已知信息，请将'(1) Having the professional technical titles and qualifications of deputy chief physician, associate professor and associate investigator in the clinical trial institution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）在该临床试验机构中具有副主任医师、副教授、副研究员等副高级以上相关专业技术职称和资质；"
    },
    {
        "instruction":"已知信息：\n'(3) Undertake technical guidance of medical device standards in each specialized field and assist in solving technical problems during the implementation of standards;'可被翻译为：（三）承担本专业领域医疗器械标准的技术指导工作，协助解决标准实施中的技术问题；\n'(2) Undertake the drafting, public consultation, technical review of medical device standards and other organizational work in each specialized field and be responsible for the technical contents and quality of the standards;'可被翻译为：（二）承担本专业领域医疗器械标准起草、征求意见、技术审查等组织工作，并对标准的技术内容和质量负责；\n\n根据上述已知信息，请将'(6) Be responsible for the consultation and explanation on technical contents of the medical device standards in each specialized field;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）负责本专业领域医疗器械标准技术内容的咨询和解释;"
    },
    {
        "instruction":"已知信息：\n'Release of a drug (or drugs) at a time other than immediately following oral administration.'可被翻译为：口服后，药物在一定时间后才释放，而不是立即释放。\n'Under certain conditions, the lowest electrolyte concentration that causes a certain sol to appear polysedimentation.'可被翻译为：在一定条件下引起某种溶胶出现聚沉的最低电解质浓度。\n\n根据上述已知信息，请将'A preparation that does not release the drug immediately, but releases the drug suddenly one or more times under certain conditions (such as after a certain time or under a certain pH or certain enzymes in body fluids).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不立即释放药物，而在某种条件下（如在体液中经过一定时间或一定pH或某些酶作用下）一次或多次突然释放药物的制剂。"
    },
    {
        "instruction":"已知信息：\n'The validation of the receptor sample analytical method should include relevant qualifications of dilution integrity, if applicable, as well as stability assessments with the highest relevant temperature in the receptor solution for the longest relevant duration; the highest relevant temperature may be warmer than the IVRT membrane surface temperature because the temperature of the receptor solution is often higher than the temperature at the surface of the membrane (e.g., the temperature of the receptor solution may be 34°C when the temperature of membrane surface is 32°C, so stability assessments with the IVRT receptor solution may be performed at 34°C for 6 hours; the temperature would be higher for an IVRT with a vaginal gel, for example).'可被翻译为：如适用，接收液中样品分析方法的验证应包括相关的稀释完整性确认，以及样品在最高相关温度的接收液中放置最长相关时间的稳定性评估；最高相关温度可以略高于IVRT膜表面温度，因为接收液的温度通常高于膜表面温度（例如，当膜表面温度为32℃时，接收液温度可能是34℃，因此，IVRT接收液的稳定性评估可以设定为34℃维持6小时；而在阴道凝胶制剂的IVRT研究中，温度会更高）。\n'The operating principles and specific test procedures differ among the various equipment; relevant procedures from the manufacturer may be used for installation, operation, and performance qualifications. The laboratory qualification of each diffusion cell should, at minimum, include: (1) measurements of the diffusional area of the orifices of the donor and receptor compartments between which the membrane is mounte; (2) the empirically measured volume of the receptor solution compartment\/vessel for each diffusion cell; (3) the stability of the temperature measured at the membrane surface (e.g., at 32°C ± 1°C), or just below the membrane, across a relevant duration (e.g., 6 hours); and (4) the rate of stirring or agitation, as applicable.'可被翻译为：每种设备的操作原理和特定测试方法均不相同；可根据生产商提供的相关规程进行安装、操作和性能确认。每个扩散池的实验室确认内容，至少应包括：1）测定供给室和接收室之间膜安装位置的孔口扩散面积；2）测量每个接收室的容积；3）在相关研究期间（如，6小时），测定膜表面或膜下温度（如，32℃±1℃）的稳定性；和4）如适用，测定搅拌速率。\n\n根据上述已知信息，请将'3. Stability of the temperature measured at the membrane surface (e.g., 32 ± 1°) across a relevant duration (e.g., 6 h for IVRT or 48 h for IVPT)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在相关持续时间内(例如，IVRT为6小时或IVPT为48小时)膜表面测量温度的稳定性(例如，32±1°)"
    },
    {
        "instruction":"已知信息：\n'Article 2 This Procedure is applicable to the domestic registration inspection of drug development site and manufacturing site organized by the National Medical Products Administration (NMPA). The Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) organizes the implementation of registration inspection work.'可被翻译为：第二条 国家药品监督管理局组织的在境内开展的药品研制、生产现场注册核查适用本程序。国家药品监督管理局食品药品审核查验中心(以下简称核查中心)组织实施注册核查工作。\n'Article 9 The inspection team shall write registration inspection and Pre-market GMP inspection reports and draw conclusions on registration inspection and Pre-market GMP inspection respectively based on the on-site inspection.'可被翻译为：第九条 检查组依据现场检查情况，分别撰写注册核查、上市前 GMP 检查报告，分别作出注册核查、上市前GMP 检查结论。\n\n根据上述已知信息，请将'Article 18 CFDI explores the establishment of a caused-related registration inspection model based on information such as the drug product archives and institutional files of the NMPA; explores the application of off-site inspection methods based on the development of information management methods; continues to improve the system of technical guidelines for inspection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十八条 核查中心基于国家药品监督管理局药品品种档案和机构档案等信息，探索建立基于风险的注册核查模式；基于信息化管理手段的发展，探索应用非现场的核查方式；持续完善核查相关技术指导原则体系。"
    },
    {
        "instruction":"已知信息：\n'A gas that, when packaged for transport, is partially liquid (or solid) at a temperature above –50 °C.'可被翻译为：一种气体，在包装运输时，在-50°C以上的温度下部分为液体(或固体)。\n'Any substance that is completely gaseous at 1.013 bar and +20 °C or has a vapour pressure exceeding 3 bar at +500 °C.'可被翻译为：在1.013 bar和+20°C时完全气态或在+500°C时蒸气压超过3bar的任何物质。\n\n根据上述已知信息，请将'A gas that, when packaged under pressure for transport, is entirely gaseous at –50 °C; this category includes all gases with a critical temperature less than or equal to –50 °C.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种在压力下包装运输时，在-50℃时完全为气态的气体;这一类气体包括临界温度小于或等于-50℃的所有气体。"
    },
    {
        "instruction":"已知信息：\n'Gauze, Purified Cotton, Sutures and Surgical Dressings'可被翻译为：纱布、净化棉布、缝合线和外 科绷带\n'The USP method for analysis of surgical dressing\/cotton\/gauze (in packages) calls for a minimum quantity of 100 mg, to be tested in each medium. It is recommended that an entire unit shall be tested in each medium for individually packaged single-use articles.'可被翻译为：USP 分析手术敷料\/棉花\/纱布（包装内）的方法要求最少 100 mg，在每种培养基中进行 测试。对于单独包装的一次性用品，建议在每种培养基中对整个单元进行测试。\n\n根据上述已知信息，请将'Analysis of Medical Devices (ex. Purified Cotton, Gauze, Sutures and Surgical Dressings)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械的分析（除净化棉、纱布、缝合线和手术敷料外）"
    },
    {
        "instruction":"已知信息：\n'The following topics should be reviewed and evaluated by a microbiologist although some aspects will also be covered by the Consumer Safety Officer during the inspection.'可被翻译为：虽然消费品安全官员亦要检查有些问题，但在检查期间，微生物专家应查看并评价以下问题\n'Pharmaceutical Microbiology Manual'可被翻译为：药物微生物手册\n\n根据上述已知信息，请将'The following topics should be reviewed and evaluated during an inspection of a pharmaceutical microbiology laboratory.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在对药物微生物实验室进行检查期间应查看和评估以下方面："
    },
    {
        "instruction":"已知信息：\n'(3) Trail objective;'可被翻译为：（三）试验目的；\n'The personnel participating in the unannounced inspection shall sign a statement of having no conflict of interest and a letter of integrity commitments. Where the inspection activities contradict or conflict with the personal interests of the personnel, a withdrawal shall be raised.'可被翻译为：参加检查的人员应当签署无利益冲突声明和廉政承诺书；所从事的检查活动与其个人利益之间可能发生矛盾或者冲突的，应当主动提出回避。\n\n根据上述已知信息，请将'(5) Capital source and possible conflict of interest of the trail;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）试验的资金来源、可能的利益冲突；"
    },
    {
        "instruction":"已知信息：\n'In the conformation, the Angle of torsion (or dihedral Angle) between each of the more connected groups (or atoms) on two adjacent atoms is +90. To +150. The range may be between -150. To -90. Conformation between ranges.'可被翻译为：在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在+90。至+150。范围间或在-150。至-90。范围间的构象。\n'Also known as \"eclipsedconformation\". In the conformation, the Angle of torsion (or dihedral Angle) between the superior groups (or atoms) connected on each of the two adjacent atoms is -30. To +30. Conformation between ranges.'可被翻译为：又称\"重叠构象（eclipsedconformation）\"。在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在-30。至+30。范围间的构象。\n\n根据上述已知信息，请将'Also known as \"staggeredconformation\" \\ In the conformation, the torsion Angle (or dihedral Angle) between the two adjacent atoms on each of the better connected groups (or atoms) is +150. To -150. Conformation between ranges.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"对位交叉构象（staggeredconformation）\\在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在+150。至-150。范围间的构象。"
    },
    {
        "instruction":"已知信息：\n'nucleic acid drug'可被翻译为：核酸类药物\n'Pentose is one of the most important in nature. Found primarily in type D form, it is the carbohydrate component of ribonucleic acid and occurs in many nucleotides and nucleotides and their derivatives.'可被翻译为：自然界中最重要的一种戊糖。主要以D型形式存在，是核糖核酸的糖类组分，并出现在许多核昔和核昔酸以及其衍生物中。\n\n根据上述已知信息，请将'Nucleic acids, nucleotides, nucleotides, or bases having medicinal properties. Including its analogues, derivatives, or polymers of such analogues or derivatives.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有药用价值的核酸、核昔酸、核昔或者碱基的统称。包括其类似物、衍生物或这些类似物、衍生物的聚合物。"
    },
    {
        "instruction":"已知信息：\n'(III) Medical device adverse event monitoring information requiring regularly release;'可被翻译为：（三）需要定期发布的医疗器械不良事件监测信息；\n'III. Statistical analysis of national medical device adverse event reports (omitted)'可被翻译为：三、全国医疗器械不良事件报告统计分析（省略）\n\n根据上述已知信息，请将'IV. Release of medical device adverse event information notification (omitted)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、医疗器械不良事件信息通报发布情况（省略）"
    },
    {
        "instruction":"已知信息：\n'Article 62 Manufacturing of imported medical devices shall conform to relevant requirements for manufacturing of medical devices in China, and accept overseas inspection organized by NMPA. The agent shall be responsible for work related to coordinating and cooperating with overseas inspection.'可被翻译为：第六十二条  进口医疗器械的生产应当符合我国医疗器械生产相关要求，并接受国家药品监督管理局组织的境外检查。代理人负责协调、配合境外检查相关工作。\n'This Announcement is applicable to the matters concerning the production of Class II and Class III medical devices with imported medical device registration certificates in China by the imported medical device registrants through their foreign invested enterprises established in China.'可被翻译为：进口医疗器械注册人通过其在境内设立的外商投资企业在境内生产第二类、第三类已获进口医疗器械注册证产品的有关事项，适用本公告。\n\n根据上述已知信息，请将'NMPA issued the Announcement on Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于进口医疗器械产品在中国境内企业生产有关事项的公告"
    },
    {
        "instruction":"已知信息：\n'For generic drugs or other products, drug registration inspection of the manufacturing site and\/or  pre-marketing GMP inspection shall be carried out based on risks, taking into consideration the circumstances such as whether Drug Manufacturing Certificate covering the corresponding manufacturing scope has been obtained and product of the same dosage form has been marketed,.'可被翻译为：对于仿制药等，根据是否已获得相应生产范围药品生产许可证且已有同剂型品种上市等情况，基于风险进行药品注册生产现场核查、上市前药品生产质量管理规范检查。\n'(1) For varieties having not passing GMP compliance inspection for manufacturing conditions of the products, pre-marketing GMP compliance inspection shall be carried out. Where drug registration on-site inspection is needed for the drug to be manufactured, the NMPA Center for Drug Evaluation shall notify the CFDI and inform the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the manufacturing site is located and the applicant; and the CFDI shall coordinate the drug regulatory department of the province, autonomous region or municipality directly under the Central Government to concurrently carry out drug registration on-site inspection and pre-marketing GMP compliance inspection.'可被翻译为：（一）未通过与生产该药品的生产条件相适应的药品生产质量管理规范符合性检查的品种，应当进行上市前的药品生产质量管理规范符合性检查。其中，拟生产药品需要进行药品注册现场核查的，国家药品监督管理局药品审评中心通知核查中心，告知相关省、自治区、直辖市药品监督管理部门和申请人。核查中心协调相关省、自治区、直辖市药品监督管理部门，同步开展药品注册现场核查和上市前的药品生产质量管理规范符合性检查；\n\n根据上述已知信息，请将'Drug registration inspection of the manufacturing site and pre-marketing GMP inspection shall be carried out for innovative drugs, modified new drugs and biological products, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于创新药、改良型新药以及生物制品等，应当进行药品注册生产现场核查和上市前药品生产质量管理规范检查。"
    },
    {
        "instruction":"已知信息：\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申请资料之日起即为受理；\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected one-off on site or within 5 working days. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容。逾期不告知的，自收到申请资料之日起即为受理；\n\n根据上述已知信息，请将'(4) If the application documents are incomplete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application documents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容以及提交补正资料的时限。逾期不告知的，自收到申请资料之日起即为受理；"
    },
    {
        "instruction":"已知信息：\n'Article 36 The inspection team shall submit the on-site inspection report, on-site inspection question sheet and related dossiers to CFDI within the prescribed time limit as required.'可被翻译为：第三十六条 核查组应当按照要求在规定时限内，将现场核查报告、现场核查问题表及相关材料报送核查中心。\n'Article 26 After receiving the recommendations for on-site inspection, the CFDI shall conduct on-site inspection within 20 days.'可被翻译为：第二十六条 核查中心接到现场检查建议后，应当在20日内进行现场检查。\n\n根据上述已知信息，请将'Article 48 The inspection team shall submit the on-site inspection report and related dossiers to CFDI within 5 days after the completion of the on-site inspection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 核查组应当在现场核查结束之日起5日内，将现场核查报告及相关资料报送核查中心。"
    },
    {
        "instruction":"已知信息：\n'corrective and preventative actions'可被翻译为：纠正和预防措施\n'Action to eliminate the cause of a potential non-conformity or other undesirable potential situation. NOTE: Preventive action is taken to prevent occurrence whereas corrective action is taken to prevent recurrence. (ISO 9000:2005)'可被翻译为：为消除潜在的违规或其他潜在的非期望状况的原因(所采取)的措施。注:采取预防措施是为了防止(事情)发生，而采取纠正措施是为了防止(事情)再次发生。(ISO 9000:2005)\n\n根据上述已知信息，请将'Corrective Action and Preventive Action – System that focuses on investigating, understanding, and correcting discrepancies while attempting to prevent their occurrence'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"纠正措施和预防措施用于调查、理解和纠正偏差并预防其再次发生的系统。"
    },
    {
        "instruction":"已知信息：\n'A limit above (>) which an impurity should be qualified.'可被翻译为：为一限度，高于此限度的降解产物需界定其安全性。\n'A limit above (>) which an impurity should be reported. Reporting threshold is the same as reporting level in Q2B.'可被翻译为：为一限度，高于此限度的杂质需报告其含量。即 Q2B 中的“报告水平”（reporting level）\n\n根据上述已知信息，请将'A limit above (>) which an impurity should be identified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为一限度，高于此限度的杂质需鉴定其结构。"
    },
    {
        "instruction":"已知信息：\n'A molecule with a symmetric element that overlaps with its own mirror image and has no chiral properties.'可被翻译为：分子中有对称元素，能与其自身镜像重合，没有手性的分子。\n'Organic compounds containing two or more polyvalent atoms, because the free rotation of single bonds causes other atoms or groups in the molecule to be arranged differently in space, this stereoscopic image of the molecule is called conformation.'可被翻译为：含有两个或两个以上多价原子的有机化合物，由于单键自由旋转导致分子中其他原子或基团在空间排列不同，分子的这种立体形象称为构象。\n\n根据上述已知信息，请将'A compound containing asymmetric atoms in a molecule, but which is not optically active because of the symmetry factor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在分子内虽然含有不对称原子，但因具有对称因素而使其不具有旋光性的化合物。"
    },
    {
        "instruction":"已知信息：\n'Cleaning - A process for removing contamination e.g. product residues or disinfectant residues.'可被翻译为：清洁：去除污染（如产品残留或消毒剂残留）的工艺。\n'Remove any residue or debris that would detrimentally impact the effectiveness of the disinfecting agent used.'可被翻译为：去除对使用的消毒剂的有效性产生不利影响的所有残留物或碎片。\n\n根据上述已知信息，请将'1.The ability of a cleaning procedure to effectively remove material, cleaning agent residue and microbial contamination.\n2.The factors that impact the ability to remove a residue from surfaces, including material of construction, the solubility of the material in different agents and the matrix of the material being cleaned.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.清洗程序有效去除物料、清洗剂残留和微生物污染的能力。\n2.影响清除表面残留物能力的因素，包括建筑材料、材料在不同介质中的溶解度和被清洁材料的基质。"
    },
    {
        "instruction":"已知信息：\n'Vials should not be soaked due to the possibility of migration of disinfectant under the closure and into the product.'可被翻译为：不应浸泡西林瓶，因为消毒剂可能通过封盖处迁移，进入产品\n'Bioburden samples should be taken from the bulk product and immediately prior to the final sterile filtration. In case where a redundant filtration set-up is used, it should be taken prior to the first filter. Systems for taking samples should be designed so as not to introduce contamination.'可被翻译为：生物负载样品应取自待包装产品，并在最终除菌过滤前即时取样。如果配备了冗余过滤装置，应在第一个过滤器之前进行取样。取样系统的设计不得引入污染。\n\n根据上述已知信息，请将'Samples taken away from the packaging line should not be returned to prevent the products from mixups or contamination.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"样品从包装生产线取走后不应当再返还，以防止产品混淆或污染。"
    },
    {
        "instruction":"已知信息：\n'Article 176 In case of identifying that a sold drug has serious quality issue, an enterprise shall immediately take measures to retrieve the drug, make records and report to the food and drug regulatory department.'可被翻译为：第一百七十六条 企业发现已售出药品有严重质量问题，应当及时采取措施追回药品并做好记录，同时向食品药品监督管理部门报告。\n'(II) Any suspected falsified drug shall be in a timely manner reported to the food and drug regulatory department;'可被翻译为：（二）怀疑为假药的，及时报告食品药品监督管理部门；\n\n根据上述已知信息，请将'Article 174 Enterprises shall publish the supervisory telephone number of food and drug regulatory department in their business premises, set up customer's book, and in a timely manner handle customer complaints of drug quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十四条 企业应当在营业场所公布食品药品监督管理部门的监督电话，设置顾客意见簿，及时处理顾客对药品质量的投诉。"
    },
    {
        "instruction":"已知信息：\n'Heating and cooling and hydraulic systems'可被翻译为：加热、冷却和液压系统\n'Isolators or RABS, which are different technologies, and the associated processes, should be designed to provide protection through separation of the grade A environment from the environment of the surrounding room.\nThe hazards introduced from entry or removal of items during processing should be minimized and supported by high capability transfer technologies or validated systems that robustly prevent contamination and are appropriate\nfor the respective technology.'可被翻译为：隔离器或 RABS（两种不同的技术）及其相关工艺的设计中，应通过将 A 级环境与周围房间环境分隔来提供保护。应尽量减少工艺过程中物品进出所带来的危害，并通过高性能转移技术或经过验证的系统提供支持，其能有效防止污染且适合于各自的技术。\n\n根据上述已知信息，请将'Major items of equipment associated with hydraulic, heating and cooling systems should, where possible, be located outside the filling room. There should be appropriate controls to contain any spillage and\/or cross contamination associated with the system fluids.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"液压、加热和冷却系统相关的设备主要部分应尽可能位于灌装室外。应有适当的控制措施来处理与系统液体相关的任何泄漏和\/或交叉污染。"
    },
    {
        "instruction":"已知信息：\n'I. The sponsors shall conduct research in accordance with the ICH guidelines as soon as possible on the basis of the existing technical requirements. The 13 ICH safety guidelines shall be adopted for non-clinical studies starting from May 1, 2020, and the starting dates of non-clinical studies shall be determined in accordance with the relevant provisions of the Good Laboratory Practice.'可被翻译为：一、申请人需在现行技术要求基础上尽早按照ICH指导原则开展研究；自2020年5月1日起开始的非临床研究适用13个ICH非临床指导原则，非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。\n'NMPA Announcement on Adopting ICH Guidelines S5 (R3) and S11'可被翻译为：国家药监局关于适用《S5（R3）》和《S11》国际人用药品注册技术协调会指导原则的公告\n\n根据上述已知信息，请将'Guidelines S5 (R3) and S11 shall be applicable to the non-clinical studies starting upon issuance of this Announcement. The designation of the starting date of nonclinical study shall be in accordance with the relevant provisions specified in the Good Laboratory Practice.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"自本公告发布之日起开始的非临床研究适用S5（R3）和S11指导原则。非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。"
    },
    {
        "instruction":"已知信息：\n'(2) Drugs that are urgently needed for public health, whose efficacy has been demonstrated by data in drug clinical trials and whose clinical values can be predicted;'可被翻译为：（二）公共卫生方面急需的药品，药物临床试验已有数据显示疗效并能预测其临床价值的；\n'Article 26 Drugs used for the treatment of severe life-threatening diseases for which there is no effective treatment and drugs urgently needed for public health, where the drug clinical trial data have shown their efficacy and predictable clinical results, may be conditionally approved, and the relevant information should be stated in the drug approval license.'可被翻译为：第二十六条 对治疗严重危及生命且尚无有效治疗手段的疾病以及公共卫生方面急需的药品，药物临床试验已有数据显示疗效并能预测其临床价值的，可以附条件批准，并在药品注册证书中载明相关事项。\n\n根据上述已知信息，请将'(1) Drugs used for treating serious life-threatening diseases for which no effective treatment is available, whose efficacy has been verified by data in drug clinical trials and whose clinical values can be predicted;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）治疗严重危及生命且尚无有效治疗手段的疾病的药品，药物临床试验已有数据证实疗效并能预测其临床价值的；"
    },
    {
        "instruction":"已知信息：\n'Article 51 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue a acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'可被翻译为：第五十一条 省、自治区、直辖市药品监督管理部门应当对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。\n'Article 57 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue an acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'可被翻译为：第五十七条 省、自治区、直辖市药品监督管理部门应当对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。\n\n根据上述已知信息，请将'Article 76 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue an acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十六条 省、自治区、直辖市药品监督管理部门对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。"
    },
    {
        "instruction":"已知信息：\n'batch culture'可被翻译为：分批培养\n'A culture method in which the cells and culture medium of microorganisms or animals and plants are loaded into the reactor at one time for culture, the cells are continuously increased, the product liquid is continuously formed, and after a period of reaction, the whole reaction system is taken out.'可被翻译为：将微生物或动植物的细胞和培养液一次性装入反应器中,进行培养，细胞不断增加，产物液不断形成,经过一段时间反应后,将整个反应体系取出的培养方法。\n\n根据上述已知信息，请将'Corresponding to batch culture. When the microorganisms were cultured in batch culture to the late exponential stage (logarithmic stage), on the one hand, they continuously flowed into the fresh medium at a certain speed; On the other hand, the culture after mixing is continuously flowed out of the incubator by overflow mode, so that it can continue to grow and produce metabolites for a long time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与分批培养相对应。当微生物以分批式培养方式培养到指数期（对数期）的后期时，一方面以一定速度连续流进新鲜培养基；另一方面经搅拌均匀后的培养物又经溢流方式不断流出培养器，从而使其能长时期进行连续生长和产生代谢产物的培养技术。"
    },
    {
        "instruction":"已知信息：\n'A continuous or discontinuous density gradient is formed with a certain medium in the centrifugal tube, and the cell suspension or homogenate is placed on the top of the medium, and the cells are stratified and separated by the action of gravity or centrifugal force field. This kind of separation can be divided into two kinds: rate zone centrifugation and equal density centrifugation. The commonly used media are chloride, sucrose and polysucrose.'可被翻译为：用一定的介质在离心管内形成一连续或不连续的密度梯度，将细胞混悬液或匀浆置于介质的顶部，通过重力或离心力场的作用使细胞分层、分离的方法。这类分离又可分为速率区带离心和等密度离心两种。常用的介质为氯化铭、蔗糖和多聚蔗糖。\n'A technical method for instrumental analysis. In the process of analysis, the sample solution is directly injected into the reagent carrier of the pipeline in the form of \"sample plug\", the sample liquid plug is driven forward by the carrier, relying on convection and diffusion to form a sample liquid belt with concentration gradient, and there are reagents in the interceptor reaction, brought into the monitor for continuous detection and processing.'可被翻译为：仪器分析的一种技术方法。在分析过程中，把试样溶液直接以“试样塞”的形式注入到管道的试剂载流中，试样液塞被载流推动前进，依靠对流和扩散形成一个具有浓度梯度的试样液带，并且在截流中有试剂进行反应，带入监测器而进行连续检测处理。\n\n根据上述已知信息，请将'The centrifuged sample is placed in a medium with a gradient distribution for horizontal or vertical centrifugation. Commonly used media are sucrose and chlorination, the former need to be prepared in advance in the centrifuge tube continuous or discontinuous gradient, the latter is prepared into a certain concentration of solution, in the centrifuge process will form a continuous gradient.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被离心样品置于成梯度分布的介质中进行水平或垂直离心。常用的介质有蔗糖及氯化铭，前者需事先在离心管中配制好连续或不连续梯度，后者配成一定浓度溶液，在离心过程中会形成连续梯度。"
    },
    {
        "instruction":"已知信息：\n'Article 67 Filing for a class I in-vitro diagnostic reagent shall be conducted prior to production.'可被翻译为：第六十七条 第一类体外诊断试剂生产前，应当办理产品备案。\n'Article 77 The filing certificate for class I medical device shall be arranged in the following form:'可被翻译为：第七十七条 第一类医疗器械备案凭证编号的编排方式为：\n\n根据上述已知信息，请将'Article 86 The filing certificate for class I in-vitro diagnostic reagent shall be arranged in the following form:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十六条 第一类体外诊断试剂备案凭证编号的编排方式为："
    },
    {
        "instruction":"已知信息：\n'Drugs that bind to adrenergic receptors and excite them to produce effects similar to those of epinephrine. It can cause vasoconstriction, increase blood pressure, dilate pupils, dilate bronchus, relax gastrointestinal muscle, accelerate heart rate, strengthen myocardial contractility and reduce mucosal secretion. Clinically, it is mainly used to raise pressure, relieve asthma, and reduce nasal mucosal congestion. Drugs include epinephrine, norepinephrine, mehydroxyamine and ephedrine.'可被翻译为：能与肾上腺素受体结合，并使其激动产生与肾上腺素相似作用的药物。可引起血管收缩、升高血压、散大瞳孔、舒张支气管、弛缓胃肠肌、加速心率、加强心肌收缩力以及减少黏膜分泌等作用。临床上主要应用于升压、平喘、减轻鼻黏膜充血等。药物有肾上腺素、去甲肾上腺素、间羟胺以及麻黄碱等。\n'Medications to relieve migraine symptoms. There are mainly HT1 receptor agonists such as Sumatriptan and dihydroergosine, among others.'可被翻译为：缓解偏头痛症状的药物。主要有HT1受体激动剂，如舒马曲坦和二氢麦角碱等。\n\n根据上述已知信息，请将'Drugs that inhibit bronchospasm, improve lung ventilation, and prevent asthma symptoms. There are: beta-2 receptor agonists, such as salbutamol, etc.; Theophylline, such as theophylline, dihydroxypropylline.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"抑制支气管痉挛，改善肺通气，防治哮喘症状发作的药物。有：β2受体激动剂，如沙丁胺醇等；茶碱类，如茶碱，二羟丙茶碱。"
    },
    {
        "instruction":"已知信息：\n'Article 29 The registrant, filing entity or contract manufacturer of medical devices shall, based on the characteristics, technical process and requirements for manufacturing environment of the manufactured products, rationally equip and use of the facilities and equipment, strengthen the management of the facilities and equipment, and maintain their effective operation.'可被翻译为：第二十九条  医疗器械注册人、备案人、受托生产企业应当按照所生产产品的特性、工艺流程以及生产环境要求合理配备、使用设施设备，加强对设施设备的管理，并保持其有效运行。\n'Article 33 The registrant, filing entity or contract manufacturer of medical devices shall establish record management procedures, to ensure the authenticity, accuracy, integrity and traceability of the records.'可被翻译为：第三十三条  医疗器械注册人、备案人、受托生产企业应当建立记录管理制度，确保记录真实、准确、完整和可追溯。\n\n根据上述已知信息，请将'The registrant, filing entity or contract manufacturer of medical devices are encouraged to establish information management system by advanced technical means, to strengthen management of the manufacturing process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励医疗器械注册人、备案人、受托生产企业采用先进技术手段，建立信息化管理系统，加强对生产过程的管理。"
    },
    {
        "instruction":"已知信息：\n'A process designed to remove or inactivate pyrogenic material (such as endotoxin) to a specified minimum quantity.'可被翻译为：去除或灭活致热物质(如内毒素)至规定最小量的过程。\n'When a thermal process is used as part of the depyrogenation process for any component or product contact equipment\/material, validation studies should be performed to demonstrate that the process provides a suitable Fh value and results in a minimum 3 log10  reduction in endotoxin concentration. When this is attained, there is no additional requirement to demonstrate sterilisation in these cases.'可被翻译为：当使用热处理作为任何组分或产品接触设备\/物料的除热原工艺的一部分时，应进行验证研究以证明该工艺 能提供合适的 Fh 值，并使内毒素浓度至少降低 3 个对数值。这一要求得到满足，不需要额外证明在这些情况下的灭菌效果。\n\n根据上述已知信息，请将'Depyrogenation - A process designed to remove or inactivate pyrogenic material (e.g. endotoxin) to a specified\nminimum quantity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除热原： 旨在将致热物质（例如内毒素）去除或灭活至规定最小量的过程。"
    },
    {
        "instruction":"已知信息：\n'agarose gel'可被翻译为：琼脂糖凝胶\n'a class of biological macromolecules widely present in living organisms, consisting of a peptide chain formed by a peptide bond between A amino acid encoded by nucleic acid through A amino group and A carboxyl group, and an active macromolecule with a specific three-dimensional structure generated by post-translational processing.'可被翻译为：生物体中广泛存在的一类生物大分子，由核酸编码的a氨基酸之间通过a氨基和a竣基形成的肽键连接而成的肽链，经翻译后加工而生成的具有特定立体结构的、有活性的大分子。\n\n根据上述已知信息，请将'After the charged AGAR is removed from the AGAR, the remaining neutral part of the charged group does not contain sulfonic acid group, carboxylic acid group, etc. The structure is a chain of polygalactose, easily soluble in boiling water, after cooling can rely on the hydrogen bond attraction between sugar groups to form a network structure of gel. The mesh size of the gel and the mechanical strength of the gel depend on the agarose concentration. It can be used as a molecular sieve and is often used for gel chromatography and electrophoresis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从琼脂中除去带电荷的琼脂胶后，剩下的不含磺酸基团、竣酸基团等带电荷基团的中性部分。结构是链状的聚半乳糖，易溶于沸水，冷却后可依靠糖基间的氢键引力形成网状结构的凝胶。凝胶的网孔大小和凝胶的机械强度取决于琼脂糖浓度。可作为分子筛，常用于凝胶层析和电泳。"
    },
    {
        "instruction":"已知信息：\n'2.2. Throughout development life cycle stages, transfers should be appropriate and proportionate to the phase of the development program to ensure product development knowledge is maintained and processes are appropriately controlled. This guideline should be applied when transferring the technology of manufacturing processes and analytical procedures relating to active pharmaceutical ingredients (APIs), isolated API intermediates, bulk drug products and finished pharmaceutical products (FPPs).'可被翻译为：在整个开发生命周期阶段，转移应适当，并与开发计划的阶段相称，从而确保产品开发知识得 到保存，工艺得到适当控制。在转移API、分离的API中间体、待包装制剂和制剂（FPP）有 关的生产工艺和分析方法技术转移时应使用本指南。\n'12.2. During the initiation phase of the project, a unit should normally identify the need for the technology transfer. This may be because of lack of capacity, transfer from development to commercial site or transfer from one company to another.'可被翻译为：在项目的启动阶段，通常应由一方识别出技术转移的需求。这可能是因为缺乏从开发转移至商业化场所或从一个公司转移至另一个公司能力。\n\n根据上述已知信息，请将'1.2. The transfer of production and control procedures of pharmaceutical products from one site to another may take place before or after obtaining regulatory marketing authorization Product transfer may therefore occur during development, during clinical trials, or for full-scale commercialization and commercial batch manufacturing. The level of rigor applied in the technology transfer should be commensurate with the respective product life cycle phase.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品生产和检测方法从一个场所转移至另一个场所可能会发生在在获得上市批准之前或之后。因此产品转移可能会在开发过程中、临床试验过程中或全面商业化及商业化批生产过程中发生。技术转移时的严格程序应与产品所处生命周期阶段相称。"
    },
    {
        "instruction":"已知信息：\n'c. RODAC\/Hycheck Sterility Control: Place an unused RODAC plate and\/or Hycheck plate within a sterile Whirl-pak® bag.'可被翻译为：RODAC\/Hycheck 无菌控制：将未使用的 RODAC 碟和\/或 Hycheck 碟放入无菌Whirl- pak®袋中。\n'5. Place the EM sample into a sterile Whirl-pak® bag and identify the bag immediately after.'可被翻译为：将 EM 样品放入 Whirl-pak®无菌袋，然后立即对袋子进行标示。\n\n根据上述已知信息，请将'd. Whirl-pak® bag Sterility Control: Include one unopened Whirl- pak® bag as a closed control.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Whirl- pak®袋的无菌控制：放入一个未开封的 Whirl- pak®袋作为密封控制。"
    },
    {
        "instruction":"已知信息：\n'Article 3 When the CFDI coordinates the collaborative inspections with provincial authorities, both parties shall, in accordance with the regulatory requirements and their respective functions, follow the concept of risk management and work together to ensure the smooth collaboration between registration inspection and Pre-market GMP inspection.'可被翻译为：第三条 核查中心协调省级局同步实施检查工作时，双方应当根据法规要求和各自职能，遵循风险管理的理念，共同合作，保证注册核查与上市前GMP 检查的有机衔接。\n'If an inspection team is formed together, the inspection team leader and team members should be qualified national GMP inspectors. The inspection team leader shall be determined by the CFDI and the provincial authority through joint discussion.'可被翻译为：如共同组建检查组，检查组长和组员均应为国家药品GMP 检查员。检查组长由核查中心和省级局共同协商确定。\n\n根据上述已知信息，请将'Article 5 After confirming the inspection arrangements with the applicant taking consideration of the characteristics, processes, risks, etc. of the product, the CFDI shall work together with the provincial authorities to agree on the work arrangements to clarify the composition of the inspection team and the inspection time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五条 核查中心根据品种的特性、工艺、风险等情况，在与申请人沟通确认检查安排后，同省级局共同商定工作安排，明确检查组组成方式和检查时间。"
    },
    {
        "instruction":"已知信息：\n'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'可被翻译为：第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。\n'Article 140: Documents and records should be established for qualification and validation as an evidence for the following intended purposes:'可被翻译为：第一百四十条 应当建立确认与验证的文件和记录，并能以文件和记录证明达到以下预定的目标：\n\n根据上述已知信息，请将'Article 73: The documents and records for equipment procurement, installation, and qualification should be archived.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十三条 应当建立并保存设备采购、安装、确认的文件和记录。"
    },
    {
        "instruction":"已知信息：\n'2.2 Drugs that contain known active ingredients with new dosage form (including new drug delivery system), new formulation process or new route of administration, and have significant clinical advantages.'可被翻译为：2.2含有已知活性成份的新剂型（包括新的给药系统）、新处方工艺、新给药途径，且具有明显临床优势的药品。\n'2.1 Drugs that contain an optical isomer of known active ingredients obtained by resolution or synthesis, or esterification of known active ingredients, or salification of known active ingredients (including salt containing hydrogen bonds or coordination bonds), or change in acid group, basic group, or metallic element of known active ingredients of salt, or formation of other non-covalent bond derivatives (e.g. ,complex, chelate or clathrate), and have significant clinical advantages.'可被翻译为：2.1含有用拆分或者合成等方法制得的已知活性成份的光学异构体，或者对已知活性成份成酯，或者对已知活性成份成盐（包括含有氢键或配位键的盐），或者改变已知盐类活性成份的酸根、碱基或金属元素，或者形成其他非共价键衍生物（如络合物、螯合物或包合物），且具有明显临床优势的药品。\n\n根据上述已知信息，请将'2.3 New compound preparations that contain known active ingredients and havesignificant clinical advantages.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.3含有已知活性成份的新复方制剂，且具有明显临床优势。"
    },
    {
        "instruction":"已知信息：\n'Article 20 Where the change management category of circumstances of change has been specified in laws, regulations or technical guidelines, MAHs shall generally determine the change management category in accordance with relevant provisions.'可被翻译为：第二十条 变更情形在法律、法规或技术指导原则中已明确变更管理类别的，持有人一般应当根据有关规定确定变更管理类别。\n'Article 22 MAHs may adjust the change management category according to the management and production technology changes, and implement the change as per the adjusted change management category upon approval or filing, or report.'可被翻译为：第二十二条 持有人可以根据管理和生产技术变化对变更管理类别进行调整，并按照调整后的变更管理类别经批准、备案后实施或报告。\n\n根据上述已知信息，请将'Article 27 The reporting category shall be managed by the MAHs in accordance with the relevant requirements for change management, which shall be indicated in the annual report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 报告类变更应当由持有人按照变更管理的有关要求进行管理，在年度报告中载明。"
    },
    {
        "instruction":"已知信息：\n'All phases in the life of the product from the initial development through marketing until the product’s discontinuation. (ICH Q9)'可被翻译为：从最初的研发到上市直至撤市的产品生命中的所有阶段。（ICH Q9）\n'1.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q8 (4))\n2.All phases in the life of a medical device, from the initial conception to final decommissioning and disposal.\n3.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (4).'可被翻译为：1.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(ICH Q8 (4))\n2.医疗器械生命周期的所有阶段，从最初的构思到最终的退役和处置。\n3.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(4)。\n\n根据上述已知信息，请将'All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q8).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一个产品从开始研发到上市，直至产品终止上市的整个过程。"
    },
    {
        "instruction":"已知信息：\n'5. Chromatogram integration'可被翻译为：5.色谱积分\n'(2) If reintegration is conducted for standard curve and the quality control chromatogram, verify whether the reintegration impacts the acceptance of the analysis batch.'可被翻译为：(2) 标准曲线和质控色谱如果进行了重积分， 核实重积分是否影响该分析批的接受。\n\n根据上述已知信息，请将'(1) Chromatogram adopts automatic integration; the same integration parameters are used in the same analysis batch. If reintegration and manual integration of chromatogram are adopted, record the reason of modification and retain the original and reintegrated chromatogram and data, which are consist with the application dossier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) 色谱使用自动积分， 同一个分析批中采用相同的积分参数。如果色谱重积分和手动积分， 记录修改理由并保留原始和重积分的图谱和数据， 与申报资料一致。"
    },
    {
        "instruction":"已知信息：\n'hazardous substance'可被翻译为：有害物质\n'toxic effect'可被翻译为：毒效应\n\n根据上述已知信息，请将'For dark yellow toxic gas. Dissolved in ethylene, tetrahydroyvean, etc., heated to 100 hours explosion; It decomposes rapidly in water and ethanol, and is relatively stable in ethyl-sweet wine. It is highly toxic and has a strong irritating effect on eyes and mucous membranes. It is an important methylation reagent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为深黄色有毒气体。溶于乙触、四氢吠喃等，加热至100工时爆炸；在水和乙醇中迅速分解，在乙醴中比较稳定。有剧毒，对眼睛和黏膜有强烈的刺激作用，为重要的甲基化试剂。"
    },
    {
        "instruction":"已知信息：\n'(1) drugs to be marketed in China for the first time;'可被翻译为：（一）首次在中国境内销售的药品；\n'Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China'可被翻译为：境外已上市境内未上市药品临床技术要求\n\n根据上述已知信息，请将'(II) drugs to be marketed in China for the first time; and'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）首次在中国境内销售的药品；"
    },
    {
        "instruction":"已知信息：\n'Article 31 The registrant, filing entity or contract manufacturer of medical devices shall enhance purchase management, establish suppliers audit system, and evaluate the suppliers, to ensure that the purchased products and services conform to relevant regulations and requirements.'可被翻译为：第三十一条  医疗器械注册人、备案人、受托生产企业应当加强采购管理，建立供应商审核制度，对供应商进行评价，确保采购产品和服务符合相关规定要求。\n'The registrant or filing entity of medical devices may sell by itself, or entrust medical device distributors to sell the medical devices registered or filed.'可被翻译为：医疗器械注册人、备案人可以自行销售，也可以委托医疗器械经营企业销售其注册、备案的医疗器械。\n\n根据上述已知信息，请将'Article 31 The medical device distributors shall purchase medical devices from medical device registrant, filing entity and distributor with legal qualification.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十一条  医疗器械经营企业应当从具有合法资质的医疗器械注册人、备案人、经营企业购进医疗器械。"
    },
    {
        "instruction":"已知信息：\n'The method of dispersing the drug in the solution of the material to form a suspension or emulsion, and then spraying the liquid into an inert hot air flow to shrink the droplets into spheres, and then drying to obtain microcapsules or microspheres.'可被翻译为：将药物分散在材料的溶液中形成混悬液或乳状液，再将此液喷入惰性热气流使液滴收缩成球形，进而干燥，得到微囊或微球的方法。\n'An emulsion having oil as the dispersing phase and water as the dispersing medium.'可被翻译为：以油为分散相，以水为分散介质的乳剂。\n\n根据上述已知信息，请将'Drugs and natural polymer materials for the water phase, emulsifier oil phase stirring emulsification, the use of polymer solution itself surface tension to form a spherical emulsion, forming a stable oil-in-water emulsion, need to add chemical crosslinking agent, amine aldehyde condensation or aldol condensation reaction, preparation of powdered microspheres method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物和天然高分子材料为水相，与含乳化剂的油相搅拌乳化，在搅拌下利用高分子溶液本身的表面张力形成球形乳滴，形成稳定的油包水型乳状液，需加入化学交联剂，发生胺醛缩合或醇醛缩合反应，制得粉末状微球的方法。"
    },
    {
        "instruction":"已知信息：\n'A subdiscipline of toxicology that developed out of immunology and toxicology. The study of the harmful effects of foreign chemicals and physical factors on the body's immune system and their mechanisms.'可被翻译为：在免疫学和毒理学基础上发展起来的一个毒理学分支学科。主要研究外源化学物质和物理因素对机体免疫系统的有害作用及其机制。\n'It uses the basic methods and techniques of toxicology to study the characteristics and mechanisms of the damaging effects of foreign chemicals on the liver.'可被翻译为：利用毒理学的基本方法和技术，研究外源化学物对肝脏的损害作用特点及其机制的学科。\n\n根据上述已知信息，请将'The branch of toxicology that studies the damaging effects of foreign chemicals on the respiratory system, explores methods of detection, and elucidates mechanisms of damage. Its research is helpful for the diagnosis, treatment, prevention and mechanism of poisoning.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究外源化学物对呼吸系统的损害作用，探讨检测方法以及阐述损害机制的毒理学分支学科。其研究有助于对中毒的诊断、治疗、预防以及中毒机制的探讨。"
    },
    {
        "instruction":"已知信息：\n'Article 16 The State supports innovation in drug development which is guided by clinical value and has clear or specific therapeutic effect on human diseases, encourages research and development of new drugs with new therapeutic mechanisms, treats serious life-threatening or rare diseases, makes use of targeted and systemic regulatory interventions for humans, and promotes technological advancement in drug development.'可被翻译为：第十六条 国家支持以临床价值为导向、对人的疾病具有明确或者特殊疗效的药物创新，鼓励具有新的治疗机理、治疗严重危及生命的疾病或者罕见病、对人体具有多靶向系统性调节干预功能等的新药研制，推动药品技术进步。\n'Article 96 The State encourages the research, development, and manufacture of drugs in shortage, and implements priority review and approval for drugs in shortage in urgent clinical needs or new drugs for prevention and treatment of serious infectious diseases and rare diseases.'可被翻译为：第九十六条 国家鼓励短缺药品的研制和生产，对临床急需的短缺药品、防治重大传染病和罕见病等疾病的新药予以优先审评审批。\n\n根据上述已知信息，请将'Article 4 The State encourages the research and development of new drugs and adopts the special review and approval with respect to innovative drugs, new drugs for serious and life-threatening diseases and to address unmet medical needs and drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四条 国家鼓励研究创制新药，对创制的新药、治疗疑难危重疾病的新药实行特殊审批。"
    },
    {
        "instruction":"已知信息：\n'Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintained to prevent microbiological contamination and to ensure a reliable source of\nwater of an appropriate quality. Measures should be taken to minimize the risk of presence of particulates, microbial contamination\/proliferation and endotoxin\/pyrogen (e.g. sloping of piping to provide complete drainage and the avoidance of dead legs). Where filters are included in the system, special attention should be given to their\nmonitoring and maintenance. Water produced should comply with the current monograph of the relevant\nPharmacopeia.'可被翻译为：水处理设施及其分配系统地设计、建造、安装、调试、确认、监测和维护应防止微生物污染，并确保高质量的可靠水源。应釆取措施，最大程度降低微粒、微生物污染\/增殖和内毒素\/热原的风险（例如倾斜管道以完全排水以及避免死角）。当系统中包含过滤器时，应特别注意对其进行监测和维护。产出的水应符合相关药典的现行各论。\n'turbulent flow'可被翻译为：紊流\n\n根据上述已知信息，请将'Water flow should remain turbulent through the pipes in water distribution systems to minimize the risk of microbial adhesion, and subsequent biofilm formation. The flow rate should be established during qualification and be routinely monitored.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"水流在水分配系统的管道中应保持湍流状态，以最大程度降低微生物粘附及随后生物膜形成的风险。应在确认过程中确定流速并进行日常监测。"
    },
    {
        "instruction":"已知信息：\n'A homogeneous suspension of the seed material derived from the master seed bank(s) at a finite passage level, dispensed in aliquots into individual containers for storage. All containers are treated identically and, once removed from storage, are not returned to the seed stock.'可被翻译为：从主种子库中提取的种子材料的均匀悬浮液，在有限传代水平上，等份分配到单独的容器中储存。所有容器的处理都是一样的，一旦从储存中取出，就不返回种子库。\n'A liquid sol with a solid as a dispersing phase, that is, a dispersing system formed by an insoluble solid dispersed in a liquid. The linear size of solid particles is above 0.1pm.'可被翻译为：以固体为分散相的液溶胶，即由不溶性的固体分散在液体中所形成的分散物系。固体粒子的线性大小在0.1pm以上。\n\n根据上述已知信息，请将'A suspension formed when the seeds are dispersed by shaking them into a sterile liquid.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将抱子转入无菌液体中振摇，使抱子分散后形成的悬浮液。"
    },
    {
        "instruction":"已知信息：\n'The absorption and distribution of drugs in the body Biotransformation and excretion.'可被翻译为：药物在体内的吸收分布生物转化和排泄。\n'Full name \"Pharmacokinetics\". It mainly studies the dynamic changes of the body's treatment of drugs, including the absorption, distribution, biotransformation and excretion processes of drugs in the body, especially the discipline of blood drug concentration changes with time.'可被翻译为：全称\"药物代谢动力学”。主要研究机体对药物的处置的动态变化，包括药物在机体内的吸收、分布、生物转化及排泄的过程，尤其是血药浓度随时间变化规律的学科。\n\n根据上述已知信息，请将'The subject of quantitative study of the dynamic laws of the absorption, distribution, biotransformation and excretion of toxicants in the body over time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"定量研究毒物在体内吸收、分布、生物转化、排泄等过程随时间变化的动态规律的学科。"
    },
    {
        "instruction":"已知信息：\n'(1) The source of the test system used in the study should be clear and compliant with the related regulation, and the relevant supporting documentation for acquisition and characterization of the test system should be kept completely; documentation for assessing suitability of the test system should be kept completely.'可被翻译为：(1)研究所需实验系统的来源应清晰合规，应完整保存 实验系统购入(转入)、质量鉴定等相关证明性文件；应完整保留适用性评估资料。\n'1. The consistency of the application dossiers with the study protocol, raw data and final report should be audited;'可被翻译为：1.核查申报资料与试验方案、原始数据、总结报告的一致性；\n\n根据上述已知信息，请将'1. The applicant and the testing facility under inspection should ensure that the original study materials retained are complete and can be provided for inspection in a timely manner, including an original copy of protocol, raw data, specimens, relevant testing reports, reserve samples of test\/control articles, an original copy of the final study report and other documentation related to the study;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.现场核查期间，申请人及被核查研究机构应确保研究 原始资料保存完整并能够及时提供、接受核查，包括试验方案的原件、原始数据、标本、相关检测报告、留样受试物和对照品、总结报告的原件以及研究有关的各种文件；"
    },
    {
        "instruction":"已知信息：\n'Article 69 Where a drug manufacturer does not conduct production of the new drug, for which an observation period is set, within two years from the date of the approval, the State Food and Drug Administration may approve the application of another drug manufacturer to produce the new drug and reset the observation period of the drug.'可被翻译为：第六十九条 药品生产企业对设立监测期的新药从获准生产之日起2年内未组织生产的，国家食品药品监督管理局可以批准其他药品生产企业提出的生产该新药的申请，并重新对该新药进行监测。\n'Article 71 Starting from the date a new drug enters the observation period, other registration applications for the same drug shall no longer be accepted. The other applicants' applications for the same drug already accepted but not yet approved for clinical trials shall be returned; upon the expiration of the observation period of the drug, the registration of a generic or import drug may be applied for.'可被翻译为：第七十一条 新药进入监测期之日起，不再受理其他申请人的同品种注册申请。已经受理但尚未批准进行药物临床试验的其他申请人同品种申请予以退回；新药监测期满后，申请人可以提出仿制药申请或者进口药品申请。\n\n根据上述已知信息，请将'Article 66 In order to protect the public health, the State Food and Drug Administration may set an observation period for any new drug approved for production. The observation period of a new drug shall be no longer than five years from the date the drug is approved for production.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十六条 国家食品药品监督管理局根据保护公众健康的要求，可以对批准生产的新药品种设立监测期。监测期自新药批准生产之日起计算，最长不得超过5年。"
    },
    {
        "instruction":"已知信息：\n'A large percentage of small volume parenterals appear to be inhibitory to the LAL gel- clot method because of low pH, or some excipient \/ active component of the product. In order to expedite the neutralization of this interfering trait, determine the lowest product dilution overcoming the interference but still within the Maximum Valid Dilution (MVD). The detailed description of this protocol is delineated in LIB No. 2433 (July 25, 1980), “A condensed procedure for diluting product in determining compatibility with the Limulus Amebocyte Lysate test for endotoxin”. In addition, the use of neutralizers such as sodium laurel sulfate or PyrosperseTM has also been described (see references).'可被翻译为：由于其低pH值，或产品的有些辅料\/活性组份，很大比例的小容量注射剂显示出对 LAL凝胶方法的抑制性。为了加快对这种干扰特性的中和，要确定克服干扰但仍在 最大有效稀释度（MVD）内的最低产品稀释级别。该方案在LIB No. 2433 (19800725) “在确定与鲎变形细胞裂解物检测内毒素的相容性时稀释产品的浓缩程 序”中有详细说明。另外，使用中和剂如月桂基硫酸钠或PyrosperseTM（参见参考 资料）。\n'7. Product Test Failure - When a firm has a final product or in-process test result that indicates a failure (USP test failure, OOS, etc.) ask– Were the results due to laboratory error or a true process contamination?'可被翻译为：产品检测失败—如果一个公司有一个成品或中控检测结果显示失败（USP 检测失败，OOS 等），询问—结果是因为实验室错误还是真正的工艺污染？\n\n根据上述已知信息，请将'When conflicting results occur within a test run, the analyst should consult USP Chapter<85> , Gel-Clot Limits Test, Interpretation, for guidance on repeat testing. As specified in Chapter<85> , if the test failure occurred at less than the maximum valid dilution (MVD), the test should be repeated using a greater dilution not exceeding the MVD. A record of this failure should be included in the laboratory results. If a test is performed at the MVD and an out-of- specification (OOS) test result occurs that cannot be attributed to testing error, continue product dilution until the actual endotoxin concentration can be calculated. These results should be recorded on your worksheets.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在同一次检测中得到相互矛盾的结果，化验员应遵守US<85>P“凝胶法限度测 试”结果诠释中的复测指导。正如第<85>章所述，如果低于MVD时检测结果不合 格，应使用不超过MVD的较大稀释倍数重复检测。该检测不合格结果记录要放在 实验室结果中。如果在MVD执行检测并得到不可归因于检测错误的OOS结果，则 要持续稀释产品直到实际内毒素浓度可计算为止。这些结果均应记录在你的工作表 中。"
    },
    {
        "instruction":"已知信息：\n'Cleanroom gowning should be performed in change rooms of an appropriate cleanliness grade to ensure\ngown cleanliness is maintained. Outdoor clothing including socks (other than personal underwear) should not be\nbrought into changing rooms leading directly to grade B and C areas. Single or two-piece facility trouser suits,\ncovering the full length of the arms and the legs, and facility socks covering the feet, should be worn before entry\nto change rooms for grades B and C. Facility suits and socks should not present a risk of contamination to the\ngowning area or processes.'可被翻译为：洁净室更衣应在适当洁净级别的更衣室进行，以确保维持工作服的洁净度。不得将包括袜子在内的便服（个\n人内衣除外）带入直接通往 B 级和 C 级区的更衣室。在进入 B 级和 C 级的更衣室之前，应穿着覆盖整个\n手臂和腿部的连体服或分体式工作服，以及覆盖脚部的工作袜。工作服和工作袜不应对更衣区或者工艺带\n来污染风险。\n'Microorganisms detected in the grade A and grade B areas should be identified to species level and the potential  impact  of such microorganisms  on product  quality  (for  each batch  implicated)  and  overall  state  of control should be evaluated. Consideration should also be given to the identification of microorganisms detected in grade C and D areas (for example where action limits or alert levels are exceeded) or following the isolation of organisms that may indicate a loss of control, deterioration in cleanliness or that may be difficult to control such as spore-forming microorganisms and moulds and at a sufficient frequency to maintain a current understanding of\nthe typical flora of these areas.'可被翻译为：如果 A 级和 B 级区监测到微生物，应将其鉴定到种，并应评估此类微生物对产品质量（每个相关批次）和 整体受控状态的潜在影响。还应考虑对 C 级和 D 级区检出的微生物进行鉴定（例如，超出行动限或警戒限）， 或在分离出可能表明洁净度失控、恶化的微生物或难以控制的微生物（例如可形成孢子的微生物和霉菌）后进行鉴定，并定期充分更新对这些区域中典型菌群的认知。\n\n根据上述已知信息，请将'A description of typical clothing required for each cleanliness grade is given below:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"各洁净级别通常要求的着装说明如下："
    },
    {
        "instruction":"已知信息：\n'The Medical Device Distribution License applies the uniform format made by NMPA, and shall be printed by the department in charge of drug supervision and administration at the level of a city divided into districts.'可被翻译为：医疗器械经营许可证由国家药品监督管理局统一样式，由设区的市级负责药品监督管理的部门印制。\n'Article 18 If a medical device manufacturer establishes the manufacturing premises across the province, autonomous region or municipality directly under the central government, it shall apply to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the manufacturing premises is located for Medical Device Manufacturing License.'可被翻译为：第十八条  医疗器械生产企业跨省、自治区、直辖市设立生产场地的，应当向新设生产场地所在地省、自治区、直辖市药品监督管理部门申请医疗器械生产许可。\n\n根据上述已知信息，请将'The Medical Device Manufacturing License applies the uniform format made by NMPA, and shall be printed by the drug regulatory department of the province, autonomous region, or municipality directly under the central government.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械生产许可证由国家药品监督管理局统一样式，由省、自治区、直辖市药品监督管理部门印制。"
    },
    {
        "instruction":"已知信息：\n'Article 65 The number of Cosmetics Manufacturing License is arranged as follows: X妆XXXXXXXX. Where, the first X refers to the abbreviation of the province, autonomous region, or municipality directly under the central government where the licensing department is located, the second to the fifth X refer to the licensing year in 4-digit, and the sixth to the ninth X refer to the licensing serial number in 4-digit.'可被翻译为：第六十五条 化妆品生产许可证编号的编排方式为：X妆XXXXXXXX。其中，第一位X代表许可部门所在省、自治区、直辖市的简称，第二位到第五位X代表4位数许可年份，第六位到第九位X代表4位数许可流水号。\n'Article 14 The Medical Device Manufacturing License consists of the original and duplicate, with a valid term of 5 years. Both the original and the duplicate shall be indicated with the license number, enterprise name, unified social credit identifier, legal representative (person in charge of the enterprise), domicile, manufacturing address, manufacturing scope, license issuing department, date of issuance, and valid term. The duplicate shall record changes in items stated in the original copy or major modification of the production line and other conditions. Items such as the enterprise name, unified social credit identifier, legal representative (person in charge of the enterprise) and domicile, etc. shall be consistent with those stated in the Business License.'可被翻译为：第十四条  医疗器械生产许可证分为正本和副本，有效期为5年。正本和副本载明许可证编号、企业名称、统一社会信用代码、法定代表人（企业负责人）、住所、生产地址、生产范围、发证部门、发证日期和有效期限。副本记载许可证正本载明事项变更以及车间或者生产线重大改造等情况。企业名称、统一社会信用代码、法定代表人（企业负责人）、住所等项目应当与营业执照中载明的相关内容一致。\n\n根据上述已知信息，请将'Article 15 The Cosmetics Manufacturing License shall be indicated with the license number, the manufacturer’s name, domicile, manufacturing address, unified social credit identifier, legal representative or responsible person, the manufacturing licensed items, expiry date, issuing authority and date of issuance, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十五条 化妆品生产许可证应当载明许可证编号、生产企业名称、住所、生产地址、统一社会信用代码、法定代表人或者负责人、生产许可项目、有效期、发证机关、发证日期等。"
    },
    {
        "instruction":"已知信息：\n'(3) the handling of unqualified drugs;'可被翻译为：（三）药品质量不合格的处理情况；\n'(3) the distribution scope and mode of medical devices;'可被翻译为：（三）医疗器械经营范围、经营方式；\n\n根据上述已知信息，请将'(3) selling drugs beyond the scope of the drug distribution certificate;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）超过药品经营许可范围销售药品的；"
    },
    {
        "instruction":"已知信息：\n'A uniform, stable mixture formed by the separation of one or more substances into another.'可被翻译为：一种或几种物质分散到另-种物质里，形成的均一的、稳定的混合物。\n'carry-over'可被翻译为：残留效应\n\n根据上述已知信息，请将'The blending of carry-over material from one grade of an excipient with another, usually due to a continuous process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常由于一个连续的过程，将一种等级的赋形剂的残留物质与另一种等级的赋形剂混合。"
    },
    {
        "instruction":"已知信息：\n'After review and approval, NMPA published the YY 0096-2019 Co-60 Teletherapy Unit and other 26 medical device industry standards, as well as the No. 1 amendment form for YY 0285.3-2017 Intravascular catheters—Sterile and single-use catheters—Part 3: Central venous catheters medical device industry standard on May 31, 2019. See Annex for the standard code, name, scope of application, date of implementation and contents of the amendment (Annex omitted).'可被翻译为：经审查和批准，国家药监局发布了YY 0096-2019《钴-60远距离治疗机》和其他26项医疗器械行业标准，以及YY0285.3-2017《血管内导管 一次性使用无菌导管 第3部分：中心静脉导管》医疗器械行业标准第1号修改单于2019年5月31日。标准编号、名称、适用范围、实施日期和修改单内容见附件（附件略）。\n'NMPA Issued 27 Medical Device Industry Standards (Covering YY 0096-2019 Co-60 Teletherapy Unit) and 1 Amendment Form'可被翻译为：关于发布YY 0096—2019《钴-60远距离治疗机》等27项医疗器械行业标准和1项修改单的公告\n\n根据上述已知信息，请将'After review and approval, NMPA published the YY0096-2019 Co-60 Teletheraphy Unit and other 26 medical device industry standards, as well as the No.1 amendment form for YY0285.3-2017 Intravascular catheters-Sterile and single-use catheters-Part 3: Central venous catheters medical device industry standard on May 31, 2019. See Annex for the standard code, name, scope of application, date of implementation and contents of the amendment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药检局于2019年5月31日发布了YY 0096-2019《钴-60远距离治疗机》等27项医疗器械行业标准和YY0285.3-2017《血管内导管 一次性使用无菌导管 第3部分：中心静脉导管》医疗器械行业标准第1号修改单已经审定通过。标准编号、名称、适用范围、实施日期和修改单内容见附件。"
    },
    {
        "instruction":"已知信息：\n'Article 126 In any of the following circumstances, a drug shall not be re-registered:'可被翻译为：第一百二十六条 有下列情形之一的药品不予再注册：\n'The sale of drugs prescribed in item (1) to item (3) of the preceding paragraph, or the use of drugs prescribed in item (1) to item (5) of the preceding paragraph by drug use institutions, shall be punished in accordance with the provisions of the preceding paragraph. In serious circumstances, where the legal representative, the principal responsible person, the persons directly in charge, and other directly responsible persons as well as other responsible personnel that have a medical license, the medical license shall be subject to revocation.'可被翻译为：销售前款第一项至第三项规定的药品，或者药品使用单位使用前款第一项至第五项规定的药品的，依照前款规定处罚；情节严重的，药品使用单位的法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。\n\n根据上述已知信息，请将'Where a drug manufacturer violates Item (IV) or (V) of the preceding paragraph, re-registration of relevant drugs shall be prohibited in accordance with requirements of the Provisions for Drug Registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品生产企业有前款规定第（四）项、第（五）项情形之一的，按照《药品注册管理办法》的规定对相应药品不予再注册。"
    },
    {
        "instruction":"已知信息：\n'Article 16 The organization being inspected and their related personnel shall, as required by the inspection team, timely specify person(s) responsible for the inspection site, open the relevant places or areas, cooperate with the inspection of related equipment and facilities, maintain normal production and operation conditions, provide true, valid and complete documents, records, receipts, vouchers, electronic data and other related materials, and truthfully answer the questions raised by the inspection team.'可被翻译为：第十六条 被检查单位及有关人员应当及时按照检查组要求，明确检查现场负责人，开放相关场所或者区域，配合对相关设施设备的检查，保持正常生产经营状态，提供真实、有效、完整的文件、记录、票据、凭证、电子数据等相关材料，如实回答检查组的询问。\n'The inspected institution shall introduce to the inspection team the development and manufacturing of the inspected variety in the institution and clarify the person in charge of the inspection site.'可被翻译为：被核查单位应当向核查组介绍核查品种在本单位开展的研究、生产等情况，明确核查现场负责人。\n\n根据上述已知信息，请将'The inspected institution shall cooperate with the inspection team, open relevant venues, provide documents, records, electronic data, etc. required for the inspection in a timely manner, answer the inspection team's inquiries truthfully, and ensure the authenticity of the information provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被核查单位应当配合核查组工作，开放相关场地，及时提供核查所需的文件、记录、电子数据等，如实回答核查组的询问，保证所提供的资料真实。"
    },
    {
        "instruction":"已知信息：\n'The procedure requires that the test be conducted with a suitable volume of product. It is advisable to begin with at least 20 mL of product. Use the original product containers whenever possible or five sterile, capped bacteriological containers of suitable size into which a suitable volume of product has been transferred. If the diluted product exhibits antimicrobial properties, specific neutralizers may need to be incorporated into the diluents or the recovery media. For purposes of testing, products have been divided into four categories:'可被翻译为：程序要求用适量产品来进行测试，建议从至少20mL的产品开始。尽可能使用原来的产品容器， 或将合适体积的产品转移到 5 个合适尺寸的无菌细菌学容器。如果稀释的产品表现出抑菌性能， 则可能需要将特定的中和剂掺入稀释剂或恢复培养基中。根据测试的目的，产品分为四类：\n'LAL manufacturers recommend the test sample to have a pH range of 6.0 to 8.0 for optimal assay performance. Since the lysate is buffered, sample dilutions in pyrogen-free water may be enough to test the sample with the LAL assay. Determine the pH of the sample with the added lysate and document the results. If pH adjustment is needed, use pyrogen-free acid, base or buffers.'可被翻译为：LAL生产商建议检测样本pH范围为6.0-8.0以优化检测表现。由于鲎试剂被缓冲， 样本在无热源水中的稀释级别可能足以使用LAL方法检测样本。将鲎试剂加入样 本中，检测pH值，记录结果。如果需要调整pH值，使用无热源的酸、碱或缓冲 液。\n\n根据上述已知信息，请将'When using commercially purchased pyrogen-free water for product dilutions, it is recommended to transfer a working volume from the original stock container to an individual pyrogen-free test tube or flask in order to minimize back contamination. Run a negative control for the working volume for each sample run.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果产品稀释使用的是商业化采购的无热源水，建议从原始存贮容器中转移工作用 体积的水至单个无热源试管或烧瓶中，以最大程度减少背景污染。每次检测样品时 均要使用工作体积的水进行阴性对照试验。"
    },
    {
        "instruction":"已知信息：\n'(5) not stating the reasons of non-acceptance or unapproval of a drug registration application by law; and'可被翻译为：（五）未依法说明不受理或者不批准药品注册申请理由的；\n'(I) The applicant fails to carry out Manufacturing Site Inspection within the prescribed time limit, or fails to accept on-site inspection within the prescribed time limit, except for the legitimate reasons of force majeure such as natural disaster or government acts;'可被翻译为：(一)除自然灾害、政府行为等不可抗力的正当理由外，申请人未在规定时限内进行生产现场核查确认，或者不能在规定时限内接受现场核查的；\n\n根据上述已知信息，请将'(5) The applicant refuses to accept drug registration inspection and testing or, without justifiable reasons, fails to accept drug registration inspection and testing within the specified timeline.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）申请人拒绝接受或者无正当理由未在规定时限内接受药品注册核查、检验的；"
    },
    {
        "instruction":"已知信息：\n'The requalification of cleanrooms and clean air equipment should be carried out periodically following defined procedures. The requalification should include at a minimum the following:'可被翻译为：洁净室和洁净空气设备的再确认应按照规定的程序定期执行。再确认应至少包括以下内容：\n'The manufacture of sterile products should be carried out in appropriate cleanrooms, entry to which should be through change rooms that act as airlocks for personnel and airlocks for equipment and materials. Cleanrooms and change rooms should be maintained to an appropriate cleanliness standard and supplied with air that has passed\nthrough filters of an appropriate efficiency. Controls and monitoring should be scientifically justified and should effectively evaluate the state of environmental conditions of cleanrooms, airlocks and pass-through hatches.'可被翻译为：无菌产品的生产应在适当的洁净室内进行，应通过更衣室（起到人员气锁及设备和物料气锁的作用）进入洁净室。洁净室和更衣室应保持适当的洁净度标准，并通过适当效率的过滤器送风。控制和监测应经过科学论证，并应有效地评估洁净室、气锁和传递窗的环境条件的状态。\n\n根据上述已知信息，请将'Appropriate requalification consisting of at least the above tests should also be carried out following completion of remedial action implemented to rectify an out of compliance equipment or facility condition or after changes to equipment, facility or processes as appropriate. The significance of a change should be determined through the change management process. Examples of changes to be considered include but are not limited to the following:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在纠正设备或设施缺陷而采取的整改措施完成后，或设备、设施或工艺的变更后，还应视情况进行上述检测进行适当的再确认。变更的重要性应通过变更管理程序确定。需要考虑的变更案例包括但不限于："
    },
    {
        "instruction":"已知信息：\n'f. <62> Microbiological Examination of Nonsterile products: Tests for Specified Microorganisms'可被翻译为：<62>非无菌药品的微生物检查\n'This section contains supplemental information for the quantitative enumeration of viable microorganisms and the determination of the absence of specified microorganisms in finished pharmaceutical products and raw materials, previously referred to as Microbial Limits Testing (MLT). The detailed procedures for these tests are not addressed in this PMM chapter because they are found in USP<60> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: TESTS FOR BURKHOLDERIA CEPACIA COMPLEX, USP<61> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: MICROBIAL ENUMERATION TESTS and MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: TESTS FOR SPECIFIED MICROORGANISMS.'可被翻译为：本部分包括活体微生物定量计数和测定成品及原料药中不得检出的特定微生物的补充信息，以 前被称为微生物限度试验（MLT）。这些测试的详细程序没有列入本PMM中，因为可以在 USP<60>“非无菌药品的微生物检查：洋葱伯克霍尔德菌复合体的检测”、USP<61>“非无菌 产品的微生物检查：微生物计数检测”和“非无菌产品的微生物检查：特定微生物检测” 中找到。\n\n根据上述已知信息，请将'e. <61> Microbiological Examination of Nonsterile products: Microbial enumeration tests'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"<61>非无菌药品的微生物检查：微生物计数"
    },
    {
        "instruction":"已知信息：\n'7. Sufficient reference samples of starting materials and finished products are retained to permit future inspection and testing of the product when necessary, and that the finished product is retained in its final package unless exceptionally large packages are produced.'可被翻译为：（七）物料和最终包装的成品应当有足够的留样，以备必要的检查或检验；除最终包装容器过大的成品外，成品的留样包装应当与最终包装相同。\n'1.Contamination of a starting material, intermediate product or finished product with another starting material or product.\n2.Contamination of a starting material, intermediate product or finished product with another starting material or product during production.\n3.Contamination of a starting material, intermediate product or finished product with another starting material or product during production.\n4.Contamination of a material or product with another material or product.\n5.Contamination of a starting material, intermediate product or finished pharmaceutical product with another starting material or product during production, storage and transportation.\n6.Contamination of a starting material, intermediate product or ﬁnished pharmaceutical product or medical product with another starting material or product, during production, storage and transportation.'可被翻译为：1.一种原料、中间产品或成品被另一种原料或产品污染。\n2.一种原料、中间产品或成品在生产过程中被另一种原料或产品污染。\n3.一种原料、中间产品或成品在生产过程中被另一种原料或产品污染。\n4.污染:一种材料或产品被另一种材料或产品污染\n5.在生产、储存、运输过程中，原料药、中间产品或药品成品被另一原料药或产品污染的。\n6.在生产、储存、运输过程中，原料药、中间产品、药品、医疗产品被其他原料药、产品污染的。\n\n根据上述已知信息，请将'A sample of a batch of starting material, packaging material, product contained in its primary packaging, or finished product that is stored for the purpose of being analysed, should the need arise. This may include storage in a suitable bulk container.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一批起始原料、包装材料、包含在其主要包装中的产品或成品的样品，如果需要，为分析目的而储存。这可能包括储存在合适的散装容器中。"
    },
    {
        "instruction":"已知信息：\n'Reactions resulting in one of the following harmful conditions due to the use of a drug: causing death; posing a life-threatening situation; causing cancer, teratogenicity, or congenital defects; leading to significant or permanent human injury or damage to organ function; resulting in hospitalization or prolonged hospital stay; causing other significant medical events, where failure to treat may lead to the aforementioned adverse reactions.'可被翻译为：因使用药品引起以下损害情形之一的反应：导致死亡；危及生命；致癌、致畸、致出生缺陷；导\n致显著的或者永久的人体伤残或者器官功能的损伤；导致住院或者住院时间延长；导致其他重要医学\n事件，如不进行治疗可能出现上述所列情况的不良反应。\n'Drugs with severe toxicity, therapeutic doses close to toxic doses, and improper use of which can cause poisoning or death.'可被翻译为：毒性剧烈、治疗剂量与中毒剂量相近，使用不当会致人中毒或死亡的药品。\n\n根据上述已知信息，请将'Medications that can pose occupational exposure risks or hazards, including those with genotoxic, carcinogenic, teratogenic effects, or those causing reproductive harm. Additionally, drugs with severe organ toxicity or other significant toxic effects at low doses fall into this category.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"能产生职业暴露危险或者危害的药品，即具有遗传毒性、致癌性、致畸性，或者对生育有损害作\n用以及在低剂量下可产生严重的器官或其他方面毒性的药品。"
    },
    {
        "instruction":"已知信息：\n'Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.'可被翻译为：违反本办法第十八条第二款规定，药品零售企业在执业药师或者其他依法经过资格认定的药学技术人员不在岗时销售处方药或者甲类非处方药的，责令限期改正，给予警告；逾期不改正的，处以一千元以下的罚款。\n'The online drug retailers shall display prescription drugs and non-prescription drugs separately, and prominently mark prescription drugs and non-prescription drugs on relevant web pages.'可被翻译为：药品网络零售企业应当将处方药与非处方药区分展示，并在相关网页上显著标示处方药、非处方药。\n\n根据上述已知信息，请将'Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经营处方药和甲类非处方药的药品零售企业，执业药师或者其他依法经资格认定的药学技术人员不在岗时，应当挂牌告知，并停止销售处方药和甲类非处方药。"
    },
    {
        "instruction":"已知信息：\n'Article 17: The quality management department should participate in all quality related activities, and review all GMP related documents. The responsibilities of quality management personnel are not permitted to be delegated to personnel of other departments.'可被翻译为：第十七条 质量管理部门应当参与所有与质量有关的活动，负责审核所有与本规范有关的文件。质量管理部门人员不得将职责委托给其他部门的人员。\n'Article 123 The quality management department or quality management personnel of enterprises shall fulfill the following responsibilities:'可被翻译为：第一百二十三条 企业应当设置质量管理部门或者配备质量管理人员，履行以下职责：\n\n根据上述已知信息，请将'Article 17 The quality management department shall fulfill the following responsibilities:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十七条 质量管理部门应当履行以下职责："
    },
    {
        "instruction":"已知信息：\n'Among the 5,574 applications requiring technical review, 4,459 were for chemical drugs, accounting for 80% of all those for technical reviews, and 300 and 815 were for TCMs and biologicals, respectively.'可被翻译为：需技术审评的5574件注册申请中，化药为4459件，占全部需技术审评的注册申请受理量的80%，中药和生物制品注册申请分别为300件和815件。\n'In 2019, 6,199 registration applications requiring technical review were accepted, increased by 11.21% as compared with those in 2018. Among them, 4,937 registration applications were for chemical drugs, increased by 10.72% as compared with those in 2018, accounting for 79.64% of the total number of registration applications requiring technical review; 257 registration applications were for TCMs, decreased by 14.33% as compared with those in 2018;1,005 registration applications were for biological products, increased by 23.3% as compared with those in 2018. The details of acceptance of registration applications for chemical drugs, TCMs and biological products requiring technical review in 2016-2019 are shown in Figure 2.'可被翻译为：2019年，受理需技术审评的注册申请6199件，较2018年增加11.21%，其中化学药注册申请为4937件，较2018年增长了10.72%，占全部需技术审评的注册申请受理量的79.64%；中药注册申请257件，较2018年降低了14.33%；生物制品注册申请1005件，较2018年增长了23.3%。2016-2019年需技术审评的化学药、中药和生物制品注册申请受理情况详见图2。\n\n根据上述已知信息，请将'Among the 6,817 registration applications with completed technical review, 300 applications were for TCMs , 1104 applications were for biological products, and 5,413 applications were for chemical drugs (accounting for about 79% of all completed reviews).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"完成技术审评的6817件注册申请中，中药注册申请300件，生物制品注册申请1104件，化学药注册申请为5413件，化学药注册申请约占全部审评完成量的79%。"
    },
    {
        "instruction":"已知信息：\n'A comprehensive applied technical discipline to study the preparation theory, production technology and quality control of drugs and their formulations, with the purpose of ensuring the effectiveness, safety and stability of drugs, and improving the compliance and bioavailability of drugs in clinical use.'可被翻译为：研究药物及其组方制剂的制备理论、生产技术和质量控制的综合应用技术学科，其目的在于保证药物有效性、安全性和稳定性，提高药物的临床使用的顺应性和生物利用度。\n'The State formulates development planning and industry policies for the vaccine industry to support development and structural optimization of the vaccine industry, and encourages scale and intensive production and constant improvement on the production process and quality of vaccines.'可被翻译为：国家制定疫苗行业发展规划和产业政策，支持疫苗产业发展和结构优化，鼓励疫苗生产规模化、集约化，不断提升疫苗生产工艺和质量水平。\n\n根据上述已知信息，请将'The branch of pharmacy that studies the industrial production of drugs and provides scientific basis and technical support for the design of new drugs and dosage forms, the improvement of production technology and the improvement of product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究药品的工业化生产，为新药和新剂型的设计、生产工艺的改进和产品质量的提高提供科学依据和技术支持的药学分支学科。"
    },
    {
        "instruction":"已知信息：\n'The estimation of the risk associated with the identified hazards. (ICH Q9)'可被翻译为：与已识别的危害相关的风险评估。（ICH Q9）\n'A systematic process for the assessment, control, communication, and review of risks to the quality of the drug product across the product lifecycle. (ICH Q9)'可被翻译为：对产品生命周期中药品质量风险进行评估、控制、沟通和回顾的系统过程。（ICHQ9）\n\n根据上述已知信息，请将'A measure of the possible consequences of a hazard. (ICH Q9)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种危害所造成可能结果的量度。（ICH Q9）"
    },
    {
        "instruction":"已知信息：\n'In both iPSC and hESC lines, it is not unusual for clones ofabnormal karyotype to arise on extended passage and overgrow the culture. Thusanalysts should monitor cultures for such abnormal cells. Traditionally, thishas been performed by karyotypic studies of metaphase spreads of the cellsusing Giemsa staining.The occurrence of nondiploid cells, even at very low incidence,can be problematic. Guidance documents such as the 2009 International Stem CellBanking Initiative are helpful to determine if such cultures should be discarded.However, newer procedures such as array comparative genome hybridization andsingle-nucleotide polymorphism arrays provide much more detailed analysis ofgenetic stability and can be used in parallel with Giemsa banding to givegreater confidence in genetic stability.'可被翻译为：在iPSC和hESC品系中，异常核型克隆在传代和培养中过度生长中比较常见。因此，分析人员应监控此类异常细胞的培养。通常通过姬姆萨染色对分裂中期细胞进行核形分析。非二倍体细胞的出现，即使发生率很低，也可能是有问题的。诸如2009年国际干细胞银行倡议之类的指导文件有助于确定是否应该丢弃此类培养物。然而，诸如比较基因组杂交和单核苷酸多态性阵列之类的较新方法提供了对遗传稳定性的更详细的分析，并且可以与Giemsa谱带结合使用，从而对遗传稳定性具有更大的信心。\n'good storage practices (gsp)'可被翻译为：良好存储规范(GSP)\n\n根据上述已知信息，请将'In addition to following good cell culture practices, analysts should note the availability of a specific guidance that contains principles and best practices in the procurement, banking, testing, and storage of hESCs for research purposes (see the ISCB 2009 reference in the Appendix). This guidance is useful for both iPSC and hESC lines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除了遵循良好的细胞培养规范外，分析人员应该还注意到一个具体的指南的可用性，其中包含用于研究目的hESCs的采购、存储机构、测试和存储的原则 (参见附录中的ISCB 2009参考)。本指南对iPSC和hESC都是实用的。"
    },
    {
        "instruction":"已知信息：\n'(1) To alter the dosage form of a non-prescription drug determined by the State Food and Drug Administration without changing the indications or functions, dosage and route of administration; or'可被翻译为：（一）经国家食品药品监督管理局确定的非处方药改变剂型，但不改变适应症或者功能主治、给药剂量以及给药途径的药品；\n'A New Drug Certificate shall not be issued to the approved registration applications for changing dosage forms without changing route of administration or claiming for new indications, with exceptions for special dosage forms such as targeting delivery, sustained release and controlled release preparations, etc.'可被翻译为：改变剂型但不改变给药途径，以及增加新适应症的注册申请获得批准后不发给新药证书；靶向制剂、缓释、控释制剂等特殊剂型除外。\n\n根据上述已知信息，请将'(2) Drugs developed by changing the dosage forms or strength of non-prescription drugs authorized by the NMPA without changing the indications, dosages or administration routes;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）经国家药品监督管理局确定的非处方药改变剂型或者规格，但不改变适应症（或者功能主治）、给药剂量以及给药途径的药品；"
    },
    {
        "instruction":"已知信息：\n'Article 299: A person should be designated as responsible for execution and coordination of recalls and should be supported by sufficient staff. This responsible person should be independent of the sales and marketing organization. If this person is not the Authorized Person, the latter should be made aware of any recall activity.'可被翻译为：第二百九十九条 应当指定专人负责组织协调召回工作，并配备足够数量的人员。产品召回负责人应当独立于销售和市场部门；如产品召回负责人不是质量受权人，则应当向质量受权人通报召回处理情况。\n'Batch records stored electronically should be protected by back-up transfer on magnetic tape, microfilm, paper or other means. It is particularly important that the data are safe, and readily available throughout the period of retention.'可被翻译为：用电子方法保存的批记录，应当采用磁带、缩微胶卷、纸质副本或其他方法进行备份，以确保记录的安全，且数据资料在保存期内便于查阅。\n\n根据上述已知信息，请将'Article 302: The distribution records should be readily available to the person(s) responsible for recalls.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三百零二条 产品召回负责人应当能够迅速查阅到药品发运记录。"
    },
    {
        "instruction":"已知信息：\n'Article 93 The State implements an essential drugs system to select essential drugs of appropriate quantities, better organize manufacturing and stockpile, improve the supply capacity for essential drugs, and satisfy the need for essential medications for disease prevention and treatment.'可被翻译为：第九十三条 国家实行基本药物制度，遴选适当数量的基本药物品种，加强组织生产和储备，提高基本药物的供给能力，满足疾病防治基本用药需求。\n'Article 66 The State buildss vaccines into the stockpile of strategic materials, implementing the stockpile at the national and provincial levels.'可被翻译为：第六十六条 国家将疫苗纳入战略物资储备，实行中央和省级两级储备。\n\n根据上述已知信息，请将'Article 92 The State implements a drug stockpile system by the establishment of national and local drug stockpile.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十二条 国家实行药品储备制度，建立中央和地方两级药品储备。"
    },
    {
        "instruction":"已知信息：\n'Article 53 Drug regulatory departments at or above the provincial level shall regularly release information on ADR reporting and monitoring.'可被翻译为：第五十三条 省级以上药品监督管理部门应当定期发布药品不良反应报告和监测情况。\n'Article 78  The content of medical device adverse event report, risk analysis and evaluation report and statistical data are the basis for strengthening   supervision and administration on medical devices and guiding proper use, but shall not serve as the basis for medical disputes, medical litigation or handling quality accident of medical devices.'可被翻译为：第七十八条  医疗器械不良事件报告的内容、风险分析评价报告和统计资料等是加强医疗器械监督管理、指导合理用械的依据，不作为医疗纠纷、医疗诉讼和处理医疗器械质量事故的依据。\n\n根据上述已知信息，请将'Article 57 The contents and statistical data of ADR reports are the basis for strengthening drug regulation and providing guidance for rational drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十七条 药品不良反应报告的内容和统计资料是加强药品监督管理、指导合理用药的依据。"
    },
    {
        "instruction":"已知信息：\n'ammonia nitrogen'可被翻译为：氨氮\n'nichrome coil'可被翻译为：镍铬线圈\n\n根据上述已知信息，请将'Nitrogen in the medium in the form of ammonia and coil ions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"培养基中以氨与卷离子形式存在的氮。"
    },
    {
        "instruction":"已知信息：\n'(7) When the multicenter clinical trial ends, the investigator of each clinical trial institution shall respectively issue the clinical trial summary, examine and verify the summary and the case reports according to relevant regulations, and submit them to the coordinating investigator and the coordinating investigator shall collect them and complete the summary report.'可被翻译为：（七）多中心临床试验结束后，各临床试验机构研究者应当分别出具临床试验小结，连同病历报告表按规定经审核后交由协调研究者汇总完成总结报告。\n'Article 86 The clinical trial report shall be signed and dated by the investigator, and submitted to the sponsor after being issued with opinions, dated and affixed with the seal of the clinical trial institution by the medical device clinical trial management department of the clinical trial institution.'可被翻译为：第八十六条 临床试验报告应当由研究者签名、注明日期，经临床试验机构医疗器械临床试验管理部门审核出具意见、注明日期并加盖临床试验机构印章后交申办者。\n\n根据上述已知信息，请将'In a multicenter clinical trial, the summaries of each clinical trial of sub-site shall be signed and dated by the investigator of the corresponding center, and reviewed, dated and affixed with the seal of the clinical trial institution by the medical device clinical trial management department of the center, and then submitted to the leading unit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"多中心临床试验中，各分中心临床试验小结应当由该中心的研究者签名并注明日期，经该中心的医疗器械临床试验管理部门审核、注明日期并加盖临床试验机构印章后交牵头单位。"
    },
    {
        "instruction":"已知信息：\n'Article 48 In case of discovering the following serious illegal acts, the operator of cosmetic e-commerce platform shall immediately suspend provision of e-commerce platform services for the marketers of cosmetics in the platform:'可被翻译为：第四十八条 化妆品电子商务平台经营者发现有下列严重违法行为的，应当立即停止向平台内化妆品经营者提供电子商务平台服务：\n'If the operators of cosmetic e-commerce platform know or shall know that the cosmetic marketers in the platform are prohibited from engaging in manufacturing and marketing of cosmetics according to law, they shall not provide e-commerce platform services to such marketers.'可被翻译为：化妆品电子商务平台经营者知道或者应当知道平台内化妆品经营者被依法禁止从事化妆品生产经营活动的，不得向其提供电子商务平台服务。\n\n根据上述已知信息，请将'If the cosmetic marketers within the platform are placed on a file for investigation or are initiated a public prosecution due to being suspected of crime related with quality and safety of cosmetics, and there are evidences proving that this might cause potential harm to human health, then the operators of cosmetic e-commerce platform could suspend provision of e-commerce platform services for the cosmetic marketers within the platform in accordance with the laws or with the service agreement and trading provisions of the platform.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因涉嫌化妆品质量安全犯罪被立案侦查或者提起公诉，且有证据证明可能危害人体健康的，化妆品电子商务平台经营者可以依法或者依据平台服务协议和交易规则暂停向平台内化妆品经营者提供电子商务平台服务。"
    },
    {
        "instruction":"已知信息：\n'Article 14 The documents for registration application or filing shall be in Chinese, where they are translated from a foreign language, the original documents shall also be provided at the same time. When referring to unpublished literature, the applicant shall provide documents proving of the owner's permission to use the information.'可被翻译为：第十四条 申请注册或者办理备案的资料应当使用中文。根据外文资料翻译的，应当同时提供原文。引用未公开发表的文献资料时，应当提供资料所有者许可使用的证明文件。\n'Article 35 A label shall be attached to the minimum sales unit of cosmetics in Chinese. The label contents shall be consistent with the sample manuscript of the product label in registration or filing documents of the cosmetics.'可被翻译为：第三十五条 化妆品的最小销售单元应当有中文标签。标签内容应当与化妆品注册或者备案资料中产品标签样稿一致。\n\n根据上述已知信息，请将'Article 12 The documents for registration application or filing shall be in Chinese. Where they are translated from another language, the original documents shall also be provided at the same time. When referring to unpublished literature, the applicant shall provide documents proving the owner’s permission to use the information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十二条 申请注册或者办理备案的资料应当使用中文。根据外文资料翻译的，应当同时提供原文。引用未公开发表的文献资料时，应当提供资料所有者许可使用的证明文件。"
    },
    {
        "instruction":"已知信息：\n'cloning efficiency'可被翻译为：克隆形成率\n'Proportion of living cells among dead cells, usually determined by staining or colony counting methods after a certain treatment interval.'可被翻译为：存活细胞与死亡细胞的比例。通常经过一段给药时间后，采用染色或集落计数的方法来确定。\n\n根据上述已知信息，请将'The efficiency of single cells to form clones. It is usually measured after seeding low numbers of cells in a suitable environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单个细胞形成克隆的能力。通常将少量细胞接种于适宜的环境培养后测量。"
    },
    {
        "instruction":"已知信息：\n'When atoms form molecules, the atomic orbitals are linearly combined into molecular orbitals, which are called bonding orbitals if the energy of the constituent molecular orbitals is lower than the energy of the atomic orbitals.'可被翻译为：原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若低于原子轨道的能量，则该分子轨道叫做成键轨道。\n'When atoms form molecules, the atomic orbitals are linearly combined into the component F orbitals, and the energy of the component molecular orbitals is equal to the energy of the atomic orbitals, then the molecular orbitals are called non-bonding orbitals.'可被翻译为：原子组成分子时，原子轨道线性组合成分F轨道，组成的分子轨道的能量若等于原子轨道的能量，则该分子轨道叫做非键轨道。\n\n根据上述已知信息，请将'When atoms form a molecule, the atomic orbitals are linearly combined into molecular orbitals, and if the energy of the constituent molecular orbitals is higher than the energy of the atomic orbitals, the molecular orbitals are called antibonding orbitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若高于原子轨道的能量，则该分子轨道叫做反键轨道。"
    },
    {
        "instruction":"已知信息：\n'A compound having a chemical structure similar to that of existing drug molecules.'可被翻译为：与现有药物分子在化学结构上具有相似性的化合物。\n'In the case of a derivative, a compound having a basic structure.'可被翻译为：对一类衍生物而言，具有基本结构的化合物。\n\n根据上述已知信息，请将'A compound having a structural characteristic necessary for the action of a drug. The compound is not metabolized or transformed in living organisms, avoiding the production of certain toxic metabolites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有发挥药物作用所必需的结构特征的化合物。该化合物在生物体内不发生代谢或转化，可避免产生某些毒性代谢产物。"
    },
    {
        "instruction":"已知信息：\n'Disordered arrangement of molecules having the same chemical structure.'可被翻译为：具有相同化学结构的分子间的无序排列。\n'Representing the bonding form and spatial arrangement of all constituent atoms in a molecule.'可被翻译为：表示分子中全部构成原子的成键形式与空间排列。\n\n根据上述已知信息，请将'The mutual repulsion caused by the spatial arrangement of groups inside the molecule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分子内部基团在空间排布造成的相互排斥作用。"
    },
    {
        "instruction":"已知信息：\n'To keep pace with the international technicalstandards for drug registration, NMPA has decided after research to apply 15 ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Guidelines, including the E1: Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-ThreateningConditions (see annex for details). The relevant matters are announced as follows:'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《E1：人群暴露程度：评估非危及生命性疾病长期治疗药物的临床安全性》等15个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n'To keep pace with the international technical standards for drug registration, NMPA has decided to apply 11 ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, including the Q2(R1): Validation of Analytical Procedures: Text and Methodology. The relevant matters are hereby announced as follows.'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《Q2（R1）：分析方法论证：正文和方法学》等11个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n\n根据上述已知信息，请将'To keep pace with the international technical standards for drug registration, NMPA has decided after research to apply 13 ICH(International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, including the S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals.The relevant matters are announced as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《S1A：药物致癌性试验必要性指导原则》等13个国际人用药品注册技术协调会（ICH）指导原则。现就有关事项公告如下。"
    },
    {
        "instruction":"已知信息：\n'A volumetric utensil for accurately removing a given volume of solution. It is a glass tube with two slender ends and an enlarged part in the middle. The bottom end of the tube is needle-shaped, and there is a ring mark in the upper part. The mark marks the volume of the liquid when the liquid is filled to the scale at the specified temperature and left to flow out naturally. The commonly used pipette has 50ml, 25ml, 20ml, 10ml, 5ml, 2ml, 1ml and other specifications.'可被翻译为：一种准确移取一定体积溶液的容量器皿。是一根两头细长而中间有膨大部分的玻璃管。管的最下端呈尖嘴状，在上部有一环形标线，该标线标示在指定的温度下把液体充满到刻度后，任其自然流出时流出液体的体积。常用的移液管有50ml、25ml、20ml、10ml、5ml、2ml、1ml等多种规格。\n'volumetric solution'可被翻译为：滴定液\n\n根据上述已知信息，请将'A graduated slender glass tube, the most basic instrument for titrating the volume of a solution in volumetric analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"容量分析中滴定溶液的体积最基本的仪器，有刻度的细长玻璃管。"
    },
    {
        "instruction":"已知信息：\n'Article 41 Based on the on-site inspection issues and related dossiers submitted by the observers, the drug regulatory authorities of the provinces, autonomous regions, and municipalities directly under the Central Government shall, in accordance with their daily supervision duties, review and confirm the rectification of the issues found in the on-site inspection of the inspected institution, and conduct follow-up inspections when necessary, and inform the review results to CDE in a timely manner.'可被翻译为：第四十一条 根据观察员报送的现场核查问题及相关材料，省、自治区、直辖市药品监督管理部门依日常监管职责对被核查单位的现场核查发现问题整改情况进行审核确认，必要时进行跟踪检查，并将审核结果及时告知药品审评中心。\n'CFDI shall feedback the problems found in the registration inspection to the drug regulatory authorities of the province, autonomous region, or municipality directly under the Central Government where the applicant and the inspected institution are located.'可被翻译为：核查中心向申请人和被核查单位所在地省、自治区、直辖市药品监督管理部门反馈注册核查发现的问题。\n\n根据上述已知信息，请将'Article 25 The drug regulatory authorities of the province, autonomous region, or municipality directly under the Central Government where the inspected institution is located shall select a drug regulatory officer as an observer to assist in the registration inspection work and be responsible for transferring the problems found in the registration inspection to the drug regulatory authorities of the province, autonomous region, or municipality directly under the Central Government.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十五条 被核查单位所在地省、自治区、直辖市药品监督管理部门选派1名药品监督管理人员作为观察员协助注册核查工作，负责将注册核查发现的问题等转送给省、自治区、直辖市药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'The involved disciplines at an organization from where a designated product, process or method is expected to be transferred.'可被翻译为：指定的产品、过程或方法预计将从该组织转移，该组织所涉及的学科。\n'receiving unit (RU). The involved disciplines at an organization where a designated product, process or method is expected to be transferred.'可被翻译为：接收方（RU）：准备接收所转移产品、工艺或方法的一方\n\n根据上述已知信息，请将'The involved disciplines at an organization where a designated product, process or method is expected to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"组织中涉及的学科，其中指定的产品、过程或方法预计将被转移。"
    },
    {
        "instruction":"已知信息：\n'Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.'可被翻译为：第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。\n'Article 18 Lot release may be conducted by means of independent dossier review or by combining dossier review with sample test, and on-site inspection may be conducted as required. For the lot release mode as well as the testing items and testing proportion for different products, the NIFDC shall organize the demonstration and each lot release institution shall conduct test in accordance with the determined mode for lot release and specifications.'可被翻译为：第十八条 批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种所采用的批签发方式及检验项目和检验比例，由中检院负责组织论证，各批签发机构按照确定的批签发方式和检验要求进行检验。\n\n根据上述已知信息，请将'Article 29 For lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. The testing items and testing frequency for lot release of vaccines shall be dynamically adjusted according to the vaccine quality risk evaluation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 疫苗批签发应当逐批进行资料审核和抽样检验。疫苗批签发检验项目和检验频次应当根据疫苗质量风险评估情况进行动态调整。"
    },
    {
        "instruction":"已知信息：\n'l. <1223> Validation of alternative microbiological methods'可被翻译为：<1223>替代微生物方法的验证\n'b. Validation of Growth-Based Rapid Microbiological Methods for Sterility Testing of Cellular and Gene Therapy Products (draft guidance, 2\/2008)'可被翻译为：基于生长快速微生物方法用于细胞和基因治疗产品无菌检测的验证（2008 年 2月，草案）\n\n根据上述已知信息，请将'Evaluation, Validation and Implementation of New Microbiological Testing Methods'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"新微生物检测方法的评估、验证和实施"
    },
    {
        "instruction":"已知信息：\n'ensure that the necessary equipment for QC is available and qualified at the RU site. The equipment used by the RU during the analytical transfer should meet the appropriate specifications in order to ensure the requirements of the method or specification are met;'可被翻译为：确保QC具备所需的仪器，并经过确认。分析方法转移期间RU所用仪器应符合适当的标准，以确保满足方法要求或标准要求；\n'10.7. Qualification and validation procedures, protocols, data and results should be appropriately recorded. The documents should be retained as defined in procedures.'可被翻译为：应适当记录确认和验证程序、方案、数据和结果。应按程序规定保存文件。\n\n根据上述已知信息，请将'10.4. Production process and analytical procedures should be appropriately transferred to the RU following documented procedures. Where validation data exist, these should be included in the \ntransfer.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产工艺和分析方法应按照文件程序妥善转移至 RU 处。如果有验证数据，应该包括在转移中。"
    },
    {
        "instruction":"已知信息：\n'1.The act whereby the regulatory authority in one jurisdiction may take into account and give significant weight to – i.e. totally or partially rely upon – evaluations performed by another regulatory authority or trusted institution in reaching its own decision. The relying authority remains responsible and accountable for decisions taken, even when it relies on the decisions and information of others (25).\n2.An act whereby a regulatory authority in one jurisdiction may take into account or give significant weight to work performed by another regulator, or other trusted institution, in reaching its own decision.'可被翻译为：1.一个司法管辖区的监管机构在做出自己的决定时，可能会考虑到另一个监管机构或值得信赖的机构所进行的评估，并给予重大重视，即完全或部分依赖。依赖机构仍然对所做的决定负责，即使它依赖于他人的决定和信息(25)。\n2.一个司法管辖区的监管机构在做出自己的决定时，可能会考虑到另一个监管机构或其他受信任的机构所做的工作或给予重大重视的行为。\n'national regulatory authority (nra)'可被翻译为：国家监管机构(NRA)\n\n根据上述已知信息，请将'Regulatory procedures facilitated by reliance, whereby a regulatory decision is solely or partially based on application of reliance. This usually involves some work by the national regulatory authority (NRA) that is practising reliance (see section 5.4 Risk-based approach). It is expected that use of reliance in these pathways will save resources and time as compared with standard pathways, while ensuring that the standards of regulatory oversight are maintained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"信赖促进了监管程序，即监管决定完全或部分基于信赖的应用。这通常涉及实施信赖的国家监管机构(NRA)的一些工作(见第5.4节基于风险的方法)。预计与标准途径相比，在这些途径中使用依赖将节省资源和时间，同时确保维持监管监督的标准。"
    },
    {
        "instruction":"已知信息：\n'Article 181: Operation procedures should include the title, code, version number, issuing department, effective date, distribution list, along with the dated signatures of author, reviewer and approver, the title, content, and change history.'可被翻译为：第一百八十一条 操作规程的内容应当包括：题目、编号、版本号、颁发部门、生效日期、分发部门以及制定人、审核人、批准人的签名并注明日期，标题、正文及变更历史。\n'Before the processing operation starts , the names, codes, batch numbers and labeling of all materials and intermediate products should also be checked , to guarantee that they are correct and in accordance with the requirements.'可被翻译为：生产操作前，还应当核对物料或中间产品的名称、代码、批号和标识，确保生产所用物料或中间产品正确且符合要求。\n\n根据上述已知信息，请将'Article 182: Premises, equipment, materials, documents and records should have codes (or reference numbers). Operation procedures should be established for the numbering\/coding system to ensure the uniqueness of the codes (or reference numbers).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百八十二条 厂房、设备、物料、文件和记录应当有编号（或代码），并制定编制编号（或代码）的操作规程，确保编号（或代码）的唯一性。"
    },
    {
        "instruction":"已知信息：\n'The MAH shall establish a marketing release procedure to review the testing results and release documents of the product released by the drug manufacturers, and the drug products can be released only after signed off by qualified person.'可被翻译为：药品上市许可持有人应当建立药品上市放行规程，对药品生产企业出厂放行的药品检验结果和放行文件进行审核，经质量受权人签字后方可上市放行。\n'Drug manufacturers shall establish drug release procedures and specify the release standards and criteria. Drug products that meet the standards and criteria shall be released upon signature by the qualified person.'可被翻译为：药品生产企业应当建立药品出厂放行规程，明确出厂放行的标准、条件。符合标准、条件的，经质量受权人签字后方可放行。\n\n根据上述已知信息，请将'Article 33 MAHs shall establish a marketing release procedure to audit drug products released by drug manufacturers. Drug products shall not be released until signed off by a qualified person and those that do not conform to national drug standards shall not be released.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十三条 药品上市许可持有人应当建立药品上市放行规程，对药品生产企业出厂放行的药品进行审核，经质量受权人签字后方可放行。不符合国家药品标准的，不得放行。"
    },
    {
        "instruction":"已知信息：\n'Environmental monitoring data and trend data generated for classified areas should be reviewed as part of product batch certification\/release. A written procedure should be available that describes the actions to be taken when data from environmental monitoring are found out of trend or exceeding the established limits. For products with short shelf life, the environmental data for the time of manufacture may not be available; in these cases, the compliance should include a review of the most recent available data. Manufacturers of these products  should\nconsider the use of rapid\/alternative methods.'可被翻译为：洁净区的环境监测数据和趋势分析数据应作为产品批次认证\/放行的一部分进行审核。应提供一份书面程序，描述当发现环境监测数据超趋势或超出既定限度时应釆取的措施。对于货架期较短的产品，可能无法获得生产时的环境数据；在这些情况下，符合性应包括对最新可用数据的审核。这些产品的生产商应考虑使用\n快速\/替代方法。\n'Alert level excursions should be documented and reviewed, and include an investigation to determine whether the excursion is a single (isolated) event or if results are indicative of an adverse trend or system deterioration. Each action limit excursion should be investigated to determine the probable root causes and any\npotential impact on the quality of products and manufacturing processes as a result of the use of the water'可被翻译为：偏离警戒限的异常情况应进行记录和审核，包括调查确定偏离是否为单个（独立）事件，或结果是否表明不良趋势或系统恶化。应对偏离行动限的每个异常情况进行调查，以确定可能的根本原因以及工艺用水对产品质量和生产工艺的任何潜在影响。\n\n根据上述已知信息，请将'All non-conformities, such as sterility test failures, environmental monitoring excursions or deviations from established procedures should be adequately investigated before certification\/release of the batch. The\ninvestigation should determine the potential impact upon process and product quality and whether any other processes or batches are potentially impacted. The reason for including or excluding a product or batch from the\nscope of the investigation should be clearly justified and recorded.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有不合格情况应在批次认证\/放行之前充分调查，例如无菌检验不通过、环境监测异常或偏离既定程序的偏差等。调查中，应确定不合格情况对工艺和产品质量的潜在影响，以及是否有可能影响任何其它工艺或批次。某一产品或批次纳入调查范围或排除在外的理由应予以明确说明并记录。"
    },
    {
        "instruction":"已知信息：\n'Provisions for Drug Recall'可被翻译为：药品召回管理办法\n'The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.'可被翻译为：《药品流通监督管理办法》于2006年12月8日经国家食品药品监督管理局局务会审议通过，现予公布，自2007年5月1日起施行。\n\n根据上述已知信息，请将'The Provisions for Drug Recall was deliberated and adopted by the executive meeting of the State Food and Drug Administration on December 6, 2007 and now is issued. These Provisions shall go into effect as of the date of promulgation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《药品召回管理办法》于2007年12月6日经国家食品药品监督管理局局务会审议通过，现予公布，自公布之日起施行。"
    },
    {
        "instruction":"已知信息：\n'An applicant who is approved to carry out clinical trials of drugs shall be the sponsor of drug clinical trials (hereinafter referred to as the sponsor).'可被翻译为：申请人获准开展药物临床试验的为药物临床试验申办者（以下简称申办者）。\n'I. Applicants should select, as far as practicable, the brand-name drug that has been approved for import registration or clinical trial in China as reference drugs for biosimilar clinical trials.'可被翻译为：一、申请人应尽可能选择已在我国获批进口注册或临床试验的原研药作为生物类似药临床试验用参照药。\n\n根据上述已知信息，请将'Article 34 When a drug clinical trial is approved, the applicant shall select institutions for the clinical trial from those certified for conducting drug clinical trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 药物临床试验批准后，申请人应当从具有药物临床试验资格的机构中选择承担药物临床试验的机构。"
    },
    {
        "instruction":"已知信息：\n'A class of inactive endogenous peptides synthesized in the liver and present in most body fluids. Converted by enzymolysis into active kinin, which is involved in inflammation, blood clotting, and complement reaction.'可被翻译为：在肝中合成并存在于绝大多数体液的一类无活性内源性肽类。经酶解作用转变成活性的激肽，后者与炎症、血液凝固、补体反应等有关。\n'A substance that lowers the level of cholesterol in the body.'可被翻译为：能降低机体内胆固醇水平的物质。\n\n根据上述已知信息，请将'A precursor substance of kinin in the body. Produced in the liver, it is -plasma 012-globulin.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"体内激肽的前体物质。产生于肝脏，是-种血浆012-球蛋白。"
    },
    {
        "instruction":"已知信息：\n'Article 132 Items and personal belongings irrelevant to drug distribution activities shall not be stored in the storage and display areas of drugs. There shall be no action in the working areas that may affect the quality and safety of drugs.'可被翻译为：第一百三十二条 在药品储存、陈列等区域不得存放与经营活动无关的物品及私人用品，在工作区域内不得有影响药品质量和安全的行为。\n'(XII) Items irrelevant to storage management shall not be stored in the storage area of drugs.'可被翻译为：（十二）药品储存作业区内不得存放与储存管理无关的物品。\n\n根据上述已知信息，请将'(XI) The unapproved personnel shall not enter the storage area, and the personnel in storage area shall not have any action affecting the quality and safety of drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）未经批准的人员不得进入储存作业区，储存作业区内的人员不得有影响药品质量和安全的行为；"
    },
    {
        "instruction":"已知信息：\n'As of January 1, 2022, for the registration application of cosmetics for spot correcting, whitening and preventing hair loss, registration persons shall submit the human efficacy test report conforming to the requirements in accordance with the Rules.'可被翻译为：自2022年1月1日起，申请祛斑美白、防脱发化妆品注册时，注册申请人应当按照规定，提交符合要求的人体功效试验报告。\n'For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed prior to May 1, 2021, registration persons shall submit the human efficacy test report prior to May 1, 2023.'可被翻译为：2021年5月1日前申请并取得注册的祛斑美白、防脱发化妆品，注册人应当在2023年5月1日前补充提交人体功效试验报告。\n\n根据上述已知信息，请将'IV. Efficacy evaluation and test report of cosmetics for spot correcting, whitening and preventing hair loss'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、关于祛斑美白和防脱发化妆品功效评价检验报告"
    },
    {
        "instruction":"已知信息：\n'According to the normal usage, dosage of the drug to prevent, diagnose or treat the disease process, occurred in the therapeutic purpose unrelated harmful reactions.'可被翻译为：按正常用法、用量应用药物预防、诊断或治疗疾病过程中，发生于治疗目的无关的有害反应。\n'therapeutic effect'可被翻译为：治疗作用\n\n根据上述已知信息，请将'The adverse reactions that occur after the therapeutic effect of drugs are the consequences of the therapeutic effect itself under the therapeutic dose.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物治疗作用之后出现的不良反应，是治疗剂量下治疗作用本身带来的后果。"
    },
    {
        "instruction":"已知信息：\n'Article 10 The persons undertaking registration or filing for medical devices shall have corresponding specialized knowledge and be familiar with the laws, rules, regulations and technical requirements of the administration on registration or filing of medical devices.'可被翻译为：第十条 办理医疗器械注册或者备案事务的人员应当具有相应的专业知识，熟悉医疗器械注册或者备案管理的法律、法规、规章和技术要求。\n'Article 104 The State establishes a professional and specialized team of drug inspectors who are familiar with drug laws and regulations and have professional knowledge of drugs.'可被翻译为：第一百零四条 国家建立职业化、专业化药品检查员队伍。检查员应当熟悉药品法律法规，具备药品专业知识。\n\n根据上述已知信息，请将'The persons who handle the application for drug registration shall have professional knowledge and be familiar with the laws and regulations on, and the technical requirements for, drug registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"办理药品注册申请事务的人员应当具有相应的专业知识，熟悉药品注册的法律、法规及技术要求。"
    },
    {
        "instruction":"已知信息：\n'Article 80 MAHs shall monitor for adverse reactions of marketed drugs, take the initiative to collect, track and analyze information on suspected adverse drug reactions, and promptly take risk control measures for drugs for which risks are identified.'可被翻译为：第八十条 药品上市许可持有人应当开展药品上市后不良反应监测，主动收集、跟踪分析疑似药品不良反应信息，对已识别风险的药品及时采取风险控制措施。\n'(3) A medical device used to monitor or influence the essential functions of another medical device, its class shall be identical to the medical device being monitored or influenced.'可被翻译为：（三）监控或者影响医疗器械主要功能的医疗器械，其分类应当与被监控、影响的医疗器械的分类一致。\n\n根据上述已知信息，请将'(3) They shall have the abilities to monitor and evaluate adverse reactions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）有不良反应监测与评价的能力。"
    },
    {
        "instruction":"已知信息：\n'Article 158: Documents should be regularly reviewed and revised. When a document has been revised, systems should exist to prevent inadvertent use of superseded documents. Distributed documents in use should be the approved current version. Those superseded and outdated documents should not be accessible in operating area except for archiving.'可被翻译为：第一百五十八条 文件应当定期审核、修订；文件修订后，应当按照规定管理，防止旧版文件的误用。分发、使用的文件应当为批准的现行文本，已撤销的或旧版文件除留档备查外，不得在工作现场出现。\n'Article 35 Enterprises shall ensure that all posts have access to necessary documents corresponding to their work contents, and carry out their work in strict accordance with the provisions.'可被翻译为：第三十五条 企业应当保证各岗位获得与其工作内容相对应的必要文件，并严格按照规定开展工作。\n\n根据上述已知信息，请将'Article 34 Enterprises shall periodically review and revise the documents, and the documents used shall be current valid versions. Documents that have been abolished or invalid shall not appear on the work site unless they are kept for reference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 企业应当定期审核、修订文件，使用的文件应当为现行有效的文本，已废止或者失效的文件除留档备查外，不得在工作现场出现。"
    },
    {
        "instruction":"已知信息：\n'Article 1 These Provisions are formulated in accordance with the Standardization Law of the People's Republic of China, the Regulations for the Implementation of the Standardization Law of the People's Republic of China and the Regulations for the Supervision and Administration of Medical Devices as well as other laws and regulations to promote progress in science and technology, ensure the safety and effectiveness of medical devices, improve health care and enhance medical device standards administration.'可被翻译为：第一条 为促进科学技术进步，保障医疗器械安全有效，提高健康保障水平，加强医疗器械标准管理，根据《中华人民共和国标准化法》《中华人民共和国标准化法实施条例》和《医疗器械监督管理条例》等法律法规，制定本办法。\n'Article 1 These Provisions are formulated in accordance with the Regulations on Supervision and Administration of Medical Devices for the purpose of strengthening the supervision and administration of medical device distribution, regulating the distribution activities of medical devices, and ensuring the safety and effectiveness of medical devices.'可被翻译为：第一条  为了加强医疗器械经营监督管理，规范医疗器械经营活动，保证医疗器械安全、有效，根据《医疗器械监督管理条例》，制定本办法。\n\n根据上述已知信息，请将'Article 2 Medical device standards stated in these Provisions refer to the unified technical requirements for the research and development, manufacturing, distribution, use, supervision and administration of medical devices which are formulated and revised by China Food and Drug Administration as per its duties and issued in accordance with the legal procedures so as.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 本办法所称医疗器械标准，是指由国家食品药品监督管理总局依据职责组织制修订，依法定程序发布，在医疗器械研制、生产、经营、使用、监督管理等活动中遵循的统一的技术要求。"
    },
    {
        "instruction":"已知信息：\n'Article 21 An enterprise to be engaged in Class II medical device distribution shall file the matter with the department in charge of drug supervision and administration at the level of a city divided into districts, and submit the related materials as prescribed in Article 10 of these Provisions (except Item (7)) to complete the distribution filing, and obtain the filing number.'可被翻译为：第二十一条  从事第二类医疗器械经营的，经营企业应当向所在地设区的市级负责药品监督管理的部门备案，并提交符合本办法第十条规定的资料（第七项除外），即完成经营备案，获取经营备案编号。\n'Article 10 An enterprise to be engaged in Class III medical device distribution shall file an application to the department in charge of drug supervision and administration at the level of a city divided into districts, and submit the following materials:'可被翻译为：第十条  从事第三类医疗器械经营的，经营企业应当向所在地设区的市级负责药品监督管理的部门提出申请，并提交下列资料：\n\n根据上述已知信息，请将'Article 22 An enterprise to be engaged in manufacturing Class I medical devices shall file the matter with the department in charge of drug supervision and administration at the level of a city divided into districts, and submit the related materials as prescribed in Article 10 of these Provisions to complete the manufacturing filing, and obtain the filing number. Where the medical device filing entities manufacture Class I medical devices by themselves, they may handle the manufacturing filing together with the product filing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条  从事第一类医疗器械生产的，应当向所在地设区的市级负责药品监督管理的部门备案，在提交本办法第十条规定的相关材料后，即完成生产备案，获取备案编号。医疗器械备案人自行生产第一类医疗器械的，可以在办理产品备案时一并办理生产备案。"
    },
    {
        "instruction":"已知信息：\n'cylinder bundle'可被翻译为：筒包\n'manifold'可被翻译为：廖\n\n根据上述已知信息，请将'An assembly of cylinders that are fastened together, interconnected by a manifold, transported and used as a unit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种钢瓶的组合，它们被固定在一起，通过歧管相互连接，作为一个整体运输和使用。"
    },
    {
        "instruction":"已知信息：\n'(2) Where an application item is not subject to the jurisdiction of the concerned departments by law, it shall be decided not to accept the application in time and informed to the applicant to apply to the relevant administrative departments;'可被翻译为：（二）申请事项依法不属于本部门职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政机关申请；\n'(1) If the subject matter of application falls within the scope of this administrative authority, and the application dossiers are complete and conform to statutory form, then the application shall be accepted;'可被翻译为：（一）申请事项属于本行政机关职权范围，申请资料齐全、符合法定形式的，应当受理申请；\n\n根据上述已知信息，请将'(4) If the subject matter of the application does not fall within the scope of this administrative authority, a decision of not accepting the application shall be made immediately, and the applicant shall be notified of applying to relevant administrative authority.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请事项不属于本行政机关职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政部门申请。"
    },
    {
        "instruction":"已知信息：\n'If an investigation finds that the conduct of the analysis included errors or events that caused the test specimens to be contaminated by the lab environment, the Sterility Test result would be invalid, and the substandard laboratory practice should be corrected to prevent this problem from recurring. For more information on how to judge investigational findings to make this evaluation, see Section XI.C1.and 2 of FDA’s guidance on Sterile Drug Products Produced by Aseptic Processing for principles and expectations for investigating a sterility positive.'可被翻译为：如果调查发现分析过程有可能导致受试样本被环境污染的错误或事件，则无菌性测 试结果可能无效，应纠正不合格的实验室作法，从而防止发生该问题。如何判断调 查发现，进行该评价的更多信息参见FDA指南《采用无菌工艺生产的无菌药品》 中无菌阳性的调查原则和要求。\n'Determine whether equipment malfunctioned or was not operated properly. If a malfunction occurred, determine whether it was likely to cause the contamination. Determine if monitoring records and any checklists or logs indicate that the ISO 5 environment was in good state of control (serious environmental quality or equipment repair issues) at the time of the sterility test. Be aware of the most likely failure modes in the equipment (e.g., laminar flow hood, glovebox, or isolator) used.'可被翻译为：确定是否设备故障，或操作不当。如果发生故障，确定是否可能导致污染。确定在 无菌测试时监测记录和检查清单或日志是否显示ISO5环境处于良好的受控状态 （严重环境质量或设备维修问题）。了解所用设备（例如，层流罩、手套箱或隔离 器）的最可能失效模式。\n\n根据上述已知信息，请将'Determine whether there was adverse environmental data. Note that a negative control failure, on its own, is not necessarily cause for invalidating a result. If a negative control was contaminated, consider whether the microbe identified is similar to, or the same as, the sterility test isolate and also consider whether there are other adverse environmental trends.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"确定是否有不良环境数据。注意阴性控制失败其本身并不一定导致结果无效。如果 阴性对照受到污染，考虑所鉴别的微生物是否类似或相同于无菌测试分离物，同时 考虑是否有其它不良环境趋势。"
    },
    {
        "instruction":"已知信息：\n'2019 China Cancer Immunotherapy Workshop Successfully Held'可被翻译为：2019中国肿瘤免疫治疗会议成功举办\n'The China Cancer Immunotherapy Workshop has been successfully held for five consecutive years with rising social attention and influence. The Workshop has provided an important academic exchange platform for Chinese and foreign drug regulatory authorities, academia and industry, promoting the exchange of professional knowledge and experience in the field of cancer immunotherapy. It has played a positive role in promoting international exchanges and cooperation in the field of drug regulation and enhancing innovation and development in the field of cancer immunotherapy.'可被翻译为：中国肿瘤免疫治疗会议已连续成功举办了5届，社会关注度和影响力不断扩大，会议为中外药品监管机构、学术界、企业界搭建了一个重要学术交流平台，促进了肿瘤免疫治疗领域的专业知识和经验交流，为推动我国药品监管领域的国际交流合作和肿瘤免疫治疗领域创新发展发挥了积极的作用。\n\n根据上述已知信息，请将'2019 China Cancer Immunotherapy Workshop was successfully held on June 29-30, 2019 in Tianjin, China. The Workshop was organized by China Center for Food and Drug International Exchange(CCFDIE),in cooperation with the Center for Drug Evaluation(CDE) of National Medical Products Administration(NMPA), Chinese American Hematologist and Oncologist Network(CAHON) and School of Medicine Tsinghua University.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年6月29日至6月30日，由中国食品药品国际交流中心(CCFDIE)主办，药品审评中心(CDE)、美国华裔血液及肿瘤专家学会(CAHON)和清华大学医学院协办的2019中国肿瘤免疫治疗会议在天津成功举办。"
    },
    {
        "instruction":"已知信息：\n'The process of the exchange and recombination of DNA fragments resulting from the breaking and joining of different DNA strands to form new DNA molecules.'可被翻译为：由于不同DNA链的断裂和连接而产生DNA片段的交换和重新组合，形成新DNA分子的过程。\n'dna strand breaks'可被翻译为：DNA链断裂\n\n根据上述已知信息，请将'If one of the two strands of plasmid DNA breaks in one or more places, the molecule can spin around, removing tension from the strand and forming a relaxed circular molecule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果质粒DNA两条链中有一条链发生-处或多处断裂，分子就能旋转而消除链的张力，形成松弛型的环状分子。"
    },
    {
        "instruction":"已知信息：\n'Media used for testing needs to be tested for growth promotion by inoculating the medium with appropriate microorganisms. It is preferable that test microorganisms be chosen for growth promotion testing (Section D).'可被翻译为：用于测试的培养基需要通过用适当微生物的培养基接种来测试促菌生长能力。最好选择测试微 生物用于促菌生长能力试验（D部分）。\n'In order to culture a pure and robust test organism, proper use and preparation of growth media (agar or broth), buffers and diluents is required. Components or final preparations of growth media, reagents or diluents may be prepared on-site and\/or purchased from outside sources. Regardless of origin, any final product made from growth media components and\/or \npreparations must be verified for identification, expiry, sterility and growth promotion, prior to \nuse in test. Refer to USP <81> for preparation, use and storage of all growth media, buffers and \ndiluents.'可被翻译为：为了培养纯净且耐用的测试生物，需要正确使用和制备生长培养基（琼脂或肉汤）、缓冲液和稀释剂。生长培养基、试剂或稀释剂的成分或成品可以现场制备和\/或从外部来源购买。无论来源如何，任何由生长培养基成分和\/或成品制备的最终产品在用于测试之前都必须进行鉴定，并确认其有效期、无菌性和促生长能力。所有生长培养基、缓冲液和稀释剂的制备、使用和储存参见 USP <81>。\n\n根据上述已知信息，请将'Both prepared and purchased media must meet the requirements of the USP growth promotion test of aerobes, anaerobes and fungi.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"无论是制备的还是购买的培养基均应满足USP的需氧菌、厌氧菌和真菌促生长测试 要求。"
    },
    {
        "instruction":"已知信息：\n'environmental control system'可被翻译为：环境控制体系\n'Environmental control, cleaning, sterilisation and monitoring of the critical extrusion, transfer and filling areas as relevant.'可被翻译为：关键挤压出区、转移区和灌装区的环境控制、清洁、灭菌和监测（如相关）。\n\n根据上述已知信息，请将'Environmental control and monitoring, both of the machine and the background in which it is placed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"环境控制和监测，包括设备及其环境。"
    },
    {
        "instruction":"已知信息：\n'Article 20 During the safety monitoring period, registrants and filing persons of new cosmetic ingredients may use the new cosmetic ingredient to produce cosmetics.'可被翻译为：第二十条 安全监测的期限内，化妆品新原料注册人、备案人可以使用该化妆品新原料生产化妆品。\n'Registrants and filing persons of new cosmetic ingredients shall, within 30 working days before a year period of safety monitoring of new cosmetic ingredients, prepare an annual report summarizing and analyzing the use and safety conditions of new ingredients, and submit it to the NMPA.'可被翻译为：化妆品新原料注册人、备案人应当在化妆品新原料安全监测每满一年前30个工作日内，汇总、分析化妆品新原料使用和安全情况，形成年度报告报送国家药品监督管理局。\n\n根据上述已知信息，请将'Article 21 Registrants and filing persons of new cosmetic ingredients shall establish a safety risk monitoring and evaluation system after the launch of new cosmetic ingredients, conduct follow-up research on the safety of new cosmetic ingredients, and continue to monitor and evaluate the use and safety of new cosmetic ingredients.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十一条 化妆品新原料注册人、备案人应当建立化妆品新原料上市后的安全风险监测和评价体系，对化妆品新原料的安全性进行追踪研究，对化妆品新原料的使用和安全情况进行持续监测和评价。"
    },
    {
        "instruction":"已知信息：\n'7. Method description, modifications, and verification along with recording of sample results and appropriate review and evaluation by management'可被翻译为：方法描述、修改和确认，以及样品结果的记录和管理人员的适当审核与评价\n'4. Clinical trial data recording and reporting'可被翻译为：4.临床试验数据记录和报告\n\n根据上述已知信息，请将'provide a documentation system capable of recording receipt and testing of samples to the required specification using approved test methods, and of reporting, recording and collating data and designation of status (approved, rejected, quarantine);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"提供可记录接收样品并采用批准的检测方法按所需标准检测样品，并报告、记录和整合数据，确定其结果（批准、拒收、隔离）的文件系统；"
    },
    {
        "instruction":"已知信息：\n'A sterilizing preparation made of medicine for injection into the body.'可被翻译为：药物制成的供注入人体内的灭菌制剂。\n'trauma therapeutic preparation'可被翻译为：创面用制剂\n\n根据上述已知信息，请将'A sterilizing preparation for ulcers, burns, and trauma sites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于溃疡、烧伤及外伤部位的灭菌制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 40 For an accepted registration application, the applicant may, prior to the administrative permission decision is made, withdraw the registration application and relevant materials, and give reasons to the food and drug regulatory department which accepted the application.'可被翻译为：第四十条 对于已受理的注册申请，申请人可以在行政许可决定作出前，向受理该申请的食品药品监督管理部门申请撤回注册申请及相关资料，并说明理由。\n'Article 169 Where there is any of the following circumstances, the State Food and Drug Administration shall withdraw the drug approval number, and announce to the public:'可被翻译为：第一百六十九条 具有下列情形之一的，由国家食品药品监督管理局注销药品批准文号，并予以公布：\n\n根据上述已知信息，请将'Article 159 In any of the circumstances prescribed in Article 69 of the Administrative Permission Law, the State Food and Drug Administration may withdraw the relevant drug approval documents upon the request of any interest party or according to its responsibilities and authorities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百五十九条 有《行政许可法》第六十九条规定情形的，国家食品药品监督管理局根据利害关系人的请求或者依据职权，可以撤销有关的药品批准证明文件。"
    },
    {
        "instruction":"已知信息：\n'Assembly of closed and sterilised SUS using intrinsic sterile connection devices.'可被翻译为：使用内部无菌连接装置组装已密封和已灭菌的 SUS。\n'Processes associated with the finishing, storage and transport of sterile products should not compromise the sterile product. Aspects that should be considered include: container integrity, risks of contamination and avoidance of degradation by ensuring that products are stored and maintained in accordance with the registered\nstorage conditions.'可被翻译为：与无菌产品的最终处理、贮存和运输相关的过程不应损害无菌产品。应考虑的方面包括：容器完整性，污染风险，以及通过确保产品按照注册贮存条件贮存和维护来避免降解。\n\n根据上述已知信息，请将'SUS  should  be  designed  to  maintain  integrity  throughout  processing  under  the  intended  operational conditions. Attention to the structural integrity of the single use components is necessary where these may be exposed to more extreme conditions (e.g. freezing and thawing processes) either during routine processing or transportation.  This  should  include verification that intrinsic  sterile  connection  devices  (both heat  sealed and mechanically sealed) remain integral under these conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SUS 的设计应能在预期操作条件和持续时间内保持完整性。在日常加工或运输过程可能出现暴露于极端条 件（例如冻融过程）的情况，有必要注意一次性组件的结构完整性。这应包括确认内部无菌连接装置（热密封和机械密封）在这些条件下保持完整。"
    },
    {
        "instruction":"已知信息：\n'(2) biological products and radioactive pharmaceuticals; and'可被翻译为：（二）生物制品、放射性药品；\n'Article 95 This GCP does not apply to in-vitro diagnostic reagents which are regulated as medical devices.'可被翻译为：第九十五条 本规范不适用于按照医疗器械管理的体外诊断试剂。\n\n根据上述已知信息，请将'(3) Biological products, radiopharmaceuticals and in-vitro diagnostic reagents regulated as drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）生物制品、放射性药品和按照药品管理的体外诊断试剂；"
    },
    {
        "instruction":"已知信息：\n'A secondary chemical reference substance is a substance whose characteristics are assigned and\/or calibrated by comparison with a primary chemical reference substance. The extent of characterization and testing of a secondary chemical reference substance may be less than  for a primary chemical reference substance. Although this definition may apply inter alia to some substances termed “working standards”, part B of these guidelines is intended to apply to secondary reference substances supplied as “official”, e.g. regional\/national standards, and not to manufacturers’ or other laboratories’ working standards.'可被翻译为：二级化学标准物质是通过与一级化学标准物质比较而确定和\/或校准其特性的物质。二级化学标准物质的表征和测试范围可能小于一级化学标准物质。虽然该定义可特别适用于一些被称为“工作标准”的物质，但本指南B部分旨在适用于作为“官方”提供的二级标准物质，例如区域\/国家标准，而不适用于制造商或其他实验室的工作标准。\n'A substance whose characteristics are assigned and\/or calibrated by comparison with a primary reference substance. The extent of characterization and testing of a secondary reference substance may be less than for a primary reference substance.Note: Often referred to as an “in-house” working standard.'可被翻译为：通过与主要标准物质比较而确定和\/或校准其特性的物质。二级标准物质的表征和测试范围可能小于一级标准物质。注:通常被称为“内部”工作标准。\n\n根据上述已知信息，请将'Secondary chemical reference substances (also called working standards) are substances whose characteristics are assigned and\/or calibrated by comparison with a primary chemical reference substance. The extent of characterization and testing of a secondary chemical reference substance may be less than for a primary chemical reference substance (7).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二级化学标准物质(也称为工作标准品)是通过与一级化学标准物质比较而确定和\/或校准其特性的物质。二级化学标准物质的表征和测试范围可能小于一级化学标准物质(7)。"
    },
    {
        "instruction":"已知信息：\n'(Ⅰ) Fail to establish the drug recall system, drug quality assurance system and adverse drug reaction monitoring system according to these Provisions;'可被翻译为：（一）未按本办法规定建立药品召回制度、药品质量保证体系与药品不良反应监测系统的；\n'(3) The sponsor fails to submit the DSUR as required;'可被翻译为：（三）申办者未按照要求提交研发期间安全性更新报告的；\n\n根据上述已知信息，请将'(3) fails to establish and implement a drug tracking system as required;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）未按照规定建立并实施药品追溯制度；"
    },
    {
        "instruction":"已知信息：\n'Article 10 In any of the following cases, the importation record filing of drugs to be imported shall proceed only after they have been tested and confirmed by the drug control institute of port that they meet the prescribed standards. If they do not meet the prescribed standards based on testing, the drug regulatory department at ports of entry shall not approve the importation record filing.'可被翻译为：第十条 下列情形的进口药品，必须经口岸药品检验所检验符合标准规定后，方可办理进口备案手续。检验不符合标准规定的，口岸药品监督管理局不予进口备案：\n'(II) the Import Drug License (or the Pharmaceutical Product License), or the Import License for narcotic drugs and psychotropic substances has expired at the time of importation record filing;'可被翻译为：（二）办理进口备案时，《进口药品注册证》（或者《医药产品注册证》），或者麻醉药品、精神药品的《进口准许证》已超过有效期的；\n\n根据上述已知信息，请将'Article 5 An importer may go through the formalities of importation record filing and port testing of drugs to be imported only after it has obtained the Import Drug License (or Pharmaceutical Product License) or Import Drug Approval issued by State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五条 进口药品必须取得国家食品药品监督管理局核发的《进口药品注册证》（或者《医药产品注册证》），或者《进口药品批件》后，方可办理进口备案和口岸检验手续。"
    },
    {
        "instruction":"已知信息：\n'5. All changes of the process or testing methods;'可被翻译为：（五）生产工艺或检验方法等的所有变更；\n'Article 254: CAPA implementation should be recorded and retained by the quality management department.'可被翻译为：第二百五十四条 实施纠正和预防措施应当有文件记录，并由质量管理部门保存。\n\n根据上述已知信息，请将'5. To record all changes during CAPA implementation;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）对实施纠正和预防措施过程中所有发生的变更应当予以记录。"
    },
    {
        "instruction":"已知信息：\n'Settle plates should be exposed for the duration of operations and changed as required after a maximum of 4 hours. Exposure time should be based on recovery studies and should not allow desiccation of the media used.'可被翻译为：沉降碟应在操作期间暴露，并在最多 4 小时后按需要更换。暴露时间应基于回收率研究，并且避免所所用培养基干燥。\n'(a)  Settle plates should be exposed in grade A and B areas for the duration of operations (including equipment set-up)  and  changed  as required after  a maximum  of 4 hours  (exposure time  should be based  on validation including recovery studies and it should not have any negative effect on the suitability of the media used).'可被翻译为：沉降碟应在操作期间（包括设备安装）暴露在 A 级和 B 级区，并在最多 4 小时后按要求更换（暴露时间应基于验证，包括回收研究，不应对所用培养基的适用性产生任何负面影响）。\n\n根据上述已知信息，请将'Individual settle plates may be exposed for less than 4 hours.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单个沉降碟的暴露时间可以少于 4 小时。"
    },
    {
        "instruction":"已知信息：\n'Article 6 Manufacturers and marketers of cosmetics shall establish, in accordance with the law, documentation system for the check and test of purchases, and product sales record, and other systems, to ensure traceability of the products.'可被翻译为：第六条 化妆品生产经营者应当依法建立进货查验记录、产品销售记录等制度，确保产品可追溯。\n'Article 4 The registrant and the filing entity of cosmetics shall establish a quality management system for cosmetics manufacturing according to law, perform obligations related to product including adverse reaction monitoring, risk control, recall etc, and shall be responsible for their quality, safety and efficacy claims of cosmetics. Manufacturers and marketers of cosmetics shall comply with laws, regulations, provisions, mandatory national standards and technical specifications in engaging in manufacturing and marketing activities and conduct vigorous management, maintain integrity and practice self-discipline, thus to ensure the quality and safety of cosmetics.'可被翻译为：第四条 化妆品注册人、备案人应当依法建立化妆品生产质量管理体系，履行产品不良反应监测、风险控制、产品召回等义务，对化妆品的质量安全和功效宣称负责。化妆品生产经营者应当依照法律、法规、规章、强制性国家标准、技术规范从事生产经营活动，加强管理，诚信自律，保证化妆品质量安全。\n\n根据上述已知信息，请将'Manufacturers and marketers of cosmetics are encouraged to adopt information technology to collect and store information on manufacturing and marketing, and establish a traceability system for quality and safety of cosmetics.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励化妆品生产经营者采用信息化手段采集、保存生产经营信息，建立化妆品质量安全追溯体系。"
    },
    {
        "instruction":"已知信息：\n'dust removal'可被翻译为：除尘\n'point extraction'可被翻译为：点提取\n\n根据上述已知信息，请将'1.Air extraction to remove dust with the extraction point located as close as possible to the source of the dust.\n2.Air extraction point located so that it effectively captures dust near its source.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.抽气除尘，抽气点尽量靠近粉尘源。\n2.排风点的位置使它能有效地在其源头附近捕获灰尘。"
    },
    {
        "instruction":"已知信息：\n'This test is performed to validate that a filter can remove bacteria from a gas or liquid. The test is usually performed using a standard organism, such as Brevundimonas diminuta, at a minimum concentration of 107 colony-forming units\/cm2'可被翻译为：进行这种测试是为了验证过滤器可以从气体或液体中去除细菌。该测试通常使用标准生物进行，如微小Brevundimonas，最低浓度为107菌落形成单位\/cm2\n'During filter validation, wherever possible, the product to be filtered should be used for bacterial retention testing of the sterilising grade filter. Where the product to be filtered is not suitable for use in bacterial retention testing, a suitable surrogate product should be justified for use in the test. The challenge organism used in the bacterial retention test should be justified.'可被翻译为：在过滤器验证过程中，应尽可能使用待过滤产品进行除菌级过滤器的细菌截留测试。如果待过滤产品不适 合用于细菌截留测试，应使用合适的替代产品进行测试并说明原因。应论证用于细菌截留试验的挑战微生物的合理性。\n\n根据上述已知信息，请将'Bacterial retention testing - This test is performed to validate that a filter can remove bacteria from a gas or liquid. The  test  is  usually  performed  using  a  standard  organism,  such  as  Brevundimonas  diminuta  at  a  minimum concentration of 107 Colony Forming Units\/cm2.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"细菌截留试验：进行该试验是为了验证过滤器可以去除气体或液体中的细菌。该试验通常采用标准微生物进行，例如最低浓度 107 CFU\/cm2 的缺陷短波单孢菌（Brevundimonas diminuta）。"
    },
    {
        "instruction":"已知信息：\n'The on-site inspection question sheet shall be signed by all members of the inspection team, observers, and the person in charge of the inspected, and shall be affixed with the official seal of the inspected institution.'可被翻译为：现场核查问题表应当由核查组全体成员、观察员、被核查单位负责人签名，并加盖被核查单位公章。\n'The inspected institution shall introduce to the inspection team the development and manufacturing of the inspected variety in the institution and clarify the person in charge of the inspection site.'可被翻译为：被核查单位应当向核查组介绍核查品种在本单位开展的研究、生产等情况，明确核查现场负责人。\n\n根据上述已知信息，请将'If the inspected institution refuses to sign and seal, the inspection team shall indicate it in the on-site inspection report. The inspected institution shall give another written explanation on the refusal of signature and seal, which shall be signed by the person in charge of the inspected institution and stamped with the official seal of the inspected institution and submitted to the inspection team.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被核查单位拒绝签字盖章的，核查组应当在现场核查报告中予以注明。被核查单位应当就拒绝签字盖章情况另行书面说明，由被核查单位负责人签字，并加盖被核查单位公章交核查组。"
    },
    {
        "instruction":"已知信息：\n'accountability'可被翻译为：问责制\n'This manual was written to reduce compendia method ambiguity and increase standardization between ORS laboratories. By providing clearer instructions to ORS labs, greater transparency can be provided to both industry and the public.'可被翻译为：本手册旨在减少药典方法的歧义并提高 ORS 实验室之间的标准化。 通过向 ORS 实验室提供 更清晰的说明，可以为行业和公众提供更大的透明度。\n\n根据上述已知信息，请将'The obligation to account for one's conduct and actions, ussually to an individual or group, but ultimately to the public. Both individuals and organizations may be accountable. There is some overlap between accountability and transparency (see transparency).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对自己的行为和行为负责的义务，通常是对个人或团体负责，但最终是对公众负责。个人和组织都有责任。问责制和透明度之间有一些重叠(见透明度)。"
    },
    {
        "instruction":"已知信息：\n'A document containing the information as set out in Appendix 1 of the guidelines that is validated and issued for a specific product by the competent authority of the exporting country and intended for use by the competent authority in the importing country or - in the absence of such an authority - by the drug procurement authority (see also section 3.5 of the guidelines). Transmission of product certificate: see sections 3.8 and 4.9 of the guidelines.Validity of product certificate: see section 3.9 of the guidelines.When to request a product certificate: see section 3.5 of the guidelines.'可被翻译为：包含指南附录1中所列信息的文件，由出口国主管部门对特定产品进行验证和签发，供进口国主管部门使用，或者在没有此类主管部门的情况下，供药品采购主管部门使用(另见指南第3.5节)。产品证书的传递:见指南第3.8节和4.9节。产品证书有效期:见指南第3.9节。何时申请产品证书:见指南第3.5节。\n'A document containing information, as set out in Appendix 3 of the guidelines, will normally be issued for each batch by the manufacturer. Furthermore, a batch certificate may exceptionally be validated or issued by the competent authority of the exporting country, particularly for vaccines, sera and other biological products. The batch certificate accompanies every major consignment (see also section 3.14 of the guidelines).'可被翻译为：如指南附录3所示，制造商通常会为每个批次签发一份包含信息的文件。此外，批号证书可例外地由出口国主管当局验证或签发，特别是对于疫苗、血清和其他生物制品。批证书随每批主要货物一起签发(另见指南第3.14节)。\n\n根据上述已知信息，请将'A document containing the information (as set out in Appendix 1 of these Guidelines) that is validated and issued for a specific starting material by the competent authority of the exporting country and intended for use by the competent authority in the importing country or in the absence of such an authority by, for example, the manufacturer of the finished product when exporting.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一份包含信息的文件(如本指南附录1所述)，由出口国主管当局就特定起始材料进行验证和签发，供进口国主管当局使用，或在没有此类当局的情况下，供成品制造商在出口时使用。"
    },
    {
        "instruction":"已知信息：\n'A constituent of blood (erythrocytes, leukocytes, platelets, cryoprecipitate and plasma) that can be prepared by various separation methods and under such conditions that it can be used either directly for therapeutic purposes or for further processing\/manufacturing.'可被翻译为：一种血液成分(红细胞、白细胞、血小板、低温沉淀和血浆)，可通过各种分离方法制备，并在可直接用于治疗目的或用于进一步加工\/制造的条件下制备。\n'The general name of antitoxin, toxoid and antiviral serum in biological products. Such as tetanus, diphtheria, snake venom antitoxin: anti-rabies serum; Anti-anthrax serum, etc.'可被翻译为：生物制品中抗毒素、类毒素、抗病毒血清的总称。如破伤风、白喉、蛇毒抗毒素:抗狂犬病血清；抗炭疽血清等。\n\n根据上述已知信息，请将'A biological material including, but not limited to, blood, serum, plasma and urine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种生物材料，包括但不限于全血、血清、血浆和尿液。"
    },
    {
        "instruction":"已知信息：\n'A single variable, usually a scale of ordered categorical ratings, which integrates objective variables and the investigator's overall impression about the state or change in state of a subject.'可被翻译为：是指将客观指标和研究者对受试者的状态或状态变化\n的总体印象综合起来所设定的一个单一指标，通常是一个有\n序分类量表。\n'rating scale'可被翻译为：刻度法\n\n根据上述已知信息，请将'The extent to which a variable (e.g. a rating scale) measures what it is supposed to measure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指一个指标（如量表）测量它所预期测量的内容的程\n度。"
    },
    {
        "instruction":"已知信息：\n'A signal for which an evaluation was completed during the reporting interval.'可被翻译为：在报告期内完成评估的信号。\n'A subject in a clinical trial who for any reason fails to continue in the trial until the last visit required of him\/her by the study protocol.'可被翻译为：是指临床试验的受试者由于任何原因不能继续按研究\n方案进行到所要求的最后一次随访。\n\n根据上述已知信息，请将'The checking and assessment of data during the period of time between trial completion (the last observation on the last subject) and the breaking of the blind, for the purpose of finalising the planned analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指在试验完成（最后一位受试者的最后一次观察）到揭盲这段时间内对数据的检查和评价，旨在最终确定分析计划。"
    },
    {
        "instruction":"已知信息：\n'A VDC consists of two compartments (a donor compartment and a receptor compartment with a sampling arm) separated by a membrane and held together by a clamp, screw top, or other means (see Figures 1–5). The VDC body (i.e., donor and receptor compartment with associated cell structures like the sampling arm and water jacket, if present) is usually made from borosilicate glass, although different materials may be used to manufacture the body and other parts of the VDC assembly. Other diffusion cells that are similar in design principles and features to those depicted in Figures 1–3 can generally be used.'可被翻译为：VDC由两个隔室(供体隔室和带采样臂的受体隔室)组成，隔室由膜隔开，并通过夹钳、螺旋顶或其他方式连接在一起(见图1-5)。VDC主体(即，供体和受体隔室与相关的池体结构，如采样臂和水套，如果存在)通常由硼硅酸盐玻璃制成，尽管可以使用不同的材料来制造主体和VDC组件的其他部分。通常可以使用与图1-3所示扩散池在设计原理和特征上相似的其他扩散池。\n'Two types of diffusion cells are commonly used for IVPT studies: the vertical diffusion cell (VDC) (see Figures 1–5) and the flow-through diffusion cell (FDC) (see Figures 8–10). Equipment features (e.g., bubble-free cells or cells with a vent hole) other than the ones depicted below may be suitable once qualified. VDCs are well characterized and can be utilized for both, IVRT and IVPT studies. FDCs are used exclusively for IVPT studies (not IVRT studies) and have the advantage that the sampling is more easily automated, which can make it easier to acquire samples at times when investigators are typically not in the laboratory (e.g., the middle of the night). VDCs and FDCs can both produce excellent results when the IVPT method is appropriately developed, and each type of cell has its advantages.'可被翻译为：两种类型的扩散池通常用于IVPT研究:垂直扩散池(VDC)(见图1-5)和流通扩散池(FDC)(见图8-10)。除了下面描述的设备特征(例如，无气泡池体或带有排气孔的池体)，一旦合格，可能也适用。VDC具有良好的特征，可用于IVRT和IVPT研究。FDC专门用于IVPT研究(而不是IVRT研究)，其优点是采样更容易自动化，这可以使研究人员通常不在实验室(例如，半夜)时更容易获取样本。当IVPT方法得到适当的发展时，VDC和FDC都可以产生优异的结果，每种类型的池体都有其优点。\n\n根据上述已知信息，请将'The VDC, immersion cells, and FDC should match the general descriptions provided below and may have design variations of the types shown among specific examples illustrated in Figures 1–5 for VDCs, Figures 6 and 7 for immersion cells, or Figures 8–10 for FDCs. The VDC, immersion cell, and FDC components should be manufactured with inert materials that do not adsorb, absorb, bind, or react with the analyte. The diffusion cell and its components should not alter the amount of diffusing drug that is measured, either by adsorbing, absorbing, binding, or reacting with the drug, or by releasing drug that was adsorbed, absorbed, bound, or reacted with in a previous experiment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"VDC、浸没池和FDC应符合下面提供的一般描述，并且可以在图1-5所示的VDC、图6和图7所示的浸没池或图8-10所示的FDC的具体示例中具有不同的设计类型。VDC、浸没池和FDC组件应使用惰性材料制造，这些材料不会吸附、吸收、结合或与分析物发生反应。扩散池及其组件不应通过吸附、吸收、结合或与药物反应，或通过释放先前实验中吸附、吸收、结合或与之反应的药物来改变所测量的扩散药物的量。"
    },
    {
        "instruction":"已知信息：\n'Article 73 The investigator shall ensure that the clinical trial data is accurately, completely, clearly and promptly entered in the case report form. The case report form shall be signed by the investigator; any change in the data shall be signed and dated by the investigator and meanwhile clear and identifiable original records shall be kept.'可被翻译为：第七十三条 研究者应当保证将临床试验数据准确、完整、清晰、及时地载入病例报告表。病例报告表由研究者签署姓名，任何数据的更改均应当由研究者签名并标注日期，同时保留原始记录，原始记录应当清晰可辨识。\n'Article 58 In the multicenter clinical trial, the sponsor shall ensure that the case report form is well designed to enable the coordinating investigator to obtain all the data from each clinical trial institution.'可被翻译为：第五十八条 在多中心临床试验中，申办者应当保证病例报告表的设计严谨合理，能够使协调研究者获得各分中心临床试验机构的所有数据。\n\n根据上述已知信息，请将'Article 80 In the clinical trial, the investigator shall ensure that any observation and finding are recorded in the correct and complete manner and that the case report form is carefully filled out. Records shall include at least:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条 在临床试验中，研究者应当确保将任何观察与发现均正确完整地予以记录，并认真填写病例报告表。记录至少应当包括："
    },
    {
        "instruction":"已知信息：\n'Article 19 MAHs, distributing enterprises and secondary medical institutions or above shall register as the users of the National Medical Device Adverse Events Monitoring Information System, voluntarily maintain the user information and report medical device adverse events. MAHs shall continuously track and handle monitoring information; in case of any change in product registration information, MAHs shall update the information in the system immediately.'可被翻译为：第十九条  持有人、经营企业和二级以上医疗机构应当注册为国家医疗器械不良事件监测信息系统用户，主动维护其用户信息，报告医疗器械不良事件。持有人应当持续跟踪和处理监测信息；产品注册信息发生变化的，应当在系统中立即更新。\n'Monitoring agencies designated by the NMPA (hereinafter referred to as national monitoring agencies) shall be responsible for unified management of all the information of medical device adverse events collected and provide feedback of relevant monitoring information of medical device adverse events to relevant monitoring agencies, MAHs, distributing enterprises or user facilities.'可被翻译为：国家药品监督管理局指定的监测机构（以下简称国家监测机构）负责对收集到的医疗器械不良事件信息进行统一管理，并向相关监测机构、持有人、经营企业或者使用单位反馈医疗器械不良事件监测相关信息。\n\n根据上述已知信息，请将'Article 3 Medical device marketing authorization holders (hereinafter referred to as MAHs) shall possess the capacities of quality management and corresponding responsibilities to ensure that the medical devices are safe and effective, establish medical device adverse event monitoring system and directly report medical device adverse events to medical device adverse event monitoring agencies (hereinafter referred to as monitoring agencies). Distributing enterprises and user facility of medical device authorized by MAHs shall report medical device adverse events to MAHs and monitoring agencies.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条  医疗器械上市许可持有人（以下简称持有人），应当具有保证医疗器械安全有效的质量管理能力和相应责任能力，建立医疗器械不良事件监测体系，向医疗器械不良事件监测技术机构（以下简称监测机构）直接报告医疗器械不良事件。由持有人授权销售的经营企业、医疗器械使用单位应当向持有人和监测机构报告医疗器械不良事件。"
    },
    {
        "instruction":"已知信息：\n'Article 119 Where drug use institutions use counterfeit drugs or inferior drugs, they shall be punished in accordance with the provisions on the sale of counterfeit drugs and inferior drugs. In serious circumstances, and if the legal representative, the principal responsible persons, the persons directly in charge, and other directly responsible persons as well as other responsible personnel have a medical license, the medical license shall be revoked.'可被翻译为：第一百一十九条 药品使用单位使用假药、劣药的，按照销售假药、零售劣药的规定处罚；情节严重的，法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。\n'Where a drug manufacturer violates Item (IV) or (V) of the preceding paragraph, re-registration of relevant drugs shall be prohibited in accordance with requirements of the Provisions for Drug Registration.'可被翻译为：药品生产企业有前款规定第（四）项、第（五）项情形之一的，按照《药品注册管理办法》的规定对相应药品不予再注册。\n\n根据上述已知信息，请将'The sale of drugs prescribed in item (1) to item (3) of the preceding paragraph, or the use of drugs prescribed in item (1) to item (5) of the preceding paragraph by drug use institutions, shall be punished in accordance with the provisions of the preceding paragraph. In serious circumstances, where the legal representative, the principal responsible person, the persons directly in charge, and other directly responsible persons as well as other responsible personnel that have a medical license, the medical license shall be subject to revocation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"销售前款第一项至第三项规定的药品，或者药品使用单位使用前款第一项至第五项规定的药品的，依照前款规定处罚；情节严重的，药品使用单位的法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。"
    },
    {
        "instruction":"已知信息：\n'Method of sterilization in saturated steam, boiling water, or circulating steam.'可被翻译为：在饱和蒸汽、沸水或流通蒸汽中进行灭菌的方法。\n'boiling sterilization'可被翻译为：煮沸灭菌\n\n根据上述已知信息，请将'The method of sterilization by heating the articles to be sterilized in boiling water.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"把待灭菌物品放入沸水中加热灭菌的方法。"
    },
    {
        "instruction":"已知信息：\n'adverse drug reaction (adr)'可被翻译为：药物不良反应\n'Adverse reactions not mentioned in the drug product labeling. If the nature, severity, consequences, or frequency of an adverse reaction differs from or is more severe than what is described in the product labeling, it should be handled according to the new adverse reaction information.'可被翻译为：药品说明书中未载明的不良反应。说明书中已有描述，但不良反应发生的性质、程度、后果或者\n频率与说明书描述不一致或者更严重的，按照新的药品不良反应处理。\n\n根据上述已知信息，请将'(IV) A new ADR refers to any adverse reaction that is not listed on the package insert. An ADR that is listed but is in consistent with or more severe than that described on the package insert in nature, severity, outcome and frequency shall be handled as a new ADR.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）新的药品不良反应，是指药品说明书中未载明的不良反应。说明书中已有描述，但不良反应发生的性质、程度、后果或者频率与说明书描述不一致或者更严重的，按照新的药品不良反应处理。"
    },
    {
        "instruction":"已知信息：\n'Article 78 Acceptance inspection personnel shall inspect and check the appearance, package, label, package insert and relevant supporting documents of the sampled drugs one by one; after the acceptance inspection, the intact samples taken shall be put back into the original packaging box, sealed and marked.'可被翻译为：第七十八条 验收人员应当对抽样药品的外观、包装、标签、说明书以及相关的证明文件等逐一进行检查、核对；验收结束后，应当将抽取的完好样品放回原包装箱，加封并标示。\n'III. The drugs imported under the same contract may be sampled as the same batch only if the drug name, country of manufacture, manufacturer, package, batch number, dosage form, strength, shipping mark and contract number are identical. If drugs are imported under the same contract but shipped in different batches, they shall be sampled in different batches.'可被翻译为：三、同一合同，药品名称、生产国家、厂商、包装、批号、剂型、规格、唛头标记以及合同编号均相同者，方可作为同批药品进行抽样；同一合同进口的药品分次到货者，分次抽样。\n\n根据上述已知信息，请将'(I) Before unsealing the sample, the outer package, shipping mark number or contract number, and name and quantity of the product shall be checked against the materials submitted for testing. After unsealing, the name of drug, the name of factory and the batch number of the drugs in the sub-package shall be checked, and whether the package is intact and clean without water stain, mildew or other material pollution shall be determined. If the drugs within part of the packages deteriorate, samples shall be taken for testing separately.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）抽样启封前，应当与报验资料核对外包装，唛头号或合同编号，以及品名、数量等。启封后应当核对小包装品名、厂名和批号等，并注意检查包装的完整性和清洁程度以及有无水迹、霉烂或其它物质污染等。如有部分包件变质，应当另行抽样检验。"
    },
    {
        "instruction":"已知信息：\n'In the 2018 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women.Reports of pediatric patients under 14 years of age accounted for 9.8%; reports of elderly patients over the age of 65 accounted for27.7% (Figure 5).'可被翻译为：2018年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者的报告占9.8%；65岁以上老年患者的报告占27.7%（图5）。\n'Patients involved in the ADR\/ADE reports'可被翻译为：药品不良反应\/事件报告涉及患者情况\n\n根据上述已知信息，请将'In the 2019 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women. Reports of pediatric patients under 14 years of age accounted for 10.2 percent; and reports of elderly patients over 65 accounted for 29.1 percent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者占10.2%；65岁及以上老年患者占29.1%。"
    },
    {
        "instruction":"已知信息：\n'CDE reviewed and approved the marketing of 10 varieties of Class 1 innovative drugs, and 58 varieties of imported brand-name drugs (including new indications).'可被翻译为：审评通过上市1类创新药10个品种，审评通过进口原研药58个品种（含新适应症）。\n'CDE accepted registration applications for 157 varieties of Class 1 innovative chemicals, covering 16 innovative NDAs (up by 100% YOY), 115 varieties of domestically produced innovative chemicals, and 42 imported ones. For such details from 2015 to 2018, see Figure 4.'可被翻译为：药审中心受理1类化药创新药注册申请157个品种，整体较2017年略有增加，其中受理创新药NDA 16个品种，较2017年增长了一倍。2018年受理的157个化药创新药注册申请中，国产化药创新药注册申请为115个品种，进口化药创新药注册申请为42个品种，2015年至2018年创新药注册申请受理情况详见图4。\n\n根据上述已知信息，请将'CDE reviewed and approved the marketing of 9 varieties of Class 1 innovative drugs, and67 varieties of imported brand-name drugs.For details, see Annexes 1 and 2.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审评通过上市1类创新药9个品种，审评通过进口原研药67个品种，具体品种详见附件1、2。"
    },
    {
        "instruction":"已知信息：\n'The holding time for sterilised equipment, components, and containers before use and during filling\/assembly.'可被翻译为：已灭菌设备、组分和容器在使用前和灌装\/装配过程中的保持时间。\n'For terminally sterilised products, the validation of terminal sterilisation processes should ensure the sterility of all critical product pathways between the component and moulded container, including areas that are not wetted during sterilisation.'可被翻译为：对于最终灭菌产品，最终灭菌工艺的验证应确保组件和成型容器之间的所有关键产品通路的无菌性，包括灭菌过程中未润湿的区域。\n\n根据上述已知信息，请将'The holding time between equipment, component, and container cleaning, drying and sterilisation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设备、组件和容器清洁、干燥和灭菌之间的保持时间。"
    },
    {
        "instruction":"已知信息：\n'For drugs marketed overseas but not marketed in China, technical requirements for clinical trials to support its marketing in China should be established in compliance with the basic logic of clinical evaluation and on the basis of full evaluation of clinical demand of Chinese patients, clinical safety and effectiveness of overseas originator drugs, influences of racial factors as well as the need of benefit\/risk evaluation in Chinese patients.'可被翻译为：境外已上市境内未上市药品的临床技术要求，应遵循临床评价基本逻辑，在充分评价中国患者临床需求、境外原研药品临床安全性和有效性、以及种族因素影响的基础上，基于中国患者获益\/风险评估的需要，确定其在境内上市需开展的临床试验技术要求。\n'For the drugs marketed overseas but not marketed in China, full evaluation should be performed for the clinical study data of the originator drugs according to the basic logic of clinical evaluation and in combination with the actual situation of the drugs, and the clinical trial requirements should be determined according to the evaluation results. For drugs with different R & D backgrounds, the clinical trials required to be carried out should be determined case by case.'可被翻译为：对于境外已上市境内未上市的药品，需结合药品具体情况，按照临床评价的基本逻辑对原研药品的临床研究数据进行充分评价，根据评价结果确定临床试验要求。对于不同研发背景的药品，其所需开展的临床试验应具体问题具体分析。\n\n根据上述已知信息，请将'If a new indication that has been approved overseas but not in China is added to drugs marketed domestically, besides complying with the above-mentioned basic logic of clinical evaluation and clinical trial requirements, analysis should be based on cases because multi-dimensional complicated factors of diseases and drugs are involved. It is suggested to communicate with regulatory authorities before application.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于境内已上市药品增加境外已批准境内未批准的新适应症的情形，除应遵循上述临床评价基本逻辑和临床试验要求外，因涉及疾病和药物等多维度复杂因素，应具体问题具体分析，建议申报前与监管机构进行沟通。"
    },
    {
        "instruction":"已知信息：\n'Development of a cryopreservation process for a clinical cell therapy must consider the consequences for the product, the patient, and the overall feasibility of the therapy. For the cell product, the manufacturer must ensure that expected cell losses because of cryopreservation and thaw occur in a manner that is reasonably predictable and must ensure that the final product administered to the patient will meet specifications for cell number, viability, and functional characteristics.'可被翻译为：开发用于临床细胞治疗的冷冻保存过程必须考虑对产品、病人和治疗整体可行性的影响。对于细胞产品,制造商必须确保由于低温贮藏和解冻产生的预期细胞损失是合理的可预见的，并且必须确保患者使用的最终产品符合细胞数量、生存能力和功能特征的规范。\n'A product that has undergone all stages of production, including packaging in its ﬁnal container and labelling. A finished pharmaceutical product may contain one or more APIs. In some cases, it may be in combination with a medical device.'可被翻译为：经过所有生产阶段的产品，包括最终容器的包装和标签。药品成品可能含有一种或多种原料药。在某些情况下，它可能与医疗器械结合使用。\n\n根据上述已知信息，请将'Although bedside thawing of cell therapy products before infusion has been a common clinical practice, the use of trained personnel in a controlled laboratory environment is now recognized asthe preferred method for thawing because it allows a more standardized process and a higher degree of control when staff must respond to a container failure,which may require product salvage in a more sterile environment. Product thawing typically is done by immersion in 37° water baths and using over wrap bags to minimize product loss and contamination in case of primary container failure. Bags may be gently kneaded during thaw to reduce temperature gradients across the bag and to accelerate thawing. The product is removed from the water bath when some ice is still present in the product but the majority of the product is thawed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尽管在输液前在床边对细胞治疗产品进行解冻是一种常见的临床过程，但现在公认受过培训的人员在受控实验室环境中解冻是首选的方案。因为这样可以使工作人员在无菌环境中通过更标准化的操作过程和更高程度的控制细胞解冻过程，并对容器故障作出响应来产品回收。解冻通常是通过浸37°水浴中并使用复温袋来完成的，以便在主容器发生故障的情况下将产品损失和污染降至最低。解冻过程中可以轻轻揉捏袋子，降低袋子上的温度梯度并加速解冻。当产品中仍然存在一些冰而大部分产品已经解冻后，将产品从水浴中取出。"
    },
    {
        "instruction":"已知信息：\n'5) Approved master manufacturing documents and operation procedures;'可被翻译为：5.经批准的工艺规程和操作规程；\n'1. The Master Manufacturing Formula:'可被翻译为：（一）生产处方：\n\n根据上述已知信息，请将'1. The review and approval of master manufacturing documents, procedures, etc;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）审核和批准产品的工艺规程、操作规程等文件；"
    },
    {
        "instruction":"已知信息：\n'Article 34 If the registrant, the filing entity and the contract manufacturer of cosmetics have suspended manufacturing for more than 1 year consecutively, it shall make comprehensive internal audit before the manufacturing is resumed, and can resume the manufacturing only after confirming that the requirements are met. The internal audit and rectification conditions shall be reported to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located within 10 workings days from date of resumption of manufacturing.'可被翻译为：第三十四条 化妆品注册人、备案人、受托生产企业连续停产1年以上，重新生产前，应当进行全面自查，确认符合要求后，方可恢复生产。自查和整改情况应当在恢复生产之日起10个工作日内向所在地省、自治区、直辖市药品监督管理部门报告。\n'Article 18 If a medical device manufacturer establishes the manufacturing premises across the province, autonomous region or municipality directly under the central government, it shall apply to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the manufacturing premises is located for Medical Device Manufacturing License.'可被翻译为：第十八条  医疗器械生产企业跨省、自治区、直辖市设立生产场地的，应当向新设生产场地所在地省、自治区、直辖市药品监督管理部门申请医疗器械生产许可。\n\n根据上述已知信息，请将'Where changes occur in the manufacturing conditions are discovered upon internal audit, so that the conditions no longer meet the requirements of Good Manufacturing Practice for cosmetics, the registrant, the filing entity and the contract manufacturer of cosmetics shall immediately take measures for rectification; upon discovering that the quality and safety of cosmetics may be affected, they shall immediately stop the manufacturing and report the matter to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located. Manufacturing can be resumed only upon removal of the risk factors affecting the quality and safety. The drug regulatory department of the province, autonomous region or municipality directly under the central government may organize on-site inspection based on actual conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经自查发现生产条件发生变化，不再符合化妆品生产质量管理规范要求的，化妆品注册人、备案人、受托生产企业应当立即采取整改措施；发现可能影响化妆品质量安全的，应当立即停止生产，并向所在地省、自治区、直辖市药品监督管理部门报告。影响质量安全的风险因素消除后，方可恢复生产。省、自治区、直辖市药品监督管理部门可以根据实际情况组织现场检查。"
    },
    {
        "instruction":"已知信息：\n'An enveloped single-stranded, RNA virus that is the causative agent of hepatitis C.'可被翻译为：丙型肝炎病毒一种包膜单链RNA病毒，是丙型肝炎的病原体\n'A non-enveloped single-stranded RNA virus that is the causative agent of hepatitis A.'可被翻译为：一种非包膜单链RNA病毒，是甲型肝炎的病原体。\n\n根据上述已知信息，请将'An enveloped double-stranded DNA virus that is the causative agent of hepatitis B.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种包膜双链DNA病毒，是乙型肝炎的病原体。"
    },
    {
        "instruction":"已知信息：\n'A distinctive combination of numbers and\/or letters which specifically identifies a batch.'可被翻译为：用于识别一个特定批的具有唯一性的数字和（或）字母的组合。\n'A set of numbers or letters plus numbers used to identify the \"lot\". Used to trace and review the manufacturing history of the drug.'可被翻译为：用于识别''批”的一组数字或字母加数字。用以追溯和审查该药品的生产历史。\n\n根据上述已知信息，请将'A unique combination of numbers, letters, and\/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用以标明一个批次的数字、字母和\/或符号的唯一组合，从中可以确定生产和分销的历史。"
    },
    {
        "instruction":"已知信息：\n'Article 45 MAHs of the medical device varieties under intensive surveillance shall, in accordance with requirements in intensive surveillance project of medical devices, carry out relevant works, voluntarily collect the adverse event reports of products and relevant risk information, write risk evaluation report and submit the report to authorities organizing the intensive surveillance project as required.'可被翻译为：第四十五条  医疗器械重点监测品种涉及的持有人应当按照医疗器械重点监测工作方案的要求开展工作，主动收集其产品的不良事件报告等相关风险信息，撰写风险评价报告，并按要求报送至重点监测工作组织部门。\n'Article 40 The registrant, filing entity or contract manufacturers of medical devices shall perform their responsibility for monitoring adverse events in accordance with relevant regulations on monitoring adverse events of medical devices, carry out monitoring of adverse events, and report their investigation, analysis, reevaluation, product risk control results, etc. to the medical devices adverse event monitoring technical institutions.'可被翻译为：第四十条  医疗器械注册人、备案人、受托生产企业应当按照医疗器械不良事件监测相关规定落实不良事件监测责任，开展不良事件监测，向医疗器械不良事件监测技术机构报告调查、分析、评价、产品风险控制等情况。\n\n根据上述已知信息，请将'Article 47 MAHs of innovative medical devices shall strengthen voluntary monitoring of innovative medical devices, formulate product monitoring plans, voluntarily collect relevant adverse event reports and product complaint information, and carry out investigation, analysis and evaluation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条  创新医疗器械持有人应当加强对创新医疗器械的主动监测，制定产品监测计划，主动收集相关不良事件报告和产品投诉信息，并开展调查、分析、评价。"
    },
    {
        "instruction":"已知信息：\n'Root cause analysis of procedural, process or equipment failure is performed in such a way that the risk to product is correctly identified and understood so that suitable corrective and preventive actions (CAPA) are implemented.'可被翻译为：对程序、工艺或设备失败进行根本原因分析，正确识别和理解产品风险，从而实施适当的纠正和预防措施（CAPA）\n'Article 252: The manufacturer should establish a corrective actions and preventive actions (CAPA) system, for the investigation of complaints, recalls, deviations, findings of self-inspections or external inspections, process performances and quality monitoring trends, etc, and take corrective actions and preventive actions. The extent and formality of investigations should be commensurate with the level of risk. The CAPA system should result in enhanced product and process understanding, and product and process improvements.'可被翻译为：第二百五十二条 企业应当建立纠正措施和预防措施系统，对投诉、召回、偏差、自检或外部检查结果、工艺性能和质量监测趋势等进行调查并采取纠正和预防措施。调查的深度和形式应当与风险的级别相适应。纠正措施和预防措施系统应当能够增进对产品和工艺的理解，改进产品和工艺。\n\n根据上述已知信息，请将'Prevention mechanisms - trend analysis, detailed investigation, root cause determination, corrective and preventive actions (CAPA) and the need for comprehensive investigational tools.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"预防机制——趋势分析、详细调查、确定根本原因、纠正和预防措施（CAPA）以及对全面调查工具的需求。"
    },
    {
        "instruction":"已知信息：\n'A liposome consisting of lipids whose phase transition temperature is slightly higher than body temperature. Its drug release is temperature-sensitive.'可被翻译为：由相转变温度稍高于体温的脂质组成的脂质体。其药物的释放对温度具有敏感性。\n'The temperature at which the solubility of ionic micelles increases sharply in water.'可被翻译为：离子型胶团在水中溶解度陡增的温度。\n\n根据上述已知信息，请将'The temperature at which a phase transition occurs in the liposome membrane. When the temperature increases, the acyl side bonds in the bilayer of liposome change from ordered to disordered, from colloidal to liquid crystal, and the cross section of the membrane increases, the thickness decreases, and the fluidity increases.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"脂质体膜发生相态转变的温度。当温度升高时，脂质体双分子层中酰基侧键可从有序排列变为无序排列，由胶晶变为液晶态，膜的横切面增加、厚度减少、流动性增加等。"
    },
    {
        "instruction":"已知信息：\n'To further unify the understanding of mandatory industry standards, and truly promote the implementation of mandatory industry standards of medical devices,in accordance with the Standardization Law of the People's Republic of China,the Regulations for the Supervision and Administration of Medical Devices,the Provisions for Mandatory National Standards and the Provisions for Medical Device Standards, on July 7, 2020, NMPA issued the notice on matters related to further strengthening management for mandatory industry standards of medical devices, requiring drug regulatory authorities at all levels to effectively maintain the legal status of mandatory industry standards,further improve the mandatory industry standard system, promote the drafting and implementation of mandatory industry standards, reinforce the publicity,implementation and training, standardize the implementation of mandatory industry standards, and reinforce the evaluation on implementation of mandatory industry standards.'可被翻译为：为进一步统一对强制性行业标准的认识，切实推进医疗器械强制性行业标准规范、有效实施，根据《中华人民共和国标准化法》《医疗器械监督管理条例》《强制性国家标准管理办法》和《医疗器械标准管理办法》，现就进一步加强医疗器械强制性行业标准管理有关事项通知：切实维护强制性行业标准的法律地位、进一步完善强制性行业标准体系、完善强制性行业标准起草和实施、加强强制性行业标准的宣贯培训、规范强制性行业标准的执行、强化强制性行业标准的实施评估。\n'III. Review of the application projects already accepted for registration before implementation of the new mandatory standards'可被翻译为：三、关于新的强制性标准实施之日前受理注册申请项目的审查\n\n根据上述已知信息，请将'Unless otherwise specified in the standard documents issued and implemented by NMPA, a medical device with the application already accepted for registration before implementation of the new standards can be reviewed and approved according to original provisions where the mandatory standards cited in the product technical requirements have changed. As of the date of implementation of the new standards, enterprises shall fully implement the new standards and their products shall meet the requirements of the new standards.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于申请注册的医疗器械，其产品技术要求中引用的强制性标准发生变化的，除国家药监局在发布实施标准文件中另有规定外，在新标准实施之日前受理注册的，可以按照原标准进行审评审批。自新标准实施之日起，企业应当全面实施新标准，产品应当符合新标准要求。"
    },
    {
        "instruction":"已知信息：\n'Rules for Labels of Prepared Slices of Chinese Crude Drugs Issued by China NMPA'可被翻译为：国家药监局关于发布《中药饮片标签管理规定》的公告\n'Article 1    The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China.'可被翻译为：第一条 为规范药品说明书和标签的管理，根据《中华人民共和国药品管理法》和《中华人民共和国药品管理法实施条例》制定本规定。\n\n根据上述已知信息，请将'To further standardize the regulation on labels of prepared slices of Chinese crude drugs, in accordance with laws, administrative regulations and provisions including the Drug Administration Law of the People's Republic of China, the Regulations for Implementation of the Drug Administration Law of the People's Republic of China and the Provisions for Drug Insert Sheets and Labels, the NMPA organized to formulate the Rules for Labels of Prepared Slices of Chinese Crude Drugs, which is hereby released and shall be implemented since August 1, 2024. The labeling of expiration date according to the Rules shall be implemented since August 1, 2025.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步规范中药饮片标签的管理，根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》《药品说明书和标签管理规定》等法律、行政法规和规章，国家药监局组织制定了《中药饮片标签管理规定》，现予发布，自2024年8月1日起施行，其中，保质期的标注自2025年8月1日起施行。"
    },
    {
        "instruction":"已知信息：\n'Article 12 National monitoring agencies shall be responsible for receiving medical device adverse events information reported by MAHs, distributing enterprises and user facility, assume relevant technical works related to medical device adverse event monitoring and re-evaluation nationwide; be responsible for the construction, maintenance and information management of national network and database of monitoring information of medical device adverse event, organize to develop technical specifications and guidelines, organize the investigation, evaluation and feedback of relevant adverse events information of the medical devices approved by the NMPA to be registered, summarize, analyze and guide relevant adverse events information of the medical devices approved by local drug regulatory departments above municipal level to be registered or filed, and investigate and evaluate group adverse events of medical device that have great influence nationwide and cause severe injuries or death and other serious consequences.'可被翻译为：第十二条  国家监测机构负责接收持有人、经营企业及使用单位等报告的医疗器械不良事件信息，承担全国医疗器械不良事件监测和再评价的相关技术工作；负责全国医疗器械不良事件监测信息网络及数据库的建设、维护和信息管理，组织制定技术规范和指导原则，组织开展国家药品监督管理局批准注册的医疗器械不良事件相关信息的调查、评价和反馈，对市级以上地方药品监督管理部门批准注册或者备案的医疗器械不良事件信息进行汇总、分析和指导，开展全国范围内影响较大并造成严重伤害或者死亡以及其他严重后果的群体医疗器械不良事件的调查和评价。\n'Article 3 Medical device marketing authorization holders (hereinafter referred to as MAHs) shall possess the capacities of quality management and corresponding responsibilities to ensure that the medical devices are safe and effective, establish medical device adverse event monitoring system and directly report medical device adverse events to medical device adverse event monitoring agencies (hereinafter referred to as monitoring agencies). Distributing enterprises and user facility of medical device authorized by MAHs shall report medical device adverse events to MAHs and monitoring agencies.'可被翻译为：第三条  医疗器械上市许可持有人（以下简称持有人），应当具有保证医疗器械安全有效的质量管理能力和相应责任能力，建立医疗器械不良事件监测体系，向医疗器械不良事件监测技术机构（以下简称监测机构）直接报告医疗器械不良事件。由持有人授权销售的经营企业、医疗器械使用单位应当向持有人和监测机构报告医疗器械不良事件。\n\n根据上述已知信息，请将'Monitoring agencies designated by the NMPA (hereinafter referred to as national monitoring agencies) shall be responsible for unified management of all the information of medical device adverse events collected and provide feedback of relevant monitoring information of medical device adverse events to relevant monitoring agencies, MAHs, distributing enterprises or user facilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药品监督管理局指定的监测机构（以下简称国家监测机构）负责对收集到的医疗器械不良事件信息进行统一管理，并向相关监测机构、持有人、经营企业或者使用单位反馈医疗器械不良事件监测相关信息。"
    },
    {
        "instruction":"已知信息：\n'Studies designed to increase the rate of chemical degradation and physical change of a drug by using exaggerated storage conditions as part of the formal stability testing programme. The data thus obtained, in addition to those derived from real-time stability studies, may be used to assess longer-term chemical effects under non-accelerated conditions and to evaluate the impact of short-term excursions outside the label storage conditions, as might occur during shipping. The results of accelerated testing studies are not always predictive of physical changes.'可被翻译为：作为正式稳定性试验计划的一部分，通过使用夸张的储存条件来提高药物的化学降解和物理变化速度的研究。由此获得的数据，除了来自实时稳定性研究的数据外，可用于评估非加速条件下的长期化学效应，并评估在标签存储条件之外的短期漂移的影响，如在运输过程中可能发生的影响。加速试验研究的结果并不总是能预测物理变化。\n'Studies designed to increase the rate of chemical degradation or physical change of a drug substance or drug product by using exaggerated storage conditions as part of the formal stability studies. Data from these studies, in addition to long term stability studies, can be used to assess longer term chemical effects at non-accelerated conditions and to evaluate the effect of short term excursions outside the label storage conditions such as might occur during shipping. Results from accelerated testing studies are not always predictive of physical changes.'可被翻译为：加速试验是通过使用超常的贮存条件来加速原料药或制剂的化学降解或物理变化。它是正式的稳定性研究的一部分。除了长期稳定性研究外，从这些研究中得到的数据也可以评估在非加速条件下更长时间内的化学变化以及评价在短期偏离标签上所注明的储存条件，如运输过程中可能遇到的情况时的影响，加速试验研究的结果有时不能预示物理变化。\n\n根据上述已知信息，请将'Studies designed to increase the rate of chemical degradation and physical change of an API or FPP by  using exaggerated storage conditions as part of the stability testing programme. The data thus obtained, in addition to those derived from long-term stability studies, may be used to assess longer term chemical effects under non-accelerated conditions and to evaluate the impact of short-term excursions outside the label storage conditions, as might occur during shipping. The results of accelerated testing studies are not always predictive of physical changes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过使用夸张的储存条件作为稳定性测试程序的一部分，旨在增加API或FPP的化学降解和物理变化速率的研究。由此获得的数据，除了来自长期稳定性研究的数据外，可用于评估非加速条件下的长期化学效应，并评估标签存储条件外的短期漂移的影响，如在运输过程中可能发生的影响。加速试验研究的结果并不总是能预测物理变化。"
    },
    {
        "instruction":"已知信息：\n'A solid preparation made of drugs and excipients filled in hollow capsules in an appropriate form.'可被翻译为：药物及辅料以适当形式填装于空心胶囊中制成的固体制剂。\n'soft capsule'可被翻译为：软胶囊剂\n\n根据上述已知信息，请将'A solid preparation prepared by filling a hollow capsule or sealing in a soft capsule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物及辅料填装于空心胶囊或密封于软质囊材中制得的固体制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 18 The personnel engaged in drug distribution and quality management of an enterprise shall comply with the qualification requirements specified in relevant laws and regulations and this GSP, and shall be under no Job Forbidden by relevant laws and regulations.'可被翻译为：第十八条 企业从事药品经营和质量管理工作的人员，应当符合有关法律法规及本规范规定的资格要求，不得有相关法律法规禁止从业的情形。\n'The State encourages and guides the operation of retail drug chains. The headquarters of a retail drug chain shall establish a unified quality management system and perform management responsibilities for the business activities of the chain retailers.'可被翻译为：国家鼓励、引导药品零售连锁经营。从事药品零售连锁经营活动的企业总部，应当建立统一的质量管理制度，对所属零售企业的经营活动履行管理责任。\n\n根据上述已知信息，请将'Article 179 The management of the headquarters of drug retail chain enterprise shall comply with the relevant provisions of the GSP for drug wholesale enterprises, and the management of its stores shall comply with the relevant provisions of the GSP for drug retail enterprises.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十九条 药品零售连锁企业总部的管理应当符合本规范药品批发企业相关规定，门店的管理应当符合本规范药品零售企业相关规定。"
    },
    {
        "instruction":"已知信息：\n'electrical conductivity'可被翻译为：电导率\n'WFI systems should include continuous monitoring systems such as Total Organic Carbon (TOC) and\nconductivity, as these may give a better indication of overall system performance than discrete sampling. Sensor locations should be based on risk.'可被翻译为：WFI 系统应包括连续监测系统，监测总有机碳（TOC）和电导率等指标，因为这些参数比离散取样更好地指示整体系统性能。传感器位置应基于风险。\n\n根据上述已知信息，请将'The reciprocal of resistivity. Is a physical indicator of the electrical conductivity of a substance. The greater the conductivity, the stronger the material conductivity, the smaller the resistance, on the contrary, the worse the conductivity, the greater the resistance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"电阻率的倒数。是表示物质导电性能的物理指标。电导率越大则物质导电性能越强，电阻就越小，反之导电性能越差，电阻越大。"
    },
    {
        "instruction":"已知信息：\n'Article 280: The contract giver is responsible for assessing the contract acceptor, via on-site audit of the conditions, technical levels and quality management status, to confirm its competence to carry out the contracted operations, and to ensure the compliance with the Provisions.'可被翻译为：第二百八十条 委托方应当对受托方进行评估，对受托方的条件、技术水平、质量管理情况进行现场考核，确认其具有完成受托工作的能力，并能保证符合本规范的要求。\n'Article 282: The contract giver should supervise the entire process of contract manufacturing or analysis.'可被翻译为：第二百八十二条 委托方应当对受托生产或检验的全过程进行监督。\n\n根据上述已知信息，请将'Article 291: The contract should clearly define that the contract giver can conduct on-site inspection or audit to the contract acceptor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百九十一条 合同应当明确规定委托方可以对受托方进行检查或现场质量审计。"
    },
    {
        "instruction":"已知信息：\n'iv. Cleaning procedures and cleaning validation'可被翻译为：清洁程序和清洁验证\n'Article 139: The premises, facilities, equipment and testing instruments should be qualified. The validated manufacturing process, operation procedures and testing methods should be used for production, operation and testing, and this validated state should be maintained.'可被翻译为：第一百三十九条 企业的厂房、设施、设备和检验仪器应当经过确认，应当采用经过验证的生产工艺、操作规程和检验方法进行生产、操作和检验，并保持持续的验证状态。\n\n根据上述已知信息，请将'The cleaning process should be validated to be able to:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"清洁程序应进行验证，确保其能够："
    },
    {
        "instruction":"已知信息：\n'Article 152 The State Food and Drug Administration shall make the review and approval decision within 20 days; where a decision cannot be made within 20 days, another ten days may be extended with the approval of the State Food and Drug Administration head in charge, and the applicant shall be informed of the reason of the time extended.'可被翻译为：第一百五十二条 国家食品药品监督管理局应当在20日内作出审批决定；20日内不能作出决定的，经主管局领导批准，可以延长10日，并应当将延长时限的理由告知申请人。\n'(5) a decision is made to give an administrative sanction of revoking the drug approval document by law; and'可被翻译为：（五）依法作出撤销药品批准证明文件的行政处罚决定的；\n\n根据上述已知信息，请将'Article 100 A decision on administrative approval shall be made within 20 days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百条 行政审批决定应当在二十日内作出。"
    },
    {
        "instruction":"已知信息：\n'(16) Medical device with measuring functions'可被翻译为：（十六）具有计量测试功能的医疗器械\n'The ability of an IVD medical device to yield results that are correlated with a particular clinical condition\/physiological state in accordance with target population and intended user (4).'可被翻译为：IVD医疗设备根据目标人群和预期用户产生与特定临床状况\/生理状态相关的结果的能力(4)。\n\n根据上述已知信息，请将'A medical device intended to measure the physiological, pathological and anatomic parameters or make quantitative determination on the energies\/substances entering or leaving the human body. The measuring results shall be accurately quantified, and the accuracy of such results may have obvious effects on patient's health and safety.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种用于测定生理、病理、解剖参数，或者定量测定进出人体的能量或物质的医疗器械，其测量结果需要精确定量，并且该结果的准确性会对患者的健康和安全产生明显影响。"
    },
    {
        "instruction":"已知信息：\n'To strengthen the supervision and guidance of medical device registration, and further improve the quality of registration review, the NMPA organized to formulation of the Guidelines for Technical Review of Vision Screener Registration and the Guidelines for Technical Review of Mammography System Registration, which were published on June 24.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《视力筛查仪注册技术审查指导原则》和《乳腺X射线系统注册技术审查指导原则》，并于6月24日发布。\n'NMPA Announcement on Issuing 2 Guidance including the Guidance for Nomenclature of the Generic Names of Neurosurgical and Cardiovascular Surgical Devices'可被翻译为：国家药监局关于发布神经和心血管手术器械通用名称命名指导原则等2项指导原则的通告\n\n根据上述已知信息，请将'NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'Article 71: The design, selection, installation, adaption and maintenance of equipment should be suitable for its intended use, minimize the risk of contamination, cross-contamination, mixups or errors, and facilitate operation, cleaning, maintenance, as well as disinfection or sterilization if necessary.'可被翻译为：第七十一条 设备的设计、选型、安装、改造和维护必须符合预定用途，应当尽可能降低产生污染、交叉污染、混淆和差错的风险，便于操作、清洁、维护，以及必要时进行的消毒或灭菌。\n'Article 80: Preventive maintenance plans and procedures should be established, and the maintenance and repair activities should be recorded.'可被翻译为：第八十条 应当制定设备的预防性维护计划和操作规程，设备的维护和维修应当有相应的记录。\n\n根据上述已知信息，请将'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。"
    },
    {
        "instruction":"已知信息：\n'Manufacturers of Prepared Slices shall fulfill relevant obligations of drug MAHs and ensure the manufacturing of Prepared Slices continuously complies with regulatory requirements.'可被翻译为：中药饮片生产企业应当履行药品上市许可持有人的相关义务，确保中药饮片生产过程持续符合法定要求。\n'The manufacturer of prepared slices of Chinese crude drugs shall perform relevant obligations as the MAH of the drug when selling the prepared slices of Chinese crude drugs.'可被翻译为：中药饮片生产企业销售其生产的中药饮片，应当履行药品上市许可持有人相关义务。\n\n根据上述已知信息，请将'(IV) For the sales of Prepared Slices, they shall be accurately weighed, and the customers shall be informed of the decocting and administration methods and corresponding precautions. The provision of decoction services for Prepared Slices shall conform to the relevant national provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）销售中药饮片做到计量准确，并告知煎服方法及注意事项；提供中药饮片代煎服务，应当符合国家有关规定。"
    },
    {
        "instruction":"已知信息：\n'The adverse event refers to an adverse medical event that occurs during the clinical trial, no matter whether it is related to the investigational medical devices.'可被翻译为：不良事件，是指在临床试验过程中出现的不利的医学事件，无论是否与试验用医疗器械相关。\n'Article 72 The investigator shall record all the adverse events occurred and the device defects found during the clinical trial and analyze the cause of the event together with the sponsor, form a written analysis report, give the opinion of continuing, suspending or terminating the trial, and report to the ethics committee for review through the medical device clinical trial management department of the clinical trial institution.'可被翻译为：第七十二条 研究者应当记录临床试验过程中发生的所有不良事件和发现的器械缺陷，并与申办者共同分析事件原因，形成书面分析报告，提出继续、暂停或者终止试验的意见，经临床试验机构医疗器械临床试验管理部门报伦理委员会审查。\n\n根据上述已知信息，请将'(14) Adverse events found in the clinical trial and the handling;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十四）临床试验中发现的不良事件以及其处理情况；"
    },
    {
        "instruction":"已知信息：\n'Provisions for Supervision of Drug Distribution'可被翻译为：药品流通监督管理办法\n'Provisions for Drug Recall (SFDA Decree No. 29) (Abolished)'可被翻译为：《药品召回管理办法》【废止】\n\n根据上述已知信息，请将'Provisions for Supervision of Drug Distribution(SFDA Decree No.26)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《药品流通监督管理办法》（局令第26号）"
    },
    {
        "instruction":"已知信息：\n'controlled vocabulary (cv)'可被翻译为：受控词汇\n'An organization currently engaged in establishing, populating on an initial basis or maintaining controlled vocabularies (ISO). For example, EDQM, ICH, \nIHTSDO.'可被翻译为：目前参与建立、在初步基础上填入或维护受控词汇（ISO）的组织。 例如，EDQM、ICH、IHTSDO。\n\n根据上述已知信息，请将'A controlled vocabulary is an established list of standardized terminology for use in indexing and retrieval of information. CVs are established lists of \npreferred terms for cataloguing or indexing information (for example as descriptors in databases). CVs can address issues of synonyms or \nstandardised headings. Sample CVs: MedDRA, ISO country codes, EDQM Routes of Administration, etc.)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"受控词汇表（CV）是一张已确定的标准术语表，用于信息的索引和检索。CV 是已确定的首选术语表，用于分类和索引信息（类似于数据库中的描述符）。CV可以解决同义词或标准化标题的问题。（CV 样例：MedDRA、ISO 国家代码、EDQM 给药途径等。）"
    },
    {
        "instruction":"已知信息：\n'Describes a process step, process condition, test requirement, or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.'可被翻译为：用以描述某个为保证药品符合要求而确立的应当被控制在预先确定的标准范围内的工艺步骤、工艺条件、试验要求或其他有关的参数或项目。\n'critical. Having the potential to impact on product quality or performance in a significant way.'可被翻译为：关键的：可能对产品质量或性能有重大影响者\n\n根据上述已知信息，请将'1.Describes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n2.Having the potential to impact on product quality or performance in a  significant way.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.描述必须控制在预定标准内的工艺步骤、工艺条件、测试要求或其他相关参数或项目，以确保原料药符合其规格。\n2.有可能对产品质量或性能产生重大影响的。"
    },
    {
        "instruction":"已知信息：\n'Article 39 The technical assessment agency shall, within 90 working days from the date of receiving the application dossiers, organize the technical evaluation in accordance with the requirements of technical evaluation, and deal with it respectively according to the following circumstances:'可被翻译为：第三十九条 技术审评机构应当自收到申请资料之日起90个工作日内，按照技术审评的要求组织开展技术审评，并根据下列情况分别作出处理：\n'The service agency shall transfer the application dossiers to the technical assessment agency within 3 working days from the date of accepting the registration application of new cosmetic ingredients.'可被翻译为：受理机构应当自受理注册申请后3个工作日内，将申请资料转交技术审评机构。\n\n根据上述已知信息，请将'Article 14 The technical assessment agency shall, within 90 working days from the date of receiving the application dossiers, organize the technical evaluation in accordance with the requirements of the technical evaluation, and deal with it separately according to the following circumstances:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 技术审评机构应当自收到申请资料之日起90个工作日内，按照技术审评的要求组织开展技术审评，并根据下列情况分别作出处理："
    },
    {
        "instruction":"已知信息：\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 5, 2020 the Guidelines for Technical Review of the Registration of Colloidal Gold Immunochromatographic Analyzers, Guidelines for Technical Review of the Registration of Follicle stimulating Hormone Detection Reagents, Guidelines for Technical Review of the Registration of Creatinine Detection Reagents, Guidelines for Technical Review of the Registration of Antinuclear Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Antithyroid Peroxidase Antibody Assay Reagents, Guidelines for Technical Review of the Registration of Glycated Albumin Assay Reagents, and the Guidelines for Technical Review of the Registration of Total Bile Acid Assay Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年3月5日发布了《胶体金免疫层析分析仪注册技术审查指导原则》《促卵泡生成素检测试剂注册技术审查指导原则》《肌酐检测试剂注册技术审查指导原则》《抗核抗体检测试剂注册技术审查指导原则》《抗甲状腺过氧化物酶抗体测定试剂注册技术审查指导原则》《糖化白蛋白测定试剂注册技术审查指导原则》和《总胆汁酸测定试剂注册技术审查指导原则》。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of EB Virus Nucleic Acid Detection Reagents, Guidelines for Technical Review of the Registration of HBV e Antigen, e Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Thalassemia-Related Gene Detection Reagents, and Guidelines for Technical Review of the Registration of HBV-Resistant Gene Mutation Detection Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2020年3月10日组织制定并发布了《EB病毒核酸检测试剂注册技术审查指导原则》《乙型肝炎病毒e抗原、e抗体检测试剂注册技术审查指导原则》《地中海贫血相关基因检测试剂注册技术审查指导原则》《乙型肝炎病毒耐药相关的基因突变检测试剂注册技术审查指导原则》。\n\n根据上述已知信息，请将'To strengthen the supervision and guidance over medical device product registration and further improve the quality of registration review, NMPA has organized the formulation of and released on October 29, 2019 the Guidelines for Technical Review of the Registration of Assay Reagents for Aspartate Aminotransferase, Guidelines for Technical Review of the Registration of Total Cholesterol Assay Reagents, Guidelines for the Technical Review of Registration of Uric Acid Determination Reagents, and Guidelines for Technical Review of the Registration of Urea Determination Reagents.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年10月29日组织制定并发布了《天门冬氨酸氨基转移酶测定试剂注册技术审查指导原则》《总胆固醇测定试剂注册技术审查指导原则》《尿酸测定试剂注册技术审查指导原则》和《尿素测定试剂注册技术审查指导原则》。"
    },
    {
        "instruction":"已知信息：\n'(II) Concealing, missing to report or submitting false report;'可被翻译为：（二）瞒报、漏报、虚假报告的；\n'(1) conceal, withhold, or omit information or make false reports of drug safety incidents;'可被翻译为：（一）瞒报、谎报、缓报、漏报药品安全事件；\n\n根据上述已知信息，请将'(2) providing false information or conceal authentic condition on purpose;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）故意提供虚假信息或者隐瞒真实情况；"
    },
    {
        "instruction":"已知信息：\n'Precision in the laboratory. That is, the influence of varying factors such as different time, different analysts, different instruments and equipment on the measurement results.'可被翻译为：实验室内的精密度。即不同时间、不同分析人员、不同仪器设备等变动因素对测定结果的影响。\n'The intra-run and inter-run precision and reproducibility may be compared for the release rate (slopes) calculated for each diffusion cell. The mean, standard deviation, and percent coefficient of variation (%CV) among slopes may be calculated within and across all runs, and a minimum intra-run and inter-run %CV≤15% is recommended. Runs may be organized to facilitate a simultaneous evaluation of intra\/inter-instrumentation and\/or intra\/inter-operator precision and reproducibility. A minimum of three independent precision and reproducibility runs is recommended.'可被翻译为：可根据每个扩散池的释放速率（斜率）计算批内精密度和批间重现性。应计算并报告所有批内和批间斜率的均值、标准偏差和变异系数（%CV），批内和批间的变异系数（%CV）均应小于等于15%。批的运行应便于仪器内\/间 和\/或 操作者内\/间的精密度和重现性的同时评估。建议至少进行三次精密度和重现性试验。\n\n根据上述已知信息，请将'1.The degree of agreement among individual results when the procedure is applied repeatedly to multiple samplings of a homogeneous sample. Precision, usually expressed as relative standard deviation, may be considered at three levels: repeatability (precision under the same operating conditions over a short period of time), intermediate precision (within laboratory variations — different days, different analysts or different equipment) and reproducibility (precision between laboratories).\n2.The degree of agreement among individual results.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.当程序重复应用于均匀样本的多个采样时，单个结果之间的一致程度。精密度通常表示为相对标准偏差，可以在三个层面上考虑:重复性(在短时间内相同操作条件下的精密度)、中间精密度(在实验室变化范围内——不同的日期、不同的分析人员或不同的设备)和再现性(实验室之间的精密度)。\n2.一致性:个别结果之间的一致程度"
    },
    {
        "instruction":"已知信息：\n'The process by which drugs or their metabolites are excreted from the body and the process by which drugs are biotransformed.'可被翻译为：体内药物或其代谢产物排出体外的过程以及药物生物转化的过程。\n'Also known as an indirect actingcarcinogen. Substances that are not directly carcinogenic in themselves, but must undergo metabolic transformation in the body before their metabolites have a carcinogenic effect.'可被翻译为：又称\"间接致癌物(indirect-actingcarcinogen)\"。本身不直接致癌，必须在体内经代谢转化，其所形成的代谢产物才具有致癌作用的物质。\n\n根据上述已知信息，请将'Prone to metabolizing inactivated drugs. A class of drugs that are rapidly excreted from the body after a step transformation into inactive metabolites in a controlled metabolic pathway and metabolic rate after the completion of the therapeutic effect in order to achieve separation of activity and toxicity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"容易代谢失活的药物。在完成治疗作用后以可控的代谢途径和代谢速率，经一步转化为无活性的代谢产物迅速排出体外，以便实现活性和毒性分离的一类药物。"
    },
    {
        "instruction":"已知信息：\n'Anticipated ambient temperature variation and duration to which a TTSPP may be exposed during transport.'可被翻译为：TTSPP在运输过程中可能暴露的预期环境温度变化和持续时间。\n'The range and pattern of temperatures and\/or humidity within a temperature controlled storage unit during normal operation.'可被翻译为：温度控制存储单元在正常运行时的温度和\/或湿度的范围和模式。\n\n根据上述已知信息，请将'An excursion event in which a TTSPP is exposed to temperatures outside the range(s) prescribed for storage and\/or transport. Temperature ranges for storage and transport may be the same or different; they are determined by the product manufacturer, based on stability data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"TTSPP暴露在超出规定的储存和\/或运输范围的温度下的偏移事件。储存和运输的温度范围可能相同，也可能不同;由产品生产厂家根据稳定性数据确定。"
    },
    {
        "instruction":"已知信息：\n'1.The practice of pharmacy aimed at providing and promoting the best use of drugs and other health care services and products, by patients and members of the public. It requires that the welfare of the patient is the pharmacist's prime concern at all times.\n2.The practice of pharmacy aimed at providing and promoting the best use of medicines and other health-care services and products by patients and members of the public. It requires that the welfare of the patient is the pharmacist’s prime concern at all times.'可被翻译为：1.药剂学旨在为病人和公众提供和促进药物及其他保健服务和产品的最佳使用的药学实践。它要求药剂师在任何时候都以病人的福利为首要考虑。\n2.旨在为病人和公众提供和促进药品及其他保健服务和产品的最佳利用的药学实践。它要求药剂师在任何时候都以病人的福利为首要考虑。\n'patient education'可被翻译为：患者用药教育\n\n根据上述已知信息，请将'A record established by a pharmacist of a patient's treatment or prevention of a disease in order to ensure the safety and effectiveness of a drug. It includes professional activities that affect the outcome of the patient's prognosis (protocol development, implementation, efficacy, adverse reaction observation, evaluation, adjustment, patient education). Available in both paper and electronic form.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为保证用药安全有效，由药师建立的患者治疗或预防疾病进行药物治疗过程的记录。包括为影响患者预后结果的专业活动（方案制定，实施，疗效、不良反应观察，评价、调整，患者教育）等内容。有纸质和电子两种形式。"
    },
    {
        "instruction":"已知信息：\n'Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.'可被翻译为：对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。\n'Article 67 For a conditionally approved drug, where the MAH fails to complete the studies as required within the specified timeline or fails to prove that the benefits outweigh risks, the NMPA shall handle the matter in accordance with the law until the Drug Approval License is revoked.'可被翻译为：第六十七条 对附条件批准的药品，持有人逾期未按照要求完成研究或者不能证明其获益大于风险的，国家药品监督管理局应当依法处理，直至注销药品注册证书。\n\n根据上述已知信息，请将'Where the Drug Approval License and its attachments require the MAH to carry out relevant post-marketing studies, the MAH shall complete the studies within the specified timeline and submit a supplementary application, filing or report as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品注册证书及附件要求持有人在药品上市后开展相关研究工作的，持有人应当在规定时限内完成并按照要求提出补充申请、备案或者报告。"
    },
    {
        "instruction":"已知信息：\n'The lot release institutions designated by the CFDA shall be responsible for the acceptance, dossier review, on-site inspection and sample testing and making the decision on lot release in accordance with the law.'可被翻译为：食品药品监管总局指定的批签发机构负责批签发的受理、资料审核、现场核实、样品检验等工作，并依法作出批签发决定。\n'Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.'可被翻译为：第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。\n\n根据上述已知信息，请将'The lot release institutions designated by the NMPA shall be responsible for the acceptance, dossier review, and sample testing and the decision-making on lot release in accordance with the law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药品监督管理局指定的批签发机构负责批签发的受理、资料审核、样品检验等工作，并依法作出批签发决定。"
    },
    {
        "instruction":"已知信息：\n'semi-permeable containers'可被翻译为：半渗透性容器\n'A solid preparation made of drugs and excipients in an appropriate form by pressing (or dropping) sealed in soft sacs.'可被翻译为：药物及辅料以适当形式通过压制法（或滴制法）密封于软质囊材中而制成的固体制剂。\n\n根据上述已知信息，请将'Containers that provide a permanent barrier to the passage of gases or solvents, e.g. sealed aluminium tubes for semisolids, sealed glass ampoules for solutions and luminium\/aluminium blisters for solid dosage forms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为气体或溶剂的通过提供永久屏障的容器，例如，用于半固体的密封铝管，用于溶液的密封玻璃安瓿和用于固体剂型的铝\/铝泡罩。"
    },
    {
        "instruction":"已知信息：\n'Article 56 If the medical device registrant and the contract manufacturer are not in the same province, autonomous region or municipality directly under the central government, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant of medical devices is located shall be responsible for carrying out supervision and inspection of the registrant’s performance of its legal duties such as operation of quality management system, adverse events monitoring and product recall, etc., and if relevant conditions of the contract manufacturer, the drug regulatory department of the place where the contract manufacturer is located shall make cooperation.'可被翻译为：第五十六条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市的，医疗器械注册人所在地省、自治区、直辖市药品监督管理部门负责对注册人质量管理体系运行、不良事件监测以及产品召回等法定义务履行情况开展监督检查，涉及受托生产企业相关情况的，受托生产企业所在地药品监督管理部门应当配合。\n'Article 57 If the registrant and the contract manufacturer of medical devices are not in the same province, autonomous region or municipality directly under the central government, and the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer is located needs to carry out cross-region inspection, it could also make inspection by means of joint inspection and entrusted inspection, etc.'可被翻译为：第五十七条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门需要跨区域开展检查的，可以采取联合检查、委托检查等方式进行。\n\n根据上述已知信息，请将'Article 58 If it is found in cross-region inspection that there is defect with the enterprise quality management system, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer of medical devices is located shall, in accordance with their respective duties, urge relevant enterprises to make prompt rectification in place as required, and inform the inspection and rectification conditions to related drug regulatory department in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条  跨区域检查中发现企业质量管理体系存在缺陷的，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门应当依据各自职责，督促相关企业严格按照要求及时整改到位，并将检查以及整改情况及时通报相关药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'Note that the linearity of release rates across different strengths of the product (which assesses the specificity of the IVRT method, with a minimum r2 value ≥ 0.95) is fundamentally different and has different scientific considerations than the linearity of the release rate for a single strength of the product across the range of the sampling times (which assesses the IVRT method’s ability to monitor the steady state release kinetics of the active ingredient, with a minimum r2 value ≥ 0.97). Despite the potential for different scientific considerations to impact the linearity of the IVRT results in each context, for well-developed and suitably controlled IVRT methods, the r2 value ≥ 0.99 is routinely observed in both contexts.'可被翻译为：需要注意的是，产品不同规格释放速率的线性关系（评估IVRT方法的专属性，要求r2≥0.95）与同一规格产品在不同采样时间点获得的释放速率线性关系（评估IVRT方法监控活性成分稳态释放动力学的能力，要求r2≥0.97）具有根本不同的科学考虑。尽管基于不同的科学考虑因素，可能会影响IVRT结果的线性关系，但对于经过良好的开发和适当控制的IVRT方法，在两者的背景下，通常都能满足r2≥0.99的要求。\n'For each cell, the individual amount of drug released is plotted versus the square root of time. The slope of the resulting line is the rate of drug release.'可被翻译为：对于每个池，单独的药物释放量与时间的平方根成曲线。所得直线的斜率为药物释放速率。\n\n根据上述已知信息，请将'When utilizing an appropriately selected receptor solution, membrane, equipment, dose, and sampling duration (as well as other potential method parameters) the release rate of the drug should be linear (when plotted as the amount of drug released versus the square root of time) and reproducible. The amount of drug product in the donor compartment should ensure that dose depletion does not occur to an extent that alters the linear (steady state) release kinetics during the duration of the test (i.e., a pseudo-infinite dose amount should be utilized). Excessive dose depletion is characterized by a nonlinear region in the plotted cumulative amount of drug released curve (when plotted as the amount of drug released versus the square root of time).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当使用适当选择的受体溶液、膜、设备、剂量和取样时间(以及其他潜在的方法参数)时，药物的释放速度应该是线性的(当绘制为药物释放量与时间的平方根时)并且可重复。给药室中的药物用量应确保在试验过程中，剂量消耗不会达到改变线性(稳态)释放动力学的程度(即，应使用伪无限剂量)。过量剂量消耗的特征是在绘制的药物累积释放量曲线中出现一个非线性区域(当绘制为药物释放量与时间的平方根时)。"
    },
    {
        "instruction":"已知信息：\n'The addition of fresh liquid at a similar flow rate during fermentation.'可被翻译为：在发酵过程中一边补入新鲜料液，一边以相近的流速放料。\n'The ratio of the volume of seed liquid fed into the fermenter to the volume of the fermentation medium in the tank.'可被翻译为：接入到发酵罐内的种子液的体积与罐内发酵培养基的体积之比。\n\n根据上述已知信息，请将'In the culture process, the culture medium is continuously added to the fermenter, while the same flow rate from the fermenter flowing out of the culture liquid fermentation mode.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在培养过程中，连续地向发酵罐中加入培养基，同时以相同的流量从发酵罐中流出培养液的发酵方式。"
    },
    {
        "instruction":"已知信息：\n'(III) Failing to submit evaluation outcome reports or submit investigation reports of group adverse events of medical device in accordance with the time limits;'可被翻译为：（三）未按照时限要求报告评价结果或者提交群体医疗器械不良事件调查报告的；\n'(2) failing to obtain and keep relevant certification documents and temperature monitoring records when receiving or purchasing vaccines;'可被翻译为：（二）接收或者购进疫苗时未按照规定索取并保存相关证明文件、温度监测记录；\n\n根据上述已知信息，请将'(III) Failing to keep the records of adverse event monitoring or preserve the records for insufficient duration;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）未保存不良事件监测记录或者保存年限不足的；"
    },
    {
        "instruction":"已知信息：\n'minimum required dilution (mrd)'可被翻译为：最低需求稀释度\n'Tabular output of all data from individual samples, QCs and calibration standards within the analytical run (e.g., for chromatography retention times, analyte and IS responses, concentrations, and dilution factors if any; for ligand binding assays analyte responses concentrations, dilution factors).'可被翻译为：分析批中单个样品、QC和校正标样的所有数据的表格输出（例如，对于色谱法有保留时间、待测物和IS响应、浓度、稀释因子（如有）、采集时间；对于配体结合分析，有待测物响应、浓度、稀释因子）。\n\n根据上述已知信息，请将'The initial dilution factor by which biological samples are diluted with buffer solution for the analysis by LBAs. The MRD may not necessarily be the ultimate dilution but should be identical for all samples including calibration standards and QCs. However, samples may require further dilution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于 LBA 分析，生物样品以缓冲液稀释的最初稀释因子。MRD可能不是最终稀释，但应对所有样品保持一致，包括校正标样和QC样品。然而样品可能需要进一步稀释。"
    },
    {
        "instruction":"已知信息：\n'reaction rate'可被翻译为：反应速率\n'A reaction in which the rate of reaction is dependent on the concentration of the reactant to the power of one.'可被翻译为：反应速率与反应物浓度的一次方相关的反应。\n\n根据上述已知信息，请将'Also known as \"reaction rate constant\". The speed at which a chemical reaction proceeds is expressed as a decrease in the concentration of the reactant or an increase in the concentration of the product per unit time. In general, when the temperature is fixed, the specific rate of the reaction is constant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"反应速率常数”。化学反应进行的快慢，用单位时间内反应物浓度的减少或生成物浓度的增加量来表示。一般来说，当温度一定时，特异反应比速为常数。"
    },
    {
        "instruction":"已知信息：\n'(II) verifying the original Certificate of Analysis for release and Certificate of Origin;'可被翻译为：（二）核查出厂检验报告书和原产地证明原件；\n'(VI)  photocopies of the Certificate of Analysis for release;'可被翻译为：（六）出厂检验报告书复印件；\n\n根据上述已知信息，请将'(I) the original Certificate of Analysis for release and Certificate of Origin is not provided, or the original copy provided is inconsistent with the photocopies submitted at the time of importation record filing;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）未提供出厂检验报告书和原产地证明原件，或者所提供的原件与申报进口备案时的复印件不符的；"
    },
    {
        "instruction":"已知信息：\n'ADR\/ADE county reporting ratio marks an important indicator for measuring the balanced development and coverage of ADR monitoring in China. The proportion of county-level reports of ADRs\/ADEs in China in 2018 was 97.9%.'可被翻译为：药品不良反应\/事件县级报告比例是衡量我国药品不良反应监测工作均衡发展及覆盖程度的重要指标之一。2018年全国药品不良反应\/事件县级报告比例为97.9%。\n'As one of the important indicators to measure the level of national ADR monitoring, the average number of reports per million people in China marked 1,119 in 2018.'可被翻译为：每百万人口平均报告数量是衡量一个国家药品不良反应监测工作水平的重要指标之一。2018年我国每百万人口平均报告数为1119份。\n\n根据上述已知信息，请将'The ratio of ADR\/ADE reports at county level constitutes one of the important indicators to measure the balanced development and coverage of ADR monitoring in China. In 2019, 97.4 percent of county-level regions across China reported ADRs\/ADEs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品不良反应\/事件县级报告比例是衡量我国药品不良反应监测工作均衡发展及覆盖程度的重要指标之一。2019年全国97.4%的县级地区报告了药品不良反应\/事件。"
    },
    {
        "instruction":"已知信息：\n'description of manufacturing steps (narrative and process maps or flow charts, and\/or master batch records), including the qualification of in-processing hold times and conditions, the order and method of raw material addition and bulk transfers between processing steps;'可被翻译为：生产步骤描述（叙述性和工艺流程图，和\/或批记录母本），包括中间体保存时长和条件的确认，原料加入和散装物料在不同工艺步骤之间的转移\n'pilot scale batch'可被翻译为：中试规模批次\n\n根据上述已知信息，请将'Batch manufacturing: Master of executed batch record; Scale up information; Risk assessment; Critical process parameters; In-process control specification; Scale up protocol and report; Process validation'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批生产： 已执行的批记录、放大信息、风险评估、关键工艺参数、中控标准、放大方案和报告、工艺验证"
    },
    {
        "instruction":"已知信息：\n'The medical device standards plan projects that are approved by China Food and Drug Administration shall be released to the public. The national standards plan project shall be submitted to the competent standardization administrative department under the State Council for approval and assignment; the industry standards plan project shall be approved and assigned by China Food and Drug Administration.'可被翻译为：国家食品药品监督管理总局审核通过的医疗器械标准计划项目，应当向社会公示。国家标准计划项目送国务院标准化行政主管部门批准下达；行业标准计划项目由国家食品药品监督管理总局批准下达。\n'Article 33 The serial number for medical device national standards shall be made in accordance with regulations of the competent standardization administrative department under the State Council. The code for medical device industry standards is composed of capitalized Chinese phonetic alphabets. The code for mandatory industry standards is \"YY\" , and that for recommended industry standards is \"YY\/T\".'可被翻译为：第三十三条 医疗器械国家标准的编号按照国务院标准化行政主管部门的规定编制。医疗器械行业标准的代号由大写汉语拼音字母等构成。强制性行业标准的代号为“YY”，推荐性行业标准的代号为“YY／Ｔ”。\n\n根据上述已知信息，请将'Medical device national standards and industry standards shall be disclosed in accordance with the relevant regulations of the competent standardization administrative department under the State Council for public reference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械国家标准、行业标准按照国务院标准化行政主管部门的相关规定进行公开，供公众查阅。"
    },
    {
        "instruction":"已知信息：\n'Article 63 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter VI of the Provisions shall prevail.'可被翻译为：第六十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。\n'Article 56 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter V of the Provisions shall prevail.'可被翻译为：第五十六条 医疗器械延续注册申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。\n\n根据上述已知信息，请将'Article 53 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter V of the Provisions shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。"
    },
    {
        "instruction":"已知信息：\n'3. County-level coverage. In 2019, the county-level coverage rate for reporting of suspected medical device adverse events in China was 96.70 percent, up by 0.80 percentage points YOY (Figure 3).'可被翻译为：3.县级覆盖率。2019年，我国可疑医疗器械不良事件报告的县级覆盖率为96.70%，比上年增加0.80个百分点（图3）。\n'3. County-level coverage In 2018, the county-level coverage of suspected medical device adverse events in China was 95.9% (Figure 3) .(II) Number of registered grassroots users nationwide As of December 31, 2018, there were a total of 275,715 grassroots user units (including manufacturing enterprises, operating companies and users) registered in the National Medical Device Adverse Event'可被翻译为：3.县级覆盖率\n\n根据上述已知信息，请将'Figure 3 County-level coverage of suspected medical device adverse event reports from 2015to 2018 in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2018年，我国可疑医疗器械不良事件报告的县级覆盖率为95.9%(图3 )。"
    },
    {
        "instruction":"已知信息：\n'(I) Determine the legal qualification of supplier;'可被翻译为：（一）确定供货单位的合法资格；\n'(III) Auditing the legal qualification of supplier and purchaser, the legality of drugs purchased and the legal qualification of sales personnel of supplier and purchasing personnel of purchaser, and conducting dynamic management according to the changes of audit contents;'可被翻译为：（三）负责对供货单位和购货单位的合法性、购进药品的合法性以及供货单位销售人员、购货单位采购人员的合法资格进行审核，并根据审核内容的变化进行动态管理；\n\n根据上述已知信息，请将'(III) Validate the legal qualification of sales personnel of supplier;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）核实供货单位销售人员的合法资格；"
    },
    {
        "instruction":"已知信息：\n'antifungal drug'可被翻译为：抗真菌药\n'Medications to treat and prevent filarial infections. Treatment medications are ethylamizine and albendazole, among others.'可被翻译为：治疗和预防丝虫感染的药物。治疗药物有乙胺嗪和阿苯达唑等。\n\n根据上述已知信息，请将'Medications to treat or prevent fungal infections. For superficial fungal infections, there are Terbuchofen and some topical antifungals; Amphotericin and fluorocytosine are suitable for deep fungal infections; Azole antifungals have antibacterial effects on both superficial and deep fungi.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防真菌感染的药物。适用于浅表真菌感染的有特比蔡芬及一些外用抗真菌药；适用于深部真菌感染的有两性霉素和氟胞嘧啶；唑类抗真菌药对浅表和深部真菌都有抗菌作用。"
    },
    {
        "instruction":"已知信息：\n'The operation of removing dissolved gases from the mobile phase in liquid chromatographic analysis. To prevent dissolved gases from forming bubbles in the flow tank of the pump or detector.'可被翻译为：液相色谱分析中除去流动相中溶解气体的操作。以免溶解的气体在泵或检测器的流通池中形成气泡。\n'The early term for capillary gas chromatography refers to gas chromatography using open tube columns (including wall coated open column and carrier coated open column). The types of open column include wall coated open column, carrier coated open column, porous layer open column and immobilized phase open column. Injection methods include shunt injection, no shunt injection and column head injection.'可被翻译为：早期对于毛细管气相色谱的称谓，指使用开管柱(包括涂壁开管柱和涂载体开管柱)的气相色谱法。开管柱的类型有涂壁开管柱、涂载体开管柱、多孔层开管柱和固定化相开管柱等。进样方式有分流进样、无分流进样 和柱头进样等。\n\n根据上述已知信息，请将'In capillary chromatography, a stream of air introduced at the exit of a capillary column. Its role is to reduce the dead volume behind the column, improve the column efficiency, meet the best gas flow rate of the detector, in order to improve the sensitivity of the detector.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"毛细管色谱分析中，在毛细管柱的出口端引入的一路气流。其作用是减少柱后的死体积，改善柱效，满足检测器的最佳气体流速，以提高检测器的灵敏度。"
    },
    {
        "instruction":"已知信息：\n'Article 46 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall organize supervision and inspection regarding supervision and administration of medical device distribution in the administrative areas.'可被翻译为：第四十六条  省、自治区、直辖市药品监督管理部门组织对本行政区域的医疗器械经营监督管理工作进行监督检查。\n'Article 13 The monitoring agencies designated by the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government (hereinafter referred to as provincial monitoring agencies) shall organize the technical works related to medical device adverse event monitoring and re-evaluation within their respective administrative regions; assume the investigation, evaluation and feedback of adverse events of the medical devices registered or filed within their respective administrative regions, and investigate and evaluate group adverse events of medical device that occurs within their respective administrative regions.'可被翻译为：第十三条  省、自治区、直辖市药品监督管理部门指定的监测机构（以下简称省级监测机构）组织开展本行政区域内医疗器械不良事件监测和再评价相关技术工作；承担本行政区域内注册或者备案的医疗器械不良事件的调查、评价和反馈，对本行政区域内发生的群体医疗器械不良事件进行调查和评价。\n\n根据上述已知信息，请将'Article 44 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government may, in accordance with the requirements for supervision and administration of medical device within their respective administrative regions, carry out provincial intensive surveillance project on Class II medical devices registered and Class I medical devices filed within their respective administrative regions by referring to Article 43 of the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十四条  省、自治区、直辖市药品监督管理部门可以根据本行政区域内医疗器械监管工作需要，参照本办法第四十三条规定，对本行政区内注册的第二类和备案的第一类医疗器械开展省级医疗器械重点监测工作。"
    },
    {
        "instruction":"已知信息：\n'(3) disturbing or obstructing vaccines-related investigation on illegal or criminal acts or safety incidents;'可被翻译为：（三）干扰、阻碍对疫苗违法行为或者疫苗安全事件的调查；\n'VI. Investigation and Punishment of Illegal Acts of Medical Devices'可被翻译为：六、关于医疗器械违法行为的查处\n\n根据上述已知信息，请将'(4) disturbing or obstructing vaccine-related investigation on illegal acts or safety incidents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）干扰、阻碍对疫苗违法行为或者疫苗安全事件的调查；"
    },
    {
        "instruction":"已知信息：\n'(II) The warehouse has smooth interior walls and ceiling as well as flat floor with tight structure of door and window;'可被翻译为：（二）库房内墙、顶光洁，地面平整，门窗结构严密；\n'Article 164 Where an enterprise establishes a warehouse, the drug storage and maintenance management in the warehouse shall comply with Section 10 of Chapter II herein.'可被翻译为：第一百六十四条 企业设置库房的，库房的药品储存与养护管理应当符合本规范第二章第十节的相关规定。\n\n根据上述已知信息，请将'Article 147 Where an enterprise establishes a warehouse, it shall ensure that the inner walls and ceiling of the warehouse are smooth and clean, the floor is flat and the doors and windows have a tight structure; and there are reliable safety protection, anti-theft and other measures.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百四十七条 企业设置库房的，应当做到库房内墙、顶光洁，地面平整，门窗结构严密；有可靠的安全防护、防盗等措施。"
    },
    {
        "instruction":"已知信息：\n'A method of separating the components of a liquid by means of the selectivity of the membrane, driven by pressure.'可被翻译为：以压力为推动力，依靠膜的选择性将液体中的组分进行分离的方法。\n'By using the size of the pore size of the microporous membrane, the particles larger than the pore size of the solution are retained to reach the process of solution clarification or separation.'可被翻译为：利用微孔膜孔径的大小，使溶液中大于膜孔径的微粒截留达到溶液澄清或分离的过程。\n\n根据上述已知信息，请将'The process of separating a solid membrane from a solution containing particles by using pressure as a driving force. When the solution passes through the microporous membrane, suspended matter (colloids, bacteria) and larger microspheres are trapped and removed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以压力为推动力，过滤含有微粒的溶液的固体膜分离过程。当溶液通过微孔膜后，悬浮物（胶体、细菌）和粒径较大的微球被截留而被除去。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory departments at the level of the municipality consisting of districts or county level shall be responsible for medical device-related adverse event monitoring within their respective administrative regions.'可被翻译为：设区的市级和县级药品监督管理部门负责本行政区域内医疗器械不良事件监测相关工作。\n'Article 13 The monitoring agencies designated by the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government (hereinafter referred to as provincial monitoring agencies) shall organize the technical works related to medical device adverse event monitoring and re-evaluation within their respective administrative regions; assume the investigation, evaluation and feedback of adverse events of the medical devices registered or filed within their respective administrative regions, and investigate and evaluate group adverse events of medical device that occurs within their respective administrative regions.'可被翻译为：第十三条  省、自治区、直辖市药品监督管理部门指定的监测机构（以下简称省级监测机构）组织开展本行政区域内医疗器械不良事件监测和再评价相关技术工作；承担本行政区域内注册或者备案的医疗器械不良事件的调查、评价和反馈，对本行政区域内发生的群体医疗器械不良事件进行调查和评价。\n\n根据上述已知信息，请将'The monitoring agencies at the level of the municipality consisting of districts or county level shall assist in carrying out technical works related to medical device adverse event monitoring within their respective administrative regions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设区的市级和县级监测机构协助开展本行政区域内医疗器械不良事件监测相关技术工作。"
    },
    {
        "instruction":"已知信息：\n'Article 13 After completion of manufacturing and testing of biological products subject to lot release administration, the lot release applicant shall fill out the Application Form for Lot Release of Biological Products in the IMS, and apply to the lot release institution under jurisdiction for lot release in the place where the MAH applying for lot release is located or the import port is set.'可被翻译为：第十三条    按照批签发管理的生物制品，批签发申请人在生产、检验完成后，应当在生物制品批签发管理系统内填写生物制品批签发申请表，并根据申请批签发产品的药品上市许可持有人所在地或者拟进口口岸所在地批签发机构设置情况，向相应属地的批签发机构申请批签发。\n'Article 47 Formats of the Application Form for Lot Release of Biological Products, the Registration Form for Lot Release of Biological Products, the Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products, the Notice of Re-review of Lot Release of Biological Products and the Notice of Re-review Result of Lot Release of Biological Products shall be developed in a unified manner and publicized by the NIFDC.'可被翻译为：第四十七条 生物制品批签发申请表、生物制品批签发登记表、生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审申请表、生物制品批签发复审结果通知书的格式由中检院统一制定并公布。\n\n根据上述已知信息，请将'Article 13 After completion of manufacturing and testing of biological products subject to lot release administration, the lot release applicant shall fill out the Application Form for Lot Release of Biological Products in the Information Management System for Lot Release, and apply to the lot release institution under jurisdiction for lot release in the place where the drug manufacturer applying for lot release is located or the place where the port at which the drug is to be imported is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十三条 按照批签发管理的生物制品在生产、检验完成后，批签发申请人应当在批签发信息管理系统内填写生物制品批签发申请表，并根据申请批签发产品的药品生产企业所在地或者拟进口口岸所在地，向相应属地的批签发机构申请批签发。"
    },
    {
        "instruction":"已知信息：\n'A graduated slender glass tube, the most basic instrument for titrating the volume of a solution in volumetric analysis.'可被翻译为：容量分析中滴定溶液的体积最基本的仪器，有刻度的细长玻璃管。\n'A titration method in which 0.05mol\/L chloramine T is used as titration agent, and the end point is indicated by potentiometric method (clamp, calomel electrode) in 2mol sulfuric acid solution and at higher temperature. It is generally used for the determination of drugs containing moonwell.'可被翻译为：以0.05mol\/L的氯胺T作为滴定剂，在2mol的硫酸溶液中及较高的温度下，以电位法（钳，甘汞电极）指示终点的一种滴定方法。一般用于含月井基药物的测定。\n\n根据上述已知信息，请将'In acid-base titration analysis, a measuring glass dropper containing a standard alkali titration solution. The lower end is a latex tube containing glass beads.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"酸碱滴定分析中，盛放标准碱滴定液的定量玻璃滴管。下端为含有玻璃珠的乳胶管。"
    },
    {
        "instruction":"已知信息：\n'Article 47 If the drug MAH is an oversea enterprise, it shall authorize a legal person within the territory of China to perform the obligations set forth in the Drug Administration Law and these Regulations, and to provide cooperation for overseas inspections.'可被翻译为：第四十七条 药品上市许可持有人为境外企业的，应当指定一家在中国境内的企业法人，履行《药品管理法》与本办法规定的药品上市许可持有人的义务，并负责协调配合境外检查工作。\n'Article 15 Where the overseas MAH changes the drug manufacturing site and the new manufacturing site is still overseas, it shall conduct study, evaluation and necessary verification in accordance with relevant technical guidelines and submit supplementary application or filing to CDE.'可被翻译为：第十五条 境外持有人变更药品生产场地且变更后生产场地仍在境外的，应按照相关技术指导原则进行研究、评估和必要的验证，向药审中心提出补充申请或备案。\n\n根据上述已知信息，请将'Article 48 Where the manufacturing site of a drug MAH is outside the territory of China, it shall organize manufacturing according to the Drug Administration Law and these Regulations and provide cooperation for overseas inspections.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 药品上市许可持有人的生产场地在境外的，应当按照《药品管理法》与本办法规定组织生产，配合境外检查工作。"
    },
    {
        "instruction":"已知信息：\n'Article 97: Water treatment plants and distribution systems should be designed, constructed, operated and maintained so as to ensure that water for pharmaceutical use meets the defined specifications. They should not be operated beyond their designed capacity.'可被翻译为：第九十七条 水处理设备及其输送系统的设计、安装、运行和维护应当确保制药用水达到设定的质量标准。水处理设备的运行不得超出其设计能力。\n'Processes and monitoring systems for sterile product manufacture should be designed, commissioned, qualified, monitored and regularly reviewed by personnel with appropriate process, engineering and microbiological knowledge.'可被翻译为：无菌产品生产工艺和监测系统应由具备适当工艺、工程和微生物知识的人员设计、调试、确认、检测和定期回顾。\n\n根据上述已知信息，请将'Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintained to prevent microbiological contamination and to ensure a reliable source of\nwater of an appropriate quality. Measures should be taken to minimize the risk of presence of particulates, microbial contamination\/proliferation and endotoxin\/pyrogen (e.g. sloping of piping to provide complete drainage and the avoidance of dead legs). Where filters are included in the system, special attention should be given to their\nmonitoring and maintenance. Water produced should comply with the current monograph of the relevant\nPharmacopeia.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"水处理设施及其分配系统地设计、建造、安装、调试、确认、监测和维护应防止微生物污染，并确保高质量的可靠水源。应釆取措施，最大程度降低微粒、微生物污染\/增殖和内毒素\/热原的风险（例如倾斜管道以完全排水以及避免死角）。当系统中包含过滤器时，应特别注意对其进行监测和维护。产出的水应符合相关药典的现行各论。"
    },
    {
        "instruction":"已知信息：\n'The design of open isolators should ensure grade A conditions with first air protection in the critical zone and unidirectional airflow that sweeps over and away from exposed products during processing.'可被翻译为：开放式隔离器的设计通过关键区域的初始气流保护和工艺过程中暴露产品上方和周围的单向流吹扫保证 A级条件。\n'RABS:\nThe background environment for RABS used for aseptic processing should correspond to a minimum of grade B and airflow pattern studies should be performed to demonstrate the absence of air ingress during interventions, including door openings if applicable.'可被翻译为：用于无菌工艺的RABS的环境应至少为 B级，并且应进行气流流型研究以证明在干预过程中没有空气进入，包括开门（如适用）。\n\n根据上述已知信息，请将'Airflow pattern studies should be performed at the interfaces of open isolators to demonstrate the absence of air ingress.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应在开放式隔离器的接口处进行气流流型研究，以证明没有空气进入。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on the Revision of the Package Insert of the Propranolol Tablets'可被翻译为：国家药监局关于修订普萘洛尔片剂说明书的公告\n'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of[Adverse reactions], [Contraindications]and [Precautions] in the package inserts of Metoclopramide. Relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对甲氧氯普胺说明书【不良反应】、【禁忌】、【注意事项】等项目进行统一修订。现将有关事项公告如下：\n\n根据上述已知信息，请将'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Precautions]in the package inserts of propranolol tablets. Relevant issues are hereby announced as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对普萘洛尔片剂说明书【注意事项】等项目进行统一修订。现将有关事项公告如下："
    },
    {
        "instruction":"已知信息：\n'Article 10 The people's governments at or above the county level shall incorporate the work of drug safety into the economic and social development plans of the people at their levels, and include funds for drug safety in their government budgets, strengthen the capacity-building of drug administration, and provide safeguards for drug safety work.'可被翻译为：第十条 县级以上人民政府应当将药品安全工作纳入本级国民经济和社会发展规划，将药品安全工作经费列入本级政府预算，加强药品监督管理能力建设，为药品安全工作提供保障。\n'Drug regulatory departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for the vaccine administration within their respective administrative regions. Departments undertaking responsibilities for drug administration (hereinafter referred to as drug regulatory departments) of the people's governments of municipalities divided into districts and at county level shall undertake the administrative duties on vaccines within their respective administrative regions. The competent health departments of people's governments at or above the county level shall undertake the administration of immunization within their respective administrative regions. Other relevant departments of the people's governments at or above the county level shall undertake the administrative duties on vaccines within the scope of their respective responsibilities.'可被翻译为：省、自治区、直辖市人民政府药品监督管理部门负责本行政区域疫苗监督管理工作。设区的市级、县级人民政府承担药品监督管理职责的部门（以下称药品监督管理部门）负责本行政区域疫苗监督管理工作。县级以上地方人民政府卫生健康主管部门负责本行政区域预防接种监督管理工作。县级以上地方人民政府其他有关部门在各自职责范围内负责与疫苗有关的监督管理工作。\n\n根据上述已知信息，请将'Article 15 Entities and individuals that have made significant contributions to drug development, manufacturing, distribution, use and supervision and administration shall be commended and rewarded by the people's government and its relevant departments at or above the county level in accordance with the relevant provisions of the State.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十五条 县级以上人民政府及其有关部门对在药品研制、生产、经营、使用和监督管理工作中做出突出贡献的单位和个人，按照国家有关规定给予表彰、奖励。"
    },
    {
        "instruction":"已知信息：\n'Different forms of administration prepared to suit therapeutic or preventive needs.'可被翻译为：为适应治疗或预防的需要而制备的不同给药形式。\n'The different forms of administration of a drug used in the prevention and treatment of a disease are new forms of a drug that have a certain function.'可被翻译为：在防治疾病的过程中所采用的药物的不同给药形式，是具有某种功能的药物新剂型。\n\n根据上述已知信息，请将'Specific varieties of different forms of administration prepared to meet the needs of treatment or prevention in accordance with the standards approved by the pharmacopoeia or the pharmaceutical administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据药典或药政管理部门批准的标准，为适应治疗或预防的需要而制备的不同给药形式的具体品种。"
    },
    {
        "instruction":"已知信息：\n'Article 81 Enterprises shall keep inventory records, and in a timely manner warehouse and register the drugs that are qualified in the acceptance inspection; those failed in the acceptance inspection shall not be warehoused and shall be instead handled by the quality management department.'可被翻译为：第八十一条 企业应当建立库存记录，验收合格的药品应当及时入库登记；验收不合格的，不得入库，并由质量管理部门处理。\n'Article 91 Invoices shall be truthfully issued for drugs sold by enterprises, ensuring the consistency among invoice, accounts, goods and amount.'可被翻译为：第九十一条 企业销售药品，应当如实开具发票，做到票、账、货、款一致。\n\n根据上述已知信息，请将'Article 88 Enterprises shall periodically carry out inventory check of drugs and ensure consistency between the accounts and goods.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十八条 企业应当对库存药品定期盘点，做到账、货相符。"
    },
    {
        "instruction":"已知信息：\n'multicomponent spectrophotometry'可被翻译为：多组分光谱分析\n'In metrology absorptiometry, a data processing method used for multi-component analysis.'可被翻译为：在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。\n\n根据上述已知信息，请将'A stoichiometric data processing method used in the analysis and detection of multi-component systems by metrological absorbance spectrophotometry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在计量学吸光光度法分析检测多组分体系时，采用的一种化学计量学数据处理方法。"
    },
    {
        "instruction":"已知信息：\n'When the availability of a given dosage form of a drug is calculated at 100%, the percentage of other dosage forms of that drug that are absorbed at the same dose.'可被翻译为：某药物指定剂型的利用度按100%计算时，该药物其他剂型在相同剂量下吸收的百分率。\n'Misallocation of drug varieties, specifications, dosages, dose switches, dosage forms and routes of administration.'可被翻译为：错误地调配药品品种、规格、剂量、剂量转换、剂型及用药途径等。\n\n根据上述已知信息，请将'The percentage of other dosage forms of a drug that can be absorbed at the same dose when the intravenous availability of a drug is calculated at 100%.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"某药物静脉注射的利用度按100%计算时，该药物其他剂型在相同剂量下吸收的百分率。"
    },
    {
        "instruction":"已知信息：\n'3. The preparation, storage and use of the laboratory reagents, solutions and culture media should follow the relevant requirements or instructions. In special cases, the laboratory reagents should be identified or tested upon reception or before use.'可被翻译为：（三）应当按照相关规定或使用说明配制、贮存和使用试剂、试液和培养基。特殊情况下，在接收或使用前，还应当对试剂进行鉴别或其他检验。\n'2. There should be records for the receipt of laboratory reagents, solutions and culture media, the date of receipt should be indicated on the container where necessary.'可被翻译为：（二）应当有接收试剂、试液、培养基的记录，必要时，应当在试剂、试液、培养基的容器上标注接收日期。\n\n根据上述已知信息，请将'8. Laboratory volumetric glassware, reagents, solutions, reference standards and culture media should be tested;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（八）应当对实验室容量分析用玻璃仪器、试剂、试液、对照品以及培养基进行质量检查。"
    },
    {
        "instruction":"已知信息：\n'1. The review and approval of master manufacturing documents, procedures, etc;'可被翻译为：（一）审核和批准产品的工艺规程、操作规程等文件；\n'Article 25 The registrant, the filing entity and the contract manufacturer of cosmetics shall establish and implement the management systems to ensure the quality and safety of cosmetics, such as material supplier selection, check and test for raw materials acceptance, manufacturing process and quality control, equipment maintenance and product test and sample retention, etc.'可被翻译为：第二十五条 化妆品注册人、备案人、受托生产企业应当建立并执行供应商遴选、原料验收、生产过程及质量控制、设备管理、产品检验及留样等保证化妆品质量安全的管理制度。\n\n根据上述已知信息，请将'(2) Management for review of the product formula, manufacturing process and material supplier, etc.;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）产品配方、生产工艺、物料供应商等的审核管理；"
    },
    {
        "instruction":"已知信息：\n'A solid substance that effectively adsorbs some of its components from a gas or liquid.'可被翻译为：能有效地从气体或液体中吸附其中某些成分的固体物质。\n'The temperature at which a substance melts from a solid phase into a liquid phase, as determined by a prescribed method. Is the physical constant of a substance.'可被翻译为：种物质按照规定的方法测定，由固相融化成液相时的温度。是物质的-项物理常数。\n\n根据上述已知信息，请将'A substance adsorbed from a solution or gas phase to the surface of another substance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从溶液或气相中被吸附至另一物质表面的物质。"
    },
    {
        "instruction":"已知信息：\n'The phenomenon of having some genes from one parent and some genes from a descendant of a different parent. The combination of genes in a recombinant offspring is different from that of either parent. Higher organisms can recombine by free combination or exchange. Lower organisms may recombine by transformation, conjugation, or transduction.'可被翻译为：产生出部分基因来自一个亲本、部分基因来自遗传性不同的另一个亲本的后代的现象。重组后代的基因组合不同于双亲中的任何一个。高等生物可以用自由结合或者交换的方法进行重组。低等生物可以用转化、接合或者转导的方法进行重组。\n'cell free system'可被翻译为：无细胞系统\n\n根据上述已知信息，请将'Also known as \"free genes\". A genetic structure that exists in a cell either in a free state or in conjunction with a chromosome. Their presence confers certain genetic traits on the cell, but their absence does not cause the cell to die.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"游离基因\"。在细胞中或以游离态、或以与染色体相结合的状态存在着的遗传结构。其存在给细胞带来一定的遗传性状，但它们的缺失并不会造成细胞的死亡。"
    },
    {
        "instruction":"已知信息：\n'A substance that changes an enzyme from inactive to active or increases its activity.'可被翻译为：使酶从无活性变为有活性或使酶活性增加的物质。\n'Antihypertensive drugs that can bind to angiotensin converting enzyme and inhibit its activity. Such as captopril, enalapril, Lisinopril, Fosinopril, Ramipril, Benazepril, etc.'可被翻译为：可与血管紧张素转化酶结合，抑制其活性的抗高血压药物。如卡托普利、依那普利、赖诺普利、福辛普利、雷米普利、苯那普利等。\n\n根据上述已知信息，请将'A non-protein component of an enzyme required for its activity. It can promote the activation of enzymes and reactants, and can be divided into coenzymes and coenzymes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种酶的活性所需要的一种非蛋白质成分。能促进酶及反应物进入活化状态，分辅基和辅酶。"
    },
    {
        "instruction":"已知信息：\n'Article 53 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter V of the Provisions shall prevail.'可被翻译为：第五十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。\n'Article 66 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter VI of the Provisions shall prevail.'可被翻译为：第六十六条 体外诊断试剂延续注册申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。\n\n根据上述已知信息，请将'Article 63 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter VI of the Provisions shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。"
    },
    {
        "instruction":"已知信息：\n'(II) Be equipped with the organization or personnel adapted to the scale of the business or use to carry out relevant works of medical device adverse event monitoring;'可被翻译为：（二）配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作；\n'(II) Failing to be equipped with the organization and personnel corresponding to the scale of business or use to carry out relevant works of medical device adverse event monitoring as required;'可被翻译为：（二）未按照要求配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作的；\n\n根据上述已知信息，请将'(II) Equipped with the organization and personnel corresponding to the products to carry out relevant works of medical device adverse event monitoring;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作；"
    },
    {
        "instruction":"已知信息：\n'Article 61 Purchase activities of an enterprise shall meet the following requirements:'可被翻译为：第六十一条 企业的采购活动应当符合以下要求：\n'The display of drug information on third-party platforms shall meet the requirements in Article 13 of these Provisions.'可被翻译为：第三方平台展示药品信息应当遵守本办法第十三条的规定。\n\n根据上述已知信息，请将'Article 161 The display of products shall meet the following requirements:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百六十一条 药品的陈列应当符合以下要求："
    },
    {
        "instruction":"已知信息：\n'Article 197: Measures should be taken to avoid, as far as possible, contamination and cross-contamination during production, for example:'可被翻译为：第一百九十七条 生产过程中应当尽可能采取措施，防止污染和交叉污染，如：\n'Article 35 Drug manufacturers shall have control measures to prevent any contamination, cross-contamination, mix-up and error, and regularly review and evaluate the suitability and effectiveness of these control measures to ensure that the drugs are qualified for the defined national drug standards and drug registration specifications and in compliance with the GMP.'可被翻译为：第三十五条 药品生产企业应当采取防止污染、交叉污染、混淆和差错的控制措施，定期检查评估控制措施的适用性和有效性，以确保药品达到规定的国家药品标准和药品注册标准，并符合药品生产质量管理规范要求。\n\n根据上述已知信息，请将'Article 198: Measures to prevent contamination and cross-contamination should be checked regularly and evaluated for their suitability and effectiveness.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百九十八条 应当定期检查防止污染和交叉污染的措施并评估其适用性和有效性。"
    },
    {
        "instruction":"已知信息：\n'In case of identifying or knowing any suspected medical device adverse event, medical device distributing enterprises, user facility shall promptly notify MAHs. Any event causing death shall be reported within 7 days and any event causing severe injuries or possibly causing severe injuries or death shall be reported within 20 days through the National Medical Device Adverse Events Monitoring Information System.'可被翻译为：医疗器械经营企业、使用单位发现或者获知可疑医疗器械不良事件的，应当及时告知持有人。其中，导致死亡的还应当在7日内，导致严重伤害、可能导致严重伤害或者死亡的在20日内，通过国家医疗器械不良事件监测信息系统报告。\n'Article 29 After reporting medical device adverse events or knowing relevant medical device adverse events through the National Medical Device Adverse Events Monitoring Information System, MAHs shall carry out subsequent investigation, analysis and evaluation as required. The evaluation results of the events causing death shall be reported to local provincial monitoring agencies where MAHs locate within 30 days and the evaluation results of the events causing severe injuries or possibly causing severe injuries or death shall be reported to local provincial monitoring agencies where MAHs locate within 45 days. If the MAH has any new identification or notification of event information and evaluation results, it shall submit a supplementary report as required.'可被翻译为：第二十九条  持有人在报告医疗器械不良事件后或者通过国家医疗器械不良事件监测信息系统获知相关医疗器械不良事件后，应当按要求开展后续调查、分析和评价，导致死亡的事件应当在30日内，导致严重伤害、可能导致严重伤害或者死亡的事件应当在45日内向持有人所在地省级监测机构报告评价结果。对于事件情况和评价结果有新的发现或者认知的，应当补充报告。\n\n根据上述已知信息，请将'Article 25 In case of identifying or knowing any suspected medical device adverse event, MAHs shall immediately investigate the cause. Any event causing death shall be reported within 7 days; and any event causing severe injuries or possibly causing severe injuries or death shall be reported within 20 days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十五条  持有人发现或者获知可疑医疗器械不良事件的，应当立即调查原因，导致死亡的应当在7日内报告；导致严重伤害、可能导致严重伤害或者死亡的应当在20日内报告。"
    },
    {
        "instruction":"已知信息：\n'excipient'可被翻译为：贝武形剂\n'Active Ingredient(s) and Strength[Not disclosed to the public]'可被翻译为：活性成分与规格[不对外公开]\n\n根据上述已知信息，请将'For complete composition including excipients, see attached[Not disclosed to the public]'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"包括辅料在内的完整处方组成（可附表）[不对外公开]"
    },
    {
        "instruction":"已知信息：\n'It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).'可被翻译为：确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。\n'All product and component contact equipment should be sterilised prior to use.'可被翻译为：所有与产品和组件接触的设备应在使用前进行灭菌。\n\n根据上述已知信息，请将'For aseptic processes, direct and indirect product contact parts should be sterilised. Direct product contact parts are those that the product passes through, such as filling needles or pumps. Indirect product contact parts are equipment parts that do not contact the product, but may come into contact with other sterilised surfaces, the\nsterility of which is critical to the overall product sterility (e.g. sterilised items such as stopper bowls and guides, and sterilised components).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于无菌工艺，直接和间接接触产品的部件应进行灭菌。直接接触产品的部件是指产品通过的部件，例如灌装针或泵。间接接触产品的部件是不接触产品的设备部件，但可能与其它灭菌表面接触，其无菌性对整个产品的无菌性至关重要（例如胶塞桶和导槽等已灭菌物品，以及已灭菌组件）。"
    },
    {
        "instruction":"已知信息：\n'In order to implement the E2B (R3) Regional Implementation Guide for Individual Case Safety Reports (hereinafter referred to as the Regional Implementation Guide), the Center for Drug Evaluation has completed the upgrade of the pharmacovigilance system during clinical trials, which was put into trial operation on January 1, 2022. Applicants shall complete the system configuration in a timely manner, and implement E2B(R3) in accordance with the Regional Implementation Guide no later than July 1,2022.'可被翻译为：为实施《个例安全性报告E2B(R3)区域实施指南》（以下简称区域实施指南），药审中心已完成对临床试验期间药物警戒系统升级改造，已于2022年1月1日上线试运行。申请人应及时完成系统配置,并按照区域实施指南要求实施E2B(R3),时间不得晚于2022年7月1日。\n'Thirdly, the construction of standards is strengthened, and the transformation and implementation of ICH related guidance is promoted. The Guidance for Clinical Safety Literature Evaluation of Marketed Drugs(Interim) and Guidance for Compiling the Annual Pharmacovigilance Report by Marketing Authorization Holders (Interim) were issued to guide MAHs in monitoring, reporting, analysis and evaluation. We steadily promoted the transformation and implementation of E2B (R3: Clinical Safety Data Management - Data Elements for Transmission of Individual Case Safety Reports) of ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use), and released the Regional Implementation Guidance for Individual Case Safety Reports E2B(R3). We promoted the application of the Medical Dictionary for Regulatory Activities(MedDRA), carried out disease term mapping research, strengthened the training for MAHs and monitoring institutions, and provide technical guarantee for full swing of ICH related Guidance.'可被翻译为：三是强化规范建设，推进ICH 相关指导原则转化实施。发布《上市药品临床安全性文献评价指导原则（试行）》《药品上市许可持有人药物警戒年度报告撰写指南（试行）》，指导持有人开展监测、报告、分析和评价工作。稳步推进国际人用药品注册技术协调会（ICH）E2B（R3）转化实施，发布《个例安全性报告E2B（R3）区域实施指南》；促进监管活动医学词典（MedDRA）应用，开展疾病术语映射研究，加强对持有人和监测机构的培训，为全面实施ICH相关指导原则提供技术保障。\n\n根据上述已知信息，请将'Notice of the Center for Drug Evaluation of NMPA on the Applicability of E2B (R3) Regional Implementation Guide to Individual Case Safety Reports during Drug Clinical Trials'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药审中心药物临床试验期间个例安全性报告适用E2B(R3)区域实施指南的通知"
    },
    {
        "instruction":"已知信息：\n'Section 5 Facilities and Equipment'可被翻译为：第五节 设施与设备\n'(6) the list of main manufacturing equipment and testing equipment;'可被翻译为：（六）主要生产设备和检验设备目录；\n\n根据上述已知信息，请将'(5) the list of main facilities and equipment for distribution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）主要经营设施、设备目录；"
    },
    {
        "instruction":"已知信息：\n'good review practices (grevp)'可被翻译为：良好审查做法(GRevP)\n'6. Other medically important events that without treatment could lead to the aforementioned outcomes.'可被翻译为：6.导致其他重要医学事件，如不进行治疗可能出现上述所列情况的。\n\n根据上述已知信息，请将'The important GRevP elements for Ras to implement in order to achieve successful review outcomes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为了获得成功的评审结果，Ras需要实施的重要GRevP元素。"
    },
    {
        "instruction":"已知信息：\n'1.7. A technology transfer should include relevant documentation, data, information and knowledge from the SU in order to enable the RU to effectively perform the specified process or procedure in, for example, production and QC. A successful transfer of technology should result in proof that the RU can routinely reproduce the transferred product, process or procedure against a predefined set of specifications as agreed between the SU and RU.'可被翻译为：技术转移应包括来自SU的相关文件、数据、信息和知识，使得RU能够有效实施指定的工艺或方法，例如生产和QC。成功的技术转移应证明RU可以常规化地按SU与RU之间预定的标准生产出所转移的产品、工艺或方法。\n'12.48. A technology transfer report should be prepared, based on the data and information obtained during the project. The supportive data should be kept and be accessible.'可被翻译为：应根据项目期间获得的数据和资料编写一份技术转让报告。支持性数据应保存并便于查阅。\n\n根据上述已知信息，请将'Records should be maintained for the activities performed during the technology transfer process (e.g. a technology transfer report). The report content should reflect the protocol and SOPs that were followed. The report should summarize the scope of the transfer, the critical parameters as obtained in the SU and RU, and the final conclusions of the transfer. Changes, deviations, investigations and relevant appropriate actions taken should be recorded. The SU should provide all the relevant supportive documents with data, results and other relevant information to facilitate a successful transfer of technology and also comparison of data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应保存技术转移过程中所执行活动的记录（例如，技术转移报告）。报告内容应反映出所遵守的方案和SOP。报告应总结转移的范围、SU和RU所得的关键参数，以及转移的最终结论。变更、偏差、调查和所采取的相关恰当措施均应有记录。SU应提供所有相关支持性文件及数据、结果和其它相关信息，以使得技术转移获得成功，同时还要对数据进行比较。"
    }
]